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This work addresses two understudied elements of inflammation and malignancy—
namely, (1) neurolymphatic remodeling during transitions in microenvironmental inflammatory
status and (2) the systemic paraneoplastic inflammatory syndrome cancer-associated cachexia
in the context of pancreatic adenocarcinoma (PDAC). Lymphatic vessels undergo dramatic
phenotypic changes in initial inflammation, wound recovery, and recurrent inflammation. We
identified complementary novel neuroremodeling behaviors under these conditions and
hypothesized that both nerve and lymphatic remodeling were directed by a tissue remodeling
factor with overlapping functions.

We found that nerve growth factor (NGF) influenced not

only nerves but also lymphatics. NGF stimulated lymphangiogenesis, inhibited lymphatic vessel
regression during wound recovery, and increased nociception. NGF induced VEGF-C protein
expression, and ablation of VEGFR-2/3 signaling abrogated NGF-mediated lymphangiogenesis,
supporting a hierarchical model of NGF-VEGF signaling with NGF functioning upstream of the
VEGF family. We next studied neurolymphatic remodeling in the context of malignancy using a
novel murine live imaging platform.

Lyve1CreERT2tdT mice inducibly express tdTomato

fluorescent protein in Lyve-1+ cells. We implanted fluorescently-labeled tumor cells into cornea
and pinna and identified tumor-specific neurolymphatic architecture signatures that are distinct
from those associated with nonmalignant inflammation, including disorganized hypersprouting
nascent lymphatic vessels and a shift in nerve morphology to a phenotype previously associated
only with wound recovery. We also found that manipulating the timing of establishment of

inflammation affected tumor cell persistence in tissue. In the final portion of this work, we
studied cancer-associated inflammation in a broader context—i.e. the paraneoplastic syndrome
cancer-associated cachexia. We sought to address discrepancies in the literature regarding
cachexia gene expression with a unique set of PDAC skeletal muscle samples harvested at rapid
autopsy and stratified based on severity of cachexia. We found differential expression of a
number of candidate targets in PDAC samples compared to cancer-free controls including FAP-α,
CAMKIIβ, FBXO32, TIE-1, and TRIM63 and challenged some previous findings. In summary, we
defined a novel role for NGF signaling in lymphatics, identified microenvironment-specific
neurolymphatic architecture signatures, and highlighted the complexity of cancer-associated
cachexia while providing new data about this syndrome in the context of PDAC.
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INTRODUCTION1

1

Portions of the material presented in this chapter have been previously published under the following
reference: (Fink et al., 2015a)

2

Pancreatic Ductal Adenocarcinoma
Statistics and Progression
Pancreatic ductal adenocarcinoma (PDAC) is the fourth-leading cause of cancer-related
death in both men and women in the United States (Siegel et al., 2016). Worldwide, PDAC
results in over 330,000 deaths annually (Torre et al., 2015). Unlike the stable or decreasing
trends of incidence and death rate achieved for other cancers in recent decades, the incidence
of PDAC continues to rise (Siegel et al., 2016). These sobering statistics underscore the critical
need for basic research examining the biology of this disease to drive development of new and
effective therapies. PDAC progresses through several histologically-defined classifications of
pre-malignant lesions, known as pancreatic intraepithelial neoplasias (PanINs), before
manifesting as infiltrating adenocarcinoma and metastasizing to distant sites. PanINs do not
show invasion into lymphatic or blood vessels or nerves (Maitra et al., 2005), but mice bearing
these lesions had increased levels of neurotrophic factors, sensory innervation, and pain
(Stopczynski et al., 2014). Progression through each PanIN stage has been linked to acquisition
of a specific mutation or set of mutations with HER2/NEU and KRAS associated with PanIN-1A
and -1B, P16/CDKN2A associated with PanIN-1B and -2, and TP53, SMAD4/DPC4, and BRCA2
associated with PanIN-3 lesions (Hruban and Adsay, 2009; Wilentz et al., 2000). The presence of
an inflammatory pancreatic microenvironment, such as that characteristic of pancreatitis, can
exacerbate K-Ras oncogene-induced development of PanIN lesions and progression to PDAC by
facilitating escape from senescence (Guerra et al., 2011) or through pancreatitis-mediated
acinar to ductal cell metaplasia (Guerra et al., 2007). Despite our knowledge of this progression
from normal parenchyma to aggressive malignancy, early detection of these histologic and
genetic deviations in patients remains challenging. Most PDAC cases are diagnosed when the
primary pancreas tumor has already metastasized to regional and distant locations (Siegel et al.,
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2015). Five-year survival decreases dramatically as stage at diagnosis increases, with PDAC
localized to the pancreas at diagnosis yielding a modest five-year survival rate of 27% compared
to just 11% on presentation with regional metastases and a devastating 2% when distant
metastases are present at diagnosis (Siegel et al., 2016). The presence of metastasis eliminates
the only therapeutic strategy with proven curative potential—surgery—and leaves patients with
debilitating rounds of chemotherapy and radiation as their only recourse to extend life a few
precious months.
This work focuses on two microenvironment-responsive tissue networks important in
cancer progression and metastasis: lymphatic vessels and nerves. Both of these systems are
intimately associated with the pancreas and their functions are markedly altered in both
inflammation and malignancy—although much remains poorly understood in these regards. In
the following sections, we will outline normal lymphatic and nerve biology generally and as it
relates to the pancreas, explore inflammation-mediated changes on these networks, and
summarize what is known about their respective roles in the pancreatic tumor
microenvironment with special emphasis on clinical diagnostic/prognostic metrics, imaging
techniques, and therapies. We will also introduce the systemic paraneoplastic inflammatory
syndrome cancer-associated cachexia in the context of pancreatic ductal adenocarcinoma.
The Lymphatic System: Normal Biology and Importance in PDAC

The lymphatic vasculature offers the most direct route from the primary tumor to the
frequently-invaded draining lymph nodes during PDAC progression. Cancer metastasis into and
through the lymphatic vasculature and lymph nodes occurs frequently in PDAC patients
(DiMagno et al., 1999; Hezel et al., 2006; Katz et al., 2008) and is strongly correlated with poor
prognosis (Benassai et al., 1999; Delcore et al., 1996; Kedra et al., 2001; Robinson et al., 2012).
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The lymphatic system is responsible for maintenance of tissue fluid homeostasis, absorption of
dietary fat, and leukocyte and antigen transport from tissues to lymph nodes for the initiation of
immune responses (Maby-El Hajjami and Petrova, 2008; Stacker et al., 2014; Tammela and
Alitalo, 2010). Originating in nearly all vascularized tissues, blind-ended lymphatic capillaries, or
initial lymphatics, are specialized for the uptake of interstitial fluids, macromolecules, and
leukocytes.

They are composed of a single layer of endothelial cells with discontinuous

intercellular junctions and lack a basement membrane (Baluk et al., 2007; Pflicke and Sixt, 2009).
The endothelial membrane of the initial lymphatics is attached to the extracellular matrix (ECM)
via anchoring filaments, which facilitate the opening of the lymphatic lumen during increased
interstitial fluid pressure (Gerli et al., 2000; Solito et al., 1997). Upon entry into the lymphatic
capillaries, lymph and its macromolecular and cellular contents are transported to larger precollecting lymphatic vessels and then to collecting vessels, composed of not just the endothelial
layer but also smooth muscles to facilitate flow and bi-leaflet valves to prevent backflow
(Bazigou et al., 2014; Leak and Burke, 1966; von der Weid and Zawieja, 2004). The afferent
collecting lymphatics enter the lymph nodes where the lymph is filtered, and upon exiting the
lymph nodes through the efferent collecting vessels, lymph passes through the major trunks of
the lymphatic system, the thoracic duct and the right lymphatic trunk, and is then returned to
the circulatory system (Alitalo and Detmar, 2012; Tammela and Alitalo, 2010).
The network of lymphatic vasculature and lymph nodes responsible for draining the
pancreas is quite complex. In the normal pancreas, lymphatic vessels are typically located near
blood vessels and are often found in the interlobular spaces of the pancreas (O'Morchoe, 1997).
Classification of pancreatic nodes has not been uniformly standardized, although pancreatic
lymph nodes are generally divided into regions based upon their location around the pancreas
and the areas of drainage of the pancreas:

head/neck, body/tail, left side, or right side
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(reviewed in (Cesmebasi et al., 2015; Isaji et al., 2004)). Studies correlating primary tumor
location and lymph node involvement following resection have helped to identify the regional
patterns and probabilities of lymph node metastasis, but more analysis is needed for consistent
accurate prediction of lymph node involvement (Fujita et al., 2010; Kanda et al., 2011;
Nagakawa et al., 1994; Sun et al., 2010).
Although clinicians and researchers understand the importance of lymphatic invasion
and lymph node involvement for pancreatic cancer patient prognosis and therapy selection, the
biological processes that govern lymphatic invasion and metastasis remain understudied. For
example, there is currently disagreement within the field as to whether lymphatic vessel
expansion at the primary tumor site and draining lymph node is necessary for lymph node
metastasis. Also, it has not been conclusively determined whether metastasis to the lymph
nodes is a sequential step in distant organ spread or a final destination for tumor cells to
promote immunosuppression. The potential role of lymphatics supporting immune suppression
has led to questions of how normal and tumor-associated lymphatic endothelia may contribute
to immune modulation within the tumor microenvironment and invaded lymph nodes either
through trafficking functions or direct interactions with immune cells. These and many more
questions have yet to be fully explained: how does the lymphatic endothelium regulate the
entry of tumor cells into vessels; how do tumor cells evade immune cell recognition within
lymphatic vessels and lymph nodes; what are the therapeutic implications of targeting
lymphangiogenesis or other lymphatic-directed functions in patients with PDAC?
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Lymphangiogenesis
Signaling and Regulation
While clearly akin to angiogenesis in many regards, progress to define the process of
lymphangiogenesis has revealed distinct molecular mechanisms that direct its inception,
regulation, and roles in inflammatory disease and malignancy. Like angiogenesis, new lymphatic
vessel growth can be directed by many growth factors and regulated by intra- and extracellular
signaling mechanisms.

Primary growth factors associated with lymphangiogenesis include

vascular endothelial growth factor-A (VEGF-A), -C, and -D signaling via vascular endothelial
growth factor receptor-2 (VEGFR-2) and -3 and neuropilin-2 (NRP-2) (Achen et al., 1998;
Bjorndahl et al., 2005b; Favier et al., 2006; Joukov et al., 1996; Oh et al., 1997a; Veikkola et al.,
2001), and angiopoietin-1 (ANG-1) and -2 signaling through receptor TIE-2 (tyrosine kinase with
immunoglobulin-like and EGF-like domains 2) (Morisada et al., 2005; Yan et al., 2012). Recent
evidence shows that in addition to the VEGFs and angiopoietins, several other chemical
messengers are also capable of directly or indirectly inducing lymphangiogenesis in vitro and/or
in vivo in experimental model systems. Such mediators include growth factors fibroblast growth
factor-2 (FGF-2) (Kubo et al., 2002), platelet-derived growth factor-BB (PDGF-BB) (Cao et al.,
2004a; Miyazaki et al., 2014), nerve growth factor (NGF) (Fink et al., 2014) (discussed in Chapter
I), insulin-like growth factor-1 (IGF-1) and -2 (Bjorndahl et al., 2005a), and hepatocyte growth
factor (HGF) (Cao et al., 2006); inflammatory cytokines interleukin-1β (IL-1β) (Peppicelli et al.,
2014; Ristimaki et al., 1998) and tumor necrosis factor-α (TNF-α) (Du et al., 2014; Peppicelli et
al., 2014; Ristimaki et al., 1998); and other non-traditional signaling molecules lipid sphingosine1-phosphate (Huang et al., 2013), cyclooxygenase 2 (COX2), and surface protein EP3/4 (Hosono
et al., 2011). A role for integrins in lymphangiogenesis has been revealed with evidence of
binding of VEGF-A, -C, and -D to lymphatic endothelial-specific integrin-α9β1 (Oommen et al.,
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2011; Vlahakis et al., 2005). While each of these factors does induce new lymphatic vessel
growth, not all lymphangiogenesis is created equal; a study of corneal lymphangiogenesis in
response to VEGF-A, VEGF-C, or FGF-2-loaded micropellets revealed differences in both
structure and function of lymphatic vessels and the proportion of blood to lymphatic vessels
induced by these growth factors (Cao et al., 2004b). In the case of indirect stimulation of
lymphangiogenesis, paracrine signals such as IL-1β (Peppicelli et al., 2014; Ristimaki et al., 1998)
and TNF-α (Du et al., 2014; Peppicelli et al., 2014; Ristimaki et al., 1998) can drive increased
expression of the VEGFs, most notably VEGF-C. This likely occurs through activation of the
nuclear factor kappa B (NFκB) promoter to induce VEGF-C expression (Du et al., 2014). Other
indirect inducers of lymphangiogenesis include COX2 and EP3/4, which may increase expression
of VEGF-C and -D to modulate cell growth during inflammation (Hosono et al., 2011), and NGF,
which increased expression of VEGF-C, but not VEGF-A, in a mouse corneal model of
lymphangiogenesis (Fink et al., 2014). Some studies have attributed the secondary production
of VEGFs, specifically VEGF-C, to an infiltrating macrophage population during periods of
inflammation and malignancy (Cursiefen et al., 2004; Huang et al., 2013; Murakami et al., 2008;
Peppicelli et al., 2014). Huang, et al., have also identified B cells and dendritic cells (DCs) as
candidate immune cell populations that may secrete VEGF-A, -C, and -D to influence lymphatic
vessel organization and growth (Huang et al., 2013). B cells have also been shown to modulate
lymphangiogenesis within lymph nodes in the context of tissue inflammation following
experimental immunization (Angeli et al., 2006). In addition to their role in secretion of
lymphangiogenic growth factors, Hall, et al., have shown that tissue macrophages may directly
contribute to new lymphatic vessel growth by transdifferentiation into a lymphatic endothelial
progenitor-like phenotype and incorporation into growing vessels (Hall et al., 2012). The roles
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of tumor-associated macrophages (TAMs) in lymphangiogenesis in the tumor microenvironment
are discussed in more detail below.
Lymphangiogenesis is further controlled by regulation of growth factor and cytokine
receptors on the lymphatic endothelial surface. Gene expression of VEGFR-1, -2, and -3 and
NRP-1, and -2 is regulated by transcription factors GATA-binding protein 2 (GATA2) and LIM
domain only 2 (LMO2) to influence both angiogenesis and lymphangiogenesis (Coma et al.,
2013).

Another transcription factor, COUP transcription factor 2 (COUP-TFII), increases

expression of Nrp-2 to augment VEGF-C signaling (Lin et al., 2010). VEGFR-2 and -3 signaling is
further modulated by bone marrow kinase in X chromosome (BMX) following its upregulation
upon VEGF-A stimulation of lymphatic endothelial cells (LECs) (Jones et al., 2010). H-, N-, and KRas can also regulate VEGFR-3 signaling by inducing the up- or downregulation of that receptor
(Ichise et al., 2010). Another mechanism of VEGFR-3 pathway signaling regulation in LECs is the
IL-1β-dependent induction of microRNA-1236 (Jones et al., 2012) and the molecular scaffolding
protein apoptosis signal-regulating kinase interacting protein-1 (AIP-1) (Zhou et al., 2014). The
SLIT2-ROBO4 (Slit homolog 2-Roundabout homolog 4) signaling axis has been shown to regulate
surrogate lymphangiogenesis behaviors in lung LECs in culture by modulating VEGF-C/VEGFR-3
pathway signaling (Yu et al., 2014).

NFκB pathway signaling has been shown to further

modulate inflammatory lymphangiogenesis by upregulating prospero-related homeobox-1
(Prox-1) and VEGFR-3 in a mouse model of peritonitis (Huang et al., 2013).
Tumor-Associated Lymphangiogenesis
The discussion above has primarily focused on the regulation of inflammatory
lymphangiogenesis typical of an injury or infection. A related, but in many ways physiologically
distinct process, is that of tumor-associated lymphangiogenesis (TALA). Factors elaborated by
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tumor cells and other supporting cell types of the tumor microenvironment, such as cancerassociated fibroblasts (CAFs), TAMs, and DCs, interact with cognate receptors on the lymphatic
endothelium both locally and in lymph nodes to influence lymphangiogenesis, lymph node
metastasis, and tumor progression. Studies of human pancreatic cancer tissues have identified
a role for TALA in lymph node metastasis and patient outcomes. Kurahara, et al., found that
high lymphatic vessel density (LVD) in PDAC head tumors predicted increased lymph node
metastasis and decreased survival; they also showed increased LVD within metastatic lymph
nodes (Kurahara et al., 2010). Wang, et al., found that increased peritumoral LVD in human
pancreatic carcinoma tissues correlated with unfavorable tumor differentiation status, increased
lymphatic vessel invasion (LVI), and more lymph node metastasis, while this was not the case for
intratumoral LVD (Wang et al., 2012). These data highlight the importance of peripancreatic
lymphatics in the progression and metastasis of pancreatic cancer and their potential utility as
both a predictor of patient outcomes and a possible therapeutic target.
As in inflammatory lymphangiogenesis, the VEGF-C/D signaling pathways appear to play
an important role in TALA, although the exact mechanisms of their activity remain somewhat
less clear. Kurahara, et al., found increased VEGF-C and -D expression in patient PDAC tumor
margins compared to the tumor interior and reported that high VEGF-C and -D expression in
tumor margins correlated with increased LVI (VEGF-C) and lymph node metastasis (VEGF-C/D)
and decreased five-year survival; expression levels of these proteins did not correlate with
either hematogenous invasion or distant metastasis (Kurahara et al., 2004). A similar study of
patient samples also showed increased VEGF-C and -D immunostaining at PDAC tumor margins
that correlated with increased LVD, lymphatic and blood vessel invasion, lymph node
metastasis, and overall survival (Zhang et al., 2007). Von Marschall, et al., corroborated these
findings with their evidence of increased VEGF-D and VEGFR-3 expression in human PDAC tissue
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and of increased LVI, presence of intra- and peritumoral lymphatics, and lymph node metastasis
(Von Marschall et al., 2005). Deletion of VEGF-D in mice resulted in impaired peritumoral
lymphangiogenesis and decreased lymph node metastasis while having no effect on lymphatic
development or inflammatory lymphangiogenesis suggesting a tumor microenvironmentspecific role for VEGF-D signaling (Koch et al., 2009). In a Rip1Tag2 model of pancreatic β-cell
carcinogenesis, Kopfstein, et al., showed that VEGF-D expression in these tumors induced
peritumoral lymphangiogenesis and lymph node and lung metastases (Kopfstein et al., 2007); a
very similar study examining the role of VEGF-C in this context found increased
lymphangiogenesis and lymph node metastasis but not distant metastases (Mandriota et al.,
2001). In an orthotopic PDAC model, treatment with anti-VEGF-C short hairpin RNA decreased
tumoral LVD and inhibited tumor growth (Shi et al., 2013). A role for microRNAs may also exist
in the regulation of pancreatic TALA. Keklikoglou, et al., recently described a mechanism of
regulation of VEGF-C production in PDAC cells by miR-206. They showed that, in addition to
regulating KRAS and annexin-A2 gene expression, restoration of miR-206 expression blocked
tumor-associated angiogenesis and lymphangiogenesis, and its overexpression in pancreatic
cancer cell lines disrupted the cell cycle restricting proliferation, impaired migration and
invasion in vitro, and delayed tumor xenograft growth in vivo (Keklikoglou et al., 2014). While
the role of hypoxia in lymphangiogenesis remains unclear, hypoxia-inducible factor 1 alpha (HIF1α) expression has been shown to correlate with VEGF-C expression in PDAC of the pancreatic
head and may be responsible for increased lymphangiogenesis and lymph node (LN) metastasis
(Tao et al., 2006). Contrary to these studies, Sipos, et al., examined the expression levels of
lymphangiogenic factors, LVD, and effects on lymph node metastasis in human PDAC and
orthotopic PDAC mouse models and found that VEGF-C and -D were not overexpressed in tumor
tissues and that LVD within tumors was decreased while peritumoral LVD was increased. They
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found no correlation between LVD or expression of VEGF-C or -D and rate of lymph node
metastasis or patient outcomes and concluded that PDAC metastasis is independent of
lymphangiogenesis (Sipos et al., 2005).
In vitro experiments have examined the effects of tumor-secreted VEGF-C on LEC
surrogate lymphangiogenesis behaviors. Supernatant from a high VEGF-C-secreting cell line,
MiaPaCa-2, increased LEC migration, and MiaPaCa-2 co-culture with LECs increased LEC
tubulogenesis (Ochi et al., 2007). These effects may be dependent on kangai-1 (KAI-1; CD82)
regulation as overexpression of that gene in MiaPaCa-2 resulted in decreased VEGF-C secretion,
lymphangiogenesis, and lymph node metastasis (Liu et al., 2014a). Re-expression of tumor
suppressor p16 in a MiaPaCa-2 orthotopic model had no effect on levels of VEGF-C or -D, but
nevertheless resulted in decreased lymphangiogenesis, LVD, and lymph node metastasis
suggesting an alternate mechanism of regulation (Schulz et al., 2008).
Overall, many studies examining the relationships among VEGF-C/D expression and
lymphatic-related phenotypes have found that high VEGF-C/D levels correlate with increased
lymphangiogenesis, lymphatic vessel invasion, and lymph node metastasis (or their surrogate in
vitro counterpart behaviors). Whether a direct pathway can be drawn from tumor-associated
lymphangiogenesis, to tumor cell invasion into lymphatic vessels, to tumor cell trafficking to
lymph nodes, to establishment of lymph node metastases, to tumor cell exit of the lymph node
by blood or lymphatic vessels and seeding of metastases at distant sites, to direct effects on
patient outcomes is still unclear. Some of the studies we have discussed have supported
portions of this pathway from lymphangiogenesis to distant metastases, but other data suggest
that disease progression does not necessarily follow this linear sequence—i.e. the concept that
lymphangiogenesis may not be required for lymphatic vessel invasion due to entry into pre-

12
existing lymphatics, or the possibility of trafficking of tumor cells to lymph nodes through blood
vessels, or the results from Sipos, et al., showing that lymph node metastasis and patient
prognosis are not linked to VEGF-C/D levels (Sipos et al., 2005). Also complicating this discussion
is the fact that tumor cells may themselves respond to VEGF-C/D signals in an autocrine manner
further influencing their metastatic behaviors. Additional studies to systematically dissect each
of the biological components of this proposed metastatic pathway are needed to concretely
define their connections and contributions to disease progression.
Traditional neural signaling molecules also act to influence lymphatic vessel biology in
the tumor microenvironment. Suppression of neural cell adhesion molecule (NCAM) induced
VEGF-C and -D expression resulting in increased lymphangiogenesis and lymph node metastasis
in the Rip1Tag2 mouse model (Crnic et al., 2004), while the presence of NCAM expression in
pancreatic cancer tissues from patients correlated with better prognosis (Tezel et al., 2001). In
another example derived from the Rip1Tag2 model, Slit2 induced Robo1 in LECs to increase
lymphangiogenesis and lymph node metastasis (Yang et al., 2010). As previously mentioned,
signaling of Slit2 through another receptor, Robo4, may also influence lymphangiogenesis
behaviors such as growth, migration, and tubulogenesis, by modulating VEGF-C/VEGFR-3
signaling (Yu et al., 2014). NRP-2, a classical semaphorin receptor and VEGF pathway coreceptor, has also been shown to be a key regulator of TALA. It is expressed on intra- and
peritumoral lymphatic vessels and lymph nodes; blocking its function in vivo decreased TALA,
impaired tumor-associated lymphatic vessel function, and reduced lymph node and distant
metastases (Caunt et al., 2008). These effects may be the result of impaired lymphatic sprouting
(Xu et al., 2010). NRP-1 and -2 are also expressed on pancreatic tumor cells themselves (Dallas
et al., 2008; Fukahi et al., 2004). In a model of colorectal cancer, TALA was stimulated by
upregulation of Nrp-2 in LECs, and LVD correlated with the level of Nrp-2 expression; this Nrp-2
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induction was mediated by integrin-α9β1 signaling in a VEGF-C/VEGFR-3 pathway-independent
manner (Ou et al., 2015).
Other signaling pathways have also been implicated in regulation of TALA. In a mouse
model

of

pancreatic β-cell

carcinoma,

both Ang-1

and

-2

induced

peritumoral

lymphangiogenesis, but this new lymphatic vessel growth did not result in increased metastasis
to either local lymph nodes or distant sites (Fagiani et al., 2011). Ang-2 expression in orthotopic
PDAC xenografts resulted in increased LVD and lymphatic metastasis, and high levels of ANG-2
in patient serum samples correlated with lymph node metastasis and decreased survival. In
MiaPaCa-2 cells, ANG-2 altered message levels of cytoskeletal and motility pathway molecules
as well as decreasing expression of tumor suppressor genes (Schulz et al., 2011).

The

transforming growth factor-β (TGF-β) pathway may also be involved in TALA as expression of
endoglin on intra- and peritumoral blood and lymphatic vessels in PDAC correlated with poor
patient prognosis (Yoshitomi et al., 2008).
PDAC Invasion of Lymphatic Vessels and Metastasis to Lymph Nodes
Background
Lymphatic vessel invasion and subsequent metastasis to the lymph nodes are early and
significant events frequently observed during pancreatic cancer progression (DiMagno et al.,
1999; Hezel et al., 2006). Although lymphatic invasion and metastasis to the lymph nodes does
not directly contribute to PDAC morbidity in patients, these pathologies are important indicators
of the metastatic potential of this disease. In the clinical setting, lymph node status is used to
assess disease progression, to select appropriate therapies, and to predict survival (Kawada and
Taketo, 2011; Nathanson et al., 2015). Nearly all studies concur that lymph node status
correlates with poor prognosis for pancreatic cancer patients (Benassai et al., 1999; Delcore et
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al., 1996; Liu et al., 2015b; Robinson et al., 2012). Studies also agree that invasion of lymph
nodes by PDAC occurs most frequently through the lymphatic vasculature rather than through
direct/contiguous extension of the primary tumor to the lymph node (Buc et al., 2014;
Konstantinidis et al., 2010; Pai et al., 2011), although direct extension to lymph nodes through
nerves is often a feature of perineural invasion. The prognostic value of mode of lymph node
invasion is still debated: some studies report poorer overall survival in patients with lymphatic
vessel-directed metastasis as compared to direct invasion (Pai et al., 2011), while other reports
show no survival difference between the two modes of lymph node invasion (Buc et al., 2014;
Konstantinidis et al., 2010). Although lymph node invasion by PDAC occurs most frequently
through the lymphatic vasculature, the LVD at the tumor site has not been conclusively
correlated with either lymph node metastasis or prognosis due to conflicting study results (Sipos
et al., 2005; Von Marschall et al., 2005; Wang et al., 2012; Zorgetto et al., 2013). This is also true
for studies examining the expression of pro-lymphangiogenic factors such as VEGF-C and -D
(Schneider et al., 2006; Sipos et al., 2005; Tang et al., 2001) (and in pancreatic endocrine tumors
(Rubbia-Brandt et al., 2004)). The lack of standardized protocols for quantifying LVD in patients
makes comparative analysis among collected data sets difficult. Some studies enumerate only
intratumoral lymphatics in whole tumor sections, while others examine tumor margins for
peritumoral lymphatics, and still others examine the sum of lymphatic vessels in both regions.
In the continued absence of a standardized method, LVD has limited value as a metric for
assessing pancreatic cancer progression.
PDAC tumors are often hypovascular with only sporadic blood and lymphatic vessels
found among the tumor cells (Feig et al., 2012). These intratumoral lymphatic vessels are
typically collapsed and nonfunctional due to direct compression by the tumor cells and the high
internal pressure of the PDAC tumor microenvironment (Olszewski et al., 2012; Padera et al.,
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2002; Schneider et al., 2006). However, even in the absence of functioning intratumoral
lymphatic vessels, tumor cells are still capable of disseminating to lymph nodes, although
identification of reliable sentinel lymph nodes remains challenging (Kanda et al., 2011). The
lymphatic vessels located at the tumor margins are frequently described as enlarged with open
lumens capable of being filled with tumor cells (Olszewski et al., 2012; Schneider et al., 2006),
and drainage studies show that these peritumoral lymphatic vessels are, in fact, functional
(Padera et al., 2002). Sipos and colleagues demonstrated that even in the absence of elevated
LVD values and active lymphangiogenesis, PDAC patients still frequently presented with lymph
node metastases (Sipos et al., 2005). This suggests that PDAC cells are capable of invading the
pre-existing lymphatic vasculature, especially enlarged vessels at tumor margins.
Mechanisms/Players
Mechanisms regulating lymphatic invasion are not completely understood, but are
gaining increasing research interest. Most of our knowledge of vascular invasion has come from
studies of the blood vasculature that are now being extended to studies of lymphatic vessel
properties and function. Initially, invasion of lymphatic vessels by tumor cells was considered to
be a passive process with increased interstitial fluid pressure driving tumor cells into draining
lymphatic vessels (Hartveit, 1990). Although increased interstitial pressure may contribute to
tumor cell invasion, the concept of lymphatic-mediated tumor metastasis as a process that
utilizes a “path of least resistance” is greatly oversimplified, and proteomics studies have
identified distinctions between primary pancreatic tumors and their corresponding lymph node
lesions (Naidoo et al., 2012). Comparisons of pancreas tumors with and without lymph node
metastases revealed differences in protein expression intrinsic to these two pathological tumor
presentations (Cui et al., 2009). In an effort to better understand the potential drivers of
lymphatic metastasis, results of studies of leukocyte intravasation into lymphatic vessels are
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now being examined for commonalities to tumor cell intravasation. Three key molecular players
of invasion have emerged as likely candidates in the regulation of tumor-lymphatic interactions
and metastasis:

chemokine signaling, paired binding of adhesion protein partners, and

alterations in lymphatic vessel barrier integrity.
Chemokines
Chemokines secreted by lymphatic endothelial cells contribute to inflammation and
initiation of immune responses in part by regulating the chemotaxis of antigen presenting cells
to the lymph nodes. These same molecules are also being studied for similar roles in tumor
metastasis to lymph nodes.

Two widely researched candidate chemokines are CCL21

(chemokine (C-C motif) ligand 21) and CXCL12 (chemokine (C-X-C motif) ligand 12) and their
respective G-protein coupled receptors (GPCRs), CCR7 (chemokine (C-C motif) receptor 7) and
CXCR4 (chemokine (C-X-C) motif receptor 4).
During normal immune responses, lymphatic endothelial cells secrete CCL21 to increase
migration of CCR7+ DCs toward the vessel and then to guide DCs to the lymph nodes (Tal et al.,
2011; Vigl et al., 2011). Tumor cells, including those of pancreatic cancer, overexpress CCR7 and
are capable of responding to CCL21 cues to facilitate their dissemination to the lymph nodes
(Gunther et al., 2005; Hwang et al., 2012; Irino et al., 2014; Muller et al., 2001; Zhao et al.,
2011). Guo, et al., noted a correlation between CCR7 expression in tumor cells and frequency of
lymph node metastasis in pancreatic cancer patients (Guo et al., 2013). Sperveslage, et al.,
confirmed these results and also demonstrated that lymphatic vessels of PDAC patients had
significantly higher expression of CCL21 compared to lymphatic vessels of the normal pancreas.
Expression of CCL21 in lymphatic vessels correlated with increased lymphatic invasion and
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lymph node metastasis in these patients, as did overexpression of CCR7 in pancreatic tumor
cells in vivo (Sperveslage et al., 2012).
The expression of CCL21 in lymphatic endothelial cells is regulated by numerous
inflammatory cytokines including TNF-α and IL-1β and is also influenced by increases in
transmural flow (Miteva et al., 2010), both of which are often present in tumor
microenvironments. In vitro co-culture work has demonstrated that CCR7-expressing tumor
cells have increased chemotaxis toward CCL21-expressing lymphatic endothelial cells (Emmett
et al., 2011; Issa et al., 2009; Shields et al., 2007). This chemotactic axis is used by tumor cells
specifically for invasion into lymphatic vessels; tumor cell chemoattraction to blood endothelial
cells does not use this mechanism (Issa et al., 2009; Pang et al., 2015). Blocking CCR7 or CCL21
expression and/or function inhibits lymphatic vessel invasion and metastasis to the lymph nodes
in vitro and in vivo (Shields et al., 2007; Wiley et al., 2001; Yu et al., 2008b). This chemokine
signaling axis appears to be regulated by and to work in concert with VEGF-C to synergistically
promote lymphatic invasion of CCR7+ and VEGFR-3+ tumor cells (Issa et al., 2009).
Another chemokine axis that influences lymphatic metastasis is that of CXCL12-CXCR4.
It has been widely documented that CXCR4-expressing tumor cells, including PDAC cells, home
to organs with high CXCL12 expression, such as the lungs, bone marrow, and lymph nodes
(Cardones et al., 2003; Cui et al., 2011; Kaifi et al., 2005; Muller et al., 2001). In PDAC patient
tissues, high expression of CXCR4 was found in tumors, while lymph nodes expressed high levels
of CXCL12 (Cui et al., 2011; Wehler et al., 2006). This expression pattern positively correlated
with increased LVD values in the pancreas, lymph node metastasis frequency, and poor disease
prognosis. Tumor-associated, but not normal uninflamed, LECs secrete ample amounts of
CXCL12 in the tumor microenvironment and attract CXCR4+ tumor cells to lymphatic vessels and
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lymph nodes (Hirakawa et al., 2009; Kim et al., 2010b). Blocking the CXCR4-CXCL12 signaling
axis has resulted in impaired lymph node metastasis in numerous tumor models (Chu et al.,
2007; Liu et al., 2014b; Uchida et al., 2011). An in vitro breast cancer model demonstrated that
CXCL12-treated LECs permitted greater transendothelial migration by breast cancer cells, and
this permissiveness could be reversed by blocking CXCR4 in the LECs (Yagi et al., 2011). An in
vivo model of melanoma demonstrated that stem-like, dual positive CD133+/CXCR4+ tumor cells
were strongly associated with CXCL12-producing LECs and that these cells were resistant to
chemotherapy (Kim et al., 2010b). Combinational treatment with a CXCR4 antagonist relieved
this resistance and increased the efficacy of chemotherapy thereby reducing tumor growth and
metastasis. This study suggested that CXCL12 secretion from lymphatic vessels supported a prometastatic and pro-survival niche for tumor cells. Further studies are required to elucidate
whether or not these types of mechanisms are employed in PDAC and/or its tumor
microenvironment.
Adhesion Proteins
Physical interactions between tumor cells and lymphatic endothelial cells may be
another crucial regulator of tumor cell intravasation. Adhesion molecules such as E-selectin,
intercellular adhesion molecule 1 (ICAM-1), and vascular adhesion molecule 1 (VCAM-1) are
typically used by DCs to gain entry into inflamed lymphatic vessels during migration toward
lymph nodes (Johnson et al., 2006; Miteva et al., 2010). Mounting evidence indicates that these
same leukocyte adhesion molecules may also be important for controlling tumor cell entry into
lymphatic vessels (Kawai et al., 2008; Viola et al., 2013; Yan et al., 2014). In a non-inflamed
state, the lymphatic endothelium does not express or only very weakly expresses these
adhesion molecules (Johnson et al., 2006; Sawa et al., 2007). Inflammatory conditions—such as
those found during infection or tumor development—or a wound healing response quickly
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increase the expression of these molecules on the lymphatic endothelium (Johnson et al., 2006;
Miteva et al., 2010).

Increased transmural flow, also characteristic of an inflamed

microenvironment, upregulates ICAM-1 and E-selectin expression on an in vitro lymphatic
endothelium resulting in increased DC binding (Miteva et al., 2010). A recent report shows that
binding and transendothelial migration of breast cancer cells is also influenced by in vitro fluid
flow, although the mechanisms governing these behaviors have not been elucidated (Pisano et
al., 2015). When placed in co-culture with tumor cells, LECs display marked upregulation of
adhesion molecules. Kawai, et al. (2008 and 2009), have demonstrated that invasive breast
cancer cells, which express the αLβ2 ligand for ICAM-1, are capable of inducing the expression of
E-selectin and ICAM-1 on lymphatic endothelial cells. They also demonstrated that blocking
ICAM-1 impaired the ability of these tumor cells to bind to a lymphatic endothelium (Kawai et
al., 2008; Kawai et al., 2009). Studies of the ability of adhesion proteins on lymphatic vessels to
regulate tumor cell entry should be expanded to pancreatic cancer cell lines to determine if
PDAC tumor cells can use similar mechanisms to bind and gain access to the lymphatic
vasculature.
Lymphatic Vessel Barrier Integrity
The intrinsic cellular and molecular organizational characteristics of lymphatic vessels
facilitate entry of immune cells and fluids from a collecting tissue bed—properties that may also
allow these vessels to support tumor cell metastasis. The initial lymphatic capillaries within
tissues are composed of only a single layer of endothelial cells with loose junctions between
neighboring cells (Leak, 1976; Maby-El Hajjami and Petrova, 2008). Unlike the tightly-formed,
continuously-arranged junctions between neighboring endothelial cells of the blood vasculature
(Dejana et al., 2009), the junctional proteins—vascular endothelial cadherin (VE-cadherin),
platelet/endothelial cell adhesion molecule-1 (PECAM-1), claudins, occludins, etc.—of initial

20
lymphatic vessels are discontinuously arranged, creating gaps between overlapping lymphatic
endothelial cells (Baluk et al., 2007). These discontinuous junctions along with preformed
openings in the basement membrane (Pflicke and Sixt, 2009) enable uptake of macromolecules,
fluids, and cells by the initial lymphatic capillaries. As lymph and cells are transported up the
lymphatic vasculature to the collecting lymphatic vessels, the discontinuous intercellular
junctions become more constant and successive to prevent leakage prior to arrival at the lymph
nodes (Baluk et al., 2007).
Data suggest that tumor cells are capable of modulating the barrier integrity of the
lymphatic endothelium to further facilitate lymphatic vessel invasion (Kerjaschki et al., 2011).
Lipoxygenase secretion by breast cancer cells has been shown to disrupt VE-cadherin junctions
and induce endothelial cell repulsion, resulting in breaches in the lymphatic endothelium.
Tumor-secreted VEGF-C also facilitates invasion by creating leaky lymphatic vasculature. VEGF-C
induces the internalization of VE-cadherin, which, in turn, promotes tumor cell transendothelial
migration (He et al., 2005; Tacconi et al., 2015). In a pancreatic tumor model, inhibiting Ang-2
signaling with a soluble Tie-2 receptor decreased lymphatic-directed metastasis to the lymph
nodes (Schulz et al., 2011). This result may be explained by studies demonstrating that Ang-2
disrupts the barrier integrity of the lymphatic endothelium and increases lymphatic permeability
through phosphorylation of VE-cadherin resulting in button-junction formation in the initial
lymphatic capillaries (Zheng et al., 2014).
Comparative Tools and Models to Study Lymphatic Biology and Tumor-Lymphatic Interactions
The discoveries of lymphatic endothelium markers such as lymphatic vessel hyaluronan
receptor-1 (Lyve-1) (Banerji et al., 1999), Prox-1 (Wigle and Oliver, 1999), VEGFR-3 (Kaipainen et
al., 1995), and podoplanin (PDPN) (Breiteneder-Geleff et al., 1997; Schacht et al., 2003;
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Wetterwald et al., 1996) have facilitated the development of new research methodologies and
models with which to study lymphatic vessel biology under homeostasis and various disease
pathologies as well as interactions between lymphatic endothelial cells, immune cells, and
tumor cells in vivo. The mouse cornea and skin have emerged as two popular mammalian
platforms for this type of work. Historically used for studies of angiogenesis, the murine corneal
model system has proven equally informative for studies of lymphatic biology because of its
unique characteristics. The normal healthy cornea harbors a single limbal lymphatic vessel ring
at its periphery and is otherwise devoid of lymphatic vessels.

Upon insult or injury,

inflammatory lymphangiogenesis occurs resulting in extension of newly-synthesized lymphatic
vessels from the limbal arcade toward the site of the stimulus.

Corneal injury can be

recapitulated experimentally by placement of sutures, mechanical debridement, or chemical
burn.

A refinement of this inflammatory model enabling more mechanistic dissection of

lymphatic vessel behavior is the corneal micropocket assay in which a micropellet can be loaded
with a protein or drug of interest and implanted into the cornea (Cao et al., 2011; Fink et al.,
2014; Kenyon et al., 1996). Further modifications of traditional acute inflammatory protocols
can induce wound recovery (Fink et al., 2014; Kelley et al., 2011a) and recurrent inflammation
(Fink et al., 2014; Kelley et al., 2013a)—two additional distinct physiological microenvironments
with

implications

for

wound

healing,

chronic

inflammatory

disease,

and

tumor

microenvironment research. Anatomical sites commonly used in skin imaging studies include
murine dorsal surface, foot pad, and pinna. Unlike the cornea, the skin is vascularized with a
dense network of lymphatic capillaries under steady state conditions. This presents an ideal
system for studies of lymphatic vessel homeostasis and remodeling, local inflammatory
lymphangiogenesis, and endothelium-immune/tumor interactions.
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Both cornea and skin have also been employed in real time live-imaging and intravital
microscopy studies (Kilarski et al., 2013; Li et al., 2012; Pflicke and Sixt, 2009; Steven et al.,
2011). Early experiments of this type relied on injection and uptake of large fluorescent
conjugate molecules such as FITC-dextran or explant immunostaining (Reviewed in (Tran Cao et
al., 2011)) to label vasculature and other tissue antigens, but recently several genetically
engineered mouse models (Bianchi et al., 2015; Choi et al., 2011; Connor et al., 2016; Hagerling
et al., 2011; Martinez-Corral et al., 2012; Truman et al., 2012) have enabled more sophisticated
lymphatic vessel-specific experimental designs. In these immunocompetent models, fluorescent
protein expression is driven by lymphatic endothelium-specific promoters such as Prox-1, Lyve1, or VEGFR-3 in either a constitutive or inducible manner.

Inducible systems offer the

advantages of titration and temporal control of fluorescence expression within the lymphatic
endothelial compartment. Fluorescently labeled tumor or immune cells may be delivered to
and tracked along with endogenously fluorescent lymphatic vessels providing insight into
intravasation/extravasation behavior, cell trafficking and fate, and spread to draining lymph
nodes. Translation of these techniques to studies of the pancreatic lymphatic vasculature
specifically would provide insight into organ-specific lymphatic vessel biology and pancreatic
tumor microenvironment contributions to lymphatic remodeling and lymphatic-mediated
metastasis.

We suggest combination of several existing technologies to examine these

questions. First, crossing a spontaneous pancreatic ductal adenocarcinoma model containing a
fluorescent reporter gene, such as the PKCY (Rhim et al., 2012) or KPCT mouse (Stopczynski et
al., 2014), with one of the available lymphatic-specific reporter mice would facilitate
visualization of cells of pancreatic origin and lymphatic vessels in two colors. Implantation of a
pancreas window (Ritsma et al., 2013) in these animals could enable long term intravital
microscopy studies of lymphatic vessel biology and tumor metastasis throughout the course of
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disease progression, from PanIN formation through advanced metastatic disease. Finally, use of
the CLARITY technique as previously described for brain (Chung and Deisseroth, 2013; Chung et
al., 2013a) in concert with multiphoton microscopy and immunofluorescent staining would
allow deep tissue visualization and reconstruction of full lymphatic vascular networks as well as
detection of other important microenvironmental structures (such as nerve and blood vascular
networks) and signaling molecules both peri- and intratumorally.
Other research and pre-clinical imaging models have further studied lymphatic vesseland lymph node-related pathologies in cancer. High resolution magenetic resonance imaging
(MRI) has proven an effective non-invasive strategy for mapping involved mouse lymph nodes in
pancreatic ductal adenocarcinoma (Zhang et al., 2013). Multiphoton laser scanning microscopy
work in a model of melanoma showed that functional lymphatic vessels are not present within
the tumor proper and that functional peri-tumoral lymphatic vessels are sufficient to mediate
metastasis (Padera et al., 2002).

Other methods of lymph node and metastasis imaging

(reviewed in (Tran Cao et al., 2011)) have included injection of dyes or radiotracers such as
Lymphoseek for lymphoscintigraphy, injection and uptake of cancer-specific radio-labeled
antibodies and their accumulation in affected lymph nodes, injection of fluorescent antibody
conjugates against the lymphatic endothelium in combination with fluorescent reporterexpressing pancreatic cancer cells, and use of combinatorial bioluminescence and fluorescence
resonance energy transfer (BRET-FRET) nanoparticles for mapping lymphovascular and node
networks (Xiong et al., 2012). Fluorescence lifetime imaging microscopy (FLIM)-FRET (Nobis et
al., 2013), optical coherence tomography (Huang et al., 1991), optical frequency domain imaging
(Vakoc et al., 2009), photoacoustic tomography (Wang et al., 2003), higher-order harmonics
generation (Wu et al., 2015), and Raman spectroscopy (Krafft and Popp, 2015) imaging
technologies offer other options for reconstructive deep tissue imaging and analysis of single
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cell signaling within an intact tumor microenvironment. Jeong and Jones, et al., have also
established a chronic lymph node window to facilitate long-term live imaging microscopy studies
of lymph node biology, angiogenesis and lymphangiogenesis, and nodal deposition of metastatic
tumor cells (Jeong et al., 2015). Application of CRISPR-Cas9 gene editing technology (Cong et al.,
2013) may also prove useful in generating new pre-clinical models suitable for lymphatic vessel
imaging in disease.
Clinical Imaging Techniques to Detect Pancreatic Cancer Lymph Node Metastasis
Despite research advances in comparative lymphatic vessel imaging, clinical imaging of
pancreatic cancer patient lymphatic networks and lymph node status has remained challenging.
Several groups have examined the utility of traditional clinical imaging platforms for detection of
lymph node metastasis with limited success. Roche, et al., have shown that examination of
peripancreatic lymph nodes by computed tomography (CT) cannot accurately predict presence
of metastatic deposits (Roche et al., 2003). Similarly, Imai, et al., showed that CT, magnetic
resonance imaging (MRI), and fluorodeoxyglucose-positron emission tomography (FDG-PET)
were not consistently accurate in predicting pre-operative para-aortic lymph node involvement
in pancreatic cancer patients (Imai et al., 2010). Conversely, another group had some success
using endoscopic ultrasound (EUS) to differentiate benign and cancerous lymph nodes and to
identify diseased pancreas; this technique has not been fully developed for widespread clinical
use (Kumon et al., 2010). Cesmebasi, et al., have recently reviewed other advances in clinical
imaging techniques including EUS and lymphotropic nanoparticle-enhanced MRI, reporting that
further refinement of these techniques may make them promising options to identify patterns
of pancreatic cancer spread (Cesmebasi et al., 2015). Other groups have focused efforts on
imaging routes of pancreatic drainage in attempts to identify sentinel lymph nodes for
pancreatic tumors arising in various locations within the pancreas. Injection of indocyanine
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green fluorescent dye into the pancreatic surface during pancreat(ic)oduodenectomy (PD)
surgery allowed visualization of pancreatic lymphatic vessels intraoperatively and resulted in
identification of seven routes of lymphatic drainage highlighting the complexity of the
pancreatic lymphatic vascular network (Hirono et al., 2012). In a similar study methylene blue
dye was injected peri- and intratumorally during pancreatic cancer resection, but the authors
concluded that detection of patterns of pancreatic lymphatic drainage and sentinel lymph node
identification were not feasible with this protocol (Kocher et al., 2007). Another group injected
activated carbon particles or regular insulin colloid at resection and examined their patterns of
spread to surgically-removed lymph nodes by histology. They documented uptake in several
groups of lymph nodes and recommended new radical resection guidelines based on their
findings (Nagakawa et al., 1994). Development and testing of additional lymphatic imaging
technologies and their adaptation to pancreatic adenocarcinoma patients may make preoperative identification of lymph node metastases a reality in the future (Karaman and Detmar,
2014; Nune et al., 2011; Sevick-Muraca et al., 2014).
Lymphatic Vessel-Nerve Interactions
Nerves and vasculature directly interact within the pancreatic microenvironment and can be
influenced by overlapping signaling pathways in development and disease. Studies have shown
that lymphatic vessels (Carlson et al., 1995; Mignini et al., 2012) and lymph nodes (Kayahara et
al., 2007) are innervated, while dorsal root ganglia (DRGs) are known to be vascularized
(Jimenez-Andrade et al., 2008). In the context of malignancy, these connections may represent
an additional route of metastatic dissemination of tumor cells from either network to the other
(Cheng et al., 2012; Ishikawa et al., 1988; Jimenez-Andrade et al., 2008; Kayahara et al., 2007).
Tracts of continuous cancer cells with fingers projecting into perineural spaces and lymphatic
vessels and lymph nodes have also been described (Kayahara et al., 2007; Suzuki et al., 1994). It

26
is well documented that vasculature and nerves can respond to the same molecular cues—
termed neurovascular guidance molecules—for development and remodeling (Bouvree et al.,
2012a; Caunt et al., 2008; Fink et al., 2014; Xu et al., 2010; Yang et al., 2010; Zhang et al., 2015),
and many of these molecules, such as NRP-1 and -2, NGF, brain-derived neurotrophic factor
(BDNF), FGF, IGF-2, netrin-1, semaphorin-3A, ephrin receptor B4, SLIT2, and ROBO1 may be
differentially expressed or have altered signaling functions in the pancreatic tumor
microenvironment, implicating them in cancer progression (Dallas et al., 2008; Fukahi et al.,
2004; Gohrig et al., 2014; He et al., 2013a; Li and Zhao, 2013; Li et al., 2014; Mancino et al.,
2011; Muller et al., 2007; Zhu et al., 1999a). As well, somatic alterations in axon guidance
pathway genes are observed in a subset of pancreatic cancer genomes (Biankin et al., 2012).
Remarkably, Chen, et al., showed that in the absence of both perineural and lymphovascular
invasion, the five-year survival rate for pancreatic adenocarcinoma patients was 71% (Chen et
al., 2010). These studies underscore the importance of both lymphatics and nerves in the
pancreatic tumor microenvironment and highlight the need for further mechanistic work
interrogating the specific contributions of these tissue networks to disease progression and
metastasis.
Pancreas-Associated Peripheral Nervous System: Normal Biology and Importance in PDAC
Nerve Microanatomy
Peripheral nerves are complex structures. The outer layer of a nerve is a tough matrix of
collagen and elastin fibers known as the epineurium. The epineurium protects and houses
several fascicles. Each fascicle is encased by a layer of endothelial cells called the perineurium
and contains several bundles of nerve fibers, often myelinated, and their supporting glia
(Schwann cells). The highly vascularized matrix within the perineurium and surrounding nerve
fiber bundles is the endoneurium (Bapat et al., 2011a). Each bundle of nerve fibers contains
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several axons projecting away from their parent cell body (residing in the brain, spinal cord,
ganglion, etc.); efferent and afferent fibers and those of different branches of the nervous
system (parasympathetic, sympathetic, sensory, etc.) may be contained within a single nerve.
Pancreatic Innervation
Nervous tissue surrounding the pancreas can be divided into six distinct regions
detectable by MRI or CT: namely, the aortic, hepatic, splenic, and celiac plexuses, the superior
mesenteric artery plexus, and the pancreatic head plexus (Zuo et al., 2012b). From this densely
innervated peripancreatic region, sensory, sympathetic, and parasympathetic nerve fibers
extend into the pancreas in nerves often closely associated with blood vessels (Bockman, 2007;
Christians and Evans, 2009; Fernandez-Cruz et al., 1999). The two primary nerve systems
innervating the pancreas are splanchnic and vagus; splanchnic nerves comprise efferent
sympathetic fibers and afferent sensory fibers; vagal nerves comprise parasympathetic efferents
and sensory afferents. Initial cell bodies of sympathetic neurons forming connections in the
splanchnic system reside in the thoracic intermediolateral cell columns of the spinal cord; these
fibers traverse sympathetic ganglia without synapse and eventually end in celiac plexus ganglia;
postganglionic sympathetic fibers terminate near cells of intrapancreatic blood vessels, exocrine
cells, or islets (Bockman, 2007). Neuronal cell bodies of parasympathetic fibers making up the
vagus nerve reside in the brainstem; unlike their splanchnic counterparts, these do not
terminate in the celiac plexus, but rather pass through it and terminate in intrapancreatic
ganglia; postganglionic fibers then extend out to exocrine cells or islets (Bockman, 2007). The
main function of pancreatic nerves is to control secretion of exocrine and endocrine products
including digestive enzymes and hormones. Direct connections between gut and pancreas,
termed the entero-pancreatic axis, also contribute to the intricacy of pancreatic innervation and
modulate pancreatic secretions (Kirchgessner and Gershon, 1990). Indirect control of islets due
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to regulation of blood flow by sympathetic innervation of vascular smooth muscle has also been
described (Rodriguez-Diaz et al., 2011). While sensory fibers serve primarily as informers of
pancreatic damage via transmission of pain signals, sensory responses to tastes and smells, as
well as detection of glucose levels in blood or duodenum, can induce a change in pancreatic
secretions (Bockman, 2007).
Perineural Invasion and Neuroremodeling in PDAC
Background
Perineural invasion (PNI) causes intense pain, often precludes curative resection, and
may provide a mechanism of recurrence following otherwise successful surgery. A feature of
several types of cancer, this devastating pathology complicates nearly all PDAC cases (Bapat et
al., 2011b; Fernandez-Cruz et al., 1999; Sergeant et al., 2009) and contributes to decreased
patient quality-of-life and reduced overall survival. As described above, the peripancreatic
region is densely innervated and the pancreas parenchyma houses intrinsic ganglia. The term
perineural invasion encompasses several specific nerve-tumor interactions including the
following: presence of tumor immediately adjacent to intra- or extrapancreatic nerve, often
applying pressure; infiltration of tumor cells into the nerve itself (may be into perineurium,
epineurium, or endoneurium); or engulfment of peripancreatic nerve plexus or intrinsic ganglia
by tumor-associated stroma (Farrow et al., 2008) or tumor proper. Nerves may also be
recruited into the primary tumor as a result of neurotrophic factor release by tumor and stellate
cells. Once inside a nerve, a tumor may extend within this space without invasion back out from
nerve into adjacent tissue (Pour et al., 2003) or intraneural tumor may be linked to extraneural
tumor at several places along an invaded nerve or continuous with tumor cells in lymphatics
(Suzuki et al., 1994). Studies have characterized patterns of perineural spread from PDAC
tumors arising in different parts of the pancreas. Pancreatic head tumors have been shown to

29
travel along the posterior hepatic plexus to the celiac plexus and ganglion, while tumors arising
in the uncinate process may follow the innervation along the inferior pancreatoduodenal artery
to the superior mesenteric artery (Yi et al., 2003). Another study classified tumors according to
their origins in either dorsal or ventral pancreas based on embryologic pancreatic development;
dorsal PDAC invaded the common hepatic artery plexus and plexus within the hepatoduodenal
ligament while ventral carcinoma invaded pancreatic head plexus 1 and 2 and superior
mesenteric artery plexus (Makino et al., 2008). Evidence suggests that PNI is an early event in
the progression of PDAC. PNI was present in two very small PDAC tumors detected incidentally
at autopsy (Case 1: 4 x 2 mm; Case 2: two separate lesions 2.6 x 0.7 mm and 1.2 x 0.5 mm)
(Kimura et al., 1998) and has been found in samples comprising all stages of PDAC.
Players and Mechanisms
PDAC cells and nerves are often described in mutually supportive roles, with each cell
type expressing receptors/ligands and elaborating factors into the microenvironment that
support the proliferation, survival, and migration of the opposing cell type. In vitro work has
demonstrated the reciprocal benefits of nerve and PDAC co-culture. T3M4 PDAC cells cocultured with rat DRGs or neurons of the myenteric plexus (MP) displayed an elongated
directional morphology targeted toward neurites prior to cell migration (Ceyhan et al., 2008),
and MiaPaCa2/mouse DRG co-cultures showed larger PDAC colony size, increased neurite
extension, enhanced proliferation, increased expression of survival genes MALT1 (mucosaassociated lymphoid tissue lymphoma translocation protein 1) and TRAF (TNF receptor
associated factor), and decreased apoptosis (Dai et al., 2007). Similarly, MP and DRG neurons
displayed increased neural density and hypertrophy when cultured in the presence of PDAC or
chronic pancreatitis (CP) tissue extracts or PDAC cell line supernatant (Demir et al., 2010).
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As with lymphatic-tumor interactions, adhesion proteins play a role in PDAC perineural
invasion. Moesin and E-cadherin were significantly associated with PNI, and moesin expression
in tumors also correlated with higher tumor grade, poor survival, and lymphovascular invasion
(Torer et al., 2007). L1 cell adhesion molecule (L1-CAM) correlated with PNI, pain, lymph node
metastasis, and vascular invasion, and was a negative prognostic factor (Ben et al., 2010).
Schwann cells surround and support nerve fibers and are responsible for their myelination.
Myelin-associated glycoprotein (MAG) is expressed by Schwann cells and has been shown to
bind mucin 1 (MUC1), a mucin overexpressed and aberrantly glycosylated in PDAC (Swanson et
al., 2007). Interestingly, the role of NCAM in PNI in PDAC and other cancers is less clear, with
conflicting reports of its expression and correlation with nerve invasion (Fukuda et al., 2008;
Kameda et al., 1999; Li et al., 2003; Solares et al., 2009). CD74 (HLA class II histocompatibility
antigen gamma chain) has also been identified as a possible contributor to PNI as it is
overexpressed in PDAC with PNI and in PDAC cell lines with a high propensity for PNI (Koide et
al., 2006).
Several studies have demonstrated the importance of the chemokine (C-X3-C motif)
receptor 1 (CX3CR1) and its sole ligand CX3CL1 (fractalkine) in PDAC PNI. CX3CR1 is present at
high levels in PDAC cell lines and patient samples, and its expression is associated with intra- and
extrapancreatic nerve invasion and tumor recurrence (Marchesi et al., 2008; Marchesi et al.,
2010). CX3CL1 is present in neural tissue both as a membrane-bound ligand and in a secreted
form; the secreted protein stimulated PDAC chemotaxis in vitro and PDAC-nerve interactions
were mediated by the membrane-bound ligand binding its receptor (Marchesi et al., 2008).
CX3CR1 is important for transendothelial migration of tumor cells (Marchesi et al., 2010) and
DCs, and CX3CL1 is upregulated and secreted from lymphatics in inflammation, mediating DC
transendothelial migration (Johnson and Jackson, 2013). CX3CL1/R1 are also overexpressed in
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chronic pancreatitis, with highest expression in patients reporting severe pain; this signaling axis
directs infiltration of inflammatory immune cells into the pancreas parenchyma and
intrapancreatic nerves and activates supporting glia, implicating it in neuropathic pain (Ceyhan
et al., 2009c).
Neurotrophic factors NGF and GDNF (glial cell-derived neurotrophic factor) have welldocumented roles in promoting PDAC PNI and associated pain. NGF and its primary receptor
TrkA (NTRK1; neurotrophic tyrosine kinase receptor type 1) are overexpressed in PDAC cells and
are also present in pancreatic nerves. Significant differences in expression levels of these
proteins were not detected among grades or stages of PDAC, but high NGF and TrkA were
correlated with increased PNI and pain (Zhu et al., 1999b). NGF, GDNF family member artemin,
and growth-associated protein 43 (GAP-43) expression levels were increased in PDAC and
adjacent normal pancreas and associated with neural hypertrophy and density (Ceyhan et al.,
2010). GAP-43 expression has also been linked to increased neural density and hypertrophy in
CP as well as pain (Ceyhan et al., 2009a). Gene expression of the primary artemin receptor,
GFRα3, also correlated with neural hypertrophy (Ceyhan et al., 2010); this study demonstrated a
field effect in which NGF and artemin induced neural aberrations in areas of the pancreas
without direct invasion of nerves by tumor. In addition to its expression in primary tumor,
artemin has been shown to be overexpressed in metastases, nerves, and blood vessels and to
promote PDAC invasion along with GFRα3/RET (Proto-oncogene tyrosine protein kinase
receptor Ret) (Ceyhan et al., 2006). (GDNF family ligands bind GFRα family receptors; receptorligand complexes bind RET receptor tyrosine kinases to initiate downstream signal transduction
(Airaksinen et al., 1999)). GDNF is also overexpressed in PDAC specimens and associated with
intrapancreatic PNI and pain, while expression of RET has been shown to predict differentiation
status, post-resection survival, and LVI (Zeng et al., 2008). In a study interrogating paracrine
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regulation of PNI by peripheral nerves, GDNF, RET, and GFRα1 were overexpressed in PDAC with
PNI; GDNF mediated longitudinal PDAC cell migration along nerve in vitro;

PDAC cells

demonstrated decreased nerve invasion to nerves derived from GDNF+/- mice; and RET inhibition
with tyrosine kinase inhibitor pyrazolopyrimidine-1 blocked PNI in vivo (Gil et al., 2010).
Other factors implicated in PDAC PNI include the receptor ligand pair epidermal growth
factor receptor (EGFR)-TNFα (Bockman et al., 1994), aberrant expression of microtubuleassociated protein MAPRE2 in PDAC and its upregulation in PNI (Abiatari et al., 2009b), and
upregulation of kinesin family member 14 (KIF14) and rho-GDP dissociation inhibitor beta
(ARHGDIβ) (Abiatari et al., 2009a).
Pain
PDAC patients often suffer from severe pain. Pancreatic pain is thought to arise from
two distinct processes—nociception and neuropathy—and may present as visceral pain or
referred somatic pain. Sensory nerves transmit nociceptive signals upon activation by noxious
stimuli within the microenvironment; tissue destruction, inflammatory factors elaborated from
infiltrating immune cells, and molecules secreted from tumor cells can contribute to stimulation
of nociception. Neuropathic pain is caused by damage to nerves themselves; desmoplastic
stroma associated with PDAC is characterized by increased internal pressure that may damage
nerves, as can direct invasion of nerves by tumor cells. Changes in the complement of nerve
fibers present in nerves supplying the pancreas due to malignancy or inflammation may
exacerbate pancreatic pain. One study showed that the number of sympathetic and cholinergic
nerve fibers in pancreatic nerves, as measured by tyrosine hydroxylase and choline
acetyltransferase staining, was lower in PDAC and CP, and this change was associated with
increased patient pain; the authors suggested that a reciprocal increase in sensory nerve fibers
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may coincide with depletion of sympathetic and cholinergic fibers, thus increasing nociceptive
capacity (Ceyhan et al., 2009b). In addition to these intrinsic alterations in nerve fiber bundle
composition, nerves in PDAC are often present at greater densities within the tissue and display
hypertrophy, as described above. Other inflammatory diseases, such as inflammatory bowel
disease (IBD) are characterized by neuropathic changes such as hypertrophy, hyperplasia, and
axonal damage (Geboes and Collins, 1998), but these patients do not report the same caliber of
pain as that experienced by PDAC patients, suggesting that neuroremodeling alone cannot
explain the pathogenesis of PDAC-associated pain.
Treatment of PDAC pain has proven challenging. The location of the celiac plexus as a
central hub within the pathway of pancreatic innervation has made it a target of pain relief
techniques. Celiac plexus blockade (injection of alcohol to destroy nerve tissue) has had limited
clinical success, likely due to referral of pain to other areas and involvement of nerves synapsing
in other ganglia. Opioid pain relievers may offer some palliation, but patients often develop
tolerance to these medications and become dependent upon ever-increasing doses of
analgesics, which in turn carry their own sets of undesirable side effects (Inturrisi, 2003).
PNI and Clinical Outcomes
As with lymphatics, nerve-specific metrics can be used to predict outcomes in PDAC
patients. A retrospective study of 153 resected PDAC patients found an inverse correlation
between incidence of intrapancreatic PNI and disease-free survival (DFS); tumor stage did not
predict presence of PNI (Shimada et al., 2011a). A prospective phase II clinical trial of 110
resected PDAC patients who received preoperative gemcitabine-based chemoradiation therapy
identified PNI as the sole predictor of abdominal cavity recurrence, and positive lymph node
status was the only predictor of distant recurrence; PNI and lymph node involvement were both
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associated with decreased DFS (Takahashi et al., 2012). A study of 51 PDAC tumor samples
found that NGF expression was positively associated with presence and degree (between
epineurium and endoneurium vs. within endoneurium) of PNI, LN metastasis, and positive
resection margins; degree of nerve infiltration was also identified as a negative prognostic factor
and correlated with TrkA expression (Ma et al., 2008). Finally, a 500+ case study of pancreatic
nerve alterations and pain found that only PDAC and CP displayed increased nerve density and
hypertrophy among other pancreatic disease states including serous/mucinous cystadenomas,
invasive/noninvasive

intraductal

papillary

mucinous

neoplasias,

benign/malignant

neuroendocrine tumors, ampullary cancer, and normal pancreas; this study also identified pain
as a negative prognostic factor in PDAC (Ceyhan et al., 2009a). MRI and CT imaging have been
used clinically to detect invaded extrapancreatic neural plexus in patients (Zuo et al., 2012a).
Perineural invasion has been implicated in local and distant recurrence after resection
(Fernandez-Cruz et al., 1999; Kayahara et al., 1993; Masui et al., 2013; Shimada et al., 2011b).
Micrometastatic deposits within nerves may foil an otherwise clean resection, and tumor cells
may find sanctuary from chemotherapeutic agents in the relatively protected environment of a
nerve. In an effort to decrease these effects, it has been suggested that extrapancreatic nerve
tissue be removed as part of radical pancreatic resection procedures (Fernandez-Cruz et al.,
1999; Kayahara et al., 1991; Kayahara et al., 1993; Masui et al., 2013; Meriggi et al., 2007; Samra
et al., 2008)
Other Players in PDAC Microenvironment
The PDAC microenvironment is arguably one of the most complex of any tumor
microenvironment, replete with CAFs, immunosuppressive leukocytes, tumor-associated
blood/lymphatic endothelial networks, nerves, and a considerably dense ECM compartment.
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Each of these components facilitates PDAC progression and dissemination and has the capacity
to influence the normal lymphatic vasculature within the pancreas.
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Figure 1. Pancreatic tumor microenvironment and lymph node metastasis. Cells of the tumor
microenvironment are essential contributors to tumor growth, perineural invasion, lymphatic
vessel invasion, and lymph node metastasis. CAFs and TAMs secrete pro-lymphangiogenic
factors and proteases needed for lymphangiogenesis and metastasis. Lymphatic vessels act as
conduits not only for tumor cell metastasis, but also for immunosuppressive cell and cytokine
transport to lymph nodes. Mutual tropism between nerves and cancer cells through secreted
cytokines and direct receptor-ligand interactions instigate perineural invasion, another route of
pancreatic tumor metastasis. Vascularization of nerves and innervation of vessels may facilitate
metastatic spread of tumor cells between these respective networks. (This figure was
previously published in Fink et al., 2015a).
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Cancer-Associated Fibroblasts
One of the most striking features of PDAC is the robust desmoplastic reaction seen
within the primary tumor. Due to their abundance in the PDAC microenvironment, CAFs exert a
strong influence over other microenvironmental cell types including the lymphatic endothelium
(Hanahan and Coussens, 2012). One of the main protein regulators of desmoplasia in PDAC is
sonic hedgehog (Shh) (Bailey et al., 2008; Tian et al., 2009). Bailey, et al. (2009), noted that Shh
signaling in the CAFs of PDAC tumors led to the creation of a pro-angiogenic and prolymphangiogenic stromal compartment. When Shh signaling was inhibited in the CAFs, LVD
decreased and lymph node metastasis was reduced. Data such as these suggest that CAFs
primarily influence the lymphatic endothelium via secretion of various effector proteins. It has
been demonstrated that CAFs of various tumor types, including PDAC, secrete a wide range of
pro-lymphangiogenic factors such as VEGF-C, VEGF-D (Duong et al., 2012; Koyama et al., 2008),
VEGF-A (Mace et al., 2013), epidermal growth factor (EGF) (Dadras, 2013), PDGF, and FGF (Feig
et al., 2012). CAFs also secrete chemokines, including CXCL12, which has been shown to
correlate with increased tumor aggressiveness, LVD values, and lymph node metastases in PDAC
patient tissues (Cui et al., 2011; Feig et al., 2013). In addition to their direct action on lymphatic
endothelia, many of these same secreted factors as well as pro-inflammatory cytokines allow
CAFs to indirectly support lymphangiogenesis and lymphatic vessel invasion through the
recruitment of pro-lymphangiogenic immune cells such as TAMs and DCs (Liao et al., 2009;
Rasanen and Vaheri, 2010). Lastly, CAFs secrete matrix metalloproteinases (MMPs) and other
proteases that remodel the ECM of tumors (Kessenbrock et al., 2010).

This remodeling

promotes tumor invasion of stroma and tumor vasculature and releases sequestered growth
factors and cytokines from the ECM for tumor growth, angiogenesis, and lymphangiogenesis. A
recent study by Shi, et al., highlights an additional protease-related mechanism by which CAFs
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may influence pancreatic cancer progression and lymphatic metastasis. Specific pancreatic
stromal compartment deletion of protease-activated receptor-2 (PAR-2), a GPCR highly
expressed in PDAC, resulted in decreased primary tumor size (due to anti-angiogenesis effects)
but increased LVD and lymph node metastases (Shi et al., 2014).
Immune Cells and Immune Regulation
One of the main functions of lymphatic vessels is to transport leukocytes to lymph
nodes for immune response initiation, uniquely positioning LECs to modulate immune responses
in ways that may support tumor progression. As immune cell trafficking conduits, LECs are
responsible for the transport of both antigens and antigen presenting cells, such as DCs, to the
lymph nodes for immune response optimization (Tal et al., 2011). By regulating the expression
and secretion of various chemokines in response to inflammation, injury, or tumor
development, LECs can alter the recruitment of immune cells to the lymph nodes, and, as a
result, influence the ensuing immune response (reviewed in (Aebischer et al., 2014; Liao and von
der Weid, 2015)). Partially due to lymphatic-directed recruitment, tumor-draining lymph nodes
demonstrate a more immunosuppressive environment as compared to normal lymph nodes
with an increased presence of regulatory T cells (Tregs), myeloid-derived suppressor cells
(MDSCs), immature and tolerogenic DCs, and immunosuppressive cytokines (Inman et al., 2014;
Munn and Mellor, 2006; Podgrabinska et al., 2009; Shields et al., 2010).

These

immunosuppressive cells and cytokines accumulate in the lymph as a result of increased
lymphatic drainage from the tumor site (Harrell et al., 2007). Within the lymph nodes TGF-β, a
major driver of immune suppression, supports the differentiation and activation of Tregs as well
as promoting tolerogenic and immature phenotypes of DCs (Ghiringhelli et al., 2005). As Tregs
differentiate and accumulate, they secrete more TGF-β to further drive immune suppression.
Interleukin-10 (IL-10) is another factor that supports the accumulation of immunosuppressive
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cells in the lymph nodes by promoting Treg activity (Seo et al., 2001b) and tolerogenic DC
function (De Smedt et al., 1997; Seo et al., 2001b). Indoleamine 2,3-dioxygenase increases the
generation of Tregs in the lymph nodes (Fallarino et al., 2006; Munn and Mellor, 2007), while
concurrently inhibiting effector T cell activity (Munn et al., 2005). Other factors implicated in
the accumulation of immunosuppressive cells in lymph nodes include interleukin-4 (IL-4), VEGFA, and prostaglandin E2 (Kim et al., 2006).
In addition to cellular and cytokine transport, LECs also transport tissue antigens (and in
the case of cancer, tumor antigens) from peripheral tissues to lymph nodes. Studies have
demonstrated that LECs, particularly those in the lymph nodes, are capable of scavenging these
tissue and tumor antigens and cross-presenting them on major histocompatibility complex-I
(MHC-I) (Hirosue et al., 2014; Lund et al., 2012). This can lead to immune tolerance through
deletion of naive CD8+ T cells as LECs lack co-stimulatory molecules needed to activate the T
cells and instead express programmed death-ligand 1 (PD-L1), an inhibitory signal for T cells
(Tewalt et al., 2012). LECs can also present scavenged exogenous tissue/tumor antigens on
MHC-II molecules and likely induce immune tolerance through interactions with the inhibitory
lymphocyte activation gene-3 (LAG-3) protein on CD8+ T cells (Rouhani et al., 2015). These
studies shed light on the phenomenon that when tumor cells are denied lymphatic vessel
experience, such as through direct implantation into lymph nodes, tumor immunity is impaired
through a robust CD8+ T cell response (Preynat-Seauve et al., 2007). LECs also modulate
immune responses by inhibiting DC maturation (Podgrabinska et al., 2009). Binding of DCs to
the lymphatic endothelium via macrophage-1 antigen (Mac-1) and ICAM-1-mediated
interactions during transendothelial migration can reduce the expression of co-stimulatory
molecules on DCs needed for T cell activation. Studies such as these inspire new ideas regarding
increased lymphangiogenesis at the tumor periphery and draining lymph nodes, suggesting that
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it may influence tumor progression in two ways:

1) increasing metastatic routes for

dissemination and 2) immune suppression through increased antigen scavenging and decreased
DC maturation leading to T cell inhibition and immune tolerance (Swartz, 2014). Further
investigation is needed to substantiate the immunosuppressive properties of the lymphatic
endothelium and its specific contribution to disease progression as a component of the tumor
microenvironment.
A reciprocal concept in relation to the capacity of LECs to affect immunity is that of
immune cells inducing effects on LECs. One such tumor infiltrating immune cell type, TAMs, can
be found in many tumor microenvironments, including PDAC (Condeelis and Pollard, 2006;
Kurahara et al., 2013; Leek and Harris, 2002; Schoppmann et al., 2002), and their presence often
correlates with poor patient prognosis (Jung et al., 2015; Kurahara et al., 2011; Sugimura et al.,
2015; Yuan et al., 2014). TAMs promote tumor lymphangiogenesis through two mechanisms:
paracrine secretion of pro-lymphangiogenic factors and transdifferentiation into LEC-like
progenitor cells. TAMs secrete high levels of VEGF-C and -D, which, in turn, increases LVD in and
around tumors (Kurahara et al., 2013; Schoppmann et al., 2002; Schoppmann et al., 2006; Wu et
al., 2012). Indeed, TAM density has been shown to significantly correlate with increased LVD,
lymphatic vessel invasion, and lymph node metastasis in many cancers (Ding et al., 2012;
Kurahara et al., 2013; Schoppmann et al., 2006; Storr et al., 2012; Zhang et al., 2011). Inhibition
or depletion of TAMs from tumor microenvironments significantly reduced LVD values and
decreased the incidence of lymph node metastases compared to tumors with TAMs present
(Fischer et al., 2007; Yang et al., 2011b; Zumsteg et al., 2009). However, depletion of TAMs did
not completely inhibit lymph node metastasis as tumor cells were still able to invade preexisting lymphatic vessels. These macrophages also secrete proteases such as MMP-2, MMP-9,
and plasmin/urokinase plasminogen activator (uPA) that remodel the extracellular
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microenvironment and release sequestered growth factors for lymphangiogenesis (Marconi et
al., 2008; Ran and Montgomery, 2012). The plasmin/uPA system is also important for the
proteolytic maturation of VEGF-C and -D increasing their affinity for VEGFR-3 (McColl et al.,
2003). It has yet to be determined if TAMs secrete any of the other factors known to promote
lymphangiogenesis.

The second way TAMs contribute to lymphangiogenesis is by

transdifferentiating into LEC-like progenitors both in inflammatory and tumor settings (Hall et
al., 2012; Hunter et al., 2014; Schledzewski et al., 2006; Zumsteg et al., 2009).
Transdifferentiated macrophages undergo genetic reprogramming (Hall et al., 2012) with
increased expression of lymphatic markers Lyve-1, Prox-1, podoplanin, and VEGFR-3 (Hall et al.,
2012; Lee et al., 2010; Maruyama et al., 2005; Zumsteg et al., 2009). Expression of LEC markers
enables TAMs to physically incorporate into the newly developing lymphatic vasculature. The
percentage of transdifferentiated TAMs within these newly formed lymphatic vessels is often
less than 10% (Lee et al., 2010; Zumsteg et al., 2009) suggesting the main mechanism by which
TAMs

promote

tumor-associated

lymphangiogenesis

is

through

secretion

of

pro-

lymphangiogenic factors.
Another Inflammation-Associated Paraneoplastic Effect of PDAC: Cancer-Associated Cachexia
Considerations of cancer often focus on the direct effects of primary tumor and
metastatic deposits on involved organs.

However, cancer often results in systemic

consequences beyond those directly attributable to compromised organ function. One such
paraneoplastic syndrome is cancer-associated cachexia. Cancer cachexia negatively affects
patient quality-of-life, decreases the efficacy of anti-tumor therapies either directly or by
reducing patient tolerance for taxing treatment regimens, and may be responsible for shortened
survival. Cachexia has been assigned both causal and complicating roles in its status as a cancer
comorbidity (Muscaritoli et al., 2015).

An international expert panel recently released a
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consensus definition of cancer cachexia stating, “Cancer cachexia [is] a multifactorial syndrome
defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot
be fully reversed by conventional nutritional support and leads to progressive functional
impairment” (Fearon et al., 2011). The nature of cachexia as a progressive disease, beginning
with understated and possibly reversible pre-cachexia symptoms and gradually advancing to a
severe refractive state requiring specialized individual patient care is well recognized; although
specific criteria for patient stratification differ among groups (Baracos, 2011; Fearon et al., 2011;
Johns et al., 2014; Martin et al., 2015). Cachexia has also been described as a disorder of
metabolic flux (Penet et al., 2011), with decreased appetite, anorexia, and early satiety
contributing to decreased nutritional intake, while increased proteolysis, lipolysis, and altered
carbohydrate metabolism promote an imbalance in anabolic and catabolic processes and
increased resting energy expenditure (Argiles et al., 2014; Baracos, 2011); together these
processes result in net weight loss, decreased skeletal muscle mass, weakness, fatigue, and
overall decreased patient quality-of-life.
PDAC patients as a population are highly susceptible to cachexia. Cancer cachexia has
been estimated to affect over 80% of pancreatic cancer patients and to directly contribute to
20% of cancer-related deaths (Argiles et al., 2014). PDAC patients with muscle loss after
treatment displayed decreased survival compared to patients with stable muscle mass or muscle
gain (Fogelman et al., 2014). Cachexia is also linked to disruption of the glucose-insulin axis
often manifested in PDAC by the onset of type II diabetes mellitus. Glucose intolerance and
insulin resistance may be implicated in loss of muscle mass in cancer-associated cachexia (Asp et
al., 2010) (Reviewed in (Honors and Kinzig, 2012)). Treatment of C26 colon tumor-bearing mice
with rosiglitazone ameliorated insulin resistance and began to reverse cachexia (Asp et al.,
2010). Additionally, a large retrospective analysis of PDAC cases and controls has documented
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an inverse relationship between fasting blood glucose (FBG) and body mass index (BMI) in the
twelve months preceding PDAC diagnosis (Pannala et al., 2009) suggesting potential utility in
early disease detection.

Glucose neurotoxicity is also linked to repeated or persistent

hyperglycemia, as is the case in diabetic neuropathy (Reviewed in (Tomlinson and Gardiner,
2008)). High FBG is also significantly associated with increased PNI, neural density, NGF and
receptor p75NTR (p75 neurotrophin receptor) expression, and PDAC death rates (Li et al., 2011a).

Of special relevance to the present work are the contributions of perineural invasion
and inflammation to cancer-associated cachexia. Inflammation is consistently ranked among
the most important driving forces behind the development and progression of cancer cachexia
(von Haehling and Anker, 2014) and has been placed with weight loss as one of the defining
features of this syndrome (Argiles et al., 2014). Circulating factors secreted from tumor cells,
supporting stromal cells, and activated immune cells in the tumor microenvironment contribute
to the development of a systemic inflammatory profile. Serum from PDAC patients or tumorbearing, but not tumor-resected, mice induced NFκB and downstream effector paired box 7
(Pax7) to promote muscle wasting (He et al., 2013b). Cachexia has been correlated with altered
immune cell infiltrates in gastrointestinal tumors and increased levels of chemokines and
inflammatory cytokines in tumor and adipose tissue compared to weight-stable cancer patients
(de Matos-Neto et al., 2015). NGF has been implicated in driving this process as well. A unifying
study by Ye and colleagues has suggested that NGF is a key regulator of tumor-associated
inflammation and has shown that oral tumor progression, pain, and cachexia can all be
ameliorated by NGF inhibition (Ye et al., 2011). Interest is rising in the possible connection
between perineural invasion and PDAC-associated cachexia with a recent study of PDAC patients
and in a mouse model of PDAC PNI showing that PNI drives astrocyte activation resulting in
decreased BMI and cachexia (Imoto et al., 2012).
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Diagnosis of cachexia—particularly that associated with cancer—remains clinically
challenging, and new approaches are needed for its recognition and management (Muscaritoli
et al., 2015). Rising obesity rates in the general populace and among cancer patients complicate
detection. Loss of skeletal muscle mass may be masked by subcutaneous and visceral fat
deposits, and establishing the etiology and threshold percentage of clinically significant
involuntary weight loss may be difficult in overweight or obese patients (Martin et al., 2013a). A
new use of routine abdominal CT scans originally ordered for PDAC diagnosis and staging is
opening the door to objective determination of cachexia status. Lumbar skeletal muscle index
can be derived from CT imaging and used to detect occult muscle wasting masked by obesity to
determine cachexia status independently of BMI (Martin et al., 2013a; Tan et al., 2009).
Summary and Points Addressed
Nerves and lymphatic vessels are two tissue networks that both participate in and are
influenced by changes in a microenvironmental tissue milieu. The specific phenotypic and
functional alterations of these networks and their regulation in acute inflammation, wound
recovery, recurrent inflammation, and tumor-associated inflammation are not well defined. We
studied these changes in cornea and skin of mice under the described inflammatory states and
in the context of melanoma or PDAC tumor microenvironments. The involvement of lymphatics
and nerves in PDAC disease progression is well established; presence of lymph node metastasis
or perineural invasion negatively affects prognosis. Another inflammation-related component
of PDAC with negative implications for patient survival is the common co-morbidity cancerassociated cachexia. We aimed to address understudied areas of inflammation and PDAC
biology, and the subsequent chapters detail our studies of the following points: (1)
neurolymphatic remodeling during transitions between tissue microenvironmental states and a
novel wound recovery-associated nerve phenotype, (2) connections between the lymphatic
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vasculature and the peripheral nervous system and the regulation of neurolymphatic
remodeling by the canonical nerve survival and patterning factor NGF, (3) distinctions in
inflammation- and cancer-associated neurolymphatic remodeling identified through use of a
novel live-imaging fluorescent mouse platform and implications of these neurolymphatic
architecture signatures for PDAC detection and treatment, and (4) gene expression profiling of
PDAC skeletal muscle samples stratified by cachexia severity vs. cancer-free controls.
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CHAPTER I.

Nerve Growth Factor Regulates

Neurolymphatic Remodeling during Corneal
Inflammation and Resolution2

2

Portions of the material presented in this chapter have been previously published under the following
reference: (Fink et al., 2014a)
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Introduction
Acute inflammation commonly results in either wound recovery or the development of
a chronic inflammatory reaction. The biologic mechanisms that direct these outcomes are not
well understood, despite the negative clinical implications of chronic inflammation. The concept
that wound recovery and the resolution of inflammation are passive processes has been
challenged by evidence that active processes trigger a switch from pro- to anti-inflammatory
mediators in the tissue microenvironment that in turn resolve inflammation (Serhan and Savill,
2005; Serhan et al., 2007; Serhan et al., 2008).
Networks of nerves, blood vasculature, and lymphatic endothelia are strikingly similar in
their anatomical organization and location. Nerves and vasculature respond to overlapping or
complementary environmental cues to direct their developmental patterning and maintenance
(Adams and Eichmann, 2010; Bouvree et al., 2012b; Chauvet et al., 2013; Gelfand et al., 2009;
Larrivee et al., 2009; Melani and Weinstein, 2010). Signals elaborated by cells of one network
may influence the behavior of cells in an adjacent network (Mukouyama et al., 2002). There is
evidence for shared neurovascular guidance pathways in conditions of tissue disruption, such as
neurodegenerative disease or malignancy (Buchler et al., 2005; Entschladen et al., 2006;
Entschladen et al., 2008; Quaegebeur et al., 2011).
We hypothesized that common mechanisms regulated neurolymphatic remodeling
during inflammation and wound recovery.

A corneal model of initial inflammation, wound

recovery, and recurrent inflammation was developed to investigate mechanisms that regulate
the structure and function of sensory nerves and lymphatic vessels, as these systems influence
pain and swelling during the resolution of inflammation. Accessibility and the neurovascular
features unique to the cornea make it an ideal system in which to examine neurolymphatic
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architecture and function during an inflammatory episode and wound recovery. The cornea is
densely innervated (Belmonte et al., 2004; McKenna and Lwigale, 2011; Muller et al., 2003;
ZANDER and WEDDELL, 1951), primarily with sensory nerves derived from the ophthalmic
branch of the trigeminal nerve (Marfurt et al., 1989). Sympathetic nerves, from the superior
cervical ganglion (Marfurt et al., 1989), and parasympathetic nerves, from the main and
accessory ciliary ganglia (Marfurt et al., 1998) are less common. During homeostasis, the
corneal vasculature is limited to a peri-corneal limbal arcade.

Angiogenesis and

lymphangiogenesis from the limbus can be stimulated experimentally using suture-induced
inflammation (Kelley et al., 2011b; Kelley et al., 2013b). In this work corneal sutures were used
to induce initial inflammation; suture removal stimulated wound recovery; and replacement of
corneal sutures induced recurrent inflammation.
Examination of several candidate neurovascular guidance molecules for mRNA
expression during initial inflammation, wound recovery, and recurrent inflammation in the
cornea revealed that NGF gene expression was tightly correlated with these distinct physiologic
states. We therefore examined the contribution of NGF to alterations in lymphatic vasculature
and neural structures during wound recovery. We also evaluated pain—a clinically-relevant
physiological measurement.
These results reveal the capacity of NGF to inhibit neurolymphatic remodeling and the
resolution of pain during wound recovery. We show for the first time that NGF can induce
lymphangiogenesis as an upstream driver of a hierarchical signaling pathway in which VEGF
family members are downstream effectors. These findings implicate NGF as a pathogenic factor
that inhibits important aspects of wound recovery.
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Materials and Methods
Mice
All experimental procedures were approved by the Institutional Animal Care and Use
Committees of Boys Town National Research Hospital and the University of Nebraska Medical
Center in accordance with NIH guidelines. Experiments were carried out in six- to ten-week-old
female 129S2/SvPasCrl mice purchased from Charles River Laboratories (Wilmington, MA).
Corneal Surgical Procedures
Prior to all surgical procedures, mice were anesthetized by intraperitoneal
administration of a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg). Mice were
euthanized by ketamine/xylazine overdose or by CO2 asphyxiation and cervical dislocation.
The corneal model of initial inflammation, wound recovery, and recurrent inflammation
was described previously, as were the injection techniques for VEGFR-2/3 decoy receptors
(Kelley et al., 2013b).
Administration of NGF during Wound Recovery
2.5S NGF (B.5017, Harlan Laboratories, Indianapolis, IN) was resuspended at 100 μg/mL
in phosphate-buffered saline (PBS), pH 7.4. Approximately 10 μL of suspension was delivered
per subconjunctival injection with a 33 gauge needle.
Micropellet Preparation and Micropocket Assay Procedures
A 4 mm2 nylon mesh was used to mold a mixture of 12% (w/w) poly(2-hydroxyethyl
methacrylate) (192066-10G, Sigma-Aldrich, St. Louis, MO) solution in 95% ethanol, sucrose
octasulfate-aluminum complex (S0652-1G, Sigma-Aldrich), and cytokine into micropellets
measuring approximately 305 μm x 305 μm x 460 μm. Experimental micropellets contained
approximately 200 ng of carrier-free recombinant mouse β-NGF (1156-NG-100/CF, R&D
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Systems), recombinant human VEGF-C, CF (2179-VC-025/CF, R&D Systems), or PBS only. A 20 or
27 gauge needle was used to create a pocket in the center of the cornea, and a fine forceps was
used to place a pellet under the corneal flap.
Immunofluorescence Imaging of Whole Mount Corneas and Axial Sections and Data Collection
Dissection and Staining
Globes were enucleated and fixed in 1% paraformaldehyde (PFA) in PBS, pH 7.4, for one
hour. Corneas were dissected out and either hemi-sectioned or slit at each quadrant with a
small incision. Fixation was repeated for one hour. Corneas were blocked and permeabilized in
a sterile-filtered PBS, pH 7.4, solution containing 5.2% BSA, 0.3% Triton X-100, and 0.2% NaN3
(blocking solution) for one hour shaking at room temperature. Primary antibodies were diluted
in blocking solution and applied to corneas overnight shaking at room temperature. Corneas
were washed in a sterile-filtered PBS, pH 7.4, solution containing 0.2% BSA, 0.3% Triton X-100,
and 0.2% NaN3 (wash buffer) three times for one hour shaking at room temperature. Secondary
antibodies were diluted in blocking solution and applied to the corneas overnight shaking at
room temperature. After three one-hour washes in wash buffer, corneas were mounted on
glass microscope slides with mounting medium containing DAPI and stored at 4°C. Primary
antibodies: pRb α-Ms β-III tubulin (ab18207, Abcam, Cambridge, MA), mRt α-Ms Lyve-1 (sc65647, Santa Cruz Biotechnology, Santa Cruz, CA), ArmHms α-Ms CD-31 (MAB1398Z, EMD
Millipore, Billerica, MA), Rt α-Ms phospho-histone H3 (H9908, Sigma-Aldrich, St. Louis, MO).
Secondary antibodies: 488 Dky α-Rb IgG (AlexaFluor A21206, Life Technologies, Carlsbad, CA),
488 Dky α-Rt IgG (AlexaFluor A21208, Life Technologies), 549 Dky α-Rt IgG (DyLight 712-505150, Jackson ImmunoResearch Laboratories, West Grove, PA), 649 Gt α-ArmHms IgG (DyLight
127-495-160, Jackson ImmunoResearch Laboratories).
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Whole Mount Imaging
Whole mount corneas were visualized on a Zeiss Axio A.1 epifluorescence microscope or
a Leica stereoscope.

100X epifluorescence images were obtained using SPOT Advanced

software (SPOT Imaging Solutions, Sterling Heights, MI). 32X stereofluorescence images were
obtained using Leica Application Suite software (Leica Microsystems, Inc., Buffalo Grove, IL).
200X and 400X z-stacks were obtained using a Zeiss 510META confocal microscope (Carl Zeiss
AG, Oberkochen, Germany). Images were compiled and analyzed using ZEN 2009, BioImageXD
(Kankaanpaa et al., 2012) and ImageJ (Schneider et al., 2012) software packages.
Quantification of Corneal Nerve Density
Epifluorescence images were color-inverted and overlaid with a 25,000 pixels2 grid with
random offset using ImageJ. Portions of the grid lying outside of or overlapping the limbal
arcade were excluded from the analysis. β-III tubulin+ nerves intersecting grid line segments
were manually counted in the X and Y directions. To derive density from counted intersections,
raw data were normalized to the number of grid squares counted in each image. Both intact
and hemisected whole mount corneas were included in the analysis.
Corneal wound bed nerve density was derived by using ImageJ to superimpose a grid
over β-III tubulin immunofluorescence photomicrographs. A line was drawn around each
wound bed and the area measured using ImageJ. Nerves intersecting gridlines within the
wound bed area were quantified and counts normalized to wound bed area.
Quantification of Corneal Nerve Clusters
Corneal nerve clusters were defined as tortuous nerve endings organized in a clustered
pattern originating from a single larger nerve and extending in three dimensions. Clusters were
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identified and counted manually from epifluorescence images of intact and hemisected corneal
whole mounts.
Quantification of Nerve Density at Micropellet
Epifluorescence or confocal images were overlaid with a 3,000 pixels2 grid with random
offset using ImageJ. Portions of the grid lying outside of the pellet were excluded from the
analysis. β-III tubulin+ nerves intersecting grid line segments were manually counted. To derive
density from counted intersections, raw data were normalized to the number of grid squares
counted in each image.
Quantification of Lymphatic Vessel Density and Length
Epi- or stereofluorescence micrographs were imported into ImageJ and overlaid with a
0.02 inches2 grid with random offset. To determine lymphatic vessel density, grid squares
displaying Lyve-1+ fluorescent signal were quantified using the Cell Counter feature of the
ImageJ software.

Grid squares intersecting the limbal arcade were excluded from the

quantification. To quantify lymphatic vessel length, the ImageJ Freehand Line tool was used to
trace along the length from origin at the limbus to tip of every-other Lyve-1+ lymphatic vessel in
stereofluorescence micrographs and the length of each line measured using the ImageJ Measure
feature.
Quantification of Lymphatic Vessel Fragments
A lymphatic vessel fragment was defined as a group of Lyve-1+ lymphatic endothelial
cells present in the cornea that was no longer continuous with vessels sprouted from the limbal
lymphatic vessel. Following exogenous administration of NGF or PBS during wound recovery,
Lyve-1 immunostained corneas were analyzed by epifluorescence microscopy. The number of
lymphatic vessel fragments per cornea was counted manually.
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Quantification of Average Remaining Wound Size
Light stereofluorescence micrographs were imported into ImageJ and the Freehand Line
and Measure Area tools were used to trace around each of the four wound beds in each image
and to quantify the areas. The area of each wound bed was treated as an individual n in further
analyses.
Aesthesiometry
A Luneau Cochet-Bonnet aesthesiometer (Ophthalmic Instrument Co., Inc., Stoughton,
MA) was used to measure corneal sensitivity. The nylon monofilament of the aesthesiometer
was extended to its full length of 6.0 cm and touched to the corneal surface until first visible
bending. Monofilament length was decreased by 0.5 cm increments and touched to the cornea
again until a blink response was elicited from the animal. If an animal held its eye closed so as
to prevent measurement, we assigned a reading of “7.0”.
In Vitro and Biochemical Assays
RNA Isolation, cDNA Library Construction, and qRT-PCR Characterization of Expression of
Neurovascular Guidance Genes and NGF Receptors Genes
Total RNA was isolated from mouse cornea, uninvolved human skeletal muscle obtained
at rapid autopsy from pancreatic cancer patients, and adult human dermal lymphatic
endothelial cells (Lonza, Walkersville, MD) by TRIzol (Life Technologies, Carlsbad, CA) or the
RNeasy Mini Kit (Qiagen, Venlo, Netherlands) according to the manufacturers’ instructions. 10
μL linear acrylamide (AM9520, 5 mg/mL, Life Technologies) was added to each corneal sample
as a carrier prior to RNA isolation. cDNA libraries were prepared using the SuperScript III FirstStrand Synthesis System (18080051, Life Technologies).

Mouse qRT-PCR reactions were

performed in triplicate and assayed on the Applied BioSystems StepOnePlus Real-Time PCR
System (Life Technologies). Expression was normalized to GAPDH. Data was analyzed using the
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ΔΔCt method. Gene expression levels in unmanipulated samples were set at 1.0. Target gene
expression levels in other tissue conditions are expressed as fold change relative to
unmanipulated control levels.
TaqMan Gene Expression Assays used for mouse qRT-PCR experiments:

GAPDH -

4352339E, NGF - Mm00443039_m1, MMP10 - Mm00444630_m1, IL1-α - Mm00439620_m1,
BDNF - Mm04230607_s1, Ntf3 - Mm00435413_s1, Nrp1 - Mm00435379_m1, Nrp2 Mm00803099_m1, Sema3e - Mm00441305_m1, Plxnd1 - Mm01184367_m1, Ntn1 Mm00500896_m1,

Ntn4

-

Mm00480462_m1,

Unc5b

-

Mm00504054_m1,

Slit2

-

Mm00662153_m1, Robo4 - Mm00452963_m1, Robo1 - Mm00803879_m1, Efnb2 Mm01215897_m1, Ephb4 - Mm01201157_m1, Notch1 - Mm00435249_m1, Cdk5 Mm00432447_g1,

FGF2

–

Mm00433287_m1,

Vegfa

-

Mm01281449_m1,

Vegfc

-

Mm00437310_m1, Vegfd - Mm00438963_m1 (Life Technologies, Carlsbad, CA).

Human qRT-PCR reactions were performed in triplicate and analyzed on a BioRad C1000
Thermal Cycler CFX96instrument (Bio-Rad Laboratories, Inc., Hercules, CA). TaqMan Gene
Expression Assays used for human qRT-PCR experiments: TBP - Hs00427521_m1, NTRK1 Hs01021011_m1, NGFR - Hs00609977_m1 (Life Technologies). Expression was normalized to
TATA box binding protein (TBP). Data was analyzed using the ΔΔCt method. Average skeletal
muscle expression levels of NTRK1 and NGFR were set at 1.0. Average receptor gene expression
levels in LEC samples were expressed as fold change relative to skeletal muscle levels. Ct values
below the level of detection were designated as 40.0, the upper limit of cycles used in these
reactions.
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Lymphatic Endothelial Cell Culture
Adult human dermal lymphatic endothelial cells (LECs) were purchased from Lonza
(Walkersville, MD) and cultured to the company’s specifications. Media used to culture LECs
was Endothelial Growth Media-2MV supplemented with recommended growth factors (EGM2MV). For serum starvation Endothelial Basal Media-2 (EBM-2) was used.
NGF and LEC Migration Assays
Lower wells of 24-well (8.0 μm pore membrane) Boyden chambers (BD Biosciences, San
Jose, CA) were loaded with 750 μL EGM-2MV media diluted 1:5 with serum-free EBM-2 and
supplemented with increasing doses of recombinant mouse NGF (0, 0.5, 1.0, 5.0 μg/ml). 2.5 x
104 LECs diluted in EBM-2 were seeded into the upper inserts of the Boyden chamber and
incubated for 24 hours. After 24 hour migration, membranes were washed with PBS and nonmigratory cells were removed by mechanical force with a cotton-tipped applicator. Cells were
then fixed and stained using Differential Quik Staining Kit (Polysciences, Inc., Warrington, PA).
Membranes were removed from the inserts and mounted on slides. A Nikon Eclipse 90i
microscope at 10X magnification was used to image four representative quadrants of the
membrane and the number of migratory LECs was quantified.
Treatment of LECs with Cytokines
1.5 x 105 LECs were seeded into 60 x 15 mm tissue culture plates and allowed to adhere
overnight. Cells were then starved for 16 hours in EBM-2. Following starvation, LECs were
treated with either fresh EBM-2 or with EBM-2 containing either 4 μg/ml recombinant NGF or
0.5 μg/ml recombinant VEGF-C for 1, 5, 15, or 30 minutes. Cells were then washed twice with
PBS and lysates collected with a radioimmunoprecipitation assay (RIPA) lysis buffer (150 mM
sodium chloride, 1% IGEPAL, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 50
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mM Tris buffer) containing a Roche mini PMSF tablet and phosphatase inhibitors sodium
fluoride, sodium pyrophosphate, and sodium orthovanadate all at 1 mM.
Immunoblotting
Lysates were prepared in RIPA buffer or RayBiotech Cell Lysis Buffer (RayBiotech, Inc.,
Norcross, GA) and were incubated with 4X SDS sample buffer and 2-mercaptoethanol and run
on NuPAGE 10% Bis-Tris gels at 150 V for 75 minutes using the XCell SureLock Mini Cell
electrophoresis system (Life Technologies, Carlsbad, CA). Transfer was accomplished using the
Mini Trans-Blot Electrophoretic Transfer Cell (BioRad Laboratories, Inc., Hercules, CA) at 100 V
for 75 minutes onto Immobilon-FL or Immobilon-P polyvinylidene fluoride (PVDF) membranes
(EMD Millipore, Billerica, MA). Blots were blocked overnight shaking at 4°C in 5% BSA in PBS
with 1X Halt Protease & Phosphatase Inhibitor Cocktail and ethylenediaminetetraacetic acid
(EDTA) (Thermo Scientific, Rockford, IL) or in 5% non-fat dehydrated milk (NFDM) in trisbuffered saline (TBS) containing 0.1% Tween-20 (TBS-T). Primary antibodies were incubated in
0.1% Tween in PBS (PBS-T) + 2.5% BSA or in TBS-T + 5% NFDM for 1 to 3.5 hours shaking at room
temperature. Blots were washed three times for 15 minutes in PBS-T or TBS-T. Secondary
antibodies were incubated in PBS-T + 2.5% BSA or TBS-T + 5% NFDM for 45 minutes to one hour
shaking at room temperature. Blots were washed three times for 15 minutes in PBS-T + 0.01%
SDS or in TBS-T followed by a one minute wash in ddH2O. Blots were imaged using the LI-COR
Odyssey fluorescence imaging system and software (Lincoln, NE) or were incubated with
chemiluminescence reagents and x-ray film developed with a Kodak X-OMAT 2000 processor.
Tubulogenesis Assays
Wells of a 96-well plate were coated with Matrigel Basement Membrane Matrix (BD
Biosciences, Bedford, MA) according to manufacturer's specifications for growth in a three
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dimensional matrix. LECs were incubated with increasing doses of recombinant human NGF,
VEGF-C, or a combination of NGF and VEGF-C diluted in EBM-2 as indicated for 30 minutes at
4°C and then added to Matrigel-coated wells (1.2 x 104 LECs/well). After four hours, LECs had
formed tube-like networks and phase contrast images were collected. Tubulogenesis was
quantified by counting the number of tubes per image. Each treatment was performed in
triplicate.
NGF ELISA
Levels of NGF protein in unmanipulated and inflamed corneas were assayed by enzymelinked immunosorbent assay (ELISA) using the Mouse NGF/β-NGF ELISA Kit (EK0470, Boster
Biotechnology Co., Ltd., Pleasanton, CA) according to the manufacturer’s instructions. Individual
corneal lysates were prepared in RayBiotech Cell Lysis Buffer (RayBiotech, Inc., Norcross, GA),
homogenized with a plastic pestle homogenizer, and cleared by centrifugation. Each sample
was divided 90/10 into two wells of the ELISA plate and diluted accordingly with sample buffer.
Right corneas from three animals made up each group. Optical density (OD) absorbance
readings were measured in triplicate using a Titertek Multiskan PLUS plate reader.
VEGF-A Protein Quantification
Levels of VEGF-A protein were quantified in corneas bearing either a PBS or NGF pellet.
We performed a corneal pocket assay and prepared lysates as described above. Lysates from
two corneas were combined to make up each sample. Six corneas comprised each group.
VEGF-A content was assayed using the Quantibody Mouse Cytokine Array 1 (RayBiotech, Inc.,
Norcross, GA). The array was scanned using the GenePix 4000B (Molecular Devices (Axon
Instruments), Silicon Valley, CA) and data was collected using the GenePix Pro software at
several PMT values ranging from 540 to 790 gain. The PMT gain 590 scan generated the best
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VEGF-A standard curve and data from this scan was analyzed using the Q-Analyzer Software for
QAM-CYT-1 (RayBiotech, Inc.).
Statistical Analysis
Data were analyzed with GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla,
CA) using Student’s T-Test or One-Way ANOVA with Dunnett’s Multiple Comparison Post-Test or
Bonferroni Post-Test. An asterisk (*) denotes the control group. A bracket between the control
and experimental groups indicates statistical significance with p < 0.05. In cases comparing two
experimental groups, a bracket between these groups indicates statistical significance with p <
0.05.
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Results
Characterization of Neural and Lymphatic Remodeling in a Corneal Model of Inflammation and
Resolution
We characterized structural and architectural changes in corneal lymphatic vessels and
nerves through four distinct physiological conditions: healthy unmanipulated cornea, initial
inflammation, wound recovery, and recurrent inflammation (Figure 2A). In this model system,
inflammation was induced by placement of a suture in each quadrant of the mouse cornea.
Suture removal stimulated wound recovery. Recurrent inflammation was induced by placement
of a second set of four sutures.

DAPI-stained corneal axial sections demonstrated gross

thickening of the visibly-wounded cornea during both initial and recurrent inflammation (Figure
3A).

Wound-recovered cornea displayed an intact epithelium and decreased to normal

thickness.

Levels of interleukin-1α (IL-1α) and matrixmetalloproteinase-10 (MMP-10)

messenger RNA by qRT-PCR were consistent with inflammation and wound recovery. IL-1α
expression was approximately six-fold higher and MMP-10 eleven-fold higher during initial
inflammation compared to unmanipulated controls. During wound recovery, levels of IL-1α and
MMP-10 decreased, and levels increased about five-fold with recurrent inflammation (Figure
3B).
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Figure 2. Corneal model of initial inflammation, wound recovery, and recurrent inflammation.
A. Schematic depicts timing of corneal suture placement and removal to induce four distinct
tissue microenvironmental conditions: healthy unmanipulated, initial inflammation, wound
recovery, and recurrent inflammation. B. Schematics illustrate two corneal mounting styles:
hemisected whole mount and whole mount.
Images are 100X epifluorescence
photomicrographs of corneas immunostained for Lyve-1 (orange) and β-III tubulin (green) and
harvested at the indicated time points. Top panel shows Lyve-1+ lymphatic vessels. Bottom
panel shows β-III tubulin+ corneal nerves. Scale bars are 100 µm. C. Lymphatic vessel density
was quantified from images like those shown in (B). D. Nerve density was quantified from
images like those shown in (B). E. Corneal nerve clusters were quantified in wound-recovered
tissue. F. A Cochet-Bonnet corneal aesthesiometer was used to measure corneal sensitivity.
(This figure was previously published in Fink et al., 2014a).
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Figure 2A, B
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1: Unmanipulated
2: Initial Inflammation
3: Wound Recovery
4: Recurrent Inflammation

Figure 2C - F
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Figure 3. Induction of inflammation, wound recovery, and recurrent inflammation in the
mouse cornea. Corneal surgeries were performed as described in Figure 1A to induce initial
inflammation, wound recovery, and recurrent inflammation. Corneas were harvested and
stained with DAPI for epifluorescence microscopy analysis or RNA was extracted for gene
expression analysis. A. Schematic depicts mount style of frozen corneal axial sections. 200X
DAPI-stained corneal axial section epifluorescence micrographs. Scale bar = 100 µm. B. qRTPCR results showing levels of gene expression of inflammatory cytokines MMP10 (left panel) and
IL1-α (right panel). (This figure was previously published in Fink et al., 2014a).

65

Figure 3
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The lymphatic vessel remodeling that occurs in this system has been previously
described (Kelley et al., 2013b). We detected inflammatory lymphangiogenesis associated with
initial inflammation, lymphatic vessel regression associated with wound recovery, and an
accelerated lymphatic vessel response termed lymphatic vessel memory associated with
recurrent inflammation (Figure 2B, C).
We uncovered novel neuroremodeling events as we characterized the distinct tissue
microenvironments generated in this model system.
immunofluorescence

revealed

three

distinct

Detection of nerves by β-III tubulin

neural

phenotypes

corresponding

to

unmanipulated, inflamed, and wound-recovered tissue states, respectively (Figure 2B).
Unmanipulated control corneas exhibited a very dense plexus of fine nerves organized in a
regular swirled distribution present just below the epithelium. These sub-epithelial nerves
stemmed from thicker branched nerves lying deep within the corneal stroma and terminated in
the epithelium. During initial inflammation, the regular swirled pattern of sub-epithelial nerves
was disrupted. These nerves appeared grossly thickened and were present at a relatively low
density. Nerves tracked toward sites of injury, often exhibiting 90 degree bends and growing
around and through suture knots. Contrary to what we anticipated, nerves in wound-recovered
tissue did not re-adopt their pre-morbid swirled morphology. Instead, nerves displayed a novel
phenotype characterized by their termination in tight tortuous groups, which we have termed
clusters.

Quantification of these clusters showed their near-exclusive presence in wound-

recovered cornea (Figure 2E). Recurrent inflammation resulted in a nerve phenotype very
similar to that of initial inflammation with low nerve density and thickened nerves turning
toward and knotting around sutures (Figure 2B, D).
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Given the different nerve morphologies observed, we investigated the possibility that
sensory nerve function was consequentially altered. A Cochet-Bonnet aesthesiometer was used
to quantify corneal sensitivity and revealed that inflamed corneas were significantly more
sensitive than unmanipulated or wound-recovered corneas (Figure 2F). This result suggested a
connection between pain and the specific neuroremodeling events that accompany
inflammation—both initial and recurrent.

Although the morphology of nerves in wound-

recovered tissue was greatly altered compared to normal cornea, nerves in wound-recovered
tissue transmitted sensitivity signals at the same level as normal healthy nerves; only inflamed
tissue was more sensitive.
Expression Profiling of NGF and Other Neurovascular Guidance Family Members
The dramatic changes in neurolymphatic anatomy during inflammation and wound
recovery led us to profile expression of several families of neurovascular guidance genes. RNA
was extracted from corneas in the following conditions: unmanipulated, initial inflammation,
wound recovery, and one-, three-, and seven-day recurrent inflammation. We sampled the
recurrent inflammation condition at three time points in order to better understand the kinetics
of a second inflammatory response. Of all of the molecules studied, we observed the most
dynamic changes in the expression of NGF (Figure 4A). NGF mRNA levels increased with
inflammation about six-fold over control and decreased during wound recovery. In recurrent
inflammation, NGF levels were increased about seven-fold over control at days one and three,
with a more modest increase of approximately four-fold observed at day seven. The robust and
rapid increase in NGF mRNA suggested that its expression was correlated with inflammation and
wound recovery.

We examined the expression of several other neurovascular guidance

molecules including two other members of the neurotrophin family: brain-derived neurotrophic
factor (Bdnf) and neurotrophin-3 (Ntf3); four members of the semaphorin/plexin-neuropilin
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signaling pathway: neuropilin-1 (Nrp1), neuropilin-2 (Nrp2), semaphorin 3e (Sema3e), and
plexin-d1 (Plxnd1); three members of the netrin/unc family: netrin-1 (Ntn1), netrin-4 (Ntn4), and
unc-5 homolog B (Unc5b); three members of the slit/robo family: slit-2 (Slit2), roundabout-4
(Robo4), and roundabout-1 (Robo1); two members of the ephrin/eph family: ephrin-b2 (Efnb2),
and Eph receptor B4 (Ephb4); as well as neurogenic locus notch homolog 1 (Notch1), cyclindependent kinase 5 (Cdk5), and fibroblast growth factor 2 (Fgf2) (Figure 5). Among these,
members of the Netrin/Unc and Ephrin/Eph signaling axes were consistently downregulated
during inflammation. We did not detect consistent patterns of changes in expression of other
neurovascular guidance gene families.
We performed an ELISA for NGF in unmanipulated and initial inflammation corneal
lysates to determine if NGF protein levels were upregulated during initial inflammation. The
results showed that NGF protein levels did not change with inflammation (Figure 4B). These
dramatic differences in transcriptional and translational regulation of NGF expression led us to
further characterize the role of NGF in neurolymphatic remodeling during inflammation and
wound recovery.
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Figure 4. NGF mRNA and protein expression during inflammation and wound recovery. A.
NGF expression (mRNA) in corneas was evaluated by qRT-PCR in healthy unmanipulated cornea
and during initial inflammation, wound recovery, and days one, three, and seven of recurrent
inflammation. B. NGF protein expression in corneal lysates was evaluated by ELISA. (This figure
was previously published in Fink et al., 2014a).
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Figure 4
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Figure 5. Changes in neurovascular guidance molecule gene expression during initial
inflammation, wound recovery, and recurrent inflammation time course. Corneal surgeries
were performed as described to induce initial inflammation, wound recovery, and a recurrent
inflammation time course. RNA was extracted for qRT-PCR analysis of genes representing
neurovascular guidance families. (This figure was previously published in Fink et al., 2014a).
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Figure 5
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Effects of Adding Exogenous NGF through Wound Recovery
We sought to investigate the effect of adding exogenous NGF during wound recovery. It
was necessary to first establish the baseline kinetics of neural and lymphatic remodeling during
wound recovery, a process that involves the resolution of inflammation. A wound recovery time
course experiment was performed in which sutures were removed and corneas were harvested
at several time points throughout the course of an extended 21-day wound recovery (Figure
6A).

Concomitantly, corneal sensitivity was evaluated by aesthesiometry as inflammation

resolved. We found that lymphatic vessel density decreased gradually throughout the wound
recovery period, while nerve density remained at a constant and relatively low level as
compared to controls from previous experiments (Figure 6B).

Nerve distribution and

morphology showed changes throughout the time course. Nerves in early wound recovery
(days one through four) displayed features similar to those observed in initial inflammation, i.e.
tracking toward sites of injury, low density, and overall thickening. Nerves at these time points
were also very densely associated with healing wound beds. By day seven of wound recovery,
nerves no longer tracked toward wound beds, but rather appeared as loose clusters or
individually following tortuous paths. Nerve thickness decreased, approaching that seen in the
normal condition. By day ten, the dense networks at wound beds were no longer evident, and
clusters were the predominant nerve phenotype visible within the corneal tissue. These clusters
persisted through day twenty-one.

Assessment of corneal sensitivity by aesthesiometry

revealed a steady decrease in the corneal hypersensitivity created by inflammation with a return
to normal levels by day seven of wound recovery (Figure 6C).
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Figure 6. Wound recovery time course. Wound recovery was stimulated by suture removal and
corneas were harvested at the indicated time points, immunostained for Lyve-1 and β-III
tubulin, and analyzed by epifluorescence microscopy.
A. 100X immunofluorescence
+
micrographs of Lyve-1 lymphatic vessels (top panel) and β-III tubulin+ nerves (bottom panel).
Scale bars = 100 µm. B. Quantification of corneal nerve density from images like those in (A). C.
Measurements of corneal sensitivity through extended wound recovery time course. (This
figure was previously published in Fink et al., 2014a).
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Figure 6
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This better understanding of the dynamic anatomical and physiological events that
accompany a period of wound recovery allowed us to test the effects of NGF administration on
specific features of wound recovery. Following suture removal to induce wound recovery,
mouse β-NGF or PBS control was administered subconjunctivally every other day for fourteen
days with commensurate aesthesiometer readings.

Lymphatic vessel density remained

significantly higher in mice treated with NGF (Figure 7A, B), and there was a significant reduction
in lymphatic vessel fragmentation (Figure 7A, E), a hallmark of normal lymphatic regression
during wound recovery (Figure 7H). We measured remaining corneal ulcers from control and
NGF-treated corneas and found no difference in average remaining wound size with NGF
administration (Figure 7A, C). While nerves did form clusters under both treatment conditions
(Figure 7A, F), mice treated with NGF showed nerves organized in dense mesh-like networks
that encompassed the wound bed (Figure 7A, D). NGF-treated corneas were significantly more
sensitive than PBS controls at days two through fourteen of wound recovery (Figure 7G).
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Figure 7. Effects of NGF administration during wound recovery on lymphatic vessel regression,
nerve density at corneal wounds, and corneal sensitivity. After removing sutures to stimulate
wound recovery, mouse β-NGF or PBS control was injected subconjunctivally every other day for
two weeks. Corneas were harvested, immunostained for Lyve-1 and β-III tubulin, and analyzed
by whole mount microscopy. A. Epifluorescence images of Lyve-1+ lymphatic vessels (left panel,
scale bar = 100 µm, 100X), bright field images showing remaining wound beds at sites of suture
placement (center panel, scale bar = 200 µm, 32X), epifluorescence images of β-III tubulin+
nerves (right panel, scale bar = 200 µm, 32X). Expanded detail shows confocal analysis of β-III
tubulin+ nerves at wound beds (offset panel far right, scale bar = 100 µm, 200X). B. Analysis of
effects of exogenous NGF administration on corneal lymphatic vessel density during wound
recovery from images like those in (A). C. Quantification of average remaining wound size
following administration of NGF or PBS. D. Nerve density at remaining wound beds quantified
from confocal immunofluorescence images. E. Quantification of lymphatic vessel fragments
discontinuous with limbal lymphatic vessel. F. Quantification of nerve clusters in woundrecovered cornea following administration of NGF or PBS. G. Measurements of corneal
sensitivity throughout wound recovery period with administration of NGF or PBS. H. 200X
confocal immunofluorescence micrograph showing lymphatic vessel fragments (arrowheads).
Scale bar = 100 µm. (This figure was previously published in Fink et al., 2014a).
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Figure 7A - C
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Figure 7D - F
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Figure 7G, H
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NGF Stimulates Lymphangiogenesis
Given the inhibition of lymphatic vessel regression by NGF, we sought to determine if
NGF was capable of inducing lymphangiogenesis in the cornea. A corneal micropocket assay
was used to test this hypothesis. Micropellets loaded with PBS control, VEGF-C, or NGF were
placed in a corneal micropocket for seven days, after which corneas were harvested and
analyzed using immunofluorescence microscopy (Figure 8A). β-III tubulin staining showed
corneal nerves tracking toward pellets in all three conditions. Nerve density did not change at
pellets loaded with cytokine (Figure 8A, B). VEGF-C and NGF stimulated lymphangiogenesis
(Figure 8A). Measurement of lymphatic vessel density (Figure 8C) and length (Figure 8D)
confirmed that VEGF-C and NGF significantly increased lymphangiogenesis over PBS control.
NGF-induced lymphatic vessels were significantly longer than those induced by VEGF-C (Figure
8D). Analysis of lymphatic endothelial cell proliferation in newly synthesized lymphatic vessels
by quantification of phosphorylated histone H3 staining in Lyve-1+ cells showed an increased
number of proliferation events in the presence of NGF and VEGF-C (Figure 8E).
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Figure 8. NGF induces lymphangiogenesis. Micropellets loaded with PBS, VEGF-C, or NGF were
positioned in a corneal micropocket. Corneas were harvested seven days after pellet
implantation, immunostained for Lyve-1, β-III tubulin, and phosphorylated histone H3 and
analyzed by whole mount and confocal microscopy. A. Epifluorescence images of β-III tubulin+
corneal nerves (top panel, scale bar = 100 µm, 100X), confocal detail images of β-III tubulin+
nerves at micropellets embedded in cornea (middle panel, scale bar = 100 µm, 100X),
epifluorescence images of Lyve-1+ lymphatic vessels (bottom panel, scale bar = 100 µm, 100X),
and confocal detail images of Lyve-1+ lymphatic vessel tip cells (bottom panel, inset, scale bar =
100 µm, 200X). B. Quantification of corneal nerve density at micropellets loaded with PBS,
VEGF-C, or NGF from confocal images like those shown in (A). C. Quantification of lymphatic
vessel density in response to cytokine micropellets from images such as those shown in (A). D.
Quantification of length of lymphatic vessel outgrowth from limbus. E. Proliferation of Lyve-1+
lymphatic endothelial cells as quantified by positive staining for phosphorylated histone H3.
(This figure was previously published in Fink et al., 2014a).

83

Figure 8A
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Figure 8B - E
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We also examined the gene expression of NGF and known lymphangiogenic cytokines
VEGF-A, -C, and -D in corneas with a PBS or NGF pocket as well as in the unmanipulated and
initial inflammation conditions. NGF gene expression increased during initial inflammation and
did not change with PBS or NGF pellet placement (Figure 9A). VEGF-A gene expression displayed
the same pattern as NGF with an increase in initial inflammation and no change in the presence
of a PBS or NGF pellet (Figure 9B). VEGF-C gene expression trended toward an increase during
initial inflammation and was significantly higher than the unmanipulated condition in the
presence of an NGF pellet (Figure 9C). VEGF-D gene expression remained unchanged in all
conditions (Figure 9D). We also assayed VEGF-A and -C protein levels in corneas with a PBS or
NGF pellet. Quantification of VEGF-A protein levels by cytokine microarray showed no change
with an NGF pellet (Figure 9E). Western blotting detected an increase in three isoforms of
VEGF-C in the presence of an NGF pellet (Figure 9F). These results show an increase in both
VEGF-C mRNA and protein in the presence of an NGF pellet, but not VEGF-A or -D, and suggest
that NGF may induce expression of VEGF-C, the canonical lymphangiogenic cytokine, in the
cornea.
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Figure 9. mRNA and protein expression profiling of lymphangiogenic cytokines. Conditions of
initial inflammation, PBS pellet, or NGF pellet were created by placement of sutures or
appropriate pellet as described. A. NGF gene expression from corneal RNA from
unmanipulated, initial inflammation, PBS pellet, and NGF pellet conditions. B. VEGF-A gene
expression. C. VEGF-C gene expression. D. VEGF-D gene expression. E. VEGF-A protein
quantification from cytokine array from corneas with PBS pellet or NGF pellet. F. VEGF-C
protein quantification by western blot from corneas with PBS pellet or NGF pellet. β-actin was
included as a loading control. (This figure was previously published in Fink et al., 2014a).
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In Vitro Interrogation of NGF Activity on Adult Human Dermal Lymphatic Endothelial Cells
Considering that NGF stimulated corneal lymphatic vessels and VEGF-C mRNA and
protein expression in vivo, we investigated whether NGF acted directly on lymphatic endothelial
cells (LECs). We examined the potential of NGF as a chemoattractant in Boyden-chamber
migration assays. NGF induced a modest but statistically significant increase in migration of
LECs (Figure 10A). Because of the low numbers of migratory cells in these assays, we postulated
that NGF might have activity only on a subpopulation of cells or that VEGF-C might be required
for robust migration. We also examined the potential of NGF to stimulate tube formation in
LECs.

Two concentrations of NGF, positive control VEGF-C, and the two cytokines in

combination were equally capable of increasing tubulogenesis in LECs cultured in Matrigel at
four hours (Figure 10B).
LECs were evaluated for expression of mRNA for canonical NGF receptors TrkA and
p75NTR by qRT-PCR. Human skeletal muscle was used as a positive control for expression of
these receptors. Gene expression of TrkA was 11.2-fold lower in LECs than in skeletal muscle
(Figure 10C). Expression of p75NTR was 317.1-fold lower in LECs than in skeletal muscle (Figure
10D). These results suggested that these receptors were not expressed on these cells.
We studied the expression of signaling phosphoproteins downstream of receptor
tyrosine kinases that are known to induce LEC proliferation and migration.

Levels of

phosphorylated mitogen-activated protein kinase 3/1 (pERK1/2) and phosphorylated AKT (pAKT)
were examined in LEC lysates treated with NGF or positive-control VEGF-C for 1, 5, 15, or 30
minutes. As expected, VEGF-C induced phosphorylation of pERK1/2 and pAKT at 15 and 30
minutes. NGF treatment did not induce phosphorylation of these downstream effectors (Figure
10E).
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Figure 10. In vitro experiments examining the effects of NGF on LECs. A. Adult human dermal
lymphatic endothelial cells (LECs) were seeded in the upper inserts of Boyden chamber
migration plates. NGF was added to the lower wells at the indicated concentrations. Migratory
cells were quantified. B. Matrigel was placed in tissue culture plate wells. LECs were incubated
with the indicated cytokines and then added to wells. Tubes were quantified at four hours. C.
RNA was extracted from LECs or positive control adult human skeletal muscle and cDNA was
synthesized. Gene expression levels of NGF receptor TrkA were quantified by qRT-PCR. D.
Gene expression levels of p75NTR in human skeletal muscle and LECs. E. RIPA lysates were made
from LECs treated with the indicated cytokines for 1, 5, 15, or 30 minutes. Western blot analysis
was performed for the indicated proteins using β-actin as a loading control. (This figure was
previously published in Fink et al., 2014a).
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Taken together, these results suggest that NGF does not act through its canonical
receptors or through typical receptor tyrosine kinase signaling pathways on populations of LECs
in culture.
VEGFR-2/3 Decoy Receptors Block NGF Pellet-Mediated Corneal Lymphangiogenesis
A combinatorial experimental approach was taken to investigate the hierarchical nature
of NGF/VEGF-C signaling in vivo. An initial set of experiments showed that subconjunctival
injection of VEGFR-2/3 decoy receptors during initial inflammation blocked suture-mediated
lymphangiogenesis while having no effect on overall corneal nerve density (Figure 11A, B). This
result

confirmed

the

efficacy

of

ablating

VEGFR-2/3

signaling

on

inflammatory

lymphangiogenesis and suggested that blocking this signaling mechanism does not affect
inflammatory neuroremodeling.
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Figure 11. VEGFR-2/3 decoy receptor treatment ablates suture-mediated lymphangiogenesis
and does not affect neural remodeling. Corneas were inflamed with four sutures on
experimental day zero. Fc control or a solution of VEGFR-2/3 decoy receptors was administered
subconjunctivally on days zero, two, and four. Corneas were harvested on day seven,
immunostained for Lyve-1 and β-III tubulin, and analyzed by whole mount epifluorescence
microscopy. A. 100X immunofluorescence micrographs of Lyve-1+ lymphatic vessels (top panel)
and β-III tubulin+ nerves (bottom panel). Scale bar = 100 µm. B. Quantification of corneal nerve
density from images like those in (A). (This figure was previously published in Fink et al., 2014a).
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We investigated the effects of VEGFR-2/3 signaling blockade on NGF-mediated
lymphangiogenesis. Micropellets loaded with PBS or NGF were placed in the cornea to induce
lymphangiogenesis followed by subconjunctival injection of VEGFR-2/3 decoy receptors or Fc
control (Figure 12A).

PBS control pellet paired with Fc control subconjunctival injection

stimulated minimal lymphangiogenesis. NGF-laden pellet and Fc control injection induced
robust lymphangiogenesis. NGF-laden pellet coupled with blockade of VEGFR-2/3 signaling by
decoy receptor injection ablated lymphangiogenesis. Lymphatic vessel density was significantly
higher in the NGF pellet and Fc injection condition, while the addition of VEGFR-2/3 decoy
receptors to the system significantly reduced lymphatic vessel density and length (Figure 12B).
These results suggest that the capacity of NGF to induce lymphangiogenesis in the cornea is
largely mediated through indirect effects (stimulation of production of VEGF-C) on cell types
other than lymphatic endothelial cells.
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Figure 12. VEGFR-2/3 decoy receptors ablate NGF pellet-mediated corneal lymphangiogenesis.
Micropellets loaded with PBS or NGF were positioned in a corneal micropocket on experimental
day zero. Fc control or a solution of VEGFR-2/3 decoy receptors was administered
subconjunctivally on days zero, two, and four. Corneas were harvested on day seven,
immunostained for Lyve-1 and β-III tubulin, and analyzed by whole mount microscopy. A. 100X
epifluorescence images of β-III tubulin+ corneal nerves (top panel) and Lyve-1+ lymphatic vessels
(bottom panel). Scale bars = 100 µm. B. Quantification of lymphatic vessel density (left panel)
and length of outgrowth from limbus (right panel). (This figure was previously published in Fink
et al., 2014a).
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Discussion
Our studies investigated the mechanistic basis for the resolution of two of the cardinal
features of inflammation—pain and tissue edema—during wound recovery. We characterized
the behavior of two classes of tissue microenvironmental structures in the cornea, the nerves
and the lymphatic vessels, during episodes of inflammation and wound healing. We show
synchronized neurolymphatic remodeling during inflammation and wound recovery that is
regulated by NGF and its downstream effectors, including VEGF-C. These studies demonstrate
that NGF stimulates lymphangiogenesis and increases pain, and they implicate NGF as a
pathogenic factor that inhibits the neural and lymphatic vascular remodeling processes
associated with wound recovery.
Neurolymphatic Remodeling and Wound Recovery
A corneal model of initial inflammation, wound recovery, and recurrent inflammation
was used to explore mechanisms that coordinately regulate neurolymphatic remodeling. This
study features experimental results from wound recovery and recurrent inflammation
conditions, two understudied physiologic states with significant clinical relevance. Histological
and biochemical results supported our conclusion that this model represents these physiologic
states.
We and others have previously shown that sutures induce lymphangiogenesis from the
corneal limbus and that suture removal stimulates wound recovery and lymphatic vessel
regression (Kelley et al., 2011b). Suture placement may transect or induce neuropraxia in a
subset of corneal nerves. However, the data presented here reveal new aspects of neural and
lymphatic responses to inflammation and injury, processes similar to severe clinical corneal
infection or direct trauma.
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During initial inflammation, we observed synthesis of new Lyve-1+ lymphatic vessels and
remodeling of β-III tubulin+ neural structures to wound-centric tracking with sharp directional
turns.

Nerves also displayed thickening and a decrease in density, similar to previous

observations (Donaghy, 2003; Ferrari et al., 2013). We visualized regressed Lyve-1+ lymphatic
vessels and β-III tubulin+ neural clusters during wound recovery.

Recurrent inflammation

accelerated the development of a lymphatic vessel network (Kelley et al., 2013b) and induced
neural remodeling, changing nerve clusters to a wound-centric organization. We also detected
marked changes in corneal sensitivity that represented a physiological consequence of neural
remodeling events. Among several classes of neurovascular guidance molecules, we identified
NGF mRNA to have increased expression during inflammation compared to unmanipulated
control and wound recovery conditions. Surprisingly, NGF protein levels were similar in control
compared to conditions of initial corneal inflammation. Expression of immature or alternately
processed biologically active forms of NGF, such as proNGF or other cleavage or posttranslationally modified products, may not have been detected by the ELISA we performed.
It is well known that several cell types present in the cornea including epithelium,
endothelium, keratocytes, and nerves express NGF and/or the NGF receptors TrkA and p75NTR
(Blanco-Mezquita et al., 2013; Lambiase et al., 1998a; Lambiase et al., 2000b; Sornelli et al.,
2010; Woo et al., 2005; You et al., 2000). Here we show that NGF inhibited the normal
processes of wound recovery by inhibiting lymphatic vessel regression, maintaining high nerve
density in wounds, and increasing pain. Interestingly, NGF did not appear to affect epithelial
wound closure. Previous studies have described conflicting results related to the effects of
manipulating the NGF pathway. Administration of NGF to the cornea has been shown to
increase presence of corneal nerves and increase rates of epithelial proliferation (BlancoMezquita et al., 2013; Esquenazi et al., 2005; You et al., 2000), improve corneal healing after
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capsaicin administration and epithelial scraping (Lambiase et al., 2012), and increase wound
closure (Lambiase et al., 2000b). Other studies have shown that NGF has no effect on wound
closure (Woo et al., 2005). Administration of an NGF blocking antibody has been shown either
to slow epithelial wound healing (Lambiase et al., 2000b) or to have no effect (Woo et al., 2005).
These different observations may reflect model-to-model variability and possibly the panregulatory functions of NGF.
NGF Induced Lymphangiogenesis
In our studies with micropellets loaded with NGF, we documented the unexpected
finding of stimulating new lymphatic vessel growth. We considered the possibility that NGF
acted directly on LECs that expressed the canonical receptors for NGF, TrkA and p75NTR, or a
non-canonical receptor tyrosine kinase. The data did not support this hypothesis, as we did not
detect TrkA and p75NTR expression or phosphorylation of two known downstream signaling
mediators, Erk and Akt, in LECs treated with NGF.

The results of LEC migration and

tubulogenesis assays were intriguing and suggested that NGF may bind to a non-canonical
receptor and transduce migratory signals via effectors other than Erk or Akt. We explored an
alternative but non-exclusive hypothesis that NGF stimulated LECs indirectly through effects on
other cell types.
Members of the VEGF family have been shown to induce lymphangiogenesis directly by
interacting with VEGF receptors expressed by LECs (Cao et al., 2004c; Jeltsch et al., 1997; Oh et
al., 1997b; Sweat et al., 2014). We explored this in vivo and showed that NGF-laden pellets
stimulated expression of VEGF-C mRNA and protein and that lymphangiogenesis stimulated by
NGF pellets was dependent upon the VEGF-A and -C signaling axes.
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This is the first report describing that NGF stimulates lymphangiogenesis, indirectly via
VEGF family members. Blocking VEGF-A and -C signaling with decoy receptors ablated both
VEGF-C- and NGF-induced lymphangiogenesis and did not affect neural remodeling. NGF pellets
have also been shown to induce angiogenesis in rat corneas (Seo et al., 2001a), and other
studies have defined a relationship between the VEGF and NGF signaling axes. Production of
VEGF-A has been documented in several models of neural development, disease, or injury and
has been shown to be stimulated by NGF administration under certain conditions, presenting
the possibility that corneal nerves are the source of one or more VEGF family members (Calza et
al., 2001; Li et al., 2013; Mukouyama et al., 2005; Nakamura et al., 2011; Samii et al., 1999;
Saygili et al., 2011). Studies with bevacizumab, which binds VEGF-A (Bock et al., 2007; Bock et
al., 2009), provide further support for crosstalk between these two signaling pathways including
changes in NGF levels (Jee and Lee, 2012; Kim et al., 2010a; Rossi et al., 2012) and nerve activity
(Bock et al., 2009; Li et al., 2011b; Yu et al., 2008a). The results of the in vivo studies presented
here support a similar model of NGF and VEGF-C cross regulation to coordinately regulate neural
structures and lymphatic vessel growth. These findings are consistent with a model in which
NGF functions as an overarching regulatory molecule with primary neural targets and
downstream secondary targets regulating lymphangiogenesis via VEGF family members.
Facilitating Wound Recovery
The resolution of inflammation and wound recovery are universally important biological
processes.

Here we investigated these processes in two basic physiologic systems, the

lymphatic vasculature and the nervous system in the cornea.

The distribution, density, and

functions of the lymphatic vessels and nerves vary considerably from organ to organ presumably
to meet the unique physiologic and pathologic challenges presented in specific
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microenvironments. Whether the operational mechanisms that we have defined in the cornea
can be generalized to other organs systems is unclear.
Other preclinical and clinical studies have investigated the contribution of NGF to
corneal disease. Consistent with the findings reported here, TrkA-/- mice display decreased
innervation of corneal stroma and epithelium and decreased corneal sensitivity (de Castro et al.,
1998), and clinical studies have shown that topical NGF treatment generally increased corneal
sensitivity (Joo et al., 2004; Lambiase et al., 2000a).

In other clinical studies, topical

administration of NGF eye drops has been perceived as generally favorable by observations of
decreased healing time and increased epithelial closure in refractive disease (Bonini et al., 2000;
Cellini et al., 2006; Lambiase et al., 1998b; Lambiase et al., 2003; Lambiase et al., 2011; Mauro et
al., 2007; Tan et al., 2006), presumably by stimulating epithelial migration (You et al., 2000). The
findings presented here suggest that NGF serves as part of a signaling hierarchy that regulates
neurolymphatic remodeling in the cornea, and that clinical strategies to block NGF function may
facilitate wound recovery by modulating these processes.
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CHAPTER II.

Defining Tumor-Induced Alterations to

Microenvironmental Neurolymphatic Networks by Live
Imaging3

3

Portions of the material presented in this chapter have been previously published under the following
references: (Fink et al., 2014b, Fink et al., 2015b)
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Introduction
We previously used a corneal model to characterize neurolymphatic remodeling events
during inflammation, wound recovery, and recurrent inflammation and identified common
regulatory mechanisms shared by both tissue networks. Here, we extended these studies to
investigate neurolymphatic remodeling dynamics and tumor-lymphatic interactions in
nonmalignant and tumor-associated inflammatory microenvironments in real time with a novel
live imaging platform.
During acute inflammation, new lymphatic vessels sprout from the existing lymphatic
vasculature in the direction of the inflammatory stimulus.

This process is directed by

lymphangiogenic cytokines and requires extensive coordination as the cells migrate through the
tissue and form new lymphatic capillaries. These newly-synthesized lymphatic vessels are
functional and can traffic inflammatory immune cells such as macrophages to and from an
inflamed area. Tissue nerve networks also undergo structural and functional changes in the
presence of inflammation.

Nerves track toward and engulf stimuli and display altered

nociceptive properties.
Lymphatic vessels and nerves are two types of tissue microenvironmental networks
often invaded by tumor cells during metastatic spread. Despite the clinical importance of
lymphatic vessel invasion, lymph node status, and perineural invasion in cancer staging,
treatment decisions, and patient outcomes, neurolymphatic remodeling in malignancy remains
an understudied biological process. Little is known about how structural changes to these
networks may be associated with the earliest events of metastasis or exploited to facilitate early
detection of malignancy.
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We used real-time live imaging microscopy to study lymphatic vessel remodeling and
tumor-lymphatic dynamics in a novel transgenic murine model and used immunostaining to
extend our studies to nerve networks. In the Lyve1CreERT2tdT mouse, tamoxifen-inducible
tdTomato fluorescent protein is expressed in Lyve-1+ cells—lymphatic, but not blood vascular,
endothelia and a subset of macrophages. This approach, coupled with the development of
customized fluorescent stereomicroscopy techniques, allowed us to visualize tdTomatoexpressing lymphatic vasculature in remarkable detail in live mice. We focused our studies on
two tissues: pinna and cornea. The respective anatomical features of the pinna and cornea
made them ideal platforms for live imaging microscopy studies of nascent and steady-state
lymphatic vessels, surgical manipulations, and delivery of tumor cells.

Two-color imaging

allowed us to simultaneously track tumor cells at single-cell resolution and morphologic changes
in lymphatic vessels.

We clearly visualized and documented several key behaviors of

metastasizing tumor cells including tumor-lymphatic interactions, presence of tumor cells in
vessels, clearing from vessels, and the accumulation of tumor cells in draining lymph nodes.
We also found differences in nerve and lymphatic architectures in suture- and tumorassociated inflammatory microenvironments. Local nerve and lymphatic remodeling behaviors
unique to malignant inflammation were induced in the vicinity of both minimal and large tumor
burdens and tracked over time; field effects extended beyond sites of tumor residence to alter
structures in adjacent regions. Tumor- and suture-associated remodeling signatures could be
induced simultaneously in either pinna or cornea at the positions of tumor cells and sutures.
These characteristic neurolymphatic architecture signatures generated in the presence of a very
small number of tumor cells and distinct from those associated with acute nonmalignant
inflammation could represent a target for early detection of malignancy.

105

Materials and Methods
Lyve1CreERT2tdT Mouse Model
All experimental procedures were approved by the Institutional Animal Care and Use
Committees of Boys Town National Research Hospital or the University of Nebraska Medical
Center in accordance with NIH guidelines. Representative Images are presented; in general,
observations were confirmed three times. The generation of this transgenic mouse model,
validation of fluorescent protein expression in the appropriate cell type, and back-crossing to
C57BL/6 has been previously described (Connor et al., 2016). In short, administration of 4hydroxytamoxifen (4-OHT) drives expression of tdTomato fluorescent protein in Lyve-1+ cells,
including the lymphatic endothelium and a subset of macrophages. Conversion of nearly all
Lyve-1+ cells is possible with high-dose 4-OHT administration, while immunofluorescence costaining for Lyve-1 shows that conversion penetrance can be titrated down to minor populations
of cells by modifications of 4-OHT dose and schedule. Fluorescent protein is most concentrated
in the nuclei of cells with diffuse cytoplasmic expression. We have shown tdTomato fluorescent
protein expression in the lymphatic vasculature present in and around several organs including
cornea, pinna, lymph node, spleen, pancreas, stomach, and intestine by live imaging and
stereofluorescence microscopy of 4-OHT-treated mice at necropsy (Figure 13).
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Figure 13. Lyve1CreERT2tdT transgenic mouse model displays tdTomato fluorescent protein
expression in lymphatic endothelium. Administration of 4-hydroxytamoxifen as described
induces tdTomato fluorescent protein expression in cells expressing the Lyve-1 promoter. Bright
field and Texas Red (TR) stereofluorescence microscopy live imaging (A, B) or imaging at
necropsy (C-G) shows tdTomato expression in lymphatic vessels in several tissues and organs.
A. Newly synthesized corneal lymphatic vessels growing out from limbal arcade in response to
sutures are tdTomato+. B. Lymphatic vessel networks present in mouse pinna under steady
state conditions express tdTomato. C. Lymph nodes (here, submandibular; magnification
greater in right panel) express tdTomator. D. Lyve-1+ cells of spleen express tdTomato. E-G.
Lymphatic tissue associated with digestive organs including pancreas, stomach, and intestine are
tdTomato+. H. Whole mount pinna. Endogenous tdTomato protein is present in nucleus,
cytoplasm, and cellular projections of lymphatic endothelial cells and survives
paraformaldehyde fixation for confocal microscopy.
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Greater magnification than at left

Figure 13
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Induction of Fluorescence with 4-hydroxytamoxifen
Expression of tdTomato protein in Lyve-1+ cells of the Lyve1CreERT2tdT mouse model
was induced by administration of 4-hydroxytamoxifen (4-OHT) suspended in sunflower oil. As
described above, this transgenic mouse was engineered to allow titration of tdTomato
expression by varying the level of 4-OHT administered to each individual animal. For all of the
experiments described in this work, expression of tdTomato fluorescent protein in all cells
expressing Lyve-1 was desired. To achieve this high level of expression, 1 mg of 4-OHT was
injected intraperitoneally each day for three days with a fourth booster dose administered as
needed.
Cell Lines
The Lyve1CreERT2tdT mouse has been back-crossed to the C57BL/6 genetic background,
enabling tumor studies with syngeneic cell lines. We used the following cell lines:

B16

melanoma, KPC pancreatic adenocarcinoma, and E0771 medullary breast carcinoma. The B16
melanoma cell line was a kind gift from Dr. James E. Talmadge at the University of Nebraska
Medical Center, Omaha, NE. The KPC cell line used in these experiments was derived in our
laboratory from a KPC mouse tumor (mouse #WT6012).

KPC mice (LSL-KrasG12D/+;LSL-

Trp53R172H/+;Pdx-1-Cre) are genetically engineered to develop spontaneous pancreatic
adenocarcinoma (Hingorani et al., 2005).

E0771 is an aggressive estrogen receptor+ (ER)

medullary breast cancer cell line (Ewens et al., 2005); it was a kind gift from Dr. Rakesh Singh at
the University of Nebraska Medical Center, Omaha, NE.
Surgical Procedures: Cornea
Surgeries were performed on the right eye of each animal.

Prior to all surgical

procedures, mice were deeply anesthetized by intraperitoneal administration of a mixture of
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ketamine (100 mg/kg) and xylazine (10 mg/kg). Topical anesthetic proparacaine was applied to
the corneal surface before surgery. Mice were euthanized by ketamine/xylazine overdose or by
CO2 asphyxiation and death ensured by cervical dislocation.
Establishment of Inflammatory and Wound Recovered Corneal Microenvironments
The corneal model of initial inflammation, wound recovery, and recurrent inflammation
was described in detail in Chapter I. Briefly, to establish initial inflammation a 10-0 nylon
monofilament suture was placed in each quadrant of the mouse cornea and left in residence for
seven days. In experiments comparing pre-sutured, simultaneously-sutured, and unsutured
environments, the pre-sutured condition was defined as placement of sutures three days prior
to tumor pellet implantation. The simultaneously-sutured condition consisted of sutures placed
immediately prior to pellet placement on the same day. For the unsutured condition, pellets
were placed in previously unmanipulated corneas.
Micropellet Preparation, Tumor Loading, and Corneal Implantation
Micropellet preparation was described in detail in Chapter I. Briefly, nylon mesh was
used to mold a mixture of 12% (w/w) poly(2-hydroxyethyl methacrylate) solution in 95% ethanol
and a sucrose octasulfate-aluminum complex into micropellets. Tumor cells were labeled with
CFSE (carboxyfluorescein diacetate, succinimidyl ester, Vybrant CFDA SE Cell Tracer Kit,
Invitrogen) or CMRA (CellTracker Orange CMRA, ThermoFisher) live cell tracker dye according to
the manufacturers’ instructions and loaded in suspension onto a micropellet ex vivo. A tumorbearing pellet was placed into a micropocket in the cornea by making a slit with a 20 or 27
gauge needle and using fine forceps to tuck the pellet under the corneal flap. Presence of CFSElabeled cells in the cornea was confirmed immediately following implantation via live imaging
fluorescence microscopy.
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Tumor Cell Injection
Labeled tumor cells were delivered to the cornea by either: injection with a 33 gauge
needle into a micropocket made with a 20 or 27 gauge needle or by pulling a 10-0 nylon
monofilament suture through a suspension of tumor cells on the surface of the cornea.
Immunofluorescence Imaging of Whole Mount Corneas
Dissection and Staining
These procedures were described in detail in Chapter I. Briefly, corneas were dissected
out of PFA-fixed globes, fixed a second time, blocked, and permeabilized. Primary antibodies
were diluted in BSA blocking solution and applied to corneas overnight shaking at room
temperature. Corneas were washed three times. Secondary antibodies were diluted in blocking
solution and applied to the corneas overnight shaking at room temperature. After three
washes, corneas were mounted and stored at 4°C. Primary antibodies: pRb α-Ms β-III tubulin
(ab18207, Abcam, Cambridge, MA), mRt α-Ms Lyve-1 (sc-65647, Santa Cruz Biotechnology,
Santa Cruz, CA). Secondary antibodies: 488 Dky α-Rb IgG (AlexaFluor A21206, Life Technologies,
Carlsbad, CA), 488 Dky α-Rt IgG (AlexaFluor A21208, Life Technologies), 549 Dky α-Rt IgG
(DyLight 712-505-150, Jackson ImmunoResearch Laboratories, West Grove, PA).
Whole Mount Imaging
Whole mount corneas were visualized on a Zeiss Axio A.1 epifluorescence microscope or
a Leica stereoscope.

100X epifluorescence images were obtained using SPOT Advanced

software (SPOT Imaging Solutions, Sterling Heights, MI). 32X stereofluorescence images were
obtained using Leica Application Suite software (Leica Microsystems, Inc., Buffalo Grove, IL).
200X and 400X z-stacks were obtained using a Zeiss 510META confocal microscope (Carl Zeiss
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AG, Oberkochen, Germany). Images were compiled and analyzed using ZEN 2009, BioImageXD
(Kankaanpaa et al., 2012) and ImageJ (Schneider et al., 2012) software packages.
Surgical Procedures: Pinna
Prior to all surgical procedures, mice were deeply anesthetized by intraperitoneal
administration of a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg). Pinna was
depilated by application of Nair Hair Removal Lotion (Church and Dwight Co, Inc., Ewing, NJ)
according to the manufacturer’s instructions. Mice were euthanized by ketamine/xylazine
overdose or by CO2 asphyxiation and death ensured by cervical dislocation.
Establishment of Local Inflammatory Microenvironment
Dissolvable (5-0 chromic gut) or nylon monofilament (10-0) sutures were placed in the
pinna. Sutures passed through both layers of ear skin. Duration of residence, number, and
location of sutures varied depending on experimental conditions and are described below as is
appropriate.
Tumor Cell Delivery
CFSE- or CMRA-labeled tumor cells were delivered to the pinna by either: end-on
injection of a large or small bolus dose of cells into and between the two layers of ear skin with a
33 gauge needle or injection at a specific location with a 33 gauge needle or pulled glass pipette
attached to a compressed gas-powered microinjector (Model PLI-100A Basic Pico-Injector 641735, Warner Instruments, Hamden, CT).
Immunofluorescence Imaging of Whole Mount Pinnae
Dissection and Staining
Intact pinnae were removed and fixed in 1% paraformaldehyde in PBS, pH 7.4, shaking
at room temperature. Sections were washed in PBS and then blocked and permeabilized in a
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sterile-filtered PBS, pH 7.4, solution containing 5.2% BSA, 0.3% Triton X-100, and 0.2% NaN3
(blocking solution) for two days at 4°C. Primary antibodies were diluted in blocking solution and
applied to pinnae overnight shaking at room temperature. Tissue was washed in a sterilefiltered PBS, pH 7.4, solution containing 0.2% BSA, 0.3% Triton X-100, and 0.2% NaN3 (wash
buffer) three times for one hour shaking at room temperature. Secondary antibodies were
diluted in blocking solution and applied overnight shaking at room temperature. After three one
hour washes, tissue was mounted for imaging and stored at 4°C.
Whole Mount Imaging
Whole mount pinnae were visualized on a Zeiss Axio A.1 epifluorescence microscope or
a Leica stereoscope.

100X epifluorescence images were obtained using SPOT Advanced

software (SPOT Imaging Solutions, Sterling Heights, MI). 32X stereofluorescence images were
obtained using Leica Application Suite software (Leica Microsystems, Inc., Buffalo Grove, IL).
200X and 400X z-stacks were obtained using a Zeiss 510META confocal microscope (Carl Zeiss
AG, Oberkochen, Germany). Images were compiled and analyzed using ZEN 2009, BioImageXD
(Kankaanpaa et al., 2012) and ImageJ (Schneider et al., 2012) software packages.
Live Imaging Microscopy: Mouse Cornea and Pinna
Mice were deeply anesthetized as described above. Imaging was performed using GFP
(Green Fluorescent Protein) and TR (Texas Red) filter sets on a Leica MZ10F modular stereo
microscope for fluorescent imaging with a Fluo III rapid filter changer, a Leica Planap × 1.0
objective, and a Leica DFC310FX camera using the Leica Application Suite software version
4.0.0.8777 (Leica Microsystems, Inc., (Buffalo Grove, IL). Imaging was performed using FITC
(fluorescein isothiocyanate) and TRITC (tetramethylrhodamine) filter sets on a Zeiss Axio
Zoom.V16 fluorescence stereo zoom microscope with a Zeiss Plan-NeofluarZ 1.0 × 0.25 NA
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objective and a Zeiss AxioCam MRm camera using ZEN 2012 Blue Edition software version
1.1.1.0 (Carl Zeiss AG, Oberkochen, Germany).
Cornea was imaged by using fine forceps to position and stabilize the globe; focus on
either limbal vasculature or central cornea was achieved in this way. Extraneous vibration from
respiratory motions was minimized by gently stabilizing the head with a large forceps.
Pinna was immobilized and mounted for imaging for up to one hour by loosely securing
it in a customized mounting apparatus consisting of small glass plates and adjustable clamps.
Positioning the pinna on this platform effectively brought the tissue into one plane and
decreased movement due to respiration. Lymphatic vessel landmarks within the tissue allowed
us to return to the same field during several imaging sessions.
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Results
Sutures Induce Inflammatory Neurolymphatic Remodeling in Mouse Pinna
We studied alterations in lymphatic vessel and nerve morphology in mouse pinna in
response to placement of sutures in live animals over several days. Lymphatic vessels are
normally present in the homeostatic mouse pinna in two plexuses within the tissue. These
plexuses are defined by uniform distribution of blind-ended lymphatic capillaries throughout the
pinna in stochastic conformations and with frequent anastomoses. We placed dissolvable
(Figure 14A, B lower panel) or nylon (Figure 14B upper panel) sutures through the pinna of
Lyve1CreERT2tdT mice in which tdTomato fluorescence had been induced by administration of 4OHT. Changes in tdTomato+ lymphatic vessel architecture were characterized over several days
following suture placement. With either suture type, we observed a local decrease in lymphatic
vessel density at the site of suture placement. Development of a “zone-of-clearing” in which no
tdTomato+ lymphatic endothelial cells were present resulted at every suture site individually,
while normal lymphatic vessel architecture as seen in homeostasis was maintained in areas
away from and between sutures (Figure 14B right panel). Several days after suture placement
we observed local lymphangiogenic sprouting into the site of wounds (Figure 14C). Single
tdTomato+ cells infiltrated areas previously devoid of lymphatic vessels around sutures. Newly
synthesized lymphatic vessel sprouts branched off of existing lymphatic vessels into wounded
regions.
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Figure 14. Sutures induce local pinna lymphatic vessel remodeling. A. Live imaging.
Dissolvable or nylon sutures were placed through the depilated Lyve1CreERT2tdT mouse pinna.
B. Live imaging. Suture placement resulted in local decrease in lymphatic vessel density and
formation of “zone-of-clearing” (dashed lines) around suture sites (*). C. Live-imaging of
mounted ear several days after suture placement (left panel, Texas Red filter; right panel, bright
field); Local sprouting into previous suture site zone-of-clearing (dashed lines higher
magnification box).
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Figure 14
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We also studied the behavior of nerves in response to suture placement in the mouse
pinna (Figure 15). As with vascular supply, each layer of ear skin is independently innervated. In
homeostasis, large nerve trunks enter the base of the pinna and fan out toward the edges with
extensive branching and anastomoses forming dense plexuses. Upon stimulation with a suture,
neuroremodeling in the pinna was similar to that observed in the cornea. A dramatic increase in
nerve density was observed at the margins of wounds. Nerve bundles tracked in an organized
manner toward the site of injury, encircled and penetrated it forming a dense net-like structure.
Sprouting lymphatic vessel tips maintained distance from the injury, while nerves were present
at greater density in this region.
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Figure 15. Sutures induce local pinna neuroremodeling. Two 5-0 chromic gut sutures were
placed through the depilated Lyve1CreERT2tdT mouse pinna. Maximum intensity projections of
100X confocal micrographs are shown. Size bars = 100 μm. Pinna nerves (β-III tubulinimmunolabeling, green) and lymphatic vessels (endogenous tdTomato+, red). A. Networks of
nerves and lymphatic vessels in homeostasis in a region away from sutures. B. Local increase in
nerve density and altered morphology in immediate vicinity of suture (*). Lymphatic vessels are
positioned away from suture site and display sprouting tips (arrows).

119

Figure 15
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Very Small Tumor Burden Induces Lymphatic Vessel Remodeling and Is Cleared from Tissue
We studied tumor behavior and lymphatic vessel response to presence of tumor cells in
the mouse pinna. We delivered varied loads of tumor cells, ranging from less than a hundred
cells to more than a million, to the pinna with and without sutures. We used live imaging
microscopy to investigate tumor-associated lymphatic vessel remodeling, to track tumor cells
through pinna tissue, and to evaluate lymph node status at necropsy.

We found that the presence of a very small tumor burden was sufficient to induce
localized lymphatic vessel remodeling (Figure 16). Lymphatic vessels in the immediate vicinity of
a group of tumor cells displayed stochastic sprouting at the site of tumor residence after seven
days. Tips of growing lymphatic vessels were often multi-sprouted, and anastomosis occurred
to form lymphatic vessel ring structures. Vessels farther away from tumor cells did not display
any alterations in morphology, likely demonstrating the localized effects of lymphangiogenic
cytokines secreted from these very small groups of cells.

We found that tumor cells disappeared from sites of residence in the tissue. By day
seven, no tumor cells were visible at their previous locations. This could indicate clearance by
activated immune cells, intravasation into blood or lymphatic vessels and transport away, or cell
death and clearance of remaining fluorescent cell debris.
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Figure 16. Tumor cells induce local unsutured pinna lymphatic vessel remodeling and are
cleared from tissue. A-F. CFSE-labeled B16 melanoma cells were injected into the
Lyve1CreERT2tdT unsutured depilated mouse pinna. Live stereofluorescence microscopy was
used to track CFSE-labeled tumor cells (green) and tdTomato-expressing lymphatic endothelial
cells (red) over seven days. Lymphatics are visible with both the Texas Red (TR) and Green
Fluorescent Protein (GFP) filter sets due to the brightness and broad fluorescence emission
spectrum of tdTomato protein. A, D. Site of CFSE-labeled B16 tumor cell residence in pinna
(arrow) on imaging day 1. B, E. Return to site of tumor cell residence on imaging day 7. Tumor
cells are no longer present. Local lymphangiogenic sprouting and anastomosis can be visualized.
C, F. Higher magnification view of lymphatic endothelial sprouts and ring anastomosis.
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Figure 16A-C
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Figure 16D-F
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Tumor Cells Enter Lymphatic Vessels and Traffic to Lymph Nodes
We designed experiments to investigate possible trafficking of tumor cells through
lymphatic vessels. This would represent a mechanism of clearance from tissue and mimic
metastasis to lymph nodes. We injected a large bolus dose of CFSE-labeled B16 melanoma cells
into the edge of the Lyve1CreERT2tdT pinna. One day after injection, lymphatic vessels half the
distance of the pinna away from the injection site and distinct from the circular region of
injected cell suspension harbored CFSE+ tumor cells. Both groups of cells and single cells could
be visualized in the lumen of lymphatic vessels (Figure 17A, top panel). Cells resident in the
extravascular pinna tissue could also be visualized in these regions, suggesting possible
intravasation/extravasation activity at these sites, although we did not directly observe these
behaviors.

The relatively stable nature of the pinna lymphatic vasculature architecture facilitated
returning to landmark vessel structures in the tissue for sequential imaging over time. We
returned to the areas of tumor-bearing lymphatic vessels on day two after injection, or 24 hours
after first observing this phenomenon. We detected no CFSE signal in the vessels that had
housed tumor cells the previous day and did not find similar groups of cells in vessels within the
neighboring tissue (Figure 17A, bottom panel). This suggested that the tumor cells had been
cleared from the pinna lymphatic vasculature and transported to the lymph nodes.
At necropsy on day seven, we examined lymph nodes for the presence of CFSE+ cells
(Figure 17B). Across experiments we found tumor cells in lymph nodes in several locations
including submandibular, axial, and inguinal nodes.
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Figure 17. Tumor cells enter unsutured pinna lymphatic vessels, are cleared from vessels, and
are present in lymph nodes at necropsy. CFSE-labeled B16 melanoma cells (green) were
injected into the periphery of the depilated Lyve-1CreERT2tdT mouse pinna. Tumor cells and
tdTomato+ lymphatic vessels (orange) were followed by live imaging stereofluorescence
microscopy. A. Tumor cells are visible in groups in lymphatic vessels on imaging day 1 (arrows,
top panel). Identification of landmark lymphatic vessel structures facilitated imaging of the
same regions 24 hours later. Tumor cells are no longer present at their previous locations
within lymphatic vessels (arrows, bottom panel). B. CFSE+ cells are present in draining lymph
nodes at necropsy.
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Figure 17
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Spatially Localized Suture- and Tumor-Associated Lymphatic Vessel Remodeling
We established that placement of a suture or delivery of a minimal tumor burden
results in two distinct patterns of skin lymphatic remodeling. We next studied these remodeling
behaviors in different contexts: first, we investigated lymphatic remodeling in the presence of a
much larger tumor burden, and second, we created distinct suture- or tumor-associated
microenvironments within the same pinna.

We first established local zones of nonmalignant inflammation with the placement of
chromic gut sutures in the Lyve1CreERT2tdT mouse pinna; one suture was placed in the center of
the pinna and another in the upper quadrant, leaving a large area free of inflammatory stimuli
(Figure 18A). After three days, a medium dose of CFSE-labeled B16 melanoma cells was injected
into the margin of the pinna opposite the sutures. Sutured locations displayed the characteristic
loss of lymphatic capillaries immediately adjacent to stimuli with some sprouting into wounded
area (Figure 18A, E). Lymphatic vessels in the area of tumor challenge appeared grossly
enlarged; closer examination at necropsy on day seven revealed dramatic hypersprouting
morphology in the tumor-associated microenvironment (Figure 18A-C). Single sprouts budded
off existing vessels in all directions; single cells not incorporated into the vascular network
infiltrated spaced between vessels; single and elongated cells lined up in thin extended chains
among larger lymphatic capillaries (Figure 18C).
Tumor cells were in close association with lymphatic vessels of both ear skin layers as
revealed by dissection at necropsy (Figure 18B). Single and groups of cells were present at
various distances from the bolus injection site within the tissue (Figure 18A-C). Lymph nodes at
necropsy were positive for tumor metastases (Figure 18D).
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Figure 18. Establishment of wound- and tumor-associated inflammatory microenvironments
in separate regions of the mouse pinna results in distinct patterns of lymphatic remodeling.
Sutures were placed in the depilated Lyve1CreERT2tdT mouse pinna. Three days later, a large
bolus dose of CFSE-labeled B16 melanoma cells in suspension was injected into the margin of
the pinna. Tumor cells and lymphatic vessels were tracked for seven days by live imaging. At
necropsy on day seven, the two layers of ear skin were separated to reveal the intact lymphatic
vessel plexuses, and the draining lymph nodes were examined for the presence of CFSE+ cells. A.
Intact pinna shows CFSE signal at site of tumor cell injection and sites of suture placement (*).
B. Two layers of ear skin are separated at necropsy. Tumor cells have moved through tissue
away from injection site. C. Higher magnification of designated area from B. Lymphatic vessels
display hypersprouting morphology in immediate vicinity of tumor cells. In the right panel,
three images taken at different focal depths were stitched together to form this micrograph.
Black lines indicated by arrows demarcate transitions between the images. D. CFSE+ cells are
present in draining lymph node. E. Higher magnification images of sites of suture placement.
Characteristic “zone-of-clearing” is present around wound. Some sprouting is present at lower
edge of right panel.
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Figure 18
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Delivery of Tumor Cells to Cornea is Feasible and Cells Are Viable
To this point, all of our work had been done in the context of an orthotopic model of
melanoma, i.e. study of B16 melanoma cells in the syngeneic murine skin. To better address
tumor-associated neuroremodeling and to track inflammatory new lymphatic vessel synthesis in
a setting normally devoid of lymphatic vessels, we transitioned our studies to a corneal live
imaging platform. Our previous work had established the utility of micropellet implantation as a
means to administer cytokine to the cornea, and we now tested this method for tumor cell
delivery. As there was some uncertainty about whether or not the corneal microenvironment
would be hospitable to tumor cells, we also tested tumor cell viability after implantation.

Several methods of loading tumor cells onto micropellets were tested, and allowing
tumor cells in high cell numbers in suspension to adhere to the pellet matrix was suitable (Figure
19A). Pellets were implanted into a pocket made by a small incision as described for cytokine
pellets, and we determined that pocket placement either in the center of the cornea or at the
midpoint between the corneal apex and temporal limbal arcade was feasible and facilitated the
desired experiments. Pellets could be placed in tissue with or without sutures without excessive
disruption of ocular globe integrity (Figure 19B, C). We also tested direct injection of tumor cell
suspension into a corneal pocket and found this to be a reasonable alternative delivery method
(Figure 19D). The most notable difference in the two techniques was the dissemination of
tumor cells from the injection site.

To ascertain tumor cell viability following injection we observed cell morphology by live
imaging and followed CFSE+ cells in culture derived from harvested corneal explants previously
injected with tumor cells. Injected tumor cells often displayed spindle shaped morphology and
cell-cell interactions visible by live imaging microscopy. CFSE-labeled cells grew out of corneal
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explants and could be subcultured and grown on coverslips for confocal microscopy (Figure
19E). CFSE signal was clearly present in cells; cells displayed expected morphology; nuclei were
intact. Variations in signal intensity indicate that rates of cell division varied among clones.
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Figure 19. Tumor cells are viable after corneal implantation. A. CFSE-labeled B16 melanoma
(shown here), E0771 breast cancer, or KPC pancreatic cancer cells were loaded onto a
micropellet ex vivo. B. Sutured mouse cornea before tumor administration. Size bar = 250 μm.
C. A tumor-bearing pellet was placed into a micropocket in the center of the cornea. Presence
of tumor cells was confirmed by live imaging immediately following pellet implantation. Size bar
= 250 μm. D. CFSE-labeled B16 melanoma cells (green) in suspension were directly injected into
the Lyve1CreERT2tdT cornea and visualized by live imaging (endogenous tdTomato fluorescence,
red). Size bar = 250 μm. E. Five days after administration of tumor cells, corneal explants were
placed in tissue culture. CFSE+ cells grew out of explants onto coverslips and were imaged by
confocal microscopy. 400X maximum intensity projection shown (CFSE, green; DAPI, blue). Size
bar = 50 μm.
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Figure 19
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Tumor Cells Induce Local Corneal Neuroremodeling
Presence of tumor cells in the cornea had both local and field effects on nerve
architecture. In the presence or absence of sutures, delivery of a modest dose of tumor cells
resulted in localized decreases in nerve density in the immediate vicinity of tumor cells (Figure
20A, B). This local effect was seen regardless of tumor position within the tissue. Nerve density
was decreased around cells located in the center or periphery of the cornea; proximity of tumor
cells to sutures also did not affect this remodeling. All classes of corneal nerves were affected,
including large stromal trunks, subepithelial leashes, and epithelial nerve endings.

Local

neuroremodeling was accompanied by broader effects. In cases in which only a few tumor cells
remained resident in the cornea after injection, we saw local nerve cluster formation and
transition of the surrounding tissue to a more wound recovery-like phenotype.

Nerves

displayed a more tortuous morphology and often terminated in small clusters (Figure 20C-E).
Addition of tumor cells to an inflammatory microenvironment attenuated typical
inflammatory neuroremodeling.

As characterized in Chapter I, in suture-mediated

nonmalignant inflammation thickened nerves drive toward stimuli and are present at extremely
high density at suture sites, often engulfing the foreign body (Figure 20F).

Here, nerve

morphology was more variable and included nerves terminating in clusters typically only seen in
wound recovery (Figure 2E), though large diameter sprouting lymphatic vessels confirmed that
the sutured tissue was inflamed (Figure 20E).
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Figure 20. Tumor cells induce local neuroremodeling in the presence or absence of sutures. A,
D. B16 melanoma cells were labeled with CMRA Orange CellTracker dye and injected into the
uninflamed cornea. Size bar = 250 μm. A. Tumor cells are resident at several locations within
the tissue (arrows). Corneas were harvested on day three and nerves stained for β-III tubulin.
Size bar = 250 μm. B. Corneas were sutured and CMRA-labeled B16 melanoma cells were
injected the same day. Arrows indicate positions of tumor residence. Tissue was harvested and
stained as in A. Size bar = 250 μm. C. CFSE-labeled B16 melanoma cells were injected into the
cornea; tissue was harvested on day nine. Size bar = 250 μm. E. Confocal micrograph of Lyve-1stained lymphatic vessels and β-III tubulin-stained nerves in the sutured cornea in the presence
of injected CFSE-labeled B16 melanoma cells (arrows). Size bar = 100 μm. F. Confocal
micrograph of suture in corneal tissue without the addition of tumor cells. Size bar = 100 μm.
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Figure 20A, B
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Figure 20C-E

138

Tumor Cells Induce Lymphangiogenesis
Our studies in the pinna were limited by the nature of that tissue’s lymphatic
vasculature. The dense regularly distributed lymphatic vessels present in homeostasis were
capable of only minor localized remodeling events after suture placement or tumor challenge.
We used the corneal platform to investigate tumor-directed new lymphatic vessel synthesis; this
was facilitated by the lack of vascularization under steady state conditions.

We injected tumor cells into micropockets in unsutured corneas. By day two (Figure
21A, upper panel), some tumor cells had migrated away from the micropocket and spread
through the corneal tissue. Many of these cells had moved to the limbal region, where nerve,
lymphatic, and blood vessel arcades are located. The majority of injected cells remained at the
injection site. By day six (Figure 21A, middle panel), new lymphatic vessels had sprouted from
the limbal vessels and were growing toward the tumor cells. Most of the cells that had migrated
away from the injection site were no longer visible in the tissue. Marked lymphangiogenesis
occurred by day eight (Figure 21A, lower panel). New lymphatic vessel growth was more
pronounced from limbal locations nearer the tumor cells, but sprouting occurred from limbal
lymphatic vessels in each corneal quadrant (Figure 21B). Single tdTomato+ cells also migrated
through the tissue toward the tumor burden. These results support the hypothesis that there is
a secreted chemotactic factor gradient emanating from tumor cells that directs lymphatic vessel
sprouting and lymphatic endothelial cell or macrophage migration toward the source of
chemoattractant.
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Figure 21. Tumor cells alone stimulate new lymphatic vessel growth. CFSE-labeled B16
melanoma cells were injected into a Lyve1CreERT2tdT mouse corneal micropocket placed near
the temporal limbus. A. Tumor cells and lymphatic vessels were monitored by fluorescence live
imaging microscopy for eight days at 32X, 50X, and 80X. Size bar = 100 μm. B. Each quadrant of
harvested tissue was imaged at 100X by epifluorescence microscopy and images were compiled
to form composite images shown. Tumor injection site is bright focus in bottom right image of
composite. Size bar = 250 μm.
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Figure 21
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Unique Lymphatic Structures Arise in Inflammatory Lymphangiogenesis in the Presence of
Tumor Cells
We identified several types of unique lymphatic vessel behavior and architecture in
tissues bearing both sutures and tumor cells (Figure 22, Figure 23, Figure 24). We previously
established that in corneal tissue inflamed by sutures alone, lymphatic vessels adopted a
chalice-like morphology as they neared the location of a suture and did not penetrate within the
immediate vicinity of the suture (Figure 2B, Figure 20F). This did not change in the presence of a
tumor pellet in the center of the cornea with sutures in each quadrant (Figure 22A). Conversely
however, hypertrophic lymphatic vessels with activated multi-sprouted tips approached and
invaded tumor pellets from all directions, completely taking them over in some cases (Figure
22A, B, Figure 24A). Tumor cells interacted with newly synthesized lymphatic vessels (Figure
22C), and single tdTomato-expressing cells could be seen in close contact with tumor cells as
well near tumor pellets (Figure 22D). Although blood vessels do not express Lyve-1 and do not,
therefore, express tdTomato fluorescent protein in the Lyve1CreERT2tdT mouse model, we were
able to visualize the contrast of dark blood flowing in these vessels against the autofluorescence
of the eye lens. Angiogenesis also occurred in these corneas, and sprouting blood capillaries
invaded tumor pellets along with lymphatics (Figure 22B, Figure 24A).

We also identified disorganized lymphatic vessels sprouting from the corneal limbus in
response to both a large injected tumor burden and tumor bearing pellets (Figure 24) in sutured
tissue. Highly irregular lymphatic endothelial sprouts with no discernable organized vascular
architecture grew out of the limbus near tumor pocket placement (Figure 23). This occurred in
tissue that was sutured the same day as tumor injection. In tissue that was pre-sutured six days
before tumor pellet placement, two types of lymphatic vessels were present (Figure 24C).
Large, well-organized vessels with both sprouting and bulbous termini typical of suture-
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mediated lymphangiogenesis were present alongside thin, disorganized, discontinuous
structures that appeared to be immature or incompletely synthesized. Many single cells were
present in these regions, many of which were elongated. Live imaging of these structures over
time with the aid of tissue landmarks highlighted their disorganized nature and suggested that
some of the larger, more typical lymphatics in these regions were well-established prior to
tumor implantation and had originally been stimulated by suturing, while the more disorganized
structures emerged in the presence of tumor burden (Figure 24B).
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Figure 22. Lymphatic vessels respond differently to suture and tumor stimuli. CFSE-labeled
B16 melanoma cells were loaded onto micropellets and placed in pockets in the center of
Lyve1CreERT2tdT corneas that had been sutured with four 10-0 nylon sutures six days earlier.
Tumor cells (green) and tdTomato+ lymphatic vessels (red) were tracked by live imaging
microscopy for several days. A. Sutures are indicated by asterisks (*). Pellets are outlined with
dashed lines. Size bar = 100 μm. B. Blood vessels are visible as dark structures against lens
autofluorescence alongside lymphatic vessels and tumor cells. Size bar = 100 μm. C. Tumor cell
interactions with newly-synthesized lymphatic vessels (arrows). Size bar = 100 μm. D. Single
tdTomato+ cells interacting with tumor cells at margins of pellet (arrows). Size bar = 100 μm.
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Figure 22A
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Figure 22B
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Figure 23. New lymphatic vessels growing in the presence of sutures and large tumor burden
are disorganized. Lyve1CreERT2tdT corneas were sutured with four 10-0 nylon sutures and
injected with a large dose of CFSE-labeled B16 melanoma cells on the same day. A. Tumor cells
(green) and lymphatic vessels (red) were tracked for eight days by live imaging microscopy.
Dashed line indicates limbus. Size bar = 100 μm. B. 100X epifluorescence micrograph of
endogenous tdTomato signal in lymphatic vessels sprouting from limbus (dashed line) in fixed
tissue after harvest on day eight. Size bar = 100 μm.
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Figure 23
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Figure 24. Presence of lymphatic vessels of two distinct morphologies in corneas bearing
sutures and tumor cells. CFSE-labeled B16 melanoma cells were loaded onto micropellets and
placed in pockets in the center of Lyve1CreERT2tdT corneas that had been sutured with four 10-0
nylon sutures six days earlier. A, B. Tumor cells and tdTomato+ lymphatic vessels were tracked
by live imaging microscopy for several days. A region of interest was identified for closer
monitoring over time with landmarks (A, Day 6, dashed box). Blue dot indicates suture
landmark. Yellow star indicates hooked lymphatic vessel landmark. Time course of images of
this region make up B. Size bar = 100 μm. C. 100X epifluorescence micrograph of tdTomato+
lymphatic vessels co-immunostained for Lyve-1 with a 549 nm emission wavelength (overlaps
tdTomato emission spectrum) secondary antibody. Size bar = 100 μm.
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Figure 24A
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Figure 24B, C
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Simultaneous Establishment of an Inflammatory Microenvironment Prolongs Tumor
Residency in Cornea
In several of our previous experiments, we noted an effect of the inflammatory status of
corneal tissue on success of prolonged tumor imaging after tumor delivery. To further study this
effect, we established three microenvironmental conditions in the cornea prior to tumor cell
injection by placing sutures at different time points and following tumor cell signal over time by
live imaging. Corneas were unsutured, sutured three days before injection of tumor cells (presutured), or sutured immediately prior to tumor injection on the same day. We performed
these experiments with two different cell lines syngeneic to C57BL/6 mice: E0771 estrogen
receptor+ medullary breast carcinoma cells and KPC pancreatic adenocarcinoma cells. Similar
results were seen with both cell lines. By day two after injection, cells were distributed
throughout the cornea in all conditions. By day four, the groups had separated. Unsutured
corneas had only a few cells remaining; these were concentrated at the injection site and near
the limbal vascular arcade. The few cells remaining in the pre-sutured corneas were resident at
the injection site and near sutures. By contrast, corneas that had been sutured the same day as
tumor injection had tumor cells distributed throughout—at the injection site, sites of sutures,
near the limbus, and in the corneal parenchyma away from any of these structures. These
results suggested that aspects of the earliest events in the establishment of a suture-mediated
inflammatory response in the cornea (before day three) affected tumor biology such that cells
remained resident at the site of this inflammatory response.
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Figure 25. Timing of inflammatory microenvironment establishment influences tumor cell
behavior in tissue. E0771 breast cancer or KPC pancreatic cancer cells were labeled with CFSE
(green) and injected into a micropocket of a C57BL/6 mouse cornea in one of the following
conditions: unsutured, sutured three days prior to tumor injection, or sutured the same day as
tumor cell administration. Live imaging was performed on days two and four post tumor
injection and corneas were harvested on day four. Harvested tissue was fixed and lymphatic
vessels were immunostained for Lyve-1 (orange). Live imaging: 32X. Epifluorescence: 100X.
Size bar = 200 μm.
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Figure 25
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Discussion
Distinct Stimulus-Dependent Neurolymphatic Remodeling Signatures and MiniMicroenvironments
We used live imaging microscopy to visualize kinetics and dynamics of lymphatic vessel
remodeling in physiologically distinct microenvironmental conditions induced by physical injury
or tumor burden. Sutures caused directional lymphangiogenic sprouting from existing vessels,
but nascent lymphatics did not enter a “zone-of-clearing” immediately surrounding each suture.
Tumor-associated lymphangiogenesis was quite different. The presence of a very small number
of tumor cells resulted in a disorganized multi-directional hypersprouting lymphangiogenic
phenotype. This effect was even more pronounced in the presence of a larger tumor burden.
Lymphatic vessels were not inhibited from entering the tissue immediately adjacent to tumor
cells; sprouting lymphatics contacted and invaded tumor-bearing pellets and interacted directly
with tumor cells. These two distinct stimulus-dependent modes of new lymphatic vessel growth
were not mutually exclusive. Placing sutures and tumor cells in the same pinna or cornea
resulted in localized lymphangiogenesis responses commensurate with stimulus type. This
intra-tissue variability, even in a region as small as one quadrant of the mouse cornea,
demonstrated the true micro nature of a microenvironment. Regardless of inflammatory status
or presence of malignancy, “tissue microenvironments” are inherently hypervariable and plastic
and are composed of an infinite number of stochastically shifting mini-microenvironments
responding to changes in local complements of cytokines, resident cell types, tissue pressure,
metabolite flux, etc.

We also found stimulus-dependent differences in neuroremodeling. Similar to the
effect on lymphatic vessels, placement of a suture resulted in a directional shift in nerve
organization, with nerves bending to track toward the stimulus. Nerves grew into and around
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suture knots at very high density. Addition of tumor cells to a sutured environment resulted in
both local and broader neuroremodeling effects. Tumor cell presence in an inflamed tissue
caused local decreases in density of nervous structures of all sizes; this was in contrast to the
effect seen upon tumor placement in unsutured tissue in which tumor cells caused local nerve
cluster formation. A transition toward a more tortuous phenotype and the presence of small
nerve clusters was also broadly seen in sutured tissue with tumor cells. The appearance of
nerve clusters in these two tissue states—unsutured + tumor and sutured + tumor—was striking
given our previous characterization of this phenotype as a feature restricted to woundrecovered tissue (sutures placed to induce inflammation, then removed to stimulate healing).
Simultaneous Inflammation Prolongs Tumor Residency
We unexpectedly found that placement of tumor cells and sutures in the cornea on the
same day prolonged tumor residency. This was an incidental finding of several preliminary
experiments with B16 melanoma cells and was confirmed using both the E0771 medullary
breast carcinoma cell line and a KPC pancreatic adenocarcinoma cell line. The majority of tumor
cells injected into the unsutured mouse cornea were no longer visible by live imaging or
epifluorescence microscopy of fixed tissue after several days. Pre-inflammation of tissue by
placement of sutures three days before tumor injection resulted in a similar loss of tumor signal,
although some cells remained near sutures and at the injection site. In striking contrast to these
two conditions, signal from tumor cells injected into the cornea on the same day as suturing was
visible for several days by live imaging as well as in fixed whole mount corneas.

We considered the possibility that in the same-day sutured condition, lymphatic vessel
sprouts (and sprouting blood vessels) would not have had sufficient time to extend and mature
as may be required for tumor cell trafficking away from the injection site. In our live imaging
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experiments we documented the simultaneous presence of “typical” large newly-synthesized
lymphatic vessels and disorganized incomplete atypical lymphatic structures in pre-sutured
tissue. The presence of larger suture-induced lymphatics in pre-sutured tissue may have
provided a means of migration out of the cornea for tumor cells in the pre-sutured condition
that was not yet available to tumor cells in the same-day sutured group. While this may be true,
we also saw loss of tumor cell signal in the unsutured condition. We showed that injection of
tumor cells is sufficient to induce lymphangiogenesis in unsutured tissue, but it seems that the
low level of lymphangiogenic sprouting in response to tumor cells in the early days of
implantation would not be sufficient to quickly clear a large injected tumor burden. If this were
the case, it would also be reasonable to assume a similar tumor-lymphangiogenesis effect in
same-day sutured tissue. Taken together, this suggested that another mechanism must explain
the extended residency of cells in the same-day group.

We also considered attack of tumor cells by phagocytic immune cells as an explanation
for loss of tumor signal.

Again, however, the similarity in tumor behavior between the

unsutured and pre-sutured conditions was confounding.

Infiltrating immune cells would

presumably travel through lymphatic and/or blood vasculature to reach the tumor site and
enter the corneal parenchyma. This could explain the difference between the pre-sutured and
same-day sutured conditions, but not the unsutured group. Relative immune privilege is a welldescribed characteristic of the unmanipulated cornea. Additionally, were phagocytic immune
cells responsible for clearing of tumor cells, we would still expect to see CFSE signal in these
cells.

While the answer to this question remains unclear, we suggest that aspects of the
earliest events of inflammation predispose tumor cell residence in the cornea. These may, in
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fact, be considered either positive or negative regulators of tumor cell behavior, depending on
point of view. Inflammatory factors in the tissue may, for example, down regulate cell migration
and proliferation causing them to stay resident at their point of injection with little diminishing
of signal. Contrariwise, factors may promote cell survival in this condition while cells without
the benefit of a new inflammatory reaction undergo cell death and signal diffuses away. It is
also possible that two different mechanisms govern loss of cell signal in the unsutured and presutured conditions. Dissecting these nuances will require more careful study, however, these
results demonstrate the importance of inflammation in the establishment and progression of a
tumor.
Additional Uses for Lyve1CreERT2tdT Live Imaging Platform
The Lyve1CreERT2tdT cornea and pinna live imaging platforms we have described here
could be used in the future to study many other aspects of basic lymphatic biology and tumorlymphatic interactions. Some key questions to be addressed might include: How does a tumor
cell intravasate into a lymphatic vessel? Do specific features of lymphatic vessel architecture or
physical properties of tumor cells affect this process?

How do circulating tumor cells in

lymphatic vessels pause, extravasate, and enter tissues to form metastases? Do these processes
differ from mechanisms used by leukocytes? Might putative druggable targets be identified that
regulate physical lymphatic remodeling?

Do other characteristics of organ-specific

microenvironments affect the biology of metastasis for tumor cells that arise there? Inflamed
corneal lymphatic vessels may be activated to facilitate immune cell trafficking. Do these
activation properties also equip lymphatic vessels to support tumor cell trafficking, or are they
not required by tumor cells? What role do Lyve-1-expressing macrophages play in lymphatic
vessel remodeling and interactions with tumor cells?

Does “flipping the switch” from

inflammation to wound recovery in the tumor microenvironment affect tumor cell proliferation
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and metastasis?

How does the presence of specific cytokines affect tumor-lymphatic

interactions? What molecular features distinguish tumor- and suture-associated lymphatic
vessels? Intravascular tumor cells from those that remain resident in tissue? Can these features
be targeted for clinical imaging?
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CHAPTER III. Pancreatic Cancer Cachexia in Rapid
Autopsy Muscle Tissue Samples
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Introduction
Pancreatic ductal adenocarcinoma patients are often plagued with the paraneoplastic
syndrome cachexia.

This progressive disease has been linked to low-grade systemic

inflammation and as such has broad effects on several aspects of patient quality-of-life.
Cachexia results in unintentional weight loss, loss of muscle mass, weakness, and increased
frailty. Cancer-associated cachexia may cause reduced tolerance for chemotherapy and has
been implicated in decreased overall survival. Despite the importance of this disease for
outcomes and quality-of-life, little is known about the effects of cachexia on skeletal muscle of
PDAC patients. The KPC mouse model of PDAC, designed to develop spontaneous pancreas
tumors, does show a cachexia phenotype (Hingorani et al., 2005), but while animal models can
provide some insight into human disease, these artificial systems often fall short in their
attempts to mirror the intricacy of the human condition.

We studied PDAC-associated cachexia in skeletal muscle samples taken from patients
within hours of death at rapid autopsy and normal control samples from cancer-free donors.
We isolated total muscular RNA and examined the expression levels of six genes reported to be
important in cachexia, involved in muscle atrophy or wasting, or activated in exercise. The
genes we studied were:

Fibroblast activation protein alpha (FAP), follistatin (FST),

calcium/calmodulin-dependent protein kinase type II subunit beta (CAMK2B), tyrosine kinase
with immunoglobulin-like and EGF-like domains 1 (TIE1), tripartite motif containing 63 (TRIM63),
and F-box protein 32 (FBXO32).

FAP-α expression has been reported in cancer-associated fibroblasts (CAFs) and stromal
cells of other tissues including skeletal muscle. Cachectic KPC mice displayed decreased skeletal
muscle mass and reduced levels of Fap and Fst gene expression (Roberts et al., 2013). We
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expected to find similar decreases in FAP and FST expression levels in our human cachexia
samples.

CAMK2B and TIE1 were identified as possible biomarkers of cancer-associated

cachexia in a study of upper gastrointestinal cancer (including pancreatic) patient muscle
samples (Stephens et al., 2010). We expected to see increased expression of these exerciseactivated genes in cachexia patients over non-cachectic or normal controls.

TRIM63 and

FBXO32 are E3 ubiquitin ligases important in the ubiquitin-proteasome pathway of protein
degradation. Studies in rat models of muscle atrophy first described the importance of the E3
ubiquitin ligase family of proteins in muscle disease. Animal homologs of human TRIM63 and
FBXO32 were consistently upregulated across models; loss of either of these enzymes resulted
in resistance to muscle wasting (Bodine et al., 2001). We expected to detect increased levels of
TRIM63 and FBXO32 in cachectic PDAC patients compared to non-cachectic patients or normal
controls.
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Materials and Methods
Rapid Autopsy Procedures
Local patients diagnosed with pancreatic cancer voluntarily enrolled in a Rapid Autopsy
Pancreas (RAP) program. Trunk-only autopsies were performed within approximately three
hours of death by a pathologist, pathology resident, and research volunteer sample collection
team at the University of Nebraska Medical Center. All abdominal organs were removed and
analyzed for presence of pancreatic adenocarcinoma grossly and by microscopic histology.
Organs typically examined and collected included: pancreas, spleen, liver, stomach, gall bladder,
adrenal gland, kidney, small bowel, large bowel, rectum, prostate, diaphragm, lung, heart apex,
omentum, nerve, lymph node, and skeletal muscle. Organs were sliced into approximately
0.75” thick sections and each section was macrodissected and annotated with regard to disease
presentation according to the following pathologic designations: primary tumor (pancreas
only), metastatic lesion, margin of primary or metastatic tumor and uninvolved parenchyma, or
uninvolved parenchyma. Dissected specimens were flash frozen in liquid nitrogen, transferred
to dry ice, and stored long-term at -80°C. Skeletal muscle was customarily collected from psoas
or pectoral muscle.
Skeletal Muscle Specimens from Normal Patients
Normal control human skeletal muscle samples were obtained from the Comparative
Human Tissue Network or the National Disease Research Interchange. Only fresh frozen muscle
from donors without a previous cancer diagnosis was accepted. Muscle samples were received
after shipment on dry ice and stored at -80°C. Demographic information for PDAC patients and
normal donors are listed in Table 1.
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Patient Characteristics
Table 1. Muscle Donor Characteristics

Mean Age
Sex (M/F)
Race
White
Hispanic
Black

PDAC Patients Normal Controls
(n=58)
(n=15)
68.03
54.73
38/20
14/1
57
0
1

14
1
0
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Designation of Cachexia Status
Cachexia status (Yes or No) was assigned at autopsy by a pathologist at the University of
Nebraska Medical Center in Omaha, NE. These two groups were further stratified into the
following categories based on weight loss, BMI, and other clinical or pathology notes: yes,
severe cachexia (S); yes, weight loss (YWL); yes, normal or overweight BMI (YN); no, weight loss
(NWL); no, normal or overweight BMI (NN); and no, obese (NOB). Patients included in group S
were of normal or underweight BMI and presented with significant weight loss of greater than
14 kg, or were of normal or underweight BMI and had a specific pathology note such as “severe
cachexia” or “emaciated; presented with extreme weakness”. YWL inclusion criteria were
normal or overweight BMI at autopsy and weight loss of greater than 3 kg. YN patients were of
normal or overweight BMI and did not have weight loss. The NWL group was composed of
patients who were not cachectic and had weight loss of greater than 3 kg. NN patients did not
have cachexia and were of normal or overweight BMI. Patients in the NOB category were not
cachectic and had a BMI in the obese range at autopsy.
Pancreatic Cancer Collaborative Registry
The Pancreatic Cancer Collaborative Registry is a database maintained by the University
of Nebraska Medical Center in Omaha, NE. This database contains demographic data about
pancreatic cancer patients as well as treatment histories, information about family members,
and lifestyle data such as alcohol and tobacco use. We had access to data from the first 50 rapid
autopsy patients, or 74% of the population included in our other analyses.
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RNA Isolation Procedure, Reagents, and Quality Control
Total RNA was isolated from muscle specimens of approximately 0.3 g in mass according
to our modified TRIzol extraction protocol optimized for skeletal muscle4. RNA concentration
and presence of contaminants was tested using a NanoDrop 1000 spectrophotometer and ND
1000 V3.6.0 software (ThermoFisher Scientific). RNA quality was tested by Fragment Analyzer
(Advanced Analytical Technologies, Inc., Ames, IA) or BioAnalyzer (Agilent Technologies, Inc.,
Santa Clara, CA).

Data was analyzed using the ProSize 2 software (Advanced Analytical

Technologies, Inc., Ames, IA) or 2100 Expert software (Agilent Technologies, Inc., Santa Clara,
CA). RNA quality value of 6.0 was set as the minimum threshold for gene expression analysis.
The average quality score for our normal control sample set was 6.8 and that of our
experimental RAP sample set was 7.6.
cDNA Library Construction and qRT-PCR
cDNA libraries were constructed using the Verso cDNA kit (Cat. #AB1453A/B,
ThermoFisher Scientific) according to the manufacturer’s instructions. An additional digestion
with RNase H (Cat. #18021071, ThermoFisher) to remove RNA-DNA duplexes was performed at
37°C for 20 minutes following cDNA synthesis. cDNA was stored at -20°C.

Gene expression was quantified by qRT-PCR using 20X TaqMan Gene Expression Assay
hydrolysis probes (Applied Biosystems) as shown in Table 2 at 1X (900 nM) in each 20 μL
reaction. Reactions were performed in triplicate using 2X Universal PCR Master Mix (Applied
Biosystems) and analyzed on a BioRad C1000 Thermal Cycler CFX96 instrument (Bio-Rad
Laboratories, Inc., Hercules, CA). Automated reaction conditions were as follows: Initial hold

4

Full protocol provided in Appendix A.
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50°C 2 minutes; Initial denaturation 95°C 10 minutes; 40 cycles of denaturation (95°C 15
seconds), annealing and extension (60°C 1 minute); Final hold 4°C.
Data Analysis and Statistics
Gene expression data were analyzed using the standard curve method.

Plasmids

containing genes of interest were purchased from Open Biosystems and DNA isolated by
QIAprep Miniprep (Qiagen) according to the manufacturer’s instructions. Standard curves were
generated by serial ten-fold dilution of plasmid DNA and amplification by qRT-PCR using TaqMan
Gene Expression Assays. R2 values and amplification efficiencies were within accepted ranges.
Standard curves were used to calculate experimental copies per reaction. These values were
normalized to housekeeping gene TBP expression levels. Standard curve regression equations
and other calculations are shown in Table 2.
Data were analyzed using statistical software GraphPad Prism 5 (GraphPad Software,
Inc., La Jolla, CA). Groups were compared using 1 way ANOVA and Tukey’s Multiple Comparison
Test post-hoc. (* indicates p < 0.05. ** indicates p < 0.01. *** indicates p < 0.001.) Pearson
correlation coefficient and associated p values were calculated for the Pancreatic Cancer Clinical
Registry data correlative analysis using this software.
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Table 2. TaqMan Gene Expression Assays and Plasmid Standard Curve Analyses
Gene
Symbol

Gene
Name

TaqMan
Gene
Expression
Assay

Vector

FAP

FST

CAMK2B

Ca l ci um/
ca l modul i nFibroblast
dependent
TATA box
activation
protei n
Follistatin
binding
ki na s e
protein
protein
type II
alpha
s ubuni t
beta

Insert

FBXO32

TRIM63

Tripartite
motif
containing
F-box
63, E3
protein 32
ubiquitin
protein
ligase

TIE1
Tyrosine
kinase
with
immunoglobulinlike and
EGF-like
domains 1

Hs009908 Hs002462 Hs003657 Hs004276 Hs010414 Hs002615 Hs001785
06_m1
56_m1
99_m1
21_m1
08_m1
90_m1
00_m1
pDNR-LIB

pOTB7

pOTB7

Open
MHS1011- MHS1011- MHS4771Biosystems
7509787
60751
99610862
Cat.#

Plasmid
Size (bp)

TBP

4161

1815

1815

pCMV-SPORT6 pBluescriptR

pINCY

pCMV-SPORT6

MHS1010- MHS1010- IHS1380- MHS1010980516668 7295752 97433020 7508594

4396

2990

BC026250 BC004107 BC019070 BC110341 BC024030

4126

4396

LIFESEQ
4042617

BC038239

Insert Size
(bp)

2648

1326

1896

1887

1212

1664

3960

Mass of
Plasmid +
Insert
(g/Copy)

7.46E-18

3.44E-18

4.07E-18

6.89E-18

4.61E-18

6.35E-18

9.16E-18

[Plasmid +
Insert]
(g/μL)

4.68E-08

2.95E-07

4.03E-07

2.76E-07

1.63E-07

4.19E-08

4.77E-07

Copies/μL 6.27E+09

8.56E+10

9.90E+10

4.00E+10

3.53E+10

6.60E+09

5.20E+10

Standard
Curve
y = -3.1370x y = -3.3203x y = -3.6087x y = -3.4411x y = -3.4374x y = -3.5086x y = -3.1577x
Regression
+ 39.764
+ 40.540
+ 42.277
+ 40.908
+ 41.074
+ 42.166
+ 34.928
(10-Fold
Dilutions)

R2

0.999

0.989

0.993

0.994

0.999

0.999

0.996

Amplification
Coefficient

2.08

2.00

1.89

1.95

1.95

1.93

2.07

% Efficiency

108.34

100.07

89.28

95.26

95.40

92.76

107.34
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Results
Differences in Gene Expression in Pancreatic Cancer Patients vs. Normal Controls
We found significant differences in gene expression levels between PDAC patient
skeletal muscle samples regardless of cachexia status and normal control skeletal muscle for all
genes analyzed except FST (Figure 26). FAP expression was lower in cancer patients compared
to normal controls. The same was true of CAMK2B expression. TIE1 levels were also decreased
in PDAC patients. TRIM63 was expressed at a higher level in both cachectic and non-cachectic
PDAC patients compared to normal controls. FBXO32 gene expression was also higher in cancer
patients than normal donors.
Differences in Gene Expression in Cachectic vs. Non-Cachectic Pancreatic Cancer Patients
There were no significant differences in the expression of any of the genes we analyzed
in skeletal muscle samples of cachectic and non-cachectic PDAC patients based on the original
Yes/No cachexia status designations. We decided to further stratify patients into subgroups
based on additional clinical and pathology notes, weight loss history, and BMI at time of death.
Cachectic and non-cachectic patients were reclassified into the following six subgroups: yes,
severe cachexia (S); yes, weight loss (YWL); yes, normal or overweight BMI (YN); no, weight loss
(NWL); no, normal or overweight BMI (NN); and no, obese (NOB). Specific inclusion criteria for
each group are described above.
Subgroup Gene Expression Analysis
There were no significant differences in gene expression between PDAC patient
subgroups for any of the genes analyzed. Gene expression in some subdivided groups was
significantly different than normal controls. YWL and NWL groups had lower expression of FAP
than controls, but the other subgroups were no longer significantly different (Figure 27). As
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with the Yes/No analysis, no subgroups showed differential FST expression compared to normal
controls (Figure 28). Expression levels of CAMK2B (Figure 29) and TIE1 (Figure 30) were
significantly lower in all subgroups compared to control levels. For TRIM63, subgroups S, YN,
NN, and NOB displayed higher expression than controls (Figure 31). S, NWL, NN, and NOB
samples had higher levels of FBXO32 than normal control muscle samples (Figure 32).
PDAC Cachexia and Alcohol Use, Tobacco Use, and Diabetes Status
We analyzed Pancreatic Cancer Collaborative Registry data on alcohol use, tobacco use,
and diabetes mellitus status of the majority of the PDAC patients included in this study (Table 3).
We found no correlation between alcohol use, tobacco use, or diabetes status with cachexia
status in our patient population. There was also no correlation of any of these variables with
one another.
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Figure 26. Cachexia gene expression normalized to TBP. Gene expression of putative cachexiaassociated genes in skeletal muscle samples from cachectic and non-cachectic pancreatic ductal
adenocarcinoma patients and normal donor controls that had no history of cancer. Data
normalized to TBP. (** indicates p < 0.01. *** indicates p < 0.001.)

171

Figure 26
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Figure 27. FAP-α gene expression based on modified cachexia status. Gene expression in
skeletal muscle samples from cachectic and non-cachectic pancreatic ductal adenocarcinoma
patients and normal donor controls that had no history of cancer. Data normalized to TBP.
(* indicates p < 0.05. ** indicates p < 0.01.)
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Figure 27
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Figure 28. FST gene expression based on modified cachexia status. Gene expression in skeletal
muscle samples from cachectic and non-cachectic pancreatic ductal adenocarcinoma patients
and normal donor controls that had no history of cancer. Data normalized to TBP. (Ns = not
significant.) There was no significant difference between any of the groups in the lower panel.
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Figure 28
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Figure 29. CAMKIIβ gene expression based on modified cachexia status. Gene expression in
skeletal muscle samples from cachectic and non-cachectic pancreatic ductal adenocarcinoma
patients and normal donor controls that had no history of cancer. Data normalized to TBP.
(* indicates p < 0.05. ** indicates p < 0.01. *** indicates p < 0.001.)
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Figure 29

178
Figure 30. TIE-1 gene expression based on modified cachexia status. Gene expression in
skeletal muscle samples from cachectic and non-cachectic pancreatic ductal adenocarcinoma
patients and normal donor controls that had no history of cancer. Data normalized to TBP.
(* indicates p < 0.05. *** indicates p < 0.001.)
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Figure 30
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Figure 31. TRIM63 gene expression based on modified cachexia status. Gene expression in
skeletal muscle samples from cachectic and non-cachectic pancreatic ductal adenocarcinoma
patients and normal donor controls that had no history of cancer. Data normalized to TBP.
(* indicates p < 0.05. ** indicates p < 0.01. *** indicates p < 0.001.)
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Figure 31
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Figure 32. FBXO32 gene expression based on modified cachexia status. Gene expression in
skeletal muscle samples from cachectic and non-cachectic pancreatic ductal adenocarcinoma
patients and normal donor controls that had no history of cancer. Data normalized to TBP.
(* indicates p < 0.05. ** indicates p < 0.01. *** indicates p < 0.001.)
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Figure 32
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Table 3. Cachexia Status Does Not Correlate with Alcohol or Tobacco Use or Diabetes
Status
Correlation Coefficient, r
Cachexia
Status
Cachexia Status

Alcohol
Use

Tobacco
Use

Diabetes
Status

0.340

0.181

-0.002

0.248

0.053

Alcohol Use
Tobacco Use

-0.015

Diabetes Status
P values
Cachexia
Status
Cachexia Status
Alcohol Use
Tobacco Use
Diabetes Status

Alcohol
Use

Tobacco
Use

Diabetes
Status

0.040

0.292

0.990

0.204

0.757
0.929
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Discussion
Previous Studies of Cachexia Gene Expression
We studied expression levels of genes previously reported to have a role in cachexia,
muscle wasting, or exercise using skeletal muscle samples taken at rapid autopsy from
pancreatic ductal adenocarcinoma patients and normal control muscle samples. We found
upregulation of FAP, TRIM63, and FBXO32 in PDAC samples irrespective of cachexia status
compared to controls. We found no significant difference in FST expression in PDAC samples
with and without cachexia and compared to normal controls.

CAMK2B and TIE1 were

downregulated in cachectic and non-cachectic PDAC skeletal muscle compared to controls. We
found no significant differences in gene expression between PDAC patients with and without
cachexia. Cancer cachexia is a progressive disease; further stratification of PDAC patients
according to severity of cachexia, however, did not reveal additional differences in gene
expression among cachectic and non-cachectic subgroups.
Several studies have examined the role of FAP-α in cancer-associated cachexia and its
relationship to FST, TRIM63, and FBXO32. Depletion of FAP+ fibroblasts by genetic ablation or
chimeric antigen receptor (CAR) T cell targeting caused muscle wasting and cachexia (Roberts et
al., 2013; Tran et al., 2013). KPC mice bearing spontaneous PDAC and mice with C26 colon
tumors developed cancer-associated cachexia and concomitant decreases in FAP-expressing
fibroblasts (Roberts et al., 2013). These cells are the major source of FST, and their loss resulted
in decreased FST levels. Decreased FST was accompanied by concomitant increases in atrogin15
and MuRF-1 (muscle RING finger protein-1) expression in cachectic mice only (Roberts et al.,

5

As much of the previous work in cancer cachexia was done in mouse models, alternative nomenclature
is often used in referring to genes. Atrogin-1 and MAFbx are alternative names for FBXO32. MuRF-1 is
another name for TRIM63.
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2013). Our findings of increased FAP expression and no change in FST levels in stand in contrast
to these mouse data. We also found parallels in gene expression of PDAC patient skeletal
muscle samples regardless of cachexia status compared to cancer-free controls, while in the KPC
mouse study, littermates and non-cachectic KPC gene expression profiles were consistently
similar while cachectic KPC samples displayed a different pattern of expression. A study of
gastric cancer patients also found no change in FST expression across patient and control
skeletal muscle samples. That group, however, did not find increased ubiquitin ligase pathway
genes; they reported no significant difference in levels of MuRF1 and atrogin-1 between cancer
patient samples and controls (D'Orlando et al., 2014). A study of several rat models of muscle
atrophy reported increased expression of MuRF1 and muscle atrophy F-box (MAFbx) (Bodine et
al., 2001). A study of human upper gastrointestinal cancers, including PDAC, found no increases
in ubiquitin ligase pathway genes TRIM63 and FBXO32 or exercise-activated genes CAMK2B and
TIE1 expression, but these genes were upregulated in mouse models (Gallagher et al., 2012).
Another study of human tissue found correlations between weight loss and the levels of
CAMK2B and TIE1, but not MuRF1 or MAFbx (Stephens et al., 2010). These discrepancies
illustrate the limitations of animal models in recapitulating human disease and heterogeneity
among cancer types and in human patient populations.
Study Limitations
Our study had several limitations. First, we had a small sample size. Nearly all of our
patients and controls were white, and the age and gender distributions of normal tissue donors
were different than those in the PDAC population. Second, normal control samples in many
cases were not derived from disease-free donors. Tissue was excluded in the event of patient
history of cancer, but many of the samples were taken from diseased limbs. Co-morbidities
associated with our control samples included gangrene, ischemia, vascular disease, and
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osteomyelitis. Finally, we profiled only gene expression. Many levels of regulation lie between
message levels and functional output of a specific protein.

The universal differences in gene expression between RAP PDAC skeletal muscle
samples and normal control samples raise the question of whether a fundamental difference in
sample sets (such as tissue handling conditions) could be responsible rather than a biological
effect. There are several reasons why we do not believe that to be the case. We used standard
nucleic acid spectrophotometry and fragmentation analysis procedures to confirm RNA quality
of each sample. The average RNA quality score for the RAP cohort was 7.6, and that of the
normal control group was 6.8, both of which were above the established lower threshold value
of 6.0 for quantitative gene expression analysis. Samples for which minimum quality thresholds
could not be achieved after two extraction attempts were excluded from our study. We also
confirmed equal expression of housekeeping gene TBP across groups. The mean TBP threshold
cycle in the RAP group was 26.27, and that of the normal control group was 27.28; two outliers
in the normal group with threshold cycle values of 31.43 and 32.65, respectively, were
responsible for this shift, and their exclusion resulted in a normal group average of 26.48.
Additionally, the bidirectional nature of the differences in experimental gene expression did not
support the notion that one sample set was universally of poorer quality than the other. Three
of the genes studied were more highly expressed in normal control samples compared to RAP
samples, one gene’s expression was not significantly different between groups, and two genes
were present at lower levels in normal samples. If the levels of all genes were lower in normal
controls than RAP samples, we might conclude that the difference in RNA quality between the
two cohorts (7.6 vs. 6.8) accounted for this difference, but that was not the case here.
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Additional Studies with RAP Tissues Based on Cachexia Status
Despite the relatively small number of patients who have been studied in the PDAC
rapid autopsy program (nearly 100), the tissue samples in our repository are some of the most
comprehensive and well-annotated in the world. We routinely collect primary pancreas tumor,
metastatic lesions from all involved organs, tumor margins, adjacent normal organ parenchyma,
and other sites not directly infiltrated by carcinoma but that may nevertheless be affected by
the systemic consequences of end-stage PDAC, such as skeletal muscle. Clinical records are also
available for these patients. Future studies extending the work done here in pancreatic cancer
cachexia could include evaluation of circulating inflammatory factors in patient serum samples,
analysis of cardiac muscle for cachexia-associated pathology, studies of how the various
pancreatic cancer treatment regimens affect cancer cachexia and vice versa, and examination of
how cachexia impacts disease progression and overall survival. Patient CT scans routinely
performed in PDAC diagnosis and staging could also be used to track development of cachexia
over time as it relates to disease progression and to include a quantifiable metric (lumbar
skeletal muscle index) in the process of assigning cachexia status (Martin et al., 2013b; Tan et
al., 2009). Finally, although diabetes status did not correlate with cachexia in this analysis,
evidence suggests a connection between diabetes mellitus and cachexia (Asp et al., 2010;
Honors and Kinzig, 2012; Pannala et al., 2009). Further studies with these unique tissues could
more carefully dissect the interplay of insulin resistance, glucose neurotoxicity, pancreatic
tumor progression, cachexia, and perineural invasion.
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DISCUSSION AND FUTURE DIRECTIONS6

6

Portions of this chapter have been published under the following references: (Fink et al., 2014a), (Fink
et al., 2015a)
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Through the exploration of three aspects of inflammation—nonmalignant- and tumorassociated neurolymphatic remodeling and crosstalk and cancer-associated cachexia—work
presented in this dissertation has: discovered a novel role of NGF in lymphatic vessel regulation
in inflammation and wound recovery; identified distinct neurolymphatic architecture signatures
present in inflammatory, wound-recovered, and tumor-associated microenvironments;
characterized distinct spatiotemporal tumor cell behaviors dependent on timing of
establishment of tissue microenvironmental inflammatory conditions; and challenged some
previous findings regarding expression of muscle atrophy and exercise-associated genes in the
paraneoplastic inflammatory syndrome PDAC cancer cachexia.

NGF and Neurolymphatic Remodeling
We first studied the resolution of two cardinal signs of non-malignant inflammation—
pain and swelling—by investigating molecular mechanisms that regulate neural and lymphatic
vessel remodeling during the resolution of corneal inflammation. A mouse model of corneal
inflammation and wound recovery was developed to study this process in vivo. We showed for
the first time activity of NGF, the prototypical nerve survival and guidance molecule, on the
lymphatic endothelium. NGF influenced the two major lymphatic vessel remodeling events that
accompany shifts in microenvironmental inflammatory status—lymphangiogenesis and
lymphatic vessel regression. The corneal micropocket assay revealed that NGF-laden pellets
stimulated lymphangiogenesis and increased protein levels of VEGF-C. Adult human dermal
lymphatic endothelial cells did not express canonical NGF receptors TrkA and p75NTR or activate
downstream MAPK- or Akt-pathway effectors in the presence of NGF, although NGF treatment
increased their migratory and tubulogenesis capacities in vitro. Blockade of the VEGFR-2/3
signaling pathway ablated NGF-mediated lymphangiogenesis in vivo. Administration of NGF also
increased pain sensation and inhibited neural remodeling and lymphatic vessel regression
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processes during wound recovery. These findings suggested a hierarchical relationship with NGF
functioning upstream of the VEGF family members, particularly VEGF-C, to stimulate
lymphangiogenesis.

Taken together, these

studies

showed that NGF stimulates

lymphangiogenesis and that NGF may act as a pathogenic factor that negatively regulates the
normal neural and lymphatic vascular remodeling events that accompany wound recovery.

Microenvironment-Specific Neurolymphatic Architecture Signatures:
Implications for Therapy
A major theme throughout this work has been the identification and characterization of
novel neurolymphatic remodeling signatures present under distinct microenvironmental
conditions. We studied neurolymphatic remodeling in two mouse organ systems with distinct
nerve and lymphatic architectures in homeostasis—cornea and pinna. The cornea is one of the
most densely innervated tissues in the body but is devoid of lymphatic vessels in homeostasis.
Each skin leaflet of the pinna houses separate uniformly-distributed nerve and lymphatic vessel
plexuses under normal physiological conditions. We used these complementary systems to
study neurolymphatic remodeling in non-malignant and tumor-associated inflammation and the
resolution of inflammation, or wound recovery. Suture or tumor stimuli were used to induce
inflammatory conditions, and the removal of sutures stimulated wound recovery. Growing
evidence suggests that the resolution of inflammation is not, however, a passive process merely
allowed by loss of inflammatory mediators as they diffuse away upon stimulus removal (Serhan
and Savill, 2005; Serhan et al., 2007; Serhan et al., 2008), and our neurolymphatic remodeling
results supported that idea. We identified distinct neurolymphatic architecture signatures
present in inflammatory, wound-recovered, and tumor-associated microenvironments. We
characterized non-malignant inflammatory lymphangiogenesis and neuroremodeling both in
initial and recurrent inflammation, and we discovered three novel rapid neuroremodeling
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phenotypes that characterized transitions into initial inflammation, from initial inflammation to
wound recovery, and from wound recovery to recurrent inflammation. We also identified novel
neurolymphatic remodeling events that accompany malignancy. We found distinct differences
in nerve and lymphatic penetration into the site of a suture stimulus as compared to the site of a
tumor including a dramatic hyper-sprouting phenotype in nascent tumor-associated lymphatic
vessels.

These findings show that neurolymphatic architecture is highly responsive to

microenvironmental conditions, and further organ-specific study of tumor-associated
neurolymphatic signatures may identify targetable aspects of these remodeling events that are
suitable for early detection imaging or treatment.
PDAC Treatments: Emphasis Lymphatics and Nerves
Due to advanced stage at diagnosis and its complex microenvironmental organization,
pancreatic ductal adenocarcinoma has proven to be very difficult to treat. Surgical removal of
the tumor is the most effective option, but only approximately 15% of cases are considered
resectable (Yeo and Cameron, 1998; Zuckerman and Ryan, 2008). Of those cases in which
resection is an option, incomplete removal of microscopic disease (R1 residual margin status)
only slightly improves patient survival over those cases presenting with unresectable metastatic
disease (Chang et al., 2009; Konstantinidis et al., 2013). Non-surgical options for pancreatic
cancer include radiation, chemotherapy, or a combination of both.

Some approved

chemotherapies for the treatment of pancreatic cancer are the use of FOLFIRINOX (combination
of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin), gemcitabine, albumin-bound paclitaxel,
and cisplatin (as well as others) (Gresham et al., 2014; Tempero et al., 2014). However, these
drugs have had limited success in prolonging patient survival.

Development of targeted

therapies that specialize in blocking crucial molecular pathways of the pancreatic tumor and its
microenvironment is becoming an increasingly attractive therapeutic option.
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Pancreatic Tumor Resection, Lymphadenectomy, and Nerve Plexus Removal
Surgical resection of pancreatic adenocarcinoma was first brought to clinical practice by
Walther Kausch in Berlin in 1909 (Gerdes et al., 2005). Beginning in the mid-1930s, American
surgeon Allen O. Whipple further employed and modified the pancreat(ic)oduodenectomy (PD)
procedure that would bear his name; he eventually condensed the surgery into a single
operation, the first of which was successfully performed in 1940 (Whipple, 1941).

In a

traditional PD the head of the pancreas is removed along with the duodenum, gall bladder, and
end of the common bile duct (Bhatti et al., 2010; Doi et al., 2007; Duanmin et al., 2013; HenneBruns et al., 1998; Henne-Bruns et al., 2000; Hirono et al., 2012; Kanda et al., 2011; Kocher et al.,
2007; Murakami et al., 2010; Sergeant et al., 2013; Zacharias et al., 2007). Several timely
surgical advances facilitated increased success of the PD as performed by Whipple and his
contemporaries including the first successful duodenectomy in a canine, the discovery that
direct immediate restoration of biliary and pancreatic secretions into the gastrointestinal tract
was not necessary for survival of patients, and the use of non-dissolvable silk suture rather than
the more temporary catgut (Howard, 1999; Whipple, 1941). Additional scientific breakthroughs
critical for decreased perioperative morbidity and mortality included the discovery and synthesis
of vitamin K, the discovery of insulin, and the description of human blood types and subsequent
establishment of blood banks (Howard, 1999; Whipple, 1941). Today, a broad range of similar
pancreatic resection procedures are in use in modern surgical practices around the world.
Differences in primary tumor placement within the pancreas—head/neck vs. body/tail—and
tumor invasion into surrounding tissues and organs often necessitate customization of resection
(Cui et al., 2011; Dansranjavin et al., 2006; Formentini et al., 2009; Kamisawa et al., 1995;
Kurahara et al., 2004; Liu et al., 2015a; Ohta et al., 1994; Pignatelli et al., 1994; Sergeant et al.,
2009; Tempia-Caliera et al., 2002; Wang et al., 2012; Yamamoto et al., 2014) beyond the
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traditional PD to such procedures as distal pancreatectomy with or without splenectomy
(Duanmin et al., 2013; Nagai et al., 2011), pancreaticogastrostomy (Zacharias et al., 2007),
pylorus-preserving PD (Doi et al., 2007; Hirono et al., 2012; Murakami et al., 2010), pylorusresecting PD (Hirono et al., 2012), subtotal stomach-preserving PD, pancreatojejunostomy,
duodenum-preserving head resection, wedge resection of inferior vena cava, and total (Kocher
et al., 2007) or regional (Tao et al., 2006) pancreatectomy (Kobayashi et al., 2010; Shimada et
al., 2006).
As with surgical treatment of other malignancies, one of the most controversial aspects
of modern pancreatic ductal adenocarcinoma resection has been the extent to which
surrounding connective tissue, lymph nodes, and neural tissue should be removed. Evidence
suggests that metastasis to lymph nodes is an early event in pancreatic cancer progression, and
presence of tumor cells in lymph nodes represents one of the most negative prognostic factors
with respect to patient outcomes (Benassai et al., 1999; Chen et al., 2010; Doi et al., 2007; Fujita
et al., 2010; Kanda et al., 2011; Nakagohri et al., 2006; Winter et al., 2006; Yamamoto et al.,
2004).

Conservative surgical views support the standard PD with loco-regional

lymphadenectomy (Evans et al., 2009; Farnell et al., 2005; Farnell et al., 2008; Gerdes et al.,
2005; Henne-Bruns et al., 1998; Henne-Bruns et al., 2000; Hirata et al., 1997; Kanda et al., 2011;
Michalski et al., 2007; Murakami et al., 2010; Nagai et al., 2011; Nimura et al., 2012; Pawlik et
al., 2005; Pederzoli et al., 1997; Pissas, 1984; Samra et al., 2008; Sergeant et al., 2013; Shimada
et al., 2006; Yeo et al., 2002), while others, most notably numerous Japanese groups, advocate
that a more radical PD with extensive removal of retroperitoneal soft tissue and extended
lymphadenectomy (Fernandez-Cruz et al., 1999; Henne-Bruns et al., 1998; Ishikawa et al., 1988;
Kanda et al., 2011; Katuchova et al., 2012; Kocher et al., 2007; Manabe et al., 1989; Masui et al.,
2013; Meriggi et al., 2007; Nakao et al., 1995; Ohta et al., 1993; Pedrazzoli et al., 1998; Riall et

195
al., 2005; Sergeant et al., 2013) results in better patient outcomes. Collected studies in Table 4
(Benassai et al., 1999; Bittner et al., 1989; Dasari et al., 2015; Doi et al., 2007; Evans et al., 2009;
Farnell et al., 2005; Farnell et al., 2008; Fernandez-Cruz et al., 1999; Fujii, 2013; Gerdes et al.,
2005; Henne-Bruns et al., 1998; Henne-Bruns et al., 2000; Hirata et al., 1997; Hirono et al., 2012;
Imai et al., 2010; Iqbal et al., 2009; Ishikawa et al., 1988; Jang et al., 2014; Kanda et al., 2011; Ke
et al., 2014; Kocher et al., 2007; Manabe et al., 1989; Masui et al., 2013; Meriggi et al., 2007;
Michalski et al., 2007; Nakao et al., 1995; Nguyen et al., 2003; Nimura et al., 2012; Ohta et al.,
1993; Pawlik et al., 2005; Pederzoli et al., 1997; Pedrazzoli et al., 1998; Pedrazzoli, 2015;
Peparini, 2015; Pissas, 1984; Riall et al., 2005; Roche et al., 2003; Samra et al., 2008;
Schoellhammer et al., 2015; Sergeant et al., 2013; Shimada et al., 2006; Svoronos et al., 2014;
Tol et al., 2014; Yeo et al., 1999; Yeo et al., 2002) demonstrate the broad range of study designs
and conclusions that have fueled this debate. A recent set of randomized, controlled clinical
trials from several centers around the world and a mathematical model of outcomes prediction
have concluded that extended lymphadenectomy does not improve survival over traditional,
more conservative resection and that quality-of-life may be decreased with more radical surgery
(Farnell et al., 2005; Farnell et al., 2008; Jang et al., 2014; Michalski et al., 2007; Nguyen et al.,
2003; Nimura et al., 2012; Pawlik et al., 2005; Pedrazzoli et al., 1998; Riall et al., 2005; Yeo et al.,
1999; Yeo et al., 2002). Leading international surgical groups have also applied their expertise to
the ongoing conversation in this field. They have recently identified lymph node stations to be
included in standard lymphadenectomy for head (5, 6, 8a, 12b1, 12b2, 12c, 13a, 3b, 14a, 14b,
17a, and 17b) and body/tail (10, 11, 18) pancreatic cancer resections (Tol et al., 2014) and have
released recommendations suggesting discontinued use of extended lymphadenectomy for
treatment of PDAC (Evans et al., 2009; Sergeant et al., 2013; Tol et al., 2014). The occasional
case report continues to demonstrate the biological diversity of pancreatic malignancy and
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challenge these recommendations.

In 2013 a Japanese group reported that extended

lymphadenectomy in a well-differentiated, chemotherapy-responsive PDAC with para-aortic
lymph node metastases resulted in patient survival of over ten years (Masui et al., 2013).
Peparini, et al., addressed para-aortic lymph node involvement (stations 16a2 and 16b1), stating
that involvement of these lymph nodes may be due to direct invasion of the primary pancreatic
tumor as opposed to dissemination and seeding of migratory cancer cells in the traditional
definition of metastasis and that their removal may favorably impact R margin status (Peparini,
2015). Clinical trials and expert consensus recommendations consistently recommend standard
lymphadenectomy over more radical resection strategies, but, as each case of pancreatic cancer
is truly a unique disease, circumstances in which extended lymph node removal is beneficial
may be more clearly defined in the future.
Controversy also exists with regard to the amount of nervous tissue that should be
removed as part of pancreatic tumor resection (Reviewed in (Fernandez-Cruz et al., 1999; Samra
et al., 2008)). Nerve invasion by PDAC cells occurs both in intrapancreatic nerves as well as
extending to peripancreatic nerve plexuses. As with lymphadenectomy, the concept of nervous
tissue removal is founded on the principle that in order to prevent recurrence, all local
reservoirs of tumor cells must be surgically eradicated. And as with other radical resection
procedures, aggressive surgical strategy must be balanced with undesirable side effects
attributable to tissue removal as peripancreatic nerve plexus removal often results in severe
diarrhea.
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Table 4. Standard (sLE) vs. Extended (eLE) Lymphadenectomy for Treatment of PDAC:

Results and Recommendations of Collected Studies

Citation

Study
Type

Results/Conclusions

Supported LE Type

Masui 2013

CR

In selected cases eLE can result in long-term patient survival: here
well-differentiated, chemotherapy-responsive pancreatic cancer
with PALN metastasis

Extended

Pedrazzoli
1998

P

Survival trends toward an increase in node positive patients with
PD + eLE and retroperitoneal tissue removal over sLE; No increase
in operative morbidity/mortality

Extended

P

Survival trends toward an increase in pylorus-preserving PD with
retroperitoneal LE and distal gastrectomy in PDAC patients, but
this may be due to increased positive resection margins in
standard resection group

Extended

Riall 2005
Benassai
1999

R

Survival increased with eLE but may be due to patient selection;
Additional prospective randomized trials are necessary

Ishikawa
1988

R

eLE and connective tissue removal is recommended for regional
control of small ( < 4 cm) tumors

Extended

Manabe
1989

R

Survival increased with radical pancreatectomy including soft
tissue removal and eLE beyond suspected positive lymph nodes

Extended

Meriggi
2007

R

Extended peripancreatic and locoregional LE including removal of
nerve and connective tissue reduces local recurrence in tumors < 4
cm in diameter

Extended

Nakao 1995

R

eLE including PALNs should be performed in patients with pancreas
head cancer

Extended

Ohta 1993

R

eLE and removal of retroperitoneal connective tissue is
recommended for curative resection in tumors macroscopically
confined to pancreas

Extended

Rv

Removal of primary tumor as well as eLE and removal of nerve
plexus, soft tissue, and portions of nearby blood vessels are
necessary to prevent tumor recurrence and spread

Extended

Rv

Modified en bloc resection (including removal of lymphatics and
neural tissue associated with superior mesenteric artery and
retropancreatic tissue) may be best for PDAC of pancreas head

FernándezCruz 1999
Samra 2008

International Group on Pancreatic Surgery accepted Japanese
Pancreas Society lymph node classification system, defined
standard and extended LE procedures, and recommended
standard LE for PDAC

Extended

Modified radical/
Intermediate

Tol 2014

Exp

Farnell
2005

P

Quality-of-life is decreased in patients following eLE with no
survival benefit; No further trials should be performed comparing
these two surgical methods

Standard

Gerdes
2005

P

Radical LE not recommended in cases of pylorus-preserving PD

Standard

Jang 2014

P

Prospective randomized clinical trial found no improvement in
survival with eLE over sLE while eLE increased morbidity

Standard

P

No difference in 5-year or disease-free survival or number of
involved lymph nodes; Local recurrence higher and quality-of-life
lower with eLE; eLE not indicated based on trials

Standard

Nimura
2012

Standard
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Pissas 1984

Yeo 2002

P

Describes pancreatic lymphatic drainage patterns and involved
lymph nodes with discussion of appropriate surgical procedures to
remove specific lymph node clusters; eLE may not be beneficial
because of close proximity of pancreatic lymphatics and thoracic
duct allowing early circulation of tumor cells

Standard

P

Extending pylorus-preserving PD with retroperitoneal LE and distal
gastrectomy does not improve survival and increases morbidity in
patients with periampullary carcinomas; eLE may show some
benefit in PDAC with long-term follow-up

Standard

HenneBruns 1998

R

Retroperitoneal eLE does not improve survival over regional LE for
pancreatic head tumors following R0 partial duodenopancreatectomy

Standard

HenneBruns 2000

R

Survival after partial PD does not improve with eLE and
retroperitoneal tissue removal over regional LE

Standard

Hirata 1997

R

eLE does not always improve PDAC outcomes and may be
responsible for increased post-operative mortality

Kanda 2011

R

A thorough but not radical degree of LE is recommended with
differential dissections indicated for head vs. body/tail tumors

Standard

Pawlik 2005

R

eLE may only benefit 0.3% of patients; Too large of a population
size would be necessary to sufficiently power a prospective trial
making it infeasible

Standard

Shimada
2006

R

eLE does not improve outcomes in the presence of positive PALNs
and is not recommended

Standard

Dasari 2015

Rv

Meta-analysis of randomized clinical trials; eLE does not improve
survival over sLE but increases morbidity

Standard

Evans 2009

Rv

Survival is not improved with eLE over sLE; Recommend sLE during
PDAC PD

Standard

Farnell
2008

Rv

Recommends standard PD without eLE based on survival and
quality-of-life outcomes of four randomized clinical trials

Standard

Fujii 2013

Rv

Title somewhat misleading; Advocates LE with sufficient removal of
LNs to provide accurate prognosis (to include lymph node ratio
metric) but does not recommend extensive eLE

Standard

Iqbal 2009

Rv

Meta-analysis 1988-2005; eLE is associated with increased patient
morbidity including delayed gastric emptying with no increase in
survival

Standard

Ke 2014

Rv

eLE is associated with poor post-operative quality-of-life; sLE is
recommended for patients with PDAC of pancreas head

Standard

Michalski
2007

Rv

Survival not improved and quality-of-life decreased with eLE; Not
indicated except perhaps in the setting of additional randomized
controlled trials

Standard

Pederzoli
1997

Rv

Current data does not show benefit of extensive LE; Additional
prospective randomized trials are necessary

Pedrazzoli
2015

Rv

Lymph node stations 6, 8a, 8p, 12a, 12b, 12c, 13a, 13b, 14a, 14b,
14c, 14d, 16b1, 17a, and 17b should be removed as part of a sLE to
accurately stage disease and decrease metastasis risk

Standard

Peparini
2015

Rv

Lymph node stations 16a2 and 16b1 (PALNs) should be included in
sLE to minimize local invasion and improve resection margins

Standard

Standard

Standard
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Schoellhammer
2015

Rv

eLE should not be implemented for PDAC patients due to lack of
improvement in patient survival

Standard

Sergeant
2013

Rv

Sufficient evidence does not exist to indicate eLE over sLE for
treatment of PDAC of pancreas head

Standard

Rv

Five-year overal survival was not improved with eLE and eLE
patients experienced a significant increase in post-operative
diarrhea; sLE with PD should be used to treat PDAC of pancreas
head

Standard

Svoronos
2014

The studies below do not directly support one type of LE over another but provide pertinent results that
should be considered in a discussion of this topic.

Hirono
2012

P

Intraoperative physiological fluorescence imaging identified 7 lymphatic drainage pathways from
pancreatic uncinate process; Removal of PALNs and skeletonization of superior mesenteric artery
may both be beneficial

Imai 2010

P

CT, MRI, and FDG-PET cannot accurately detect presence or absence of lymph node metastases;
Intraoperative examination of frozen sections is recommended

Kocher
2007

P

Sentinel pancreas lymph nodes were not identified intraoperatively; Prediction of positive lymph
nodes to guide selective resection was not possible

Nguyen
2003

P

There is no difference in quality-of-life metrics in standard vs. radical resection 2.2 years following
surgery

Roche 2003

P

Preoperative CT does not accurately predict positive lymph nodes especially in the case of
micrometastasis and should not preclude curative resection or direct LE decisions

Yeo 1999

P

Extending pylorus-preserving PD with retroperitoneal LE and distal gastrectomy does not increase
morbidity and mortality over standard resection; More time and greater numbers of patients are
needed to assess survival benefit

Bittner
1989

R

Surgery for pancreatic cancer does not increase morbidity or mortality over other abdominal
oncologic surgeries; Resection only benefits TNM stage I population

Doi 2007

R

PALN metastasis correlated with increased mortality; Upon intraoperative confirmation of PALN
metastasis alternative treatment strategies should be considered due to short survival duration
even with eLE

CR: Case report, Exp: Expert consensus statement, LE: Lymphadenectomy--(e) Extended, (s) Standard, P:
Prospective study, PALN: Para-aortic lymph node, PD: Pancreat(ic)oduodenectomy, PDAC: Pancreatic
ductal adenocarcinoma, R: Retrospective study, Rv: Review

*This table was previously published in Fink et al., 2015a.
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Outcomes Prediction: Lymphatic-Specific Metrics
Outcomes prediction for pancreatic cancer patients has traditionally been based on
stage classification according to the TNM (tumor, node, metastasis) system at diagnosis (Santi et
al., 2011). Pancreatic cancer is rarely diagnosed in a pre-metastatic state. Unlike perineural
invasion, which is nearly universally accepted to negatively impact survival, the utility of
lymphatic-specific metrics in predicting patient outcomes is less well understood and
appreciated. Comprehensive examination of lymph node and lymphatic vessel involvement
would provide clinicians with important information about the progression characteristics of an
individual patient’s tumor such as its pattern and route of spread, likelihood of local/distant
recurrence, and potential immunomodulatory effects.

Four outcomes predictive metrics

specifically address lymph node/lymphatic vessel involvement: lymph node disease (LND),
lymph node burden (LNB), lymph node ratio (LNR), and lymphatic vessel invasion (LVI). Each of
these measures provides distinct information regarding disease pathology and may be useful in
refining prognoses. LND is defined as the confirmed presence of metastatic tumor cells in at
least one lymph node. The total number of positive lymph nodes confirmed at resection
constitutes LNB. LNR is the ratio of the number of positive nodes to the total number of nodes
examined (John et al., 2013). LNR has been shown to be an effective tool to further stratify the
TNM stage N1 patient population for outcomes prediction while decreasing likelihood of
understaging and stage migration (Berger et al., 2004; Pawlik et al., 2007; Slidell et al., 2008).
LVI may refer to lymphatic vessel invasion as determined by immunohistochemical staining of
tissue sections or more broadly, to lymphovascular invasion, which may or may not distinguish
between invaded hematogenous and lymphogenous vessels (Chen et al., 2010; Safuan et al.,
2012). The relative prognostic value of each of these lymph node-/lymphatic vasculaturespecific metrics is controversial. Prospective and retrospective clinical studies evaluating the
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utility of these criteria are collected in Table 5 (Ausborn et al., 2013; Berger et al., 2004; Bhatti et
al., 2010; Chen et al., 2010; House et al., 2007; John et al., 2013; Konstantinidis et al., 2010; La
Torre et al., 2011; Murakami et al., 2010; Nakagohri et al., 2006; Pawlik et al., 2007; Riediger et
al., 2009; Robinson et al., 2012; Schwarz and Smith, 2006; Sergeant et al., 2009; Sierzega et al.,
2006; Slidell et al., 2008; Smith and Mezhir, 2014; Tol et al., 2015; Yamamoto et al., 2014).
Contradictory conclusions from these studies highlight the remaining need for additional work
before use of these metrics is informative in the general clinical setting.
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Table 5. Lymphatic-Specific Outcomes Metrics: Lymph Node Disease (LND), Lymph Node
Burden (LNB), Lymph Node Ratio (LNR), Lymphatic Vessel Invasion (LVI)

Analyzed/Significant Metrics7
Citation

Conclusions/Recommendations

Ausborn 2013

High LNR is associated with decreased overall survival of
PDAC patients only when 53BP1 expression is low

Berger 2004

LNR > 0.15, not number of LNs examined, predicts
overall survival and disease-free survival in patients with
PDAC

Bhatti 2010

LNR is a better predictor of overall survival than LNB or
LND in PDAC

Chen 2010

Lymphovascular invasion (may be blood or lymphatic
vessels) predicts 5-year survival in periampullary cancer
and PDAC patients

LND

LNB

LNR

Presence of LND predicts survival in PDAC patients; In

House 2007 node positive disease, LNB and LNR are good predictors
of survival

John 2013

Konstantinidis
2010

7

LNB and LNR can be used to predict cancer-specific
survival in patients with PDAC of pancreas head
regardless of resection margin status
Regional lymph node metastasis and direct lymph node
invasion equally negatively impact survival; LNR ≥ 0.2,
LNB, and LVI are useful predictors of prognosis of PDAC
patients

La Torre 2011

LND and LNR are both predictive of prognosis in PDAC
patients; LNR maintains significance on multivariate
analysis

Murakami
2010

LND and LNB, not LNR, predict overall survival in PDAC
patients; LNR also significant in univariate analysis

Nakagohri
2006

LND and LVI are predictors of 3-year survival; LND is best
predictor of all analyzed for PDAC patients

White: metric not analyzed; Light gray: metric analyzed but not statistically significant; Dark gray:
statistically significant metric

LVI
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Pawlik 2007

LNR predicts prognosis and disease-specific survival in
PDAC patients

Riediger 2009

LNR, not LND or LNB, predicts overall survival in PDAC
patients

Robinson 2012

LND and LNR are good predictors of 5-year survival of
PDAC patients; LNR better when > 0.15
Number of lymph nodes examined and number of

Schwarz 2006 negative lymph nodes identified predict survival for
exocrine pancreatic cancer patients
Extracapsular LNR predicts overall survival as does

Sergeant 2009 overall LNR; LNB predicts disease-free survival in PDAC
patients

Sierzega 2006

LND predicts prognosis in patients with PDAC of
pancreas head; In node positive disease, LNR > 0.2
predicts survival; Specifically, Group 8 and 12 lymph
nodes were prognostic

Slidell 2008

Number of positive LNs, presence of LND, and LNR are
significantly associated with survival in PDAC patients

Smith 2014

New predictive tool available for LNR and survival that
incorporates specific patient metrics and includes
population characteristics

Tol 2015
Yamamoto
2014

LNR above 0.18 predicts 3-year survival in PDAC patients
LNB and LNR are predictors of PDAC patient prognosis,
not LVI; LNR is best predictor of all metrics examined

*This table was previously published in Fink et al., 2015a.
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A major challenge in pancreatic cancer biology and treatment is the presence in lymph
nodes of single or small clusters of tumor cells that are not detected by routine
histopathological staining techniques (Bogoevski et al., 2004; Demeure et al., 1998; Katuchova
et al., 2012; Milsmann et al., 2005; Ridwelski et al., 2001). Similar to insufficient surgical
removal of primary lymph nodes (Berger et al., 2004; House et al., 2007; Meriggi et al., 2007;
Pawlik et al., 2007; Schwarz and Smith, 2006; Slidell et al., 2008), failure to detect occult
micrometastatic deposits in nodes may result in patient misclassification, understaging, and
improperly informed outcomes prediction. Descriptions of “skip metastases” in which primary
lymph nodes are negative but metastases are established in secondary nodes or distant organ
sites (Farnell et al., 2005; Golse et al., 2013; Mao et al., 1995) may be attributable, at least in
part, to this phenomenon. Emerging immunohistochemical and molecular techniques such as
epithelial cell adhesion molecule (EpCAM/Ber-EP4) (Bogoevski et al., 2004; Milsmann et al.,
2005), cytokeratin (Katuchova et al., 2012; Ridwelski et al., 2001), and carbohydrate antigen 199 (CA19-9; sialyl-Lewis A) staining (Ridwelski et al., 2001), and polymerase chain reaction for
mutant KRAS (Demeure et al., 1998) have demonstrated efficacy in occult tumor cell detection
in nodes, but their adaptation from the research laboratory to practical clinical application will
require more extensive study.
Targeting Tumor Vasculature
Anti-angiogenic therapies were originally developed to starve tumors of important
nutrients and oxygen and to reduce the number of potential routes for dissemination. However,
clinical trials demonstrated that, when used alone, anti-angiogenic therapy was not sufficient to
improve patient survival.

Unexpectedly though, the results indicated that anti-angiogenic

therapy significantly improved survival of patients with solid tumors when used in combination
with conventional chemotherapies (Hurwitz et al., 2004; Saltz et al., 2008; Sandler et al., 2006).
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These findings led to the evolution of the current vascular normalization theory: the use of antiangiogenic therapy to block aberrant tumor angiogenesis and alleviate vessel dysfunction (Goel
et al., 2012). By restoring the balance between pro- and anti-angiogenic factors, anti-angiogenic
therapies improved vessel organization, stabilized cell-to-cell junctions, increased pericyte
coverage, and, consequently, reduced fluid leakage. All these factors, in turn, relieved blood
flow irregularities resulting in improved delivery of chemotherapy to all parts of the tumor (Goel
et al., 2011). Unfortunately, in the setting of pancreatic cancer, anti-angiogenic therapies have
had either no effect or only transient effects on improving patient survival even when used in
combination with standard chemotherapies (Bergers and Hanahan, 2008; Kindler et al., 2010;
Sahora et al., 2014; Sohal et al., 2013; Van Cutsem et al., 2009). PDAC tumors are unusually
hypovascular and desmoplastic negating the ability of even normalized vessels to deliver
therapy (Tamburrino et al., 2013). The failure of anti-angiogenic therapy in PDAC may also be
the result of tumor cells circumventing the VEGF-A/VEGFR-1 blockade through autocrine or
paracrine secretion of alternative angiogenic factors, such as the prototypical lymphangiogenic
factors which have overlapping angiogenic functions (Bergers and Hanahan, 2008; Cao et al.,
1998; Chien et al., 2009; Scavelli et al., 2004).
Targeting the tumor lymphatic vasculature as a treatment for cancer is beginning to gain
interest among both basic and clinical research groups with the primary focus on antilymphangiogenic therapies.

Lymphangiogenic growth factors are not critical for the

maintenance of adult lymphatic vessels in homeostasis. This allows for extended treatment
with anti-lymphangiogenic therapies in tumor settings without disruption of pre-existing vessels
and with minimal drug-induced toxicities (Karpanen et al., 2006; Lin et al., 2005). Numerous
pre-clinical in vivo studies have demonstrated that blocking pro-lymphangiogenic factors VEGF-C
and VEGF-D and their receptor VEGFR-3 significantly reduces tumor lymphangiogenesis and
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lymph node metastases in many tumor types including pancreatic (Koch et al., 2009), breast (He
et al., 2008; Karpanen et al., 2001; Krishnan et al., 2003; Roberts et al., 2006), melanoma (Lin et
al., 2005), renal (Stacker et al., 2001), lung (He et al., 2002; He et al., 2005), gastric (Chen et al.,
2005; Shimizu et al., 2004), prostate (Burton et al., 2008), hepatocellular (Thelen et al., 2008),
and bladder (Yang et al., 2011a). Other protein targets of lymphangiogenesis that have shown
promise in inhibiting lymphatic metastasis in vivo include the VEGFR-3 co-receptor Nrp-2 (Caunt
et al., 2008; Ou et al., 2015) and the angiopoietins Ang-1 and -2 (Holopainen et al., 2012; Neal
and Wakelee, 2010). Currently, two humanized neutralizing antibodies are in clinical trials for
patients with solid tumors: VGX-100, which inhibits VEGF-C (NCT01514123) and IMC-3C5, which
inhibits VEGFR-3 (NCT01288989).
The blockade of a single VEGF/VEGFR pathway will likely be insufficient to inhibit tumor
lymphangiogenesis and lymph node metastasis due to the multiple compensatory and
overlapping roles of the VEGF ligands and receptors (Alitalo and Detmar, 2012; Bjorndahl et al.,
2005b; Da et al., 2008; Scavelli et al., 2004). Other growth mechanisms outside of VEGF/VEGFR
signaling may also regulate lymphangiogenesis in the tumor setting, such as PDGF-BB/PDGFR
(Cao et al., 2004a) and FGF/FGFR(Cao et al., 2012). Receptor tyrosine kinase inhibitors (RTKIs)
often target multiple receptors allowing them to inhibit several signaling pathways
simultaneously—including the VEGFR pathways. Both pre-clinical comparative studies and
clinical trials have determined the safety and efficacy of numerous anti-angiogenic/lymphangiogenic RTKIs for the treatment of cancer including foretinib (Chen et al., 2015),
cediranib (Heckman et al., 2008; Padera et al., 2008), and axitinib (Grunwald and Merseburger,
2012; Rixe et al., 2007; Spano et al., 2008). Some of these RTKIs have also been approved for
clinical use. Sorafenib, which inhibits VEGFR-1 and -3, PDGFR-β, FGFR-1, and Raf proteins, has
been approved for renal cell (RCC) and hepatocellular carcinomas (Procopio et al., 2012; Reataza
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and Imagawa, 2014; Wilhelm et al., 2004); sunitinib, which inhibits VEGFR-1 and -3, and PDGFRα and -β, has been approved to treat pancreatic neuroendocrine tumors, RCC, and
gastrointestinal stromal tumors (Detry et al., 2013; Khagi and Saif, 2015; Kodera et al., 2011;
Mankal and O'Reilly, 2013); and pazopanib, which inhibits VEGFR-1 and -3, PDGFR-α and -β, and
FGFR, has been approved to treat RCC and soft tissue sarcoma (Ahn et al., 2013; Schutz et al.,
2011; Verweij and Sleijfer, 2013) (RTKIs further reviewed in (Stacker et al., 2014)). Vatalanib,
which inhibits VEGFR-1, -2, and -3, and PDGFR-β, is currently in clinical trials for the treatment of
various solid tumors including pancreatic, ovarian, and breast cancers. This RTKI has been
shown to directly inhibit angiogenesis, lymphangiogenesis, and tumor growth in pre-clinical
models of pancreatic cancer as well as other cancer models (Baker et al., 2002; Drevs et al.,
2000; Lin et al., 2002; Sini et al., 2008; Solorzano et al., 2001). In a recent clinical trial, vatalanib
resulted in a partial or stable response for some metastatic pancreatic cancer patients who had
initially failed gemcitabine treatment (Dragovich et al., 2014). Many of these lymphangiogenic
receptor-targeting RTKIs hold promise for the treatment of early-diagnosed and resectable
cancers (Alitalo and Detmar, 2012).

Unfortunately, these are not typical characteristics of

pancreatic cancer, and, consequently, many of these drugs have failed to significantly improve
pancreatic cancer patient survival (Cardin et al., 2014; Goncalves et al., 2012; Kindler et al.,
2011; Spano et al., 2008).
Lymphangiogenesis is not the only manner by which the lymphatic vasculature can
promote tumor progression. As discussed previously, pre-existing lymphatic vessels can directly
facilitate metastasis by transporting tumor cells to distant sites. Lymphatic endothelia may also
contribute to immune suppression by altering DC and T cell responses.

However, these

functions are poorly understood and much more work needs to be done to determine if these
functions can be specifically targeted in lymphatic vessels for the treatment of cancer.
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Using Lymphatic Vessels to Deliver Therapies to Lymph Nodes
In pancreatic cancer, metastasis to lymph nodes and distant sites has often already
occurred by the time of diagnosis. Anti-lymphangiogenic therapies may inhibit further tumor
cell dissemination but will do little to reduce the growth of metastatic tumors that have already
seeded at distant sites (He et al., 2005; Hoshida et al., 2006; Padera et al., 2008). Successful
treatment of tumor-invaded lymph nodes has been particularly difficult to achieve. Resection of
invaded lymph nodes would intuitively seem to be a promising strategy; however, as discussed
above, current clinical imaging technologies cannot reliably detect single cell or microscopic
lymph node metastases (Nune et al., 2011; Sevick-Muraca et al., 2014), and excision of an
excessive number of lymph nodes is controversial due to conflicting evidence regarding its
survival benefits and concerns about post-operative quality-of-life (Michalski et al., 2007; Witte
et al., 2011). Also, conventional intravenously-administered therapies display poor access to
lymphatic vessels and lymph nodes resulting in sub-optimal drug concentrations within lymph
nodes (O'Hagan et al., 1992). This enables tumor cells present within lymph nodes to evade
treatment and potentiate future recurrence. Using the lymphatic vasculature as a delivery
system for cancer therapies to the lymph nodes has gained increasing interest. For therapies to
be effectively taken up by lymphatic vessels and not blood capillaries requires specific
characteristics of drug formulations such as being of a particular size and molecular weight,
lipophilicity and surface charge of the drug carrier, and concentrations of the drug and carrier
(reviewed in (Ali Khan et al., 2013; Singh et al., 2014)). A few anti-cancer drugs have been
formulated to target the lymphatic system and have shown promise in vivo:

a methyl

poly(ethylene glycol)-distearoylphosphatidylethanolamine micelle containing doxorubicin reduced the size of lymph node metastases in a melanoma model (Li et al., 2015); addition of
polyethylene glycol (PEGylation) to interferon-α2 demonstrated anti-tumor efficacy in the lymph
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nodes of rats with breast cancer (Kaminskas et al., 2013); cisplatin conjugated to a copolymer
block of poly(ethylene oxide)-block-poly(lysine) successfully treated lymph node metastases in a
model of squamous cell carcinoma (Dunne et al., 2007); and gemcitabine loaded onto magnetic
multiwalled carbon nanotubes resulted in better uptake of gemcitabine in the lymph nodes and
regression of lymph node metastases in a subcutaneous model of pancreatic cancer (Yang et al.,
2011a). The field of lymphatic-based drug delivery is still in its infancy and more studies are
required to demonstrate efficacy and feasibility in patients.

New Murine Platforms for Real-Time Live Imaging Studies of PDAC-Associated
Neurolymphatic Remodeling
Translation of the findings presented here to clinically-meaningful therapies or imaging
signatures would require considerable additional development.

The live imaging

neurolymphatic remodeling studies presented in this dissertation were performed in mouse
cornea and pinna—two accessible tissues housing neurolymphatic networks with distinct
properties in homeostasis and inflammation. We used B16 melanoma cells for the majority of
our experiments and in so doing created an orthotopic system in the mouse skin and a pseudoorthotopic environment in the mouse cornea mimicking corneal melanoma. We tracked tumor
cells over time through cornea and pinna lymphatic vessels by real time live imaging microscopy
and showed that they entered lymphatic vessels, were cleared from sites identifiable for several
days by tissue landmarks, and eventually trafficked to draining lymph nodes. Entry of tumor
cells into lymphatic vessels was a relatively rare event, and properties of tumor cells trafficking
through the cornea could be influenced by the inflammatory status of that tissue at the time of
cell delivery.

These systems have provided insight into many aspects of neurolymphatic

remodeling and tumor metastasis, but extrapolation of these microenvironment-dependent
principles to PDAC requires study under more appropriate organ-specific conditions.

An
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interesting intermediate step in the transition to the pancreas would be the use of PDAC
organoids (Boj et al., 2015) in skin or corneal live imaging experiments. Organoids better
represent the complexity of a tumor microenvironment and would likely be amenable to use in
both of our established platforms.

Of interest for future work is the development of an intravital imaging system
specifically designed to track pancreatic tumorigenesis, tumor-lymphatic/-nerve/-blood vessel
interactions, and pancreatitis- and malignancy-associated neurolymphatic and blood vascular
remodeling in the pancreas. Development of such a platform would first require the generation
of a multi-color mouse model in which nerves, lymphatics, and blood vessels expressed distinct
fluorescent reporter proteins. Pancreatitis studies could be performed in these triple-transgenic
reporter animals by one or more previously established methods such as cerulein injection or
Coxsackie virus challenge.

Traditional orthotopic surgery protocols could be used with

syngeneic fluorescent reporter cell lines to study tumor-associated neurovascular remodeling
and tumor-neurovascular interactions. An alternative strategy in lieu of cell line implantation
that would also enable studies of premalignant PanIN lesions would be use of the PKCY (Rhim et
al., 2012) or KPCT (Stopczynski et al., 2014) modifications of the original autochthonous KPC
PDAC model which include fluorescent reporter proteins in cells of the pancreas. Live imaging
could be accomplished by implantation of a pancreas window as has been previously described
(Ritsma et al., 2013). This platform could also be used to identify subgroups of tumor cells that
preferentially migrate to/through one of the tissue networks of interest—nerves, lymphatics, or
blood vessels. Live imaging data could be complemented by further studies at necropsy and of
extracted tissues.
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We have performed preliminary proof-of-concept experiments to demonstrate the
feasibility of deep tissue imaging reconstruction of vasculature networks in fixed pancreas.
tdTomato fluorescent protein was constitutively expressed in Tie-2+ cells using Cre recombinase
technology. This enabled visualization of both blood and lymphatic endothelium by live imaging
and in fixed tissue. We developed a modified CLARITY protocol in which cellular lipids were
removed to facilitate 2-photon microscopy of intact organs or thick sections up to approximately
500 μm. Figure 33 shows one example of 3D blood and lymphatic vasculature reconstruction
performed in Tie2CretdT mouse pancreas. Both large vessels and capillary structures can be
visualized, and we are confident that inflammation- or malignancy-induced vascular architecture
changes could be identified using this technology. We have also optimized immunostaining
protocols for CLARITY hydrogel-perfused organs, which would enable hypothesis-driven
interrogation of tissue remodeling and tumor metastasis mechanisms.
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Figure 33. Tie2CretdT pancreatic blood and lymphatic vessel network revealed by CLARITY and
2-photon microscopy. TdTomato fluorescent protein is expressed under the control of the Tie-2
promoter. Tie-2 is expressed in blood and lymphatic endothelial cells. Tie2CretdT mice were
perfused with CLARITY hydrogel monomer solution as described (Chung and Deisseroth, 2013;
Chung et al., 2013b) to facilitate penetration of hydrogel deep into body organs. Pancreases
were harvested and further clarified according to the CLARITY protocol. 2-photon confocal
imaging was performed on approximately 500 μm thick pancreas sections. A. 100X maximum
intensity projection. B. 3D projection of A.
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Figure 33
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This multi-fluorescent imaging platform would enable at least two other lines of
experimental investigation. First, live fluorescent neurovascular cells could be sorted out of
pancreas

(or

adjacent

lymph

nodes

or

neural

plexuses)

with

or

without

orthotopic/autochthonous PDAC tumor to identify tumor-dependent distinctions in biological
processes and molecular characteristics of these cells, i.e. by in vitro assays such as migration,
tubulogenesis, proliferation, cytokine stimulation, signaling, neurite outgrowth, etc., or by RNAsequencing. Similarly, tumor cells found in pancreatic lymphatic vessels or nerves could be
extracted by laser capture microdissection; or these experiments could be carried out in the
absence of tumor cells to interrogate pancreas-specific differences in homeostatic, nonmalignant inflammatory, and wound-recovered microenvironments. Second, identification of
pancreas-specific neurovascular remodeling events that accompany premalignant PanIN lesions
or very small tumors could be used in early detection of PDAC. We have demonstrated in this
work that very small numbers of tumor cells induce local neurolymphatic remodeling signatures
that are distinguishable from those caused by non-malignant inflammation and that these local
remodeling events are sometimes accompanied by broader field effects outside the immediate
“mini-microenvironment” of a group of tumor cells. These tenets of neurolymphatic remodeling
may hold true in the pancreatic microenvironment and may be targetable for imaging.

Objective Measurement of PDAC Patient Cachexia Status and Correlation with
Other Metrics
Determination of cachexia status of patients enrolled in the pancreatic cancer rapid
autopsy (RAP) program remains somewhat subjective. Designation of cachexia status at autopsy
is not based solely on measurable criteria but rather on the appearance of the body. Notes in
pathology autopsy reports contain such phrases as “marked cachexia of the extremities,” “the
muscles appear somewhat atrophic,” “there is grossly apparent muscle wasting that is more
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prominent in the torso and upper extremities,” “the body is that of a thin/cachectic elderly
male,” and “the extremities are thin.” Differences in diagnostic criteria among pathologists
performing autopsies could result in inconsistent status designations over the course of many
autopsies. In the studies presented in Chapter III, we have tried to minimize this potential bias
by including additional clinical criteria in our subgroup analysis. While definitions of clinicallymeaningful weight loss vary and may be confounded by the rising numbers of overweight and
obese patients, one of the hallmark features of cachexia is significant unintentional weight loss;
thus, we included it in our modified cachexia status stratification strategy. Other clinical notes,
too, provided some insight into deterioration of patient function that could be linked to
cachexia with such phrases as, “presented with weight loss, extreme weakness, fatigue,
decreased energy, decreased oral intake” etc., “required parenteral nutrition secondary to
malnutrition,” “complains of decreased body mass and weight,” and the somewhat
contradictory “cachectic but comfortable-appearing,” documented in the records of RAP
patients. Other factors linked to end-stage disease may also contribute to inconsistencies in
designation of cachexia status at autopsy. In at least one RAP case cachexia status was
determined to be negative, but this was qualified by the note that “if present, [cachexia] was
masked by anasarca8.” Another case notes the presence of pitting edema9 in the extremities,
which might also conceal cachexia.

A new use of an old imaging technology may help to ameliorate challenges in cachexia
status designation (Martin et al., 2013a; Tan et al., 2009). Trunk CT scans are routinely used in

8

Anasarca is generalized edema throughout large portions of the body due to accumulation of fluid
subcutaneously or in connective tissue.
9
Pitting edema is characterized by the persistence of an indentation when pressure is applied to an area
of swelling.
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PDAC diagnosis and repeated over time to track tumor progression, metastasis, and response to
treatment. These scans capture a region of the lumbar spine that can be used to compute
lumbar skeletal muscle index. This metric objectively quantifies muscle mass independent of
BMI and is not complicated by factors that may confound visual cachexia diagnosis such as
increased subcutaneous fat or generalized edema. The majority of the patients in our RAP
program have the necessary scans available, and we are currently working to apply this method
to obtain an unbiased skeletal muscle index to serve as an additional criterion in the final
designation of cachexia status.

The broad spectrum of tissues available from our cohort of PDAC RAP patients would
facilitate many additional musculature-based studies. In addition to skeletal muscle, changes to
cardiac muscle have also been reported in models of cachexia. Cachectic C26 colon tumorbearing mice had impaired cardiac function associated with structural changes in musculature
and appearance of fibrosis (Tian et al., 2010). A differential gene expression signature in tumorbearing mice compared to tumor-free controls included increased levels of the E3 ubiquitin
ligases MuRF-1 and atrogin-1 as well as differential expression of B-type natriuretic peptide
(BNP), c-Fos, peroxisome proliferator-activated receptor-α (PPAR- α), and carnitine
palmitoyltransferase1-β (CPT1- β), and the re-emergence of fetal proteins MHC-β and Glucose
transporter (GLUT)-1 (from MHC-α and GLUT-4) (Tian et al., 2011). Murine adenocarcinoma cell
line 16 (MAC16) tumor-bearing nude mice developed cancer cachexia and also showed
increased MuRF-1 and MAFbx gene expression; these changes were attributed to increased
oxidation in cardiac muscle (Hinch et al., 2013). Another group has recently identified a
“cachexokine cocktail” of seven tumor-secreted factors that are necessary and sufficient to alter
cardiomyocyte metabolic pathways and cause cellular atrophy; these factors are: bridging
integrator 1, syntaxin 7, multiple inositol-polyphosphate phosphatase 1, glucosidase alpha acid,

217
chemokine ligand 2, adamts like 4, and ataxin-10 (Schafer et al., 2015). Studies of cardiac
cachexia in mouse models of PDAC or human PDAC tissue samples are lacking. Heart apex is
routinely harvested as part of our rapid autopsy procedures. An examination of molecular
changes in cardiac muscle in cachectic vs. non-cachectic patients would provide another level of
insight into this systemic disease. Of particular interest in PDAC samples would be studies of
GLUT transporter dysregulation and oxidative stress. The interplay between cardiac cachexia
and chemotherapy-induced cardiac toxicity is poorly understood and could also be investigated.
Similarly understudied are the effects of PDAC-associated cachexia on smooth muscle. Many
patients succumb to respiratory failure in end stage PDAC; little is known about effects of
cachexia on diaphragm.

Studies of alterations in vasculature- and gastrointestinal tract-

associated smooth muscle could also be carried out in our sample set.

The nature of systemic inflammation in PDAC-associated cachexia could also be
interrogated with these samples. One of the most important aspects of our RAP program is that
it is ongoing; new patients are continuously enrolled, and studies that require fresh tissue
samples can be designed along with use of clinical samples taken throughout disease
progression. A set of interesting questions would be how serum inflammatory cytokine profiles
change as cachexia develops, how chemotherapy cycles affect these systemic markers, and how
the composition of intratumoral infiltrating immune cell populations responds to or drives these
changes.

Fresh tumor harvest could facilitate expansion of specific inflammatory cell

subpopulations and tumor cells for more detailed study of paracrine signaling and supportive vs.
anti-tumor properties of immune cells in the PDAC tumor microenvironment.

Similarly,

relationships between glucose toxicity and perineural invasion or chemotherapy-induced
peripheral neuropathy could be investigated in these well-annotated samples.
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Outlook for the Future
Advances in surgical, radiation, and chemotherapeutic treatment regimens for
pancreatic cancer have not greatly impacted overall survival rates for patients afflicted with this
devastating disease. Early spread of tumor cells to lymph nodes, into nerves, and to distant sites
often precludes curative resection, facilitates cancer chemoresistance and immune evasion, and
decreases overall survival. The lymphatic and nervous systems represent two of the major
understudied players in the tumor microenvironment and in the process of tumor metastasis.
The intrinsic functional and structural characteristics of the lymphatic system suggest roles in
immune regulation, cell trafficking, and interactions with other tissue networks and cell types,
while the nearly 100% incidence of PDAC perineural invasion, mutual tumor-nerve tropism and
paracrine secretions, and debilitating pain highlight the importance of nerves in the tumor
microenvironment. Distortion of the physiological processes of lymphangiogenesis and
neurogenesis in the tumor microenvironment and consequent effects on the biology of
lymphatics, nerves, and tumor cells are complex and complicate targeting strategies. Clinical
efforts to detect and use lymph node status or presence of PNI to inform treatment decisions,
guide pancreatectomy, and stratify patients into prognostic cohorts have improved but remain
inconsistent across groups and are not yet standardized or broadly applied. Identification,
refinement, and directed studies of lymphatic- and nerve-specific metrics have highlighted the
importance of these criteria as additional prognostic factors in this disease. Development of
pre-clinical models of tumor-associated neurolymphatic remodeling, PNI, and lymph node
metastasis and new lymphatic-directed clinical therapeutics represent two significant areas of
current research. Live imaging studies in genetically engineered models that recapitulate both
molecular and behavioral signatures of specific cancer types will improve our understanding of
the earliest events in tumor-associated neurolymphatic remodeling, tumor-lymphatic/-nerve
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interactions, and lymph node and perineural invasion. Translation of these and other preclinical
findings to clinically-relevant diagnostic criteria or therapeutic interventions remains an
underexplored but promising strategy to ultimately improve PDAC patient quality-of-life and
outcomes.

220
Reference List
Abiatari, I., DeOliveira, T., Kerkadze, V., Schwager, C., Esposito, I., Giese, N.A., Huber, P.,
Bergman, F., Abdollahi, A., Friess, H., and Kleeff, J. (2009a). Consensus transcriptome signature
of perineural invasion in pancreatic carcinoma. Mol. Cancer. Ther. 8, 1494-1504.
Abiatari, I., Gillen, S., DeOliveira, T., Klose, T., Bo, K., Giese, N.A., Friess, H., and Kleeff, J. (2009b).
The microtubule-associated protein MAPRE2 is involved in perineural invasion of pancreatic
cancer cells. Int. J. Oncol. 35, 1111-1116.
Achen, M.G., Jeltsch, M., Kukk, E., Makinen, T., Vitali, A., Wilks, A.F., Alitalo, K., and Stacker, S.A.
(1998). Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF
receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl. Acad. Sci. U. S. A. 95, 548-553.
Adams, R.H., and Eichmann, A. (2010). Axon guidance molecules in vascular patterning. Cold
Spring Harb Perspect. Biol. 2, a001875.
Aebischer, D., Iolyeva, M., and Halin, C. (2014). The inflammatory response of lymphatic
endothelium. Angiogenesis 17, 383-393.
Ahn, H.K., Choi, J.Y., Kim, K.M., Kim, H., Choi, S.H., Park, S.H., Park, J.O., Lim, H.Y., Kang, W.K.,
Lee, J., and Park, Y.S. (2013). Phase II study of pazopanib monotherapy in metastatic
gastroenteropancreatic neuroendocrine tumours. Br. J. Cancer 109, 1414-1419.
Airaksinen, M.S., Titievsky, A., and Saarma, M. (1999). GDNF family neurotrophic factor
signaling: four masters, one servant? Mol. Cell. Neurosci. 13, 313-325.
Ali Khan, A., Mudassir, J., Mohtar, N., and Darwis, Y. (2013). Advanced drug delivery to the
lymphatic system: lipid-based nanoformulations. Int. J. Nanomedicine 8, 2733-2744.
Alitalo, A., and Detmar, M. (2012). Interaction of tumor cells and lymphatic vessels in cancer
progression. Oncogene 31, 4499-4508.
Angeli, V., Ginhoux, F., Llodra, J., Quemeneur, L., Frenette, P.S., Skobe, M., Jessberger, R.,
Merad, M., and Randolph, G.J. (2006). B cell-driven lymphangiogenesis in inflamed lymph nodes
enhances dendritic cell mobilization. Immunity 24, 203-215.
Argiles, J.M., Busquets, S., Stemmler, B., and Lopez-Soriano, F.J. (2014). Cancer cachexia:
understanding the molecular basis. Nat. Rev. Cancer. 14, 754-762.
Asp, M.L., Tian, M., Wendel, A.A., and Belury, M.A. (2010). Evidence for the contribution of
insulin resistance to the development of cachexia in tumor-bearing mice. Int. J. Cancer 126, 756763.
Ausborn, N.L., Wang, T., Wentz, S.C., Washington, M.K., Merchant, N.B., Zhao, Z., Shyr, Y.,
Chakravarthy, A.B., and Xia, F. (2013). 53BP1 expression is a modifier of the prognostic value of
lymph node ratio and CA 19-9 in pancreatic adenocarcinoma. BMC Cancer 13, 155-2407-13-155.

221
Bailey, J.M., Swanson, B.J., Hamada, T., Eggers, J.P., Singh, P.K., Caffery, T., Ouellette, M.M., and
Hollingsworth, M.A. (2008). Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin.
Cancer Res. 14, 5995-6004.
Baker, C.H., Solorzano, C.C., and Fidler, I.J. (2002). Blockade of vascular endothelial growth
factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human
pancreatic cancer. Cancer Res. 62, 1996-2003.
Baluk, P., Fuxe, J., Hashizume, H., Romano, T., Lashnits, E., Butz, S., Vestweber, D., Corada, M.,
Molendini, C., Dejana, E., and McDonald, D.M. (2007). Functionally specialized junctions
between endothelial cells of lymphatic vessels. J. Exp. Med. 204, 2349-2362.
Banerji, S., Ni, J., Wang, S.X., Clasper, S., Su, J., Tammi, R., Jones, M., and Jackson, D.G. (1999).
LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan.
J. Cell Biol. 144, 789-801.
Bapat, A.A., Hostetter, G., Von Hoff, D.D., and Han, H. (2011). Perineural invasion and associated
pain in pancreatic cancer. Nat. Rev. Cancer. 11, 695-707.
Baracos, V.E. (2011). Pitfalls in defining and quantifying cachexia. J. Cachexia Sarcopenia Muscle
2, 71-73.
Bazigou, E., Wilson, J.T., and Moore, J.E.,Jr. (2014). Primary and secondary lymphatic valve
development: molecular, functional and mechanical insights. Microvasc. Res. 96, 38-45.
Belmonte, C., Acosta, M.C., and Gallar, J. (2004). Neural basis of sensation in intact and injured
corneas. Exp. Eye Res. 78, 513-525.
Ben, Q.W., Wang, J.C., Liu, J., Zhu, Y., Yuan, F., Yao, W.Y., and Yuan, Y.Z. (2010). Positive
expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic
ductal adenocarcinoma. Ann. Surg. Oncol. 17, 2213-2221.
Benassai, G., Mastrorilli, M., Mosella, F., and Mosella, G. (1999). Significance of lymph node
metastases in the surgical management of pancreatic head carcinoma. J. Exp. Clin. Cancer Res.
18, 23-28.
Berger, A.C., Watson, J.C., Ross, E.A., and Hoffman, J.P. (2004). The metastatic/examined lymph
node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic
adenocarcinoma. Am. Surg. 70, 235-40; discussion 240.
Bergers, G., and Hanahan, D. (2008). Modes of resistance to anti-angiogenic therapy. Nat. Rev.
Cancer. 8, 592-603.
Bhatti, I., Peacock, O., Awan, A.K., Semeraro, D., Larvin, M., and Hall, R.I. (2010). Lymph node
ratio versus number of affected lymph nodes as predictors of survival for resected pancreatic
adenocarcinoma. World J. Surg. 34, 768-775.

222
Bianchi, R., Teijeira, A., Proulx, S.T., Christiansen, A.J., Seidel, C.D., Rulicke, T., Makinen, T.,
Hagerling, R., Halin, C., and Detmar, M. (2015). A transgenic Prox1-Cre-tdTomato reporter
mouse for lymphatic vessel research. PLoS One 10, e0122976.
Biankin, A.V., Waddell, N., Kassahn, K.S., Gingras, M.C., Muthuswamy, L.B., Johns, A.L., Miller,
D.K., Wilson, P.J., Patch, A.M., Wu, J., et al. (2012). Pancreatic cancer genomes reveal
aberrations in axon guidance pathway genes. Nature 491, 399-405.
Bittner, R., Roscher, R., Safi, F., Dopfer, H.P., Scholzel, E., and Beger, H.G. (1989). Effect of tumor
size and lymph node status on the prognosis of pancreatic cancer. Chirurg 60, 240-245.
Bjorndahl, M., Cao, R., Nissen, L.J., Clasper, S., Johnson, L.A., Xue, Y., Zhou, Z., Jackson, D.,
Hansen, A.J., and Cao, Y. (2005a). Insulin-like growth factors 1 and 2 induce lymphangiogenesis
in vivo. Proc. Natl. Acad. Sci. U. S. A. 102, 15593-15598.
Bjorndahl, M.A., Cao, R., Burton, J.B., Brakenhielm, E., Religa, P., Galter, D., Wu, L., and Cao, Y.
(2005b). Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and
lymphatic metastasis. Cancer Res. 65, 9261-9268.
Blanco-Mezquita, T., Martinez-Garcia, C., Proenca, R., Zieske, J.D., Bonini, S., Lambiase, A., and
Merayo-Lloves, J. (2013). Nerve growth factor promotes corneal epithelial migration by
enhancing expression of matrix metalloprotease-9. Invest. Ophthalmol. Vis. Sci. 54, 3880-3890.
Bock, F., Onderka, J., Dietrich, T., Bachmann, B., Kruse, F.E., Paschke, M., Zahn, G., and
Cursiefen, C. (2007). Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis
and lymphangiogenesis. Invest. Ophthalmol. Vis. Sci. 48, 2545-2552.
Bock, F., Onderka, J., Rummelt, C., Dietrich, T., Bachmann, B., Kruse, F.E., Schlotzer-Schrehardt,
U., and Cursiefen, C. (2009). Safety profile of topical VEGF neutralization at the cornea. Invest.
Ophthalmol. Vis. Sci. 50, 2095-2102.
Bockman, D.E. (2007). Nerves in the pancreas: what are they for? Am. J. Surg. 194 (Suppl to
October 2007), S61-S64.
Bockman, D.E., Buchler, M., and Beger, H.G. (1994). Interaction of pancreatic ductal carcinoma
with nerves leads to nerve damage. Gastroenterology 107, 219-230.
Bodine, S.C., Latres, E., Baumhueter, S., Lai, V.K., Nunez, L., Clarke, B.A., Poueymirou, W.T.,
Panaro, F.J., Na, E., Dharmarajan, K., et al. (2001). Identification of ubiquitin ligases required for
skeletal muscle atrophy. Science 294, 1704-1708.
Bogoevski, D., Yekebas, E.F., Schurr, P., Kaifi, J.T., Kutup, A., Erbersdobler, A., Pantel, K., and
Izbicki, J.R. (2004). Mode of spread in the early phase of lymphatic metastasis in pancreatic
ductal adenocarcinoma: prognostic significance of nodal microinvolvement. Ann. Surg. 240, 9931000; discussion 1000-1.

223
Boj, S.F., Hwang, C.I., Baker, L.A., Chio, I.I., Engle, D.D., Corbo, V., Jager, M., Ponz-Sarvise, M.,
Tiriac, H., Spector, M.S., et al. (2015). Organoid models of human and mouse ductal pancreatic
cancer. Cell 160, 324-338.
Bonini, S., Lambiase, A., Rama, P., Caprioglio, G., and Aloe, L. (2000). Topical treatment with
nerve growth factor for neurotrophic keratitis. Ophthalmology 107, 1347-51; discussion 1351-2.
Bouvree, K., Brunet, I., Del Toro, R., Gordon, E., Prahst, C., Cristofaro, B., Mathivet, T., Xu, Y.,
Soueid, J., Fortuna, V., et al. (2012). Semaphorin3A, Neuropilin-1, and PlexinA1 are required for
lymphatic valve formation. Circ. Res. 111, 437-445.
Breiteneder-Geleff, S., Matsui, K., Soleiman, A., Meraner, P., Poczewski, H., Kalt, R., Schaffner,
G., and Kerjaschki, D. (1997). Podoplanin, novel 43-kd membrane protein of glomerular
epithelial cells, is down-regulated in puromycin nephrosis. Am. J. Pathol. 151, 1141-1152.
Buc, E., Couvelard, A., Kwiatkowski, F., Dokmak, S., Ruszniewski, P., Hammel, P., Belghiti, J., and
Sauvanet, A. (2014). Adenocarcinoma of the pancreas: Does prognosis depend on mode of
lymph node invasion? Eur. J. Surg. Oncol. 40, 1578-1585.
Buchler, P., Gazdhar, A., Schubert, M., Giese, N., Reber, H.A., Hines, O.J., Giese, T., Ceyhan, G.O.,
Muller, M., Buchler, M.W., and Friess, H. (2005). The Notch signaling pathway is related to
neurovascular progression of pancreatic cancer. Ann. Surg. 242, 791-800, discussion 800-1.
Burton, J.B., Priceman, S.J., Sung, J.L., Brakenhielm, E., An, D.S., Pytowski, B., Alitalo, K., and Wu,
L. (2008). Suppression of prostate cancer nodal and systemic metastasis by blockade of the
lymphangiogenic axis. Cancer Res. 68, 7828-7837.
Calza, L., Giardino, L., Giuliani, A., Aloe, L., and Levi-Montalcini, R. (2001). Nerve growth factor
control of neuronal expression of angiogenetic and vasoactive factors. Proc. Natl. Acad. Sci. U. S.
A. 98, 4160-4165.
Cao, R., Bjorndahl, M.A., Gallego, M.I., Chen, S., Religa, P., Hansen, A.J., and Cao, Y. (2006).
Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action.
Blood 107, 3531-3536.
Cao, R., Bjorndahl, M.A., Religa, P., Clasper, S., Garvin, S., Galter, D., Meister, B., Ikomi, F.,
Tritsaris, K., Dissing, S., et al. (2004a). PDGF-BB induces intratumoral lymphangiogenesis and
promotes lymphatic metastasis. Cancer. Cell. 6, 333-345.
Cao, R., Eriksson, A., Kubo, H., Alitalo, K., Cao, Y., and Thyberg, J. (2004). Comparative evaluation
of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular
fenestrations, and permeability. Circ. Res. 94, 664-670.
Cao, R., Ji, H., Feng, N., Zhang, Y., Yang, X., Andersson, P., Sun, Y., Tritsaris, K., Hansen, A.J.,
Dissing, S., and Cao, Y. (2012). Collaborative interplay between FGF-2 and VEGF-C promotes
lymphangiogenesis and metastasis. Proc. Natl. Acad. Sci. U. S. A. 109, 15894-15899.

224
Cao, R., Lim, S., Ji, H., Zhang, Y., Yang, Y., Honek, J., Hedlund, E.M., and Cao, Y. (2011). Mouse
corneal lymphangiogenesis model. Nat. Protoc. 6, 817-826.
Cao, Y., Linden, P., Farnebo, J., Cao, R., Eriksson, A., Kumar, V., Qi, J.H., Claesson-Welsh, L., and
Alitalo, K. (1998). Vascular endothelial growth factor C induces angiogenesis in vivo. Proc. Natl.
Acad. Sci. U. S. A. 95, 14389-14394.
Cardin, D.B., Goff, L., Li, C.I., Shyr, Y., Winkler, C., DeVore, R., Schlabach, L., Holloway, M.,
McClanahan, P., Meyer, K., et al. (2014). Phase II trial of sorafenib and erlotinib in advanced
pancreatic cancer. Cancer. Med. 3, 572-579.
Cardones, A.R., Murakami, T., and Hwang, S.T. (2003). CXCR4 enhances adhesion of B16 tumor
cells to endothelial cells in vitro and in vivo via beta(1) integrin. Cancer Res. 63, 6751-6757.
Carlson, S.L., Albers, K.M., Beiting, D.J., Parish, M., Conner, J.M., and Davis, B.M. (1995). NGF
modulates sympathetic innervation of lymphoid tissues. J. Neurosci. 15, 5892-5899.
Caunt, M., Mak, J., Liang, W.C., Stawicki, S., Pan, Q., Tong, R.K., Kowalski, J., Ho, C., Reslan, H.B.,
Ross, J., et al. (2008). Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer. Cell.
13, 331-342.
Cellini, M., Bendo, E., Bravetti, G.O., and Campos, E.C. (2006). The use of nerve growth factor in
surgical wound healing of the cornea. Ophthalmic Res. 38, 177-181.
Cesmebasi, A., Malefant, J., Patel, S.D., Du Plessis, M., Renna, S., Tubbs, R.S., and Loukas, M.
(2015). The surgical anatomy of the lymphatic system of the pancreas. Clin. Anat. 28, 527-537.
Ceyhan, G.O., Bergmann, F., Kadihasanoglu, M., Altintas, B., Demir, I.E., Hinz, U., Muller, M.W.,
Giese, T., Buchler, M.W., Giese, N.A., and Friess, H. (2009a). Pancreatic neuropathy and
neuropathic pain--a comprehensive pathomorphological study of 546 cases. Gastroenterology
136, 177-186.e1.
Ceyhan, G.O., Demir, I.E., Altintas, B., Rauch, U., Thiel, G., Muller, M.W., Giese, N.A., Friess, H.,
and Schafer, K.H. (2008). Neural invasion in pancreatic cancer: a mutual tropism between
neurons and cancer cells. Biochem. Biophys. Res. Commun. 374, 442-447.
Ceyhan, G.O., Demir, I.E., Rauch, U., Bergmann, F., Muller, M.W., Buchler, M.W., Friess, H., and
Schafer, K.H. (2009b). Pancreatic neuropathy results in "neural remodeling" and altered
pancreatic innervation in chronic pancreatitis and pancreatic cancer. Am. J. Gastroenterol. 104,
2555-2565.
Ceyhan, G.O., Deucker, S., Demir, I.E., Erkan, M., Schmelz, M., Bergmann, F., Muller, M.W.,
Giese, T., Buchler, M.W., Giese, N.A., and Friess, H. (2009c). Neural fractalkine expression is
closely linked to pain and pancreatic neuritis in human chronic pancreatitis. Lab. Invest. 89, 347361.

225
Ceyhan, G.O., Giese, N.A., Erkan, M., Kerscher, A.G., Wente, M.N., Giese, T., Buchler, M.W., and
Friess, H. (2006). The neurotrophic factor artemin promotes pancreatic cancer invasion. Ann.
Surg. 244, 274-281.
Ceyhan, G.O., Schafer, K.H., Kerscher, A.G., Rauch, U., Demir, I.E., Kadihasanoglu, M., Bohm, C.,
Muller, M.W., Buchler, M.W., Giese, N.A., Erkan, M., and Friess, H. (2010). Nerve growth factor
and artemin are paracrine mediators of pancreatic neuropathy in pancreatic adenocarcinoma.
Ann. Surg. 251, 923-931.
Chang, D.K., Johns, A.L., Merrett, N.D., Gill, A.J., Colvin, E.K., Scarlett, C.J., Nguyen, N.Q., Leong,
R.W., Cosman, P.H., Kelly, M.I., et al. (2009). Margin clearance and outcome in resected
pancreatic cancer. J. Clin. Oncol. 27, 2855-2862.
Chauvet, S., Burk, K., and Mann, F. (2013). Navigation rules for vessels and neurons: cooperative
signaling between VEGF and neural guidance cues. Cell Mol. Life Sci. 70, 1685-1703.
Chen, H.M., Tsai, C.H., and Hung, W.C. (2015). Foretinib inhibits angiogenesis,
lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and
TIE-2 signaling. Oncotarget 6, 14940-14952.
Chen, J.W., Bhandari, M., Astill, D.S., Wilson, T.G., Kow, L., Brooke-Smith, M., Toouli, J., and
Padbury, R.T. (2010). Predicting patient survival after pancreaticoduodenectomy for malignancy:
histopathological criteria based on perineural infiltration and lymphovascular invasion. HPB
(Oxford) 12, 101-108.
Chen, Z., Varney, M.L., Backora, M.W., Cowan, K., Solheim, J.C., Talmadge, J.E., and Singh, R.K.
(2005). Down-regulation of vascular endothelial cell growth factor-C expression using small
interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous
metastasis and enhances survival. Cancer Res. 65, 9004-9011.
Cheng, P., Jin, G., Hu, X., Shi, M., Zhang, Y., Liu, R., Zhou, Y., Shao, C., Zheng, J., and Zhu, M.
(2012). Analysis of tumor-induced lymphangiogenesis and lymphatic vessel invasion of
pancreatic carcinoma in the peripheral nerve plexus. Cancer. Sci. 103, 1756-1763.
Chien, M.H., Ku, C.C., Johansson, G., Chen, M.W., Hsiao, M., Su, J.L., Inoue, H., Hua, K.T., Wei,
L.H., and Kuo, M.L. (2009). Vascular endothelial growth factor-C (VEGF-C) promotes
angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway.
Carcinogenesis 30, 2005-2013.
Choi, I., Chung, H.K., Ramu, S., Lee, H.N., Kim, K.E., Lee, S., Yoo, J., Choi, D., Lee, Y.S., Aguilar, B.,
and Hong, Y.K. (2011). Visualization of lymphatic vessels by Prox1-promoter directed GFP
reporter in a bacterial artificial chromosome-based transgenic mouse. Blood 117, 362-365.
Christians, K., and Evans, D.B. (2009). Pancreaticoduodenectomy and vascular resection:
persistent controversy and current recommendations. Ann. Surg. Oncol. 16, 789-791.

226
Chu, H., Zhou, H., Liu, Y., Liu, X., Hu, Y., and Zhang, J. (2007). Functional expression of CXC
chemokine recepter-4 mediates the secretion of matrix metalloproteinases from mouse
hepatocarcinoma cell lines with different lymphatic metastasis ability. Int. J. Biochem. Cell Biol.
39, 197-205.
Chung, K., and Deisseroth, K. (2013). CLARITY for mapping the nervous system. Nat. Methods 10,
508-513.
Chung, K., Wallace, J., Kim, S.Y., Kalyanasundaram, S., Andalman, A.S., Davidson, T.J.,
Mirzabekov, J.J., Zalocusky, K.A., Mattis, J., Denisin, A.K., et al. (2013). Structural and molecular
interrogation of intact biological systems. Nature 497, 332-337.
Coma, S., Allard-Ratick, M., Akino, T., van Meeteren, L.A., Mammoto, A., and Klagsbrun, M.
(2013). GATA2 and Lmo2 control angiogenesis and lymphangiogenesis via direct transcriptional
regulation of neuropilin-2. Angiogenesis 16, 939-952.
Condeelis, J., and Pollard, J.W. (2006). Macrophages: obligate partners for tumor cell migration,
invasion, and metastasis. Cell 124, 263-266.
Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini,
L.A., and Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science
339, 819-823.
Connor, A.L., Kelley, P.M., and Tempero, R.M. (2016). Lymphatic endothelial lineage assemblage
during corneal lymphangiogenesis. Lab. Invest. 96, 270-282.
Crnic, I., Strittmatter, K., Cavallaro, U., Kopfstein, L., Jussila, L., Alitalo, K., and Christofori, G.
(2004). Loss of neural cell adhesion molecule induces tumor metastasis by up-regulating
lymphangiogenesis. Cancer Res. 64, 8630-8638.
Cui, K., Zhao, W., Wang, C., Wang, A., Zhang, B., Zhou, W., Yu, J., Sun, Z., and Li, S. (2011). The
CXCR4-CXCL12 pathway facilitates the progression of pancreatic cancer via induction of
angiogenesis and lymphangiogenesis. J. Surg. Res. 171, 143-150.
Cui, Y., Wu, J., Zong, M., Song, G., Jia, Q., Jiang, J., and Han, J. (2009). Proteomic profiling in
pancreatic cancer with and without lymph node metastasis. Int. J. Cancer 124, 1614-1621.
Cursiefen, C., Chen, L., Borges, L.P., Jackson, D., Cao, J., Radziejewski, C., D'Amore, P.A., Dana,
M.R., Wiegand, S.J., and Streilein, J.W. (2004). VEGF-A stimulates lymphangiogenesis and
hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J. Clin.
Invest. 113, 1040-1050.
Da, M.X., Wu, Z., and Tian, H.W. (2008). Tumor lymphangiogenesis and lymphangiogenic growth
factors. Arch. Med. Res. 39, 365-372.
Dadras, S.S. (2013). An unexpected role for EGF in lymphangiogenesis-mediated melanoma
metastasis to sentinel lymph nodes. J. Invest. Dermatol. 133, 14-16.

227
Dai, H., Li, R., Wheeler, T., Ozen, M., Ittmann, M., Anderson, M., Wang, Y., Rowley, D., Younes,
M., and Ayala, G.E. (2007). Enhanced survival in perineural invasion of pancreatic cancer: an in
vitro approach. Hum. Pathol. 38, 299-307.
Dallas, N.A., Gray, M.J., Xia, L., Fan, F., van Buren, G.,2nd, Gaur, P., Samuel, S., Lim, S.J.,
Arumugam, T., Ramachandran, V., Wang, H., and Ellis, L.M. (2008). Neuropilin-2-mediated
tumor growth and angiogenesis in pancreatic adenocarcinoma. Clin. Cancer Res. 14, 8052-8060.
Dansranjavin, T., Mobius, C., Tannapfel, A., Bartels, M., Wittekind, C., Hauss, J., and Witzigmann,
H. (2006). E-cadherin and DAP kinase in pancreatic adenocarcinoma and corresponding lymph
node metastases. Oncol. Rep. 15, 1125-1131.
Dasari, B.V., Pasquali, S., Vohra, R.S., Smith, A.M., Taylor, M.A., Sutcliffe, R.P., Muiesan, P.,
Roberts, K.J., Isaac, J., and Mirza, D.F. (2015). Extended Versus Standard Lymphadenectomy for
Pancreatic Head Cancer: Meta-Analysis of Randomized Controlled Trials. J. Gastrointest. Surg.
19, 1725-1732.
de Castro, F., Silos-Santiago, I., Lopez de Armentia, M., Barbacid, M., and Belmonte, C. (1998).
Corneal innervation and sensitivity to noxious stimuli in trkA knockout mice. Eur. J. Neurosci. 10,
146-152.
de Matos-Neto, E.M., Lima, J.D., de Pereira, W.O., Figueredo, R.G., Riccardi, D.M., Radloff, K.,
das Neves, R.X., Camargo, R.G., Maximiano, L.F., Tokeshi, F., et al. (2015). Systemic Inflammation
in Cachexia - Is Tumor Cytokine Expression Profile the Culprit? Front. Immunol. 6, 629.
De Smedt, T., Van Mechelen, M., De Becker, G., Urbain, J., Leo, O., and Moser, M. (1997). Effect
of interleukin-10 on dendritic cell maturation and function. Eur. J. Immunol. 27, 1229-1235.
Dejana, E., Orsenigo, F., Molendini, C., Baluk, P., and McDonald, D.M. (2009). Organization and
signaling of endothelial cell-to-cell junctions in various regions of the blood and lymphatic
vascular trees. Cell Tissue Res. 335, 17-25.
Delcore, R., Rodriguez, F.J., Forster, J., Hermreck, A.S., and Thomas, J.H. (1996). Significance of
lymph node metastases in patients with pancreatic cancer undergoing curative resection. Am. J.
Surg. 172, 463-8; discussion 468-9.
Demeure, M.J., Doffek, K.M., Komorowski, R.A., and Wilson, S.D. (1998). Adenocarcinoma of the
pancreas: detection of occult metastases in regional lymph nodes by a polymerase chain
reaction-based assay. Cancer 83, 1328-1334.
Demir, I.E., Ceyhan, G.O., Rauch, U., Altintas, B., Klotz, M., Muller, M.W., Buchler, M.W., Friess,
H., and Schafer, K.H. (2010). The microenvironment in chronic pancreatitis and pancreatic
cancer induces neuronal plasticity. Neurogastroenterol. Motil. 22, 480-90, e112-3.
Detry, B., Blacher, S., Erpicum, C., Paupert, J., Maertens, L., Maillard, C., Munaut, C., Sounni,
N.E., Lambert, V., Foidart, J.M., et al. (2013). Sunitinib inhibits inflammatory corneal
lymphangiogenesis. Invest. Ophthalmol. Vis. Sci. 54, 3082-3093.

228
DiMagno, E.P., Reber, H.A., and Tempero, M.A. (1999). AGA technical review on the
epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American
Gastroenterological Association. Gastroenterology 117, 1464-1484.
Ding, M., Fu, X., Tan, H., Wang, R., Chen, Z., and Ding, S. (2012). The effect of vascular
endothelial growth factor C expression in tumor-associated macrophages on lymphangiogenesis
and lymphatic metastasis in breast cancer. Mol. Med. Rep. 6, 1023-1029.
Doi, R., Kami, K., Ito, D., Fujimoto, K., Kawaguchi, Y., Wada, M., Kogire, M., Hosotani, R.,
Imamura, M., and Uemoto, S. (2007). Prognostic implication of para-aortic lymph node
metastasis in resectable pancreatic cancer. World J. Surg. 31, 147-154.
Donaghy, M. (2003). Enlarged peripheral nerves. Practical Neurology 3, 40-45.
D'Orlando, C., Marzetti, E., Francois, S., Lorenzi, M., Conti, V., di Stasio, E., Rosa, F., Brunelli, S.,
Doglietto, G.B., Pacelli, F., and Bossola, M. (2014). Gastric cancer does not affect the expression
of atrophy-related genes in human skeletal muscle. Muscle Nerve 49, 528-533.
Dragovich, T., Laheru, D., Dayyani, F., Bolejack, V., Smith, L., Seng, J., Burris, H., Rosen, P.,
Hidalgo, M., Ritch, P., et al. (2014). Phase II trial of vatalanib in patients with advanced or
metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).
Cancer Chemother. Pharmacol. 74, 379-387.
Drevs, J., Hofmann, I., Hugenschmidt, H., Wittig, C., Madjar, H., Muller, M., Wood, J., MartinyBaron, G., Unger, C., and Marme, D. (2000). Effects of PTK787/ZK 222584, a specific inhibitor of
vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis,
vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. 60, 48194824.
Du, Q., Jiang, L., Wang, X., Wang, M., She, F., and Chen, Y. (2014). Tumor necrosis factor-alpha
promotes the lymphangiogenesis of gallbladder carcinoma through nuclear factor-kappaBmediated upregulation of vascular endothelial growth factor-C. Cancer. Sci. 105, 1261-1271.
Duanmin, H., Chao, X., and Qi, Z. (2013). eEF1A2 protein expression correlates with lymph node
metastasis and decreased survival in pancreatic ductal adenocarcinoma.
Hepatogastroenterology 60, 870-875.
Dunne, A.A., Boerner, H.G., Kukula, H., Schlaad, H., Wiegand, S., Werner, J.A., and Antonietti, M.
(2007). Block copolymer carrier systems for translymphatic chemotherapy of lymph node
metastases. Anticancer Res. 27, 3935-3940.
Duong, T., Koopman, P., and Francois, M. (2012). Tumor lymphangiogenesis as a potential
therapeutic target. J. Oncol. 2012, 204946.
Emmett, M.S., Lanati, S., Dunn, D.B., Stone, O.A., and Bates, D.O. (2011). CCR7 mediates
directed growth of melanomas towards lymphatics. Microcirculation 18, 172-182.

229
Entschladen, F., Palm, D., Lang, K., Drell, T.L.,4th, and Zaenker, K.S. (2006). Neoneurogenesis:
tumors may initiate their own innervation by the release of neurotrophic factors in analogy to
lymphangiogenesis and neoangiogenesis. Med. Hypotheses 67, 33-35.
Entschladen, F., Palm, D., Niggemann, B., and Zaenker, K.S. (2008). The cancer's nervous tooth:
Considering the neuronal crosstalk within tumors. Semin. Cancer Biol. 18, 171-175.
Esquenazi, S., Bazan, H.E., Bui, V., He, J., Kim, D.B., and Bazan, N.G. (2005). Topical combination
of NGF and DHA increases rabbit corneal nerve regeneration after photorefractive keratectomy.
Invest. Ophthalmol. Vis. Sci. 46, 3121-3127.
Evans, D.B., Farnell, M.B., Lillemoe, K.D., Vollmer, C.,Jr, Strasberg, S.M., and Schulick, R.D.
(2009). Surgical treatment of resectable and borderline resectable pancreas cancer: expert
consensus statement. Ann. Surg. Oncol. 16, 1736-1744.
Ewens, A., Mihich, E., and Ehrke, M.J. (2005). Distant metastasis from subcutaneously grown
E0771 medullary breast adenocarcinoma. Anticancer Res. 25, 3905-3915.
Fagiani, E., Lorentz, P., Kopfstein, L., and Christofori, G. (2011). Angiopoietin-1 and -2 exert
antagonistic functions in tumor angiogenesis, yet both induce lymphangiogenesis. Cancer Res.
71, 5717-5727.
Fallarino, F., Grohmann, U., You, S., McGrath, B.C., Cavener, D.R., Vacca, C., Orabona, C., Bianchi,
R., Belladonna, M.L., Volpi, C., et al. (2006). The combined effects of tryptophan starvation and
tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory
phenotype in naive T cells. J. Immunol. 176, 6752-6761.
Farnell, M.B., Aranha, G.V., Nimura, Y., and Michelassi, F. (2008). The role of extended
lymphadenectomy for adenocarcinoma of the head of the pancreas: strength of the evidence. J.
Gastrointest. Surg. 12, 651-656.
Farnell, M.B., Pearson, R.K., Sarr, M.G., DiMagno, E.P., Burgart, L.J., Dahl, T.R., Foster, N.,
Sargent, D.J., and Pancreas Cancer Working Group. (2005). A prospective randomized trial
comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended
lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 138, 618-28;
discussion 628-30.
Farrow, B., Albo, D., and Berger, D.H. (2008). The role of the tumor microenvironment in the
progression of pancreatic cancer. J. Surg. Res. 149, 319-328.
Favier, B., Alam, A., Barron, P., Bonnin, J., Laboudie, P., Fons, P., Mandron, M., Herault, J.P.,
Neufeld, G., Savi, P., Herbert, J.M., and Bono, F. (2006). Neuropilin-2 interacts with VEGFR-2 and
VEGFR-3 and promotes human endothelial cell survival and migration. Blood 108, 1243-1250.
Fearon, K., Strasser, F., Anker, S.D., Bosaeus, I., Bruera, E., Fainsinger, R.L., Jatoi, A., Loprinzi, C.,
MacDonald, N., Mantovani, G., et al. (2011). Definition and classification of cancer cachexia: an
international consensus. Lancet Oncol. 12, 489-495.

230
Feig, C., Gopinathan, A., Neesse, A., Chan, D.S., Cook, N., and Tuveson, D.A. (2012). The pancreas
cancer microenvironment. Clin. Cancer Res. 18, 4266-4276.
Feig, C., Jones, J.O., Kraman, M., Wells, R.J., Deonarine, A., Chan, D.S., Connell, C.M., Roberts,
E.W., Zhao, Q., Caballero, O.L., et al. (2013). Targeting CXCL12 from FAP-expressing carcinomaassociated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc.
Natl. Acad. Sci. U. S. A. 110, 20212-20217.
Fernandez-Cruz, L., Johnson, C., and Dervenis, C. (1999). Locoregional dissemination and
extended lymphadenectomy in pancreatic cancer. Dig. Surg. 16, 313-319.
Ferrari, G., Hajrasouliha, A.R., Sadrai, Z., Ueno, H., Chauhan, S.K., and Dana, R. (2013). Nerves
and neovessels inhibit each other in the cornea. Invest. Ophthalmol. Vis. Sci. 54, 813-820.
Fink, D.M., Connor, A.L., Kelley, P.M., Steele, M.M., Hollingsworth, M.A., and Tempero, R.M.
(2014a). Nerve growth factor regulates neurolymphatic remodeling during corneal inflammation
and resolution. PLoS One 9, e112737.
Fink, D.M., Connor, A.L., Kelley, P.M., Tempero, R.M., and Hollingsworth, M.A. Metastatic tumor
migration in lymphatic vessels revealed by real-time intravital imaging [abstract]. In:
Proceedings of the 105th Annual Meeting of the American Association for Cancer Research;
2014b Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; (2014b). Abstract nr 4942.
Fink, D.M., Steele, M.M., and Hollingsworth, M.A. (2015a). The lymphatic system and pancreatic
cancer. Cancer Lett. 2015 Dec 29. pii:S0304-3835(15)00745-4. doi:
10.1016/j.canlet.2015.11.048. [Epub ahead of print].
Fink, D.M., Connor, A.L., Kelley, P.M., Tempero, R.M., and Hollingsworth, M.A. Inflamed and
wound recovered tumor microenvironment contributions to lymphatic-mediated metastasis
[abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer
Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; (2015b). Abstract nr 5220.
Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., Chorianopoulos, E.,
Liesenborghs, L., Koch, M., De Mol, M., et al. (2007). Anti-PlGF inhibits growth of VEGF(R)inhibitor-resistant tumors without affecting healthy vessels. Cell 131, 463-475.
Fogelman, D.R., Holmes, H., Mohammed, K., Katz, M.H., Prado, C.M., Lieffers, J., Garg, N.,
Varadhachary, G.R., Shroff, R., Overman, M.J., et al. (2014). Does IGFR1 inhibition result in
increased muscle mass loss in patients undergoing treatment for pancreatic cancer? J. Cachexia
Sarcopenia Muscle 5, 307-313.
Formentini, A., Prokopchuk, O., Strater, J., Kleeff, J., Grochola, L.F., Leder, G., Henne-Bruns, D.,
Korc, M., and Kornmann, M. (2009). Interleukin-13 exerts autocrine growth-promoting effects
on human pancreatic cancer, and its expression correlates with a propensity for lymph node
metastases. Int. J. Colorectal Dis. 24, 57-67.

231
Fujii, T. (2013). Extended lymphadenectomy in pancreatic cancer is crucial. World J. Surg. 37,
1778-1781.
Fujita, T., Nakagohri, T., Gotohda, N., Takahashi, S., Konishi, M., Kojima, M., and Kinoshita, T.
(2010). Evaluation of the prognostic factors and significance of lymph node status in invasive
ductal carcinoma of the body or tail of the pancreas. Pancreas 39, e48-54.
Fukahi, K., Fukasawa, M., Neufeld, G., Itakura, J., and Korc, M. (2004). Aberrant expression of
neuropilin-1 and -2 in human pancreatic cancer cells. Clin. Cancer Res. 10, 581-590.
Fukuda, M., Kusama, K., and Sakashita, H. (2008). Cimetidine inhibits salivary gland tumor cell
adhesion to neural cells and induces apoptosis by blocking NCAM expression. BMC Cancer 8,
376-2407-8-376.
Gallagher, I.J., Stephens, N.A., MacDonald, A.J., Skipworth, R.J., Husi, H., Greig, C.A., Ross, J.A.,
Timmons, J.A., and Fearon, K.C. (2012). Suppression of skeletal muscle turnover in cancer
cachexia: evidence from the transcriptome in sequential human muscle biopsies. Clin. Cancer
Res. 18, 2817-2827.
Geboes, K., and Collins, S. (1998). Structural abnormalities of the nervous system in Crohn's
disease and ulcerative colitis. Neurogastroenterol. Motil. 10, 189-202.
Gelfand, M.V., Hong, S., and Gu, C. (2009). Guidance from above: common cues direct distinct
signaling outcomes in vascular and neural patterning. Trends Cell Biol. 19, 99-110.
Gerdes, B., Ramaswamy, A., Bartsch, D.K., and Rothmund, M. (2005). Peripyloric lymph node
metastasis is a rare condition in carcinoma of the pancreatic head. Pancreas 31, 88-92.
Gerli, R., Solito, R., Weber, E., and Agliano, M. (2000). Specific adhesion molecules bind
anchoring filaments and endothelial cells in human skin initial lymphatics. Lymphology 33, 148157.
Ghiringhelli, F., Puig, P.E., Roux, S., Parcellier, A., Schmitt, E., Solary, E., Kroemer, G., Martin, F.,
Chauffert, B., and Zitvogel, L. (2005). Tumor cells convert immature myeloid dendritic cells into
TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 202,
919-929.
Gil, Z., Cavel, O., Kelly, K., Brader, P., Rein, A., Gao, S.P., Carlson, D.L., Shah, J.P., Fong, Y., and
Wong, R.J. (2010). Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves. J.
Natl. Cancer Inst. 102, 107-118.
Goel, S., Duda, D.G., Xu, L., Munn, L.L., Boucher, Y., Fukumura, D., and Jain, R.K. (2011).
Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 91,
1071-1121.
Goel, S., Wong, A.H., and Jain, R.K. (2012). Vascular normalization as a therapeutic strategy for
malignant and nonmalignant disease. Cold Spring Harb Perspect. Med. 2, a006486.

232
Gohrig, A., Detjen, K.M., Hilfenhaus, G., Korner, J.L., Welzel, M., Arsenic, R., Schmuck, R., Bahra,
M., Wu, J.Y., Wiedenmann, B., and Fischer, C. (2014). Axon guidance factor SLIT2 inhibits neural
invasion and metastasis in pancreatic cancer. Cancer Res. 74, 1529-1540.
Golse, N., Lebeau, R., Lombard-Bohas, C., Hervieu, V., Ponchon, T., and Adham, M. (2013).
Lymph node involvement beyond peripancreatic region in pancreatic head cancers: when results
belie expectations. Pancreas 42, 239-248.
Goncalves, A., Gilabert, M., Francois, E., Dahan, L., Perrier, H., Lamy, R., Re, D., Largillier, R.,
Gasmi, M., Tchiknavorian, X., et al. (2012). BAYPAN study: a double-blind phase III randomized
trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with
advanced pancreatic cancer. Ann. Oncol. 23, 2799-2805.
Gresham, G.K., Wells, G.A., Gill, S., Cameron, C., and Jonker, D.J. (2014). Chemotherapy
regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC
Cancer 14, 471-2407-14-471.
Grunwald, V., and Merseburger, A.S. (2012). Axitinib for the treatment of patients with
advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment. Onco
Targets Ther. 5, 111-117.
Guerra, C., Collado, M., Navas, C., Schuhmacher, A.J., Hernandez-Porras, I., Canamero, M.,
Rodriguez-Justo, M., Serrano, M., and Barbacid, M. (2011). Pancreatitis-induced inflammation
contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer. Cell. 19,
728-739.
Guerra, C., Schuhmacher, A.J., Canamero, M., Grippo, P.J., Verdaguer, L., Perez-Gallego, L.,
Dubus, P., Sandgren, E.P., and Barbacid, M. (2007). Chronic pancreatitis is essential for induction
of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer. Cell. 11, 291302.
Gunther, K., Leier, J., Henning, G., Dimmler, A., Weissbach, R., Hohenberger, W., and Forster, R.
(2005). Prediction of lymph node metastasis in colorectal carcinoma by expressionof chemokine
receptor CCR7. Int. J. Cancer 116, 726-733.
Guo, J., Lou, W., Ji, Y., and Zhang, S. (2013). Effect of CCR7, CXCR4 and VEGF-C on the lymph
node metastasis of human pancreatic ductal adenocarcinoma. Oncol. Lett. 5, 1572-1578.
Hagerling, R., Pollmann, C., Kremer, L., Andresen, V., and Kiefer, F. (2011). Intravital two-photon
microscopy of lymphatic vessel development and function using a transgenic Prox1 promoterdirected mOrange2 reporter mouse. Biochem. Soc. Trans. 39, 1674-1681.
Hall, K.L., Volk-Draper, L.D., Flister, M.J., and Ran, S. (2012). New model of macrophage
acquisition of the lymphatic endothelial phenotype. PLoS One 7, e31794.
Hanahan, D., and Coussens, L.M. (2012). Accessories to the crime: functions of cells recruited to
the tumor microenvironment. Cancer. Cell. 21, 309-322.

233
Harrell, M.I., Iritani, B.M., and Ruddell, A. (2007). Tumor-induced sentinel lymph node
lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am. J. Pathol. 170,
774-786.
Hartveit, E. (1990). Attenuated cells in breast stroma: the missing lymphatic system of the
breast. Histopathology 16, 533-543.
He, H., Di, Y., Liang, M., Yang, F., Yao, L., Hao, S., Li, J., Jiang, Y., Jin, C., and Fu, D. (2013a). The
microRNA-218 and ROBO-1 signaling axis correlates with the lymphatic metastasis of pancreatic
cancer. Oncol. Rep. 30, 651-658.
He, W.A., Berardi, E., Cardillo, V.M., Acharyya, S., Aulino, P., Thomas-Ahner, J., Wang, J.,
Bloomston, M., Muscarella, P., Nau, P., et al. (2013b). NF-kappaB-mediated Pax7 dysregulation
in the muscle microenvironment promotes cancer cachexia. J. Clin. Invest. 123, 4821-4835.
He, X.W., Liu, T., Chen, Y.X., Cheng, D.J., Li, X.R., Xiao, Y., and Feng, Y.L. (2008). Calcium
carbonate nanoparticle delivering vascular endothelial growth factor-C siRNA effectively inhibits
lymphangiogenesis and growth of gastric cancer in vivo. Cancer Gene Ther. 15, 193-202.
He, Y., Kozaki, K., Karpanen, T., Koshikawa, K., Yla-Herttuala, S., Takahashi, T., and Alitalo, K.
(2002). Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking
vascular endothelial growth factor receptor 3 signaling. J. Natl. Cancer Inst. 94, 819-825.
He, Y., Rajantie, I., Pajusola, K., Jeltsch, M., Holopainen, T., Yla-Herttuala, S., Harding, T., Jooss,
K., Takahashi, T., and Alitalo, K. (2005). Vascular endothelial cell growth factor receptor 3mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via
lymphatic vessels. Cancer Res. 65, 4739-4746.
Heckman, C.A., Holopainen, T., Wirzenius, M., Keskitalo, S., Jeltsch, M., Yla-Herttuala, S., Wedge,
S.R., Jurgensmeier, J.M., and Alitalo, K. (2008). The tyrosine kinase inhibitor cediranib blocks
ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Cancer Res. 68, 4754-4762.
Henne-Bruns, D., Vogel, I., Luttges, J., Kloppel, G., and Kremer, B. (2000). Surgery for ductal
adenocarcinoma of the pancreatic head: staging, complications, and survival after regional
versus extended lymphadenectomy. World J. Surg. 24, 595-601; discussion 601-2.
Henne-Bruns, D., Vogel, I., Luttges, J., Kloppel, G., and Kremer, B. (1998). Ductal adenocarcinoma
of the pancreas head: survival after regional versus extended lymphadenectomy.
Hepatogastroenterology 45, 855-866.
Hezel, A.F., Kimmelman, A.C., Stanger, B.Z., Bardeesy, N., and Depinho, R.A. (2006). Genetics
and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20, 1218-1249.
Hinch, E.C., Sullivan-Gunn, M.J., Vaughan, V.C., McGlynn, M.A., and Lewandowski, P.A. (2013).
Disruption of pro-oxidant and antioxidant systems with elevated expression of the ubiquitin

234
proteosome system in the cachectic heart muscle of nude mice. J. Cachexia Sarcopenia Muscle
4, 287-293.
Hingorani, S.R., Wang, L., Multani, A.S., Combs, C., Deramaudt, T.B., Hruban, R.H., Rustgi, A.K.,
Chang, S., and Tuveson, D.A. (2005). Trp53R172H and KrasG12D cooperate to promote
chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.
Cancer. Cell. 7, 469-483.
Hirakawa, S., Detmar, M., Kerjaschki, D., Nagamatsu, S., Matsuo, K., Tanemura, A., Kamata, N.,
Higashikawa, K., Okazaki, H., Kameda, K., et al. (2009). Nodal lymphangiogenesis and metastasis:
Role of tumor-induced lymphatic vessel activation in extramammary Paget's disease. Am. J.
Pathol. 175, 2235-2248.
Hirata, K., Sato, T., Mukaiya, M., Yamashiro, K., Kimura, M., Sasaki, K., and Denno, R. (1997).
Results of 1001 pancreatic resections for invasive ductal adenocarcinoma of the pancreas. Arch.
Surg. 132, 771-6; discussion 777.
Hirono, S., Tani, M., Kawai, M., Okada, K., Miyazawa, M., Shimizu, A., Uchiyama, K., and Yamaue,
H. (2012). Identification of the lymphatic drainage pathways from the pancreatic head guided by
indocyanine green fluorescence imaging during pancreaticoduodenectomy. Dig. Surg. 29, 132139.
Hirosue, S., Vokali, E., Raghavan, V.R., Rincon-Restrepo, M., Lund, A.W., Corthesy-Henrioud, P.,
Capotosti, F., Halin Winter, C., Hugues, S., and Swartz, M.A. (2014). Steady-state antigen
scavenging, cross-presentation, and CD8+ T cell priming: a new role for lymphatic endothelial
cells. J. Immunol. 192, 5002-5011.
Holopainen, T., Saharinen, P., D'Amico, G., Lampinen, A., Eklund, L., Sormunen, R., Anisimov, A.,
Zarkada, G., Lohela, M., Helotera, H., et al. (2012). Effects of angiopoietin-2-blocking antibody
on endothelial cell-cell junctions and lung metastasis. J. Natl. Cancer Inst. 104, 461-475.
Honors, M.A., and Kinzig, K.P. (2012). The role of insulin resistance in the development of
muscle wasting during cancer cachexia. J. Cachexia Sarcopenia Muscle 3, 5-11.
Hoshida, T., Isaka, N., Hagendoorn, J., di Tomaso, E., Chen, Y.L., Pytowski, B., Fukumura, D.,
Padera, T.P., and Jain, R.K. (2006). Imaging steps of lymphatic metastasis reveals that vascular
endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph
nodes: therapeutic implications. Cancer Res. 66, 8065-8075.
Hosono, K., Suzuki, T., Tamaki, H., Sakagami, H., Hayashi, I., Narumiya, S., Alitalo, K., and Majima,
M. (2011). Roles of prostaglandin E2-EP3/EP4 receptor signaling in the enhancement of
lymphangiogenesis during fibroblast growth factor-2-induced granulation formation.
Arterioscler. Thromb. Vasc. Biol. 31, 1049-1058.
House, M.G., Gonen, M., Jarnagin, W.R., D'Angelica, M., DeMatteo, R.P., Fong, Y., Brennan, M.F.,
and Allen, P.J. (2007). Prognostic significance of pathologic nodal status in patients with resected
pancreatic cancer. J. Gastrointest. Surg. 11, 1549-1555.

235
Howard, J.M. (1999). Development and progress in resective surgery for pancreatic cancer.
World J. Surg. 23, 901-906.
Hruban, R.H., and Adsay, N.V. (2009). Molecular classification of neoplasms of the pancreas.
Hum. Pathol. 40, 612-623.
Huang, D., Swanson, E.A., Lin, C.P., Schuman, J.S., Stinson, W.G., Chang, W., Hee, M.R., Flotte, T.,
Gregory, K., and Puliafito, C.A. (1991). Optical coherence tomography. Science 254, 1178-1181.
Huang, W.C., Nagahashi, M., Terracina, K.P., and Takabe, K. (2013). Emerging Role of
Sphingosine-1-phosphate in Inflammation, Cancer, and Lymphangiogenesis. Biomolecules 3,
10.3390/biom3030408.
Hunter, K.E., Palermo, C., Kester, J.C., Simpson, K., Li, J.P., Tang, L.H., Klimstra, D.S., Vlodavsky, I.,
and Joyce, J.A. (2014). Heparanase promotes lymphangiogenesis and tumor invasion in
pancreatic neuroendocrine tumors. Oncogene 33, 1799-1808.
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J.,
Baron, A., Griffing, S., Holmgren, E., et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342.
Hwang, T.L., Lee, L.Y., Wang, C.C., Liang, Y., Huang, S.F., and Wu, C.M. (2012). CCL7 and CCL21
overexpression in gastric cancer is associated with lymph node metastasis and poor prognosis.
World J. Gastroenterol. 18, 1249-1256.
Ichise, T., Yoshida, N., and Ichise, H. (2010). H-, N- and Kras cooperatively regulate lymphatic
vessel growth by modulating VEGFR3 expression in lymphatic endothelial cells in mice.
Development 137, 1003-1013.
Imai, H., Doi, R., Kanazawa, H., Kamo, N., Koizumi, M., Masui, T., Iwanaga, Y., Kawaguchi, Y.,
Takada, Y., Isoda, H., and Uemoto, S. (2010). Preoperative assessment of para-aortic lymph node
metastasis in patients with pancreatic cancer. Int. J. Clin. Oncol. 15, 294-300.
Imoto, A., Mitsunaga, S., Inagaki, M., Aoyagi, K., Sasaki, H., Ikeda, M., Nakachi, K., Higuchi, K.,
and Ochiai, A. (2012). Neural invasion induces cachexia via astrocytic activation of neural route
in pancreatic cancer. Int. J. Cancer 131, 2795-2807.
Inman, K.S., Francis, A.A., and Murray, N.R. (2014). Complex role for the immune system in
initiation and progression of pancreatic cancer. World J. Gastroenterol. 20, 11160-11181.
Inturrisi, C.E. (2003). Pharmacology of analgesia: basic principles. In Cancer Pain: Assessment
and Management, Bruera, E. D., and Portenoy, R. K. eds., (Cambridge, UK: Cambridge University
Press) pp. 111-123.
Iqbal, N., Lovegrove, R.E., Tilney, H.S., Abraham, A.T., Bhattacharya, S., Tekkis, P.P., and Kocher,
H.M. (2009). A comparison of pancreaticoduodenectomy with extended
pancreaticoduodenectomy: a meta-analysis of 1909 patients. Eur. J. Surg. Oncol. 35, 79-86.

236
Irino, T., Takeuchi, H., Matsuda, S., Saikawa, Y., Kawakubo, H., Wada, N., Takahashi, T.,
Nakamura, R., Fukuda, K., Omori, T., and Kitagawa, Y. (2014). CC-Chemokine receptor CCR7: a
key molecule for lymph node metastasis in esophageal squamous cell carcinoma. BMC Cancer
14, 291-2407-14-291.
Isaji, S., Kawarada, Y., and Uemoto, S. (2004). Classification of pancreatic cancer: comparison of
Japanese and UICC classifications. Pancreas 28, 231-234.
Ishikawa, O., Ohhigashi, H., Sasaki, Y., Kabuto, T., Fukuda, I., Furukawa, H., Imaoka, S., and
Iwanaga, T. (1988). Practical usefulness of lymphatic and connective tissue clearance for the
carcinoma of the pancreas head. Ann. Surg. 208, 215-220.
Issa, A., Le, T.X., Shoushtari, A.N., Shields, J.D., and Swartz, M.A. (2009). Vascular endothelial
growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote
invasive phenotype. Cancer Res. 69, 349-357.
Jang, J.Y., Kang, M.J., Heo, J.S., Choi, S.H., Choi, D.W., Park, S.J., Han, S.S., Yoon, D.S., Yu, H.C.,
Kang, K.J., Kim, S.G., and Kim, S.W. (2014). A prospective randomized controlled study
comparing outcomes of standard resection and extended resection, including dissection of the
nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann. Surg. 259,
656-664.
Jee, D., and Lee, W.K. (2012). Inhibitory effect of intravitreal injection of bevacizumab on nerve
growth factor. Curr. Eye Res. 37, 408-415.
Jeltsch, M., Kaipainen, A., Joukov, V., Meng, X., Lakso, M., Rauvala, H., Swartz, M., Fukumura, D.,
Jain, R.K., and Alitalo, K. (1997). Hyperplasia of lymphatic vessels in VEGF-C transgenic mice.
Science 276, 1423-1425.
Jeong, H.S., Jones, D., Liao, S., Wattson, D.A., Cui, C.H., Duda, D.G., Willett, C.G., Jain, R.K., and
Padera, T.P. (2015). Investigation of the Lack of Angiogenesis in the Formation of Lymph Node
Metastases. J. Natl. Cancer Inst. 107, 10.1093/jnci/djv155. Print 2015 Sep.
Jimenez-Andrade, J.M., Herrera, M.B., Ghilardi, J.R., Vardanyan, M., Melemedjian, O.K., and
Mantyh, P.W. (2008). Vascularization of the dorsal root ganglia and peripheral nerve of the
mouse: implications for chemical-induced peripheral sensory neuropathies. Mol. Pain 4, 108069-4-10.
John, B.J., Naik, P., Ironside, A., Davidson, B.R., Fusai, G., Gillmore, R., Watkins, J., and Rahman,
S.H. (2013). Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph
nodal burden and lymph node ratio are the only prognostic factors associated with survival. HPB
(Oxford) 15, 674-680.
Johns, N., Hatakeyama, S., Stephens, N.A., Degen, M., Degen, S., Frieauff, W., Lambert, C., Ross,
J.A., Roubenoff, R., Glass, D.J., Jacobi, C., and Fearon, K.C. (2014). Clinical classification of cancer
cachexia: phenotypic correlates in human skeletal muscle. PLoS One 9, e83618.

237
Johnson, L.A., Clasper, S., Holt, A.P., Lalor, P.F., Baban, D., and Jackson, D.G. (2006). An
inflammation-induced mechanism for leukocyte transmigration across lymphatic vessel
endothelium. J. Exp. Med. 203, 2763-2777.
Johnson, L.A., and Jackson, D.G. (2013). The chemokine CX3CL1 promotes trafficking of dendritic
cells through inflamed lymphatics. J. Cell. Sci. 126, 5259-5270.
Jones, D., Li, Y., He, Y., Xu, Z., Chen, H., and Min, W. (2012). Mirtron microRNA-1236 inhibits
VEGFR-3 signaling during inflammatory lymphangiogenesis. Arterioscler. Thromb. Vasc. Biol. 32,
633-642.
Jones, D., Xu, Z., Zhang, H., He, Y., Kluger, M.S., Chen, H., and Min, W. (2010). Functional
analyses of the bone marrow kinase in the X chromosome in vascular endothelial growth factorinduced lymphangiogenesis. Arterioscler. Thromb. Vasc. Biol. 30, 2553-2561.
Joo, M.J., Yuhan, K.R., Hyon, J.Y., Lai, H., Hose, S., Sinha, D., and O'Brien, T.P. (2004). The effect
of nerve growth factor on corneal sensitivity after laser in situ keratomileusis. Arch. Ophthalmol.
122, 1338-1341.
Joukov, V., Pajusola, K., Kaipainen, A., Chilov, D., Lahtinen, I., Kukk, E., Saksela, O., Kalkkinen, N.,
and Alitalo, K. (1996). A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4
(VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15, 290-298.
Jung, K.Y., Cho, S.W., Kim, Y.A., Kim, D., Oh, B.C., Park do, J., and Park, Y.J. (2015). Cancers with
Higher Density of Tumor-Associated Macrophages Were Associated with Poor Survival Rates. J.
Pathol. Transl. Med. 49, 318-324.
Kaifi, J.T., Yekebas, E.F., Schurr, P., Obonyo, D., Wachowiak, R., Busch, P., Heinecke, A., Pantel,
K., and Izbicki, J.R. (2005). Tumor-cell homing to lymph nodes and bone marrow and CXCR4
expression in esophageal cancer. J. Natl. Cancer Inst. 97, 1840-1847.
Kaipainen, A., Korhonen, J., Mustonen, T., van Hinsbergh, V.W., Fang, G.H., Dumont, D.,
Breitman, M., and Alitalo, K. (1995). Expression of the fms-like tyrosine kinase 4 gene becomes
restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. U. S. A. 92, 35663570.
Kameda, K., Shimada, H., Ishikawa, T., Takimoto, A., Momiyama, N., Hasegawa, S., Misuta, K.,
Nakano, A., Nagashima, Y., and Ichikawa, Y. (1999). Expression of highly polysialylated neural cell
adhesion molecule in pancreatic cancer neural invasive lesion. Cancer Lett. 137, 201-207.
Kaminskas, L.M., Ascher, D.B., McLeod, V.M., Herold, M.J., Le, C.P., Sloan, E.K., and Porter, C.J.
(2013). PEGylation of interferon alpha2 improves lymphatic exposure after subcutaneous and
intravenous administration and improves antitumour efficacy against lymphatic breast cancer
metastases. J. Control. Release 168, 200-208.
Kamisawa, T., Isawa, T., Koike, M., Tsuruta, K., and Okamoto, A. (1995). Hematogenous
metastases of pancreatic ductal carcinoma. Pancreas 11, 345-349.

238
Kanda, M., Fujii, T., Nagai, S., Kodera, Y., Kanzaki, A., Sahin, T.T., Hayashi, M., Yamada, S.,
Sugimoto, H., Nomoto, S., et al. (2011). Pattern of lymph node metastasis spread in pancreatic
cancer. Pancreas 40, 951-955.
Kankaanpaa, P., Paavolainen, L., Tiitta, S., Karjalainen, M., Paivarinne, J., Nieminen, J.,
Marjomaki, V., Heino, J., and White, D.J. (2012). BioImageXD: an open, general-purpose and
high-throughput image-processing platform. Nat. Methods 9, 683-689.
Karaman, S., and Detmar, M. (2014). Mechanisms of lymphatic metastasis. J. Clin. Invest. 124,
922-928.
Karpanen, T., Egeblad, M., Karkkainen, M.J., Kubo, H., Yla-Herttuala, S., Jaattela, M., and Alitalo,
K. (2001). Vascular endothelial growth factor C promotes tumor lymphangiogenesis and
intralymphatic tumor growth. Cancer Res. 61, 1786-1790.
Karpanen, T., Wirzenius, M., Makinen, T., Veikkola, T., Haisma, H.J., Achen, M.G., Stacker, S.A.,
Pytowski, B., Yla-Herttuala, S., and Alitalo, K. (2006). Lymphangiogenic growth factor
responsiveness is modulated by postnatal lymphatic vessel maturation. Am. J. Pathol. 169, 708718.
Katuchova, J., Bober, J., Katuch, V., and Radonak, J. (2012). Significance of lymph node
micrometastasis in pancreatic cancer patients. Eur. Surg. Res. 48, 10-15.
Katz, M.H., Hwang, R., Fleming, J.B., and Evans, D.B. (2008). Tumor-node-metastasis staging of
pancreatic adenocarcinoma. CA Cancer. J. Clin. 58, 111-125.
Kawada, K., and Taketo, M.M. (2011). Significance and mechanism of lymph node metastasis in
cancer progression. Cancer Res. 71, 1214-1218.
Kawai, Y., Kaidoh, M., and Ohhashi, T. (2008). MDA-MB-231 produces ATP-mediated ICAM-1dependent facilitation of the attachment of carcinoma cells to human lymphatic endothelial
cells. Am. J. Physiol. Cell. Physiol. 295, C1123-32.
Kawai, Y., Kaidoh, M., Yokoyama, Y., Sano, K., and Ohhashi, T. (2009). Chemokine CCL2 facilitates
ICAM-1-mediated interactions of cancer cells and lymphatic endothelial cells in sentinel lymph
nodes. Cancer. Sci. 100, 419-428.
Kayahara, M., Nagakawa, T., Konishi, I., Ueno, K., Ohta, T., and Miyazaki, I. (1991).
Clinicopathological study of pancreatic carcinoma with particular reference to the invasion of
the extrapancreatic neural plexus. Int. J. Pancreatol. 10, 105-111.
Kayahara, M., Nagakawa, T., Ueno, K., Ohta, T., Takeda, T., and Miyazaki, I. (1993). An evaluation
of radical resection for pancreatic cancer based on the mode of recurrence as determined by
autopsy and diagnostic imaging. Cancer 72, 2118-2123.
Kayahara, M., Nakagawara, H., Kitagawa, H., and Ohta, T. (2007). The nature of neural invasion
by pancreatic cancer. Pancreas 35, 218-223.

239
Ke, K., Chen, W., and Chen, Y. (2014). Standard and extended lymphadenectomy for
adenocarcinoma of the pancreatic head: a meta-analysis and systematic review. J.
Gastroenterol. Hepatol. 29, 453-462.
Kedra, B., Popiela, T., Sierzega, M., and Precht, A. (2001). Prognostic factors of long-term
survival after resective procedures for pancreatic cancer. Hepatogastroenterology 48, 17621766.
Keklikoglou, I., Hosaka, K., Bender, C., Bott, A., Koerner, C., Mitra, D., Will, R., Woerner, A.,
Muenstermann, E., Wilhelm, H., Cao, Y., and Wiemann, S. (2014). MicroRNA-206 functions as a
pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic
adenocarcinoma by targeting ANXA2 and KRAS genes. Oncogene
Kelley, P.M., Connor, A.L., and Tempero, R.M. (2013). Lymphatic vessel memory stimulated by
recurrent inflammation. Am. J. Pathol. 182, 2418-2428.
Kelley, P.M., Steele, M.M., and Tempero, R.M. (2011). Regressed lymphatic vessels develop
during corneal repair. Lab. Invest. 91, 1643-1651.
Kenyon, B.M., Voest, E.E., Chen, C.C., Flynn, E., Folkman, J., and D'Amato, R.J. (1996). A model of
angiogenesis in the mouse cornea. Invest. Ophthalmol. Vis. Sci. 37, 1625-1632.
Kerjaschki, D., Bago-Horvath, Z., Rudas, M., Sexl, V., Schneckenleithner, C., Wolbank, S., Bartel,
G., Krieger, S., Kalt, R., Hantusch, B., et al. (2011). Lipoxygenase mediates invasion of
intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary
carcinoma xenografts in mouse. J. Clin. Invest. 121, 2000-2012.
Kessenbrock, K., Plaks, V., and Werb, Z. (2010). Matrix metalloproteinases: regulators of the
tumor microenvironment. Cell 141, 52-67.
Khagi, S., and Saif, M.W. (2015). Pancreatic neuroendocrine tumors: targeting the molecular
basis of disease. Curr. Opin. Oncol. 27, 38-43.
Kilarski, W.W., Guc, E., Teo, J.C., Oliver, S.R., Lund, A.W., and Swartz, M.A. (2013). Intravital
immunofluorescence for visualizing the microcirculatory and immune microenvironments in the
mouse ear dermis. PLoS One 8, e57135.
Kim, E.C., Lee, W.S., and Kim, M.S. (2010a). The inhibitory effects of bevacizumab eye drops on
NGF expression and corneal wound healing in rats. Invest. Ophthalmol. Vis. Sci. 51, 4569-4573.
Kim, M., Koh, Y.J., Kim, K.E., Koh, B.I., Nam, D.H., Alitalo, K., Kim, I., and Koh, G.Y. (2010b). CXCR4
signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic
niche. Cancer Res. 70, 10411-10421.
Kim, R., Emi, M., Tanabe, K., and Arihiro, K. (2006). Tumor-driven evolution of
immunosuppressive networks during malignant progression. Cancer Res. 66, 5527-5536.

240
Kimura, W., Morikane, K., Esaki, Y., Chan, W.C., and Pour, P.M. (1998). Histologic and biologic
patterns of microscopic pancreatic ductal adenocarcinomas detected incidentally at autopsy.
Cancer 82, 1839-1849.
Kindler, H.L., Ioka, T., Richel, D.J., Bennouna, J., Letourneau, R., Okusaka, T., Funakoshi, A.,
Furuse, J., Park, Y.S., Ohkawa, S., et al. (2011). Axitinib plus gemcitabine versus placebo plus
gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised
phase 3 study. Lancet Oncol. 12, 256-262.
Kindler, H.L., Niedzwiecki, D., Hollis, D., Sutherland, S., Schrag, D., Hurwitz, H., Innocenti, F.,
Mulcahy, M.F., O'Reilly, E., Wozniak, T.F., et al. (2010). Gemcitabine plus bevacizumab compared
with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the
Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 28, 3617-3622.
Kirchgessner, A.L., and Gershon, M.D. (1990). Innervation of the pancreas by neurons in the gut.
J. Neurosci. 10, 1626-1642.
Kobayashi, K., Sadakari, Y., Ohtsuka, T., Takahata, S., Nakamura, M., Mizumoto, K., and Tanaka,
M. (2010). Factors in intraductal papillary mucinous neoplasms of the pancreas predictive of
lymph node metastasis. Pancreatology 10, 720-725.
Koch, M., Dettori, D., Van Nuffelen, A., Souffreau, J., Marconcini, L., Wallays, G., Moons, L.,
Bruyere, F., Oliviero, S., Noel, A., et al. (2009). VEGF-D deficiency in mice does not affect
embryonic or postnatal lymphangiogenesis but reduces lymphatic metastasis. J. Pathol. 219,
356-364.
Kocher, H.M., Sohail, M., Benjamin, I.S., and Patel, A.G. (2007). Technical limitations of lymph
node mapping in pancreatic cancer. Eur. J. Surg. Oncol. 33, 887-891.
Kodera, Y., Katanasaka, Y., Kitamura, Y., Tsuda, H., Nishio, K., Tamura, T., and Koizumi, F. (2011).
Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast
cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Cancer
Res. 13, R66.
Koide, N., Yamada, T., Shibata, R., Mori, T., Fukuma, M., Yamazaki, K., Aiura, K., Shimazu, M.,
Hirohashi, S., Nimura, Y., and Sakamoto, M. (2006). Establishment of perineural invasion models
and analysis of gene expression revealed an invariant chain (CD74) as a possible molecule
involved in perineural invasion in pancreatic cancer. Clin. Cancer Res. 12, 2419-2426.
Konstantinidis, I.T., Deshpande, V., Zheng, H., Wargo, J.A., Fernandez-del Castillo, C., Thayer,
S.P., Androutsopoulos, V., Lauwers, G.Y., Warshaw, A.L., and Ferrone, C.R. (2010). Does the
mechanism of lymph node invasion affect survival in patients with pancreatic ductal
adenocarcinoma? J. Gastrointest. Surg. 14, 261-267.
Konstantinidis, I.T., Warshaw, A.L., Allen, J.N., Blaszkowsky, L.S., Castillo, C.F., Deshpande, V.,
Hong, T.S., Kwak, E.L., Lauwers, G.Y., Ryan, D.P., et al. (2013). Pancreatic ductal

241
adenocarcinoma: is there a survival difference for R1 resections versus locally advanced
unresectable tumors? What is a "true" R0 resection? Ann. Surg. 257, 731-736.
Kopfstein, L., Veikkola, T., Djonov, V.G., Baeriswyl, V., Schomber, T., Strittmatter, K., Stacker,
S.A., Achen, M.G., Alitalo, K., and Christofori, G. (2007). Distinct roles of vascular endothelial
growth factor-D in lymphangiogenesis and metastasis. Am. J. Pathol. 170, 1348-1361.
Koyama, H., Kobayashi, N., Harada, M., Takeoka, M., Kawai, Y., Sano, K., Fujimori, M., Amano, J.,
Ohhashi, T., Kannagi, R., et al. (2008). Significance of tumor-associated stroma in promotion of
intratumoral lymphangiogenesis: pivotal role of a hyaluronan-rich tumor microenvironment.
Am. J. Pathol. 172, 179-193.
Krafft, C., and Popp, J. (2015). The many facets of Raman spectroscopy for biomedical analysis.
Anal. Bioanal Chem. 407, 699-717.
Krishnan, J., Kirkin, V., Steffen, A., Hegen, M., Weih, D., Tomarev, S., Wilting, J., and Sleeman, J.P.
(2003). Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C
and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats.
Cancer Res. 63, 713-722.
Kubo, H., Cao, R., Brakenhielm, E., Makinen, T., Cao, Y., and Alitalo, K. (2002). Blockade of
vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2induced lymphangiogenesis in mouse cornea. Proc. Natl. Acad. Sci. U. S. A. 99, 8868-8873.
Kumon, R.E., Pollack, M.J., Faulx, A.L., Olowe, K., Farooq, F.T., Chen, V.K., Zhou, Y., Wong, R.C.,
Isenberg, G.A., Sivak, M.V., Chak, A., and Deng, C.X. (2010). In vivo characterization of pancreatic
and lymph node tissue by using EUS spectrum analysis: a validation study. Gastrointest. Endosc.
71, 53-63.
Kurahara, H., Shinchi, H., Mataki, Y., Maemura, K., Noma, H., Kubo, F., Sakoda, M., Ueno, S.,
Natsugoe, S., and Takao, S. (2011). Significance of M2-polarized tumor-associated macrophage
in pancreatic cancer. J. Surg. Res. 167, e211-9.
Kurahara, H., Takao, S., Maemura, K., Mataki, Y., Kuwahata, T., Maeda, K., Sakoda, M., Iino, S.,
Ishigami, S., Ueno, S., Shinchi, H., and Natsugoe, S. (2013). M2-polarized tumor-associated
macrophage infiltration of regional lymph nodes is associated with nodal lymphangiogenesis
and occult nodal involvement in pN0 pancreatic cancer. Pancreas 42, 155-159.
Kurahara, H., Takao, S., Maemura, K., Shinchi, H., Natsugoe, S., and Aikou, T. (2004). Impact of
vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its
relationship to lymph node metastasis. Clin. Cancer Res. 10, 8413-8420.
Kurahara, H., Takao, S., Shinchi, H., Maemura, K., Mataki, Y., Sakoda, M., Hayashi, T., Kuwahata,
T., Minami, K., Ueno, S., and Natsugoe, S. (2010). Significance of lymphangiogenesis in primary
tumor and draining lymph nodes during lymphatic metastasis of pancreatic head cancer. J. Surg.
Oncol. 102, 809-815.

242
La Torre, M., Cavallini, M., Ramacciato, G., Cosenza, G., Rossi Del Monte, S., Nigri, G., Ferri, M.,
Mercantini, P., and Ziparo, V. (2011). Role of the lymph node ratio in pancreatic ductal
adenocarcinoma. Impact on patient stratification and prognosis. J. Surg. Oncol. 104, 629-633.
Lambiase, A., Aloe, L., Mantelli, F., Sacchetti, M., Perrella, E., Bianchi, P., Rocco, M.L., and Bonini,
S. (2012). Capsaicin-induced corneal sensory denervation and healing impairment are reversed
by NGF treatment. Invest. Ophthalmol. Vis. Sci. 53, 8280-8287.
Lambiase, A., Bonini, S., Aloe, L., Rama, P., and Bonini, S. (2000a). Anti-inflammatory and healing
properties of nerve growth factor in immune corneal ulcers with stromal melting. Arch.
Ophthalmol. 118, 1446-1449.
Lambiase, A., Bonini, S., Micera, A., Rama, P., Bonini, S., and Aloe, L. (1998a). Expression of nerve
growth factor receptors on the ocular surface in healthy subjects and during manifestation of
inflammatory diseases. Invest. Ophthalmol. Vis. Sci. 39, 1272-1275.
Lambiase, A., Manni, L., Bonini, S., Rama, P., Micera, A., and Aloe, L. (2000b). Nerve growth
factor promotes corneal healing: structural, biochemical, and molecular analyses of rat and
human corneas. Invest. Ophthalmol. Vis. Sci. 41, 1063-1069.
Lambiase, A., Manni, L., Rama, P., and Bonini, S. (2003). Clinical application of nerve growth
factor on human corneal ulcer. Arch. Ital. Biol. 141, 141-148.
Lambiase, A., Mantelli, F., Sacchetti, M., Rossi, S., Aloe, L., and Bonini, S. (2011). Clinical
applications of NGF in ocular diseases. Arch. Ital. Biol. 149, 283-292.
Lambiase, A., Rama, P., Bonini, S., Caprioglio, G., and Aloe, L. (1998b). Topical treatment with
nerve growth factor for corneal neurotrophic ulcers. N. Engl. J. Med. 338, 1174-1180.
Larrivee, B., Freitas, C., Suchting, S., Brunet, I., and Eichmann, A. (2009). Guidance of vascular
development: lessons from the nervous system. Circ. Res. 104, 428-441.
Leak, L.V. (1976). The structure of lymphatic capillaries in lymph formation. Fed. Proc. 35, 18631871.
Leak, L.V., and Burke, J.F. (1966). Fine structure of the lymphatic capillary and the adjoining
connective tissue area. Am. J. Anat. 118, 785-809.
Lee, J.Y., Park, C., Cho, Y.P., Lee, E., Kim, H., Kim, P., Yun, S.H., and Yoon, Y.S. (2010). Podoplaninexpressing cells derived from bone marrow play a crucial role in postnatal lymphatic
neovascularization. Circulation 122, 1413-1425.
Leek, R.D., and Harris, A.L. (2002). Tumor-associated macrophages in breast cancer. J. Mammary
Gland Biol. Neoplasia 7, 177-189.

243
Li, J., Ma, Q., Liu, H., Guo, K., Li, F., Li, W., Han, L., Wang, F., and Wu, E. (2011a). Relationship
between neural alteration and perineural invasion in pancreatic cancer patients with
hyperglycemia. PLoS One 6, e17385.
Li, J.L., Goh, C.C., Keeble, J.L., Qin, J.S., Roediger, B., Jain, R., Wang, Y., Chew, W.K., Weninger,
W., and Ng, L.G. (2012). Intravital multiphoton imaging of immune responses in the mouse ear
skin. Nat. Protoc. 7, 221-234.
Li, M., Zhao, J., Qiao, J., Song, C., and Zhao, Z. (2014). EphB4 regulates the growth and migration
of pancreatic cancer cells. Tumour Biol. 35, 6855-6859.
Li, M., and Zhao, Z. (2013). Clinical implications of EphB4 receptor expression in pancreatic
cancer. Mol. Biol. Rep. 40, 1735-1741.
Li, R., Wheeler, T., Dai, H., and Ayala, G. (2003). Neural cell adhesion molecule is upregulated in
nerves with prostate cancer invasion. Hum. Pathol. 34, 457-461.
Li, W., Kohara, H., Uchida, Y., James, J.M., Soneji, K., Cronshaw, D.G., Zou, Y.R., Nagasawa, T.,
and Mukouyama, Y.S. (2013). Peripheral nerve-derived CXCL12 and VEGF-A regulate the
patterning of arterial vessel branching in developing limb skin. Dev. Cell. 24, 359-371.
Li, X., Dong, Q., Yan, Z., Lu, W., Feng, L., Xie, C., Xie, Z., Su, B., and Liu, M. (2015). MPEG-DSPE
polymeric micelle for translymphatic chemotherapy of lymph node metastasis. Int. J. Pharm.
487, 8-16.
Li, Z., Burns, A.R., Han, L., Rumbaut, R.E., and Smith, C.W. (2011b). IL-17 and VEGF are necessary
for efficient corneal nerve regeneration. Am. J. Pathol. 178, 1106-1116.
Liao, D., Luo, Y., Markowitz, D., Xiang, R., and Reisfeld, R.A. (2009). Cancer associated fibroblasts
promote tumor growth and metastasis by modulating the tumor immune microenvironment in
a 4T1 murine breast cancer model. PLoS One 4, e7965.
Liao, S., and von der Weid, P.Y. (2015). Lymphatic system: an active pathway for immune
protection. Semin. Cell Dev. Biol. 38, 83-89.
Lin, B., Podar, K., Gupta, D., Tai, Y.T., Li, S., Weller, E., Hideshima, T., Lentzsch, S., Davies, F., Li,
C., et al. (2002). The vascular endothelial growth factor receptor tyrosine kinase inhibitor
PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow
microenvironment. Cancer Res. 62, 5019-5026.
Lin, F.J., Chen, X., Qin, J., Hong, Y.K., Tsai, M.J., and Tsai, S.Y. (2010). Direct transcriptional
regulation of neuropilin-2 by COUP-TFII modulates multiple steps in murine lymphatic vessel
development. J. Clin. Invest. 120, 1694-1707.
Lin, J., Lalani, A.S., Harding, T.C., Gonzalez, M., Wu, W.W., Luan, B., Tu, G.H., Koprivnikar, K.,
VanRoey, M.J., He, Y., Alitalo, K., and Jooss, K. (2005). Inhibition of lymphogenous metastasis

244
using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor.
Cancer Res. 65, 6901-6909.
Liu, Q.H., Shi, M.L., Bai, J., and Zheng, J.N. (2015a). Identification of ANXA1 as a lymphatic
metastasis and poor prognostic factor in pancreatic ductal adenocarcinoma. Asian Pac. J.
Cancer. Prev. 16, 2719-2724.
Liu, X., Guo, X.Z., Li, H.Y., Chen, J., Ren, L.N., and Wu, C.Y. (2014a). KAI1 inhibits
lymphangiogenesis and lymphatic metastasis of pancreatic cancer in vivo. Hepatobiliary.
Pancreat. Dis. Int. 13, 87-92.
Liu, X., Xiao, Q., Bai, X., Yu, Z., Sun, M., Zhao, H., Mi, X., Wang, E., Yao, W., Jin, F., et al. (2014b).
Activation of STAT3 is involved in malignancy mediated by CXCL12-CXCR4 signaling in human
breast cancer. Oncol. Rep. 32, 2760-2768.
Liu, Z., Luo, G., Guo, M., Jin, K., Xiao, Z., Liu, L., Liu, C., Xu, J., Ni, Q., Long, J., and Yu, X. (2015b).
Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with
resected pancreatic cancer. Pancreatology 15, 253-258.
Lund, A.W., Duraes, F.V., Hirosue, S., Raghavan, V.R., Nembrini, C., Thomas, S.N., Issa, A.,
Hugues, S., and Swartz, M.A. (2012). VEGF-C promotes immune tolerance in B16 melanomas and
cross-presentation of tumor antigen by lymph node lymphatics. Cell. Rep. 1, 191-199.
Ma, J., Jiang, Y., Jiang, Y., Sun, Y., and Zhao, X. (2008). Expression of nerve growth factor and
tyrosine kinase receptor A and correlation with perineural invasion in pancreatic cancer. J.
Gastroenterol. Hepatol. 23, 1852-1859.
Maby-El Hajjami, H., and Petrova, T.V. (2008). Developmental and pathological
lymphangiogenesis: from models to human disease. Histochem. Cell Biol. 130, 1063-1078.
Mace, T.A., Ameen, Z., Collins, A., Wojcik, S., Mair, M., Young, G.S., Fuchs, J.R., Eubank, T.D.,
Frankel, W.L., Bekaii-Saab, T., Bloomston, M., and Lesinski, G.B. (2013). Pancreatic cancerassociated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3dependent manner. Cancer Res. 73, 3007-3018.
Maitra, A., Fukushima, N., Takaori, K., and Hruban, R.H. (2005). Precursors to invasive pancreatic
cancer. Adv. Anat. Pathol. 12, 81-91.
Makino, I., Kitagawa, H., Ohta, T., Nakagawara, H., Tajima, H., Ohnishi, I., Takamura, H., Tani, T.,
and Kayahara, M. (2008). Nerve plexus invasion in pancreatic cancer: spread patterns on
histopathologic and embryological analyses. Pancreas 37, 358-365.
Manabe, T., Ohshio, G., Baba, N., Miyashita, T., Asano, N., Tamura, K., Yamaki, K., Nonaka, A.,
and Tobe, T. (1989). Radical pancreatectomy for ductal cell carcinoma of the head of the
pancreas. Cancer 64, 1132-1137.

245
Mancino, M., Ametller, E., Gascon, P., and Almendro, V. (2011). The neuronal influence on
tumor progression. Biochim. Biophys. Acta 1816, 105-118.
Mandriota, S.J., Jussila, L., Jeltsch, M., Compagni, A., Baetens, D., Prevo, R., Banerji, S., Huarte, J.,
Montesano, R., Jackson, D.G., et al. (2001). Vascular endothelial growth factor-C-mediated
lymphangiogenesis promotes tumour metastasis. EMBO J. 20, 672-682.
Mankal, P., and O'Reilly, E. (2013). Sunitinib malate for the treatment of pancreas malignancies-where does it fit? Expert Opin. Pharmacother. 14, 783-792.
Mao, C., Domenico, D.R., Kim, K., Hanson, D.J., and Howard, J.M. (1995). Observations on the
developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings
of 154 autopsies. Arch. Surg. 130, 125-134.
Marchesi, F., Locatelli, M., Solinas, G., Erreni, M., Allavena, P., and Mantovani, A. (2010). Role of
CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer. J.
Neuroimmunol. 224, 39-44.
Marchesi, F., Piemonti, L., Fedele, G., Destro, A., Roncalli, M., Albarello, L., Doglioni, C., Anselmo,
A., Doni, A., Bianchi, P., et al. (2008). The chemokine receptor CX3CR1 is involved in the neural
tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res. 68, 90609069.
Marconi, C., Bianchini, F., Mannini, A., Mugnai, G., Ruggieri, S., and Calorini, L. (2008). Tumoral
and macrophage uPAR and MMP-9 contribute to the invasiveness of B16 murine melanoma
cells. Clin. Exp. Metastasis 25, 225-231.
Marfurt, C.F., Jones, M.A., and Thrasher, K. (1998). Parasympathetic innervation of the rat
cornea. Exp. Eye Res. 66, 437-448.
Marfurt, C.F., Kingsley, R.E., and Echtenkamp, S.E. (1989). Sensory and sympathetic innervation
of the mammalian cornea. A retrograde tracing study. Invest. Ophthalmol. Vis. Sci. 30, 461-472.
Martin, L., Birdsell, L., Macdonald, N., Reiman, T., Clandinin, M.T., McCargar, L.J., Murphy, R.,
Ghosh, S., Sawyer, M.B., and Baracos, V.E. (2013). Cancer cachexia in the age of obesity: skeletal
muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol.
31, 1539-1547.
Martin, L., Senesse, P., Gioulbasanis, I., Antoun, S., Bozzetti, F., Deans, C., Strasser, F., Thoresen,
L., Jagoe, R.T., Chasen, M., et al. (2015). Diagnostic criteria for the classification of cancerassociated weight loss. J. Clin. Oncol. 33, 90-99.
Martinez-Corral, I., Olmeda, D., Dieguez-Hurtado, R., Tammela, T., Alitalo, K., and Ortega, S.
(2012). In vivo imaging of lymphatic vessels in development, wound healing, inflammation, and
tumor metastasis. Proc. Natl. Acad. Sci. U. S. A. 109, 6223-6228.

246
Maruyama, K., Ii, M., Cursiefen, C., Jackson, D.G., Keino, H., Tomita, M., Van Rooijen, N.,
Takenaka, H., D'Amore, P.A., Stein-Streilein, J., Losordo, D.W., and Streilein, J.W. (2005).
Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive
macrophages. J. Clin. Invest. 115, 2363-2372.
Masui, T., Kubota, T., Aoki, K., Nakanishi, Y., Miyamoto, T., Nagata, J., Morino, K., Fukugaki, A.,
Takamura, M., Sugimoto, S., Onuma, H., and Tokuka, A. (2013). Long-term survival after
resection of pancreatic ductal adenocarcinoma with para-aortic lymph node metastasis: case
report. World J. Surg. Oncol. 11, 195-7819-11-195.
Mauro, C., Pietro, L., and Emilio, C.C. (2007). The use of nerve growth factor in herpetic keratitis:
a case report. J. Med. Case Rep. 1, 124.
McColl, B.K., Baldwin, M.E., Roufail, S., Freeman, C., Moritz, R.L., Simpson, R.J., Alitalo, K.,
Stacker, S.A., and Achen, M.G. (2003). Plasmin activates the lymphangiogenic growth factors
VEGF-C and VEGF-D. J. Exp. Med. 198, 863-868.
McKenna, C.C., and Lwigale, P.Y. (2011). Innervation of the mouse cornea during development.
Invest. Ophthalmol. Vis. Sci. 52, 30-35.
Melani, M., and Weinstein, B.M. (2010). Common factors regulating patterning of the nervous
and vascular systems. Annu. Rev. Cell Dev. Biol. 26, 639-665.
Meriggi, F., Gramigna, P., and Forni, E. (2007). Extended lymphadenectomy in cephalic
pancreatoduodenectomy. Personal observations. Hepatogastroenterology 54, 549-555.
Michalski, C.W., Kleeff, J., Wente, M.N., Diener, M.K., Buchler, M.W., and Friess, H. (2007).
Systematic review and meta-analysis of standard and extended lymphadenectomy in
pancreaticoduodenectomy for pancreatic cancer. Br. J. Surg. 94, 265-273.
Mignini, F., Sabbatini, M., Coppola, L., and Cavallotti, C. (2012). Analysis of nerve supply pattern
in human lymphatic vessels of young and old men. Lymphat Res. Biol. 10, 189-197.
Milsmann, C., Fuzesi, L., Werner, C., Becker, H., and Horstmann, O. (2005). Significance of occult
lymphatic tumor spread in pancreatic cancer. Chirurg 76, 1064-1072.
Miteva, D.O., Rutkowski, J.M., Dixon, J.B., Kilarski, W., Shields, J.D., and Swartz, M.A. (2010).
Transmural flow modulates cell and fluid transport functions of lymphatic endothelium. Circ.
Res. 106, 920-931.
Miyazaki, H., Yoshimatsu, Y., Akatsu, Y., Mishima, K., Fukayama, M., Watabe, T., and Miyazono,
K. (2014). Expression of platelet-derived growth factor receptor beta is maintained by Prox1 in
lymphatic endothelial cells and is required for tumor lymphangiogenesis. Cancer. Sci. 105, 11161123.

247
Morisada, T., Oike, Y., Yamada, Y., Urano, T., Akao, M., Kubota, Y., Maekawa, H., Kimura, Y.,
Ohmura, M., Miyamoto, T., et al. (2005). Angiopoietin-1 promotes LYVE-1-positive lymphatic
vessel formation. Blood 105, 4649-4656.
Mukouyama, Y.S., Gerber, H.P., Ferrara, N., Gu, C., and Anderson, D.J. (2005). Peripheral nervederived VEGF promotes arterial differentiation via neuropilin 1-mediated positive feedback.
Development 132, 941-952.
Mukouyama, Y.S., Shin, D., Britsch, S., Taniguchi, M., and Anderson, D.J. (2002). Sensory nerves
determine the pattern of arterial differentiation and blood vessel branching in the skin. Cell 109,
693-705.
Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M.E., McClanahan, T., Murphy, E.,
Yuan, W., Wagner, S.N., et al. (2001). Involvement of chemokine receptors in breast cancer
metastasis. Nature 410, 50-56.
Muller, L.J., Marfurt, C.F., Kruse, F., and Tervo, T.M. (2003). Corneal nerves: structure, contents
and function. Exp. Eye Res. 76, 521-542.
Muller, M.W., Giese, N.A., Swiercz, J.M., Ceyhan, G.O., Esposito, I., Hinz, U., Buchler, P., Giese,
T., Buchler, M.W., Offermanns, S., and Friess, H. (2007). Association of axon guidance factor
semaphorin 3A with poor outcome in pancreatic cancer. Int. J. Cancer 121, 2421-2433.
Munn, D.H., and Mellor, A.L. (2007). Indoleamine 2,3-dioxygenase and tumor-induced tolerance.
J. Clin. Invest. 117, 1147-1154.
Munn, D.H., and Mellor, A.L. (2006). The tumor-draining lymph node as an immune-privileged
site. Immunol. Rev. 213, 146-158.
Munn, D.H., Sharma, M.D., Baban, B., Harding, H.P., Zhang, Y., Ron, D., and Mellor, A.L. (2005).
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to
indoleamine 2,3-dioxygenase. Immunity 22, 633-642.
Murakami, M., Zheng, Y., Hirashima, M., Suda, T., Morita, Y., Ooehara, J., Ema, H., Fong, G.H.,
and Shibuya, M. (2008). VEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well
as angiogenesis indirectly via macrophage recruitment. Arterioscler. Thromb. Vasc. Biol. 28, 658664.
Murakami, Y., Uemura, K., Sudo, T., Hayashidani, Y., Hashimoto, Y., Nakashima, A., Yuasa, Y.,
Kondo, N., Ohge, H., and Sueda, T. (2010). Number of metastatic lymph nodes, but not lymph
node ratio, is an independent prognostic factor after resection of pancreatic carcinoma. J. Am.
Coll. Surg. 211, 196-204.
Muscaritoli, M., Molfino, A., Lucia, S., and Rossi Fanelli, F. (2015). Cachexia: a preventable
comorbidity of cancer. A T.A.R.G.E.T. approach. Crit. Rev. Oncol. Hematol. 94, 251-259.

248
Nagai, K., Doi, R., Koizumi, M., Masui, T., Kawaguchi, Y., Yoshizawa, A., and Uemoto, S. (2011).
Noninvasive intraductal papillary mucinous neoplasm with para-aortic lymph node metastasis:
report of a case. Surg. Today 41, 147-152.
Nagakawa, T., Kobayashi, H., Ueno, K., Ohta, T., Kayahara, M., and Miyazaki, I. (1994). Clinical
study of lymphatic flow to the paraaortic lymph nodes in carcinoma of the head of the pancreas.
Cancer 73, 1155-1162.
Naidoo, K., Jones, R., Dmitrovic, B., Wijesuriya, N., Kocher, H., Hart, I.R., and Crnogorac-Jurcevic,
T. (2012). Proteome of formalin-fixed paraffin-embedded pancreatic ductal adenocarcinoma
and lymph node metastases. J. Pathol. 226, 756-763.
Nakagohri, T., Kinoshita, T., Konishi, M., Takahashi, S., and Gotohda, N. (2006). Nodal
involvement is strongest predictor of poor survival in patients with invasive adenocarcinoma of
the head of the pancreas. Hepatogastroenterology 53, 447-451.
Nakamura, K., Tan, F., Li, Z., and Thiele, C.J. (2011). NGF activation of TrkA induces vascular
endothelial growth factor expression via induction of hypoxia-inducible factor-1alpha. Mol. Cell.
Neurosci. 46, 498-506.
Nakao, A., Harada, A., Nonami, T., Kaneko, T., Murakami, H., Inoue, S., Takeuchi, Y., and Takagi,
H. (1995). Lymph node metastases in carcinoma of the head of the pancreas region. Br. J. Surg.
82, 399-402.
Nathanson, S.D., Shah, R., and Rosso, K. (2015). Sentinel lymph node metastases in cancer:
causes, detection and their role in disease progression. Semin. Cell Dev. Biol. 38, 106-116.
Neal, J., and Wakelee, H. (2010). AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody
for the potential treatment of cancer. Curr. Opin. Mol. Ther. 12, 487-495.
Nguyen, T.C., Sohn, T.A., Cameron, J.L., Lillemoe, K.D., Campbell, K.A., Coleman, J., Sauter, P.K.,
Abrams, R.A., Hruban, R.H., and Yeo, C.J. (2003). Standard vs. radical pancreaticoduodenectomy
for periampullary adenocarcinoma: a prospective, randomized trial evaluating quality of life in
pancreaticoduodenectomy survivors. J. Gastrointest. Surg. 7, 1-9; discussion 9-11.
Nimura, Y., Nagino, M., Takao, S., Takada, T., Miyazaki, K., Kawarada, Y., Miyagawa, S.,
Yamaguchi, A., Ishiyama, S., Takeda, Y., et al. (2012). Standard versus extended
lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of
the pancreas: long-term results of a Japanese multicenter randomized controlled trial. J.
Hepatobiliary. Pancreat. Sci. 19, 230-241.
Nobis, M., McGhee, E.J., Morton, J.P., Schwarz, J.P., Karim, S.A., Quinn, J., Edward, M., Campbell,
A.D., McGarry, L.C., Evans, T.R., et al. (2013). Intravital FLIM-FRET imaging reveals dasatinibinduced spatial control of src in pancreatic cancer. Cancer Res. 73, 4674-4686.
Nune, S.K., Gunda, P., Majeti, B.K., Thallapally, P.K., and Forrest, M.L. (2011). Advances in
lymphatic imaging and drug delivery. Adv. Drug Deliv. Rev. 63, 876-885.

249
Ochi, N., Matsuo, Y., Sawai, H., Yasuda, A., Takahashi, H., Sato, M., Funahashi, H., Okada, Y., and
Manabe, T. (2007). Vascular endothelial growth factor-C secreted by pancreatic cancer cell line
promotes lymphatic endothelial cell migration in an in vitro model of tumor lymphangiogenesis.
Pancreas 34, 444-451.
Oh, S.J., Jeltsch, M.M., Birkenhager, R., McCarthy, J.E., Weich, H.A., Christ, B., Alitalo, K., and
Wilting, J. (1997). VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in
the differentiated avian chorioallantoic membrane. Dev. Biol. 188, 96-109.
O'Hagan, D., Christy, N., and Davis, S. (1992). Particulates and lymphatic drug delivery. In
Lymphatic transport of drugs, Charman, W., and Stella, V. eds., (Boca Raton, FL, USA: CRC Press
Inc.) pp. 279-280-315.
Ohta, T., Nagakawa, T., Ueno, K., Kayahara, M., Mori, K., Kobayashi, H., Takeda, T., and Miyazaki,
I. (1993). The mode of lymphatic and local spread of pancreatic carcinomas less than 4.0 cm in
size. Int. Surg. 78, 208-212.
Ohta, T., Terada, T., Nagakawa, T., Tajima, H., Itoh, H., Fonseca, L., and Miyazaki, I. (1994).
Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated
metastatic lesions. Br. J. Cancer 69, 152-156.
Olszewski, W.L., Stanczyk, M., Gewartowska, M., Domaszewska-Szostek, A., and Durlik, M.
(2012). Lack of functioning intratumoral lymphatics in colon and pancreas cancer tissue.
Lymphat Res. Biol. 10, 112-117.
O'Morchoe, C.C. (1997). Lymphatic system of the pancreas. Microsc. Res. Tech. 37, 456-477.
Oommen, S., Gupta, S.K., and Vlahakis, N.E. (2011). Vascular endothelial growth factor A (VEGFA) induces endothelial and cancer cell migration through direct binding to integrin
{alpha}9{beta}1: identification of a specific {alpha}9{beta}1 binding site. J. Biol. Chem. 286, 10831092.
Ou, J.J., Wei, X., Peng, Y., Zha, L., Zhou, R.B., Shi, H., Zhou, Q., and Liang, H.J. (2015). Neuropilin-2
mediates lymphangiogenesis of colorectal carcinoma via a VEGFC/VEGFR3 independent
signaling. Cancer Lett. 358, 200-209.
Padera, T.P., Kadambi, A., di Tomaso, E., Carreira, C.M., Brown, E.B., Boucher, Y., Choi, N.C.,
Mathisen, D., Wain, J., Mark, E.J., Munn, L.L., and Jain, R.K. (2002). Lymphatic metastasis in the
absence of functional intratumor lymphatics. Science 296, 1883-1886.
Padera, T.P., Kuo, A.H., Hoshida, T., Liao, S., Lobo, J., Kozak, K.R., Fukumura, D., and Jain, R.K.
(2008). Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and
VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol. Cancer. Ther. 7, 2272-2279.
Pai, R.K., Beck, A.H., Mitchem, J., Linehan, D.C., Chang, D.T., Norton, J.A., and Pai, R.K. (2011).
Pattern of lymph node involvement and prognosis in pancreatic adenocarcinoma: direct lymph
node invasion has similar survival to node-negative disease. Am. J. Surg. Pathol. 35, 228-234.

250
Pang, M.F., Georgoudaki, A.M., Lambut, L., Johansson, J., Tabor, V., Hagikura, K., Jin, Y., Jansson,
M., Alexander, J.S., Nelson, C.M., et al. (2015). TGF-beta1-induced EMT promotes targeted
migration of breast cancer cells through the lymphatic system by the activation of CCR7/CCL21mediated chemotaxis. Oncogene
Pannala, R., Leibson, C.L., Rabe, K.G., Timmons, L.J., Ransom, J., de Andrade, M., Petersen, G.M.,
and Chari, S.T. (2009). Temporal association of changes in fasting blood glucose and body mass
index with diagnosis of pancreatic cancer. Am. J. Gastroenterol. 104, 2318-2325.
Pawlik, T.M., Abdalla, E.K., Barnett, C.C., Ahmad, S.A., Cleary, K.R., Vauthey, J.N., Lee, J.E., Evans,
D.B., and Pisters, P.W. (2005). Feasibility of a randomized trial of extended lymphadenectomy
for pancreatic cancer. Arch. Surg. 140, 584-9; discussion 589-91.
Pawlik, T.M., Gleisner, A.L., Cameron, J.L., Winter, J.M., Assumpcao, L., Lillemoe, K.D., Wolfgang,
C., Hruban, R.H., Schulick, R.D., Yeo, C.J., and Choti, M.A. (2007). Prognostic relevance of lymph
node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 141, 610-618.
Pederzoli, P., Bassi, C., Falconi, M., and Pedrazzoli, S. (1997). Does the extent of lymphatic
resection affect the outcome in pancreatic cancer? Digestion 58, 536-541.
Pedrazzoli, S. (2015). Extent of lymphadenectomy to associate with pancreaticoduodenectomy
in patients with pancreatic head cancer for better tumor staging. Cancer Treat. Rev. 41, 577-587.
Pedrazzoli, S., DiCarlo, V., Dionigi, R., Mosca, F., Pederzoli, P., Pasquali, C., Kloppel, G., Dhaene,
K., and Michelassi, F. (1998). Standard versus extended lymphadenectomy associated with
pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the
pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann.
Surg. 228, 508-517.
Penet, M.F., Gadiya, M.M., Krishnamachary, B., Nimmagadda, S., Pomper, M.G., Artemov, D.,
and Bhujwalla, Z.M. (2011). Metabolic signatures imaged in cancer-induced cachexia. Cancer
Res. 71, 6948-6956.
Peparini, N. (2015). Mesopancreas: A boundless structure, namely the rationale for dissection of
the paraaortic area in pancreaticoduodenectomy for pancreatic head carcinoma. World J.
Gastroenterol. 21, 2865-2870.
Peppicelli, S., Bianchini, F., and Calorini, L. (2014). Inflammatory cytokines induce vascular
endothelial growth factor-C expression in melanoma-associated macrophages and stimulate
melanoma lymph node metastasis. Oncol. Lett. 8, 1133-1138.
Pflicke, H., and Sixt, M. (2009). Preformed portals facilitate dendritic cell entry into afferent
lymphatic vessels. J. Exp. Med. 206, 2925-2935.
Pignatelli, M., Ansari, T.W., Gunter, P., Liu, D., Hirano, S., Takeichi, M., Kloppel, G., and Lemoine,
N.R. (1994). Loss of membranous E-cadherin expression in pancreatic cancer: correlation with
lymph node metastasis, high grade, and advanced stage. J. Pathol. 174, 243-248.

251
Pisano, M., Triacca, V., Barbee, K.A., and Swartz, M.A. (2015). An in vitro model of the tumorlymphatic microenvironment with simultaneous transendothelial and luminal flows reveals
mechanisms of flow enhanced invasion. Integr. Biol. (Camb) 7, 525-533.
Pissas, A. (1984). Anatomoclinical and anatomosurgical essay on the lymphatic circulation of the
pancreas. Anat. Clin. 6, 255-280.
Podgrabinska, S., Kamalu, O., Mayer, L., Shimaoka, M., Snoeck, H., Randolph, G.J., and Skobe, M.
(2009). Inflamed lymphatic endothelium suppresses dendritic cell maturation and function via
Mac-1/ICAM-1-dependent mechanism. J. Immunol. 183, 1767-1779.
Pour, P.M., Bell, R.H., and Batra, S.K. (2003). Neural invasion in the staging of pancreatic cancer.
Pancreas 26, 322-325.
Preynat-Seauve, O., Contassot, E., Schuler, P., Piguet, V., French, L.E., and Huard, B. (2007).
Extralymphatic tumors prepare draining lymph nodes to invasion via a T-cell cross-tolerance
process. Cancer Res. 67, 5009-5016.
Procopio, G., Verzoni, E., Testa, I., Nicolai, N., Salvioni, R., and Debraud, F. (2012). Experience
with sorafenib in the treatment of advanced renal cell carcinoma. Ther. Adv. Urol. 4, 303-313.
Quaegebeur, A., Lange, C., and Carmeliet, P. (2011). The neurovascular link in health and
disease: molecular mechanisms and therapeutic implications. Neuron 71, 406-424.
Ran, S., and Montgomery, K.E. (2012). Macrophage-mediated lymphangiogenesis: the emerging
role of macrophages as lymphatic endothelial progenitors. Cancers (Basel) 4, 618-657.
Rasanen, K., and Vaheri, A. (2010). Activation of fibroblasts in cancer stroma. Exp. Cell Res. 316,
2713-2722.
Reataza, M., and Imagawa, D.K. (2014). Advances in managing hepatocellular carcinoma. Front.
Med. 8, 175-189.
Rhim, A.D., Mirek, E.T., Aiello, N.M., Maitra, A., Bailey, J.M., McAllister, F., Reichert, M., Beatty,
G.L., Rustgi, A.K., Vonderheide, R.H., Leach, S.D., and Stanger, B.Z. (2012). EMT and
dissemination precede pancreatic tumor formation. Cell 148, 349-361.
Riall, T.S., Cameron, J.L., Lillemoe, K.D., Campbell, K.A., Sauter, P.K., Coleman, J., Abrams, R.A.,
Laheru, D., Hruban, R.H., and Yeo, C.J. (2005). Pancreaticoduodenectomy with or without distal
gastrectomy and extended retroperitoneal lymphadenectomy for periampullary
adenocarcinoma--part 3: update on 5-year survival. J. Gastrointest. Surg. 9, 1191-204; discussion
1204-6.
Ridwelski, K., Meyer, F., Fahlke, J., Kasper, U., Roessner, A., and Lippert, H. (2001). Value of
cytokeratin and Ca 19-9 antigen in immunohistological detection of disseminated tumor cells in
lymph nodes in pancreas carcinoma. Chirurg 72, 920-926.

252
Riediger, H., Keck, T., Wellner, U., zur Hausen, A., Adam, U., Hopt, U.T., and Makowiec, F. (2009).
The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J.
Gastrointest. Surg. 13, 1337-1344.
Ristimaki, A., Narko, K., Enholm, B., Joukov, V., and Alitalo, K. (1998). Proinflammatory cytokines
regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C.
J. Biol. Chem. 273, 8413-8418.
Ritsma, L., Steller, E.J., Ellenbroek, S.I., Kranenburg, O., Borel Rinkes, I.H., and van Rheenen, J.
(2013). Surgical implantation of an abdominal imaging window for intravital microscopy. Nat.
Protoc. 8, 583-594.
Rixe, O., Bukowski, R.M., Michaelson, M.D., Wilding, G., Hudes, G.R., Bolte, O., Motzer, R.J.,
Bycott, P., Liau, K.F., Freddo, J., et al. (2007). Axitinib treatment in patients with cytokinerefractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 8, 975-984.
Roberts, E.W., Deonarine, A., Jones, J.O., Denton, A.E., Feig, C., Lyons, S.K., Espeli, M., Kraman,
M., McKenna, B., Wells, R.J., et al. (2013). Depletion of stromal cells expressing fibroblast
activation protein-alpha from skeletal muscle and bone marrow results in cachexia and anemia.
J. Exp. Med. 210, 1137-1151.
Roberts, N., Kloos, B., Cassella, M., Podgrabinska, S., Persaud, K., Wu, Y., Pytowski, B., and
Skobe, M. (2006). Inhibition of VEGFR-3 activation with the antagonistic antibody more potently
suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res. 66,
2650-2657.
Robinson, S.M., Rahman, A., Haugk, B., French, J.J., Manas, D.M., Jaques, B.C., Charnley, R.M.,
and White, S.A. (2012). Metastatic lymph node ratio as an important prognostic factor in
pancreatic ductal adenocarcinoma. Eur. J. Surg. Oncol. 38, 333-339.
Roche, C.J., Hughes, M.L., Garvey, C.J., Campbell, F., White, D.A., Jones, L., and Neoptolemos,
J.P. (2003). CT and pathologic assessment of prospective nodal staging in patients with ductal
adenocarcinoma of the head of the pancreas. AJR Am. J. Roentgenol. 180, 475-480.
Rodriguez-Diaz, R., Abdulreda, M.H., Formoso, A.L., Gans, I., Ricordi, C., Berggren, P.O., and
Caicedo, A. (2011). Innervation patterns of autonomic axons in the human endocrine pancreas.
Cell. Metab. 14, 45-54.
Rossi, S., Mantelli, F., Lambiase, A., and Aloe, L. (2012). Bevacizumab eye drop treatment
stimulates tear secretion in rats through changes in VEGF and NGF lacrimal gland levels. Arch.
Ital. Biol. 150, 15-21.
Rouhani, S.J., Eccles, J.D., Riccardi, P., Peske, J.D., Tewalt, E.F., Cohen, J.N., Liblau, R., Makinen,
T., and Engelhard, V.H. (2015). Roles of lymphatic endothelial cells expressing peripheral tissue
antigens in CD4 T-cell tolerance induction. Nat. Commun. 6, 6771.

253
Rubbia-Brandt, L., Terris, B., Giostra, E., Dousset, B., Morel, P., and Pepper, M.S. (2004).
Lymphatic vessel density and vascular endothelial growth factor-C expression correlate with
malignant behavior in human pancreatic endocrine tumors. Clin. Cancer Res. 10, 6919-6928.
Safuan, S., Storr, S.J., Patel, P.M., and Martin, S.G. (2012). A comparative study of adhesion of
melanoma and breast cancer cells to blood and lymphatic endothelium. Lymphat Res. Biol. 10,
173-181.
Sahora, K., Schindl, M., Kuehrer, I., Eisenhut, A., Werba, G., Brostjan, C., Telek, B., Ba'ssalamah,
A., Stift, J., Schoppmann, S.F., and Gnant, M. (2014). A phase II trial of two durations of
Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic
cancer. Anticancer Res. 34, 2377-2384.
Saltz, L.B., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M.,
Yang, T.S., Rivera, F., et al. (2008). Bevacizumab in combination with oxaliplatin-based
chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
J. Clin. Oncol. 26, 2013-2019.
Samii, A., Unger, J., and Lange, W. (1999). Vascular endothelial growth factor expression in
peripheral nerves and dorsal root ganglia in diabetic neuropathy in rats. Neurosci. Lett. 262,
159-162.
Samra, J.S., Gananadha, S., and Hugh, T.J. (2008). Surgical management of carcinoma of the
head of pancreas: extended lymphadenectomy or modified en bloc resection? ANZ J. Surg. 78,
228-236.
Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A., Lilenbaum, R., and
Johnson, D.H. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung
cancer. N. Engl. J. Med. 355, 2542-2550.
Santi, I., Brandt, A., and Hemminki, K. (2011). What is the major prognostic factor in tumornode-metastasis staging of pancreatic adenocarcinoma? Ann. Surg. Oncol. 18, 300-301.
Sawa, Y., Sugimoto, Y., Ueki, T., Ishikawa, H., Sato, A., Nagato, T., and Yoshida, S. (2007). Effects
of TNF-alpha on leukocyte adhesion molecule expressions in cultured human lymphatic
endothelium. J. Histochem. Cytochem. 55, 721-733.
Saygili, E., Pekassa, M., Saygili, E., Rackauskas, G., Hommes, D., Noor-Ebad, F., Gemein, C., Zink,
M.D., Schwinger, R.H., Weis, J., et al. (2011). Mechanical stretch of sympathetic neurons induces
VEGF expression via a NGF and CNTF signaling pathway. Biochem. Biophys. Res. Commun. 410,
62-67.
Scavelli, C., Vacca, A., Di Pietro, G., Dammacco, F., and Ribatti, D. (2004). Crosstalk between
angiogenesis and lymphangiogenesis in tumor progression. Leukemia 18, 1054-1058.

254
Schacht, V., Ramirez, M.I., Hong, Y.K., Hirakawa, S., Feng, D., Harvey, N., Williams, M., Dvorak,
A.M., Dvorak, H.F., Oliver, G., and Detmar, M. (2003). T1alpha/podoplanin deficiency disrupts
normal lymphatic vasculature formation and causes lymphedema. EMBO J. 22, 3546-3556.
Schafer, M., Oeing, C.U., Rohm, M., Baysal-Temel, E., Lehmann, L.H., Bauer, R., Volz, H.C.,
Boutros, M., Sohn, D., Sticht, C., et al. (2015). Ataxin-10 is part of a cachexokine cocktail
triggering cardiac metabolic dysfunction in cancer cachexia. Mol. Metab. 5, 67-78.
Schledzewski, K., Falkowski, M., Moldenhauer, G., Metharom, P., Kzhyshkowska, J., Ganss, R.,
Demory, A., Falkowska-Hansen, B., Kurzen, H., Ugurel, S., et al. (2006). Lymphatic endotheliumspecific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macrophages in
malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro:
implications for the assessment of lymphangiogenesis. J. Pathol. 209, 67-77.
Schneider, C.A., Rasband, W.S., and Eliceiri, K.W. (2012). NIH Image to ImageJ: 25 years of image
analysis. Nat. Methods 9, 671-675.
Schneider, M., Buchler, P., Giese, N., Giese, T., Wilting, J., Buchler, M.W., and Friess, H. (2006).
Role of lymphangiogenesis and lymphangiogenic factors during pancreatic cancer progression
and lymphatic spread. Int. J. Oncol. 28, 883-890.
Schoellhammer, H.F., Goldner, B.S., Kim, J., and Singh, G. (2015). Beyond the whipple operation:
radical resections for cancers of the head of the pancreas. Indian. J. Surg. Oncol. 6, 41-46.
Schoppmann, S.F., Birner, P., Stockl, J., Kalt, R., Ullrich, R., Caucig, C., Kriehuber, E., Nagy, K.,
Alitalo, K., and Kerjaschki, D. (2002). Tumor-associated macrophages express lymphatic
endothelial growth factors and are related to peritumoral lymphangiogenesis. Am. J. Pathol.
161, 947-956.
Schoppmann, S.F., Fenzl, A., Nagy, K., Unger, S., Bayer, G., Geleff, S., Gnant, M., Horvat, R.,
Jakesz, R., and Birner, P. (2006). VEGF-C expressing tumor-associated macrophages in lymph
node positive breast cancer: impact on lymphangiogenesis and survival. Surgery 139, 839-846.
Schulz, P., Fischer, C., Detjen, K.M., Rieke, S., Hilfenhaus, G., von Marschall, Z., Bohmig, M., Koch,
I., Kehrberger, J., Hauff, P., et al. (2011). Angiopoietin-2 drives lymphatic metastasis of
pancreatic cancer. FASEB J. 25, 3325-3335.
Schulz, P., Scholz, A., Rexin, A., Hauff, P., Schirner, M., Wiedenmann, B., and Detjen, K. (2008).
Inducible re-expression of p16 in an orthotopic mouse model of pancreatic cancer inhibits
lymphangiogenesis and lymphatic metastasis. Br. J. Cancer 99, 110-117.
Schutz, F.A., Choueiri, T.K., and Sternberg, C.N. (2011). Pazopanib: Clinical development of a
potent anti-angiogenic drug. Crit. Rev. Oncol. Hematol. 77, 163-171.
Schwarz, R.E., and Smith, D.D. (2006). Extent of lymph node retrieval and pancreatic cancer
survival: information from a large US population database. Ann. Surg. Oncol. 13, 1189-1200.

255
Seo, K., Choi, J., Park, M., and Rhee, C. (2001a). Angiogenesis effects of nerve growth factor
(NGF) on rat corneas. J. Vet. Sci. 2, 125-130.
Seo, N., Hayakawa, S., Takigawa, M., and Tokura, Y. (2001b). Interleukin-10 expressed at early
tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse
of antitumour immunity. Immunology 103, 449-457.
Sergeant, G., Ectors, N., Fieuws, S., Aerts, R., and Topal, B. (2009). Prognostic relevance of
extracapsular lymph node involvement in pancreatic ductal adenocarcinoma. Ann. Surg. Oncol.
16, 3070-3079.
Sergeant, G., Melloul, E., Lesurtel, M., Deoliveira, M.L., and Clavien, P.A. (2013). Extended
lymphadenectomy in patients with pancreatic cancer is debatable. World J. Surg. 37, 1782-1788.
Serhan, C.N., Brain, S.D., Buckley, C.D., Gilroy, D.W., Haslett, C., O'Neill, L.A., Perretti, M., Rossi,
A.G., and Wallace, J.L. (2007). Resolution of inflammation: state of the art, definitions and
terms. FASEB J. 21, 325-332.
Serhan, C.N., Chiang, N., and Van Dyke, T.E. (2008). Resolving inflammation: dual antiinflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8, 349-361.
Serhan, C.N., and Savill, J. (2005). Resolution of inflammation: the beginning programs the end.
Nat. Immunol. 6, 1191-1197.
Sevick-Muraca, E.M., Kwon, S., and Rasmussen, J.C. (2014). Emerging lymphatic imaging
technologies for mouse and man. J. Clin. Invest. 124, 905-914.
Shi, K., Queiroz, K.C., Roelofs, J.J., van Noesel, C.J., Richel, D.J., and Spek, C.A. (2014). Proteaseactivated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a
murine pancreatic cancer model. J. Pathol. 234, 398-409.
Shi, Y., Tong, M., Wu, Y., Yang, Z., Hoffman, R.M., Zhang, Y., Tian, Y., Qi, M., Lin, Y., Liu, Y., et al.
(2013). VEGF-C ShRNA inhibits pancreatic cancer growth and lymphangiogenesis in an
orthotopic fluorescent nude mouse model. Anticancer Res. 33, 409-417.
Shields, J.D., Emmett, M.S., Dunn, D.B., Joory, K.D., Sage, L.M., Rigby, H., Mortimer, P.S.,
Orlando, A., Levick, J.R., and Bates, D.O. (2007). Chemokine-mediated migration of melanoma
cells towards lymphatics--a mechanism contributing to metastasis. Oncogene 26, 2997-3005.
Shields, J.D., Kourtis, I.C., Tomei, A.A., Roberts, J.M., and Swartz, M.A. (2010). Induction of
lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science
328, 749-752.
Shimada, K., Nara, S., Esaki, M., Sakamoto, Y., Kosuge, T., and Hiraoka, N. (2011). Intrapancreatic
nerve invasion as a predictor for recurrence after pancreaticoduodenectomy in patients with
invasive ductal carcinoma of the pancreas. Pancreas 40, 464-468.

256
Shimada, K., Sakamoto, Y., Sano, T., and Kosuge, T. (2006). The role of paraaortic lymph node
involvement on early recurrence and survival after macroscopic curative resection with
extended lymphadenectomy for pancreatic carcinoma. J. Am. Coll. Surg. 203, 345-352.
Shimizu, K., Kubo, H., Yamaguchi, K., Kawashima, K., Ueda, Y., Matsuo, K., Awane, M.,
Shimahara, Y., Takabayashi, A., Yamaoka, Y., and Satoh, S. (2004). Suppression of VEGFR-3
signaling inhibits lymph node metastasis in gastric cancer. Cancer. Sci. 95, 328-333.
Siegel, R.L., Miller, K.D., and Jemal, A. (2016). Cancer statistics, 2016. CA Cancer. J. Clin. 66, 7-30.
Siegel, R.L., Miller, K.D., and Jemal, A. (2015). Cancer statistics, 2015. CA Cancer. J. Clin. 65, 5-29.
Sierzega, M., Popiela, T., Kulig, J., and Nowak, K. (2006). The ratio of metastatic/resected lymph
nodes is an independent prognostic factor in patients with node-positive pancreatic head
cancer. Pancreas 33, 240-245.
Singh, I., Swami, R., Khan, W., and Sistla, R. (2014). Lymphatic system: a prospective area for
advanced targeting of particulate drug carriers. Expert Opin. Drug Deliv. 11, 211-229.
Sini, P., Samarzija, I., Baffert, F., Littlewood-Evans, A., Schnell, C., Theuer, A., Christian, S., Boos,
A., Hess-Stumpp, H., Foekens, J.A., et al. (2008). Inhibition of multiple vascular endothelial
growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is
sufficient to sensitize tumor cells to platinum-based chemotherapeutics. Cancer Res. 68, 15811592.
Sipos, B., Kojima, M., Tiemann, K., Klapper, W., Kruse, M.L., Kalthoff, H., Schniewind, B., Tepel, J.,
Weich, H., Kerjaschki, D., and Kloppel, G. (2005). Lymphatic spread of ductal pancreatic
adenocarcinoma is independent of lymphangiogenesis. J. Pathol. 207, 301-312.
Slidell, M.B., Chang, D.C., Cameron, J.L., Wolfgang, C., Herman, J.M., Schulick, R.D., Choti, M.A.,
and Pawlik, T.M. (2008). Impact of total lymph node count and lymph node ratio on staging and
survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based
analysis. Ann. Surg. Oncol. 15, 165-174.
Smith, B.J., and Mezhir, J.J. (2014). An interactive Bayesian model for prediction of lymph node
ratio and survival in pancreatic cancer patients. J. Am. Med. Inform. Assoc. 21, e203-11.
Sohal, D.P., Metz, J.M., Sun, W., Giantonio, B.J., Plastaras, J.P., Ginsberg, G., Kochman, M.L.,
Teitelbaum, U.R., Harlacker, K., Heitjan, D.F., et al. (2013). Toxicity study of gemcitabine,
oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and
radiotherapy, in patients with locally advanced pancreatic cancer. Cancer Chemother.
Pharmacol. 71, 1485-1491.
Solares, C.A., Brown, I., Boyle, G.M., Parsons, P.G., and Panizza, B. (2009). Neural cell adhesion
molecule expression: no correlation with perineural invasion in cutaneous squamous cell
carcinoma of the head and neck. Head Neck 31, 802-806.

257
Solito, R., Alessandrini, C., Fruschelli, M., Pucci, A.M., and Gerli, R. (1997). An immunological
correlation between the anchoring filaments of initial lymph vessels and the neighboring elastic
fibers: a unified morphofunctional concept. Lymphology 30, 194-202.
Solorzano, C.C., Baker, C.H., Bruns, C.J., Killion, J.J., Ellis, L.M., Wood, J., and Fidler, I.J. (2001).
Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK
787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Cancer Biother. Radiopharm. 16, 359-370.
Sornelli, F., Lambiase, A., Mantelli, F., and Aloe, L. (2010). NGF and NGF-receptor expression of
cultured immortalized human corneal endothelial cells. Mol. Vis. 16, 1439-1447.
Spano, J.P., Chodkiewicz, C., Maurel, J., Wong, R., Wasan, H., Barone, C., Letourneau, R., Bajetta,
E., Pithavala, Y., Bycott, P., et al. (2008). Efficacy of gemcitabine plus axitinib compared with
gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised
phase II study. Lancet 371, 2101-2108.
Sperveslage, J., Frank, S., Heneweer, C., Egberts, J., Schniewind, B., Buchholz, M., Bergmann, F.,
Giese, N., Munding, J., Hahn, S.A., et al. (2012). Lack of CCR7 expression is rate limiting for
lymphatic spread of pancreatic ductal adenocarcinoma. Int. J. Cancer 131, E371-81.
Stacker, S.A., Caesar, C., Baldwin, M.E., Thornton, G.E., Williams, R.A., Prevo, R., Jackson, D.G.,
Nishikawa, S., Kubo, H., and Achen, M.G. (2001). VEGF-D promotes the metastatic spread of
tumor cells via the lymphatics. Nat. Med. 7, 186-191.
Stacker, S.A., Williams, S.P., Karnezis, T., Shayan, R., Fox, S.B., and Achen, M.G. (2014).
Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat. Rev. Cancer. 14, 159-172.
Stephens, N.A., Gallagher, I.J., Rooyackers, O., Skipworth, R.J., Tan, B.H., Marstrand, T., Ross,
J.A., Guttridge, D.C., Lundell, L., Fearon, K.C., and Timmons, J.A. (2010). Using transcriptomics to
identify and validate novel biomarkers of human skeletal muscle cancer cachexia. Genome Med.
2, 1.
Steven, P., Bock, F., Huttmann, G., and Cursiefen, C. (2011). Intravital two-photon microscopy of
immune cell dynamics in corneal lymphatic vessels. PLoS One 6, e26253.
Stopczynski, R.E., Normolle, D.P., Hartman, D.J., Ying, H., DeBerry, J.J., Bielefeldt, K., Rhim, A.D.,
DePinho, R.A., Albers, K.M., and Davis, B.M. (2014). Neuroplastic changes occur early in the
development of pancreatic ductal adenocarcinoma. Cancer Res. 74, 1718-1727.
Storr, S.J., Safuan, S., Mitra, A., Elliott, F., Walker, C., Vasko, M.J., Ho, B., Cook, M., Mohammed,
R.A., Patel, P.M., et al. (2012). Objective assessment of blood and lymphatic vessel invasion and
association with macrophage infiltration in cutaneous melanoma. Mod. Pathol. 25, 493-504.
Sugimura, K., Miyata, H., Tanaka, K., Takahashi, T., Kurokawa, Y., Yamasaki, M., Nakajima, K.,
Takiguchi, S., Mori, M., and Doki, Y. (2015). High infiltration of tumor-associated macrophages is

258
associated with a poor response to chemotherapy and poor prognosis of patients undergoing
neoadjuvant chemotherapy for esophageal cancer. J. Surg. Oncol. 111, 752-759.
Sun, W., Leong, C.N., Zhang, Z., and Lu, J.J. (2010). Proposing the lymphatic target volume for
elective radiation therapy for pancreatic cancer: a pooled analysis of clinical evidence. Radiat.
Oncol. 5, 28-717X-5-28.
Suzuki, M., Takahashi, T., Ouchi, K., and Matsuno, S. (1994). Perineural tumor invasion and its
relation with the lymphogenous spread in human and experimental carcinoma of bile duct. A
computer-aided 3-D reconstruction study. Tohoku J. Exp. Med. 172, 17-28.
Svoronos, C., Tsoulfas, G., Katsourakis, A., Noussios, G., Chatzitheoklitos, E., and Marakis, N.G.
(2014). Role of extended lymphadenectomy in the treatment of pancreatic head
adenocarcinoma: review and meta-analysis. ANZ J. Surg. 84, 706-711.
Swanson, B.J., McDermott, K.M., Singh, P.K., Eggers, J.P., Crocker, P.R., and Hollingsworth, M.A.
(2007). MUC1 is a counter-receptor for myelin-associated glycoprotein (Siglec-4a) and their
interaction contributes to adhesion in pancreatic cancer perineural invasion. Cancer Res. 67,
10222-10229.
Swartz, M.A. (2014). Immunomodulatory roles of lymphatic vessels in cancer progression.
Cancer. Immunol. Res. 2, 701-707.
Sweat, R.S., Sloas, D.C., and Murfee, W.L. (2014). VEGF-C Induces Lymphangiogenesis and
Angiogenesis in the Rat Mesentery Culture Model. Microcirculation
Tacconi, C., Correale, C., Gandelli, A., Spinelli, A., Dejana, E., D'Alessio, S., and Danese, S. (2015).
Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote
colorectal cancer invasion. Gastroenterology 148, 1438-51.e8.
Takahashi, H., Ohigashi, H., Ishikawa, O., Gotoh, K., Yamada, T., Nagata, S., Tomita, Y., Eguchi, H.,
Doki, Y., and Yano, M. (2012). Perineural invasion and lymph node involvement as indicators of
surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based
chemoradiation therapy for resectable pancreatic cancer. Ann. Surg. 255, 95-102.
Tal, O., Lim, H.Y., Gurevich, I., Milo, I., Shipony, Z., Ng, L.G., Angeli, V., and Shakhar, G. (2011). DC
mobilization from the skin requires docking to immobilized CCL21 on lymphatic endothelium
and intralymphatic crawling. J. Exp. Med. 208, 2141-2153.
Tamburrino, A., Piro, G., Carbone, C., Tortora, G., and Melisi, D. (2013). Mechanisms of
resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer
therapy. Front. Pharmacol. 4, 56.
Tammela, T., and Alitalo, K. (2010). Lymphangiogenesis: Molecular mechanisms and future
promise. Cell 140, 460-476.

259
Tan, B.H., Birdsell, L.A., Martin, L., Baracos, V.E., and Fearon, K.C. (2009). Sarcopenia in an
overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin. Cancer
Res. 15, 6973-6979.
Tan, M.H., Bryars, J., and Moore, J. (2006). Use of nerve growth factor to treat congenital
neurotrophic corneal ulceration. Cornea 25, 352-355.
Tang, R.F., Itakura, J., Aikawa, T., Matsuda, K., Fujii, H., Korc, M., and Matsumoto, Y. (2001).
Overexpression of lymphangiogenic growth factor VEGF-C in human pancreatic cancer. Pancreas
22, 285-292.
Tao, J., Li, T., Li, K., Xiong, J., Yang, Z., Wu, H., and Wang, C. (2006). Effect of HIF-1alpha on VEGFC induced lymphangiogenesis and lymph nodes metastases of pancreatic cancer. J. Huazhong
Univ. Sci. Technolog Med. Sci. 26, 562-564.
Tempero, M.A., Malafa, M.P., Behrman, S.W., Benson, A.B.,3rd, Casper, E.S., Chiorean, E.G.,
Chung, V., Cohen, S.J., Czito, B., Engebretson, A., et al. (2014). Pancreatic adenocarcinoma,
version 2.2014: featured updates to the NCCN guidelines. J. Natl. Compr. Canc Netw. 12, 10831093.
Tempia-Caliera, A.A., Horvath, L.Z., Zimmermann, A., Tihanyi, T.T., Korc, M., Friess, H., and
Buchler, M.W. (2002). Adhesion molecules in human pancreatic cancer. J. Surg. Oncol. 79, 93100.
Tewalt, E.F., Cohen, J.N., Rouhani, S.J., Guidi, C.J., Qiao, H., Fahl, S.P., Conaway, M.R., Bender,
T.P., Tung, K.S., Vella, A.T., et al. (2012). Lymphatic endothelial cells induce tolerance via PD-L1
and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Blood 120, 47724782.
Tezel, E., Kawase, Y., Takeda, S., Oshima, K., and Nakao, A. (2001). Expression of neural cell
adhesion molecule in pancreatic cancer. Pancreas 22, 122-125.
Thelen, A., Scholz, A., Benckert, C., von Marschall, Z., Schroder, M., Wiedenmann, B., Neuhaus,
P., Rosewicz, S., and Jonas, S. (2008). VEGF-D promotes tumor growth and lymphatic spread in a
mouse model of hepatocellular carcinoma. Int. J. Cancer 122, 2471-2481.
Tian, H., Callahan, C.A., DuPree, K.J., Darbonne, W.C., Ahn, C.P., Scales, S.J., and de Sauvage, F.J.
(2009). Hedgehog signaling is restricted to the stromal compartment during pancreatic
carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 106, 4254-4259.
Tian, M., Asp, M.L., Nishijima, Y., and Belury, M.A. (2011). Evidence for cardiac atrophic
remodeling in cancer-induced cachexia in mice. Int. J. Oncol. 39, 1321-1326.
Tian, M., Nishijima, Y., Asp, M.L., Stout, M.B., Reiser, P.J., and Belury, M.A. (2010). Cardiac
alterations in cancer-induced cachexia in mice. Int. J. Oncol. 37, 347-353.

260
Tol, J.A., Brosens, L.A., van Dieren, S., van Gulik, T.M., Busch, O.R., Besselink, M.G., and Gouma,
D.J. (2015). Impact of lymph node ratio on survival in patients with pancreatic and periampullary
cancer. Br. J. Surg. 102, 237-245.
Tol, J.A., Gouma, D.J., Bassi, C., Dervenis, C., Montorsi, M., Adham, M., Andren-Sandberg, A.,
Asbun, H.J., Bockhorn, M., Buchler, M.W., et al. (2014). Definition of a standard
lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by
the International Study Group on Pancreatic Surgery (ISGPS). Surgery 156, 591-600.
Tomlinson, D.R., and Gardiner, N.J. (2008). Glucose neurotoxicity. Nat. Rev. Neurosci. 9, 36-45.
Torer, N., Kayaselcuk, F., Nursal, T.Z., Yildirim, S., Tarim, A., Noyan, T., and Karakayali, H. (2007).
Adhesion molecules as prognostic markers in pancreatic adenocarcinoma. J. Surg. Oncol. 96,
419-423.
Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., and Jemal, A. (2015). Global cancer
statistics, 2012. CA Cancer. J. Clin. 65, 87-108.
Tran Cao, H.S., McElroy, M., Kaushal, S., Hoffman, R.M., and Bouvet, M. (2011). Imaging of the
interaction of cancer cells and the lymphatic system. Adv. Drug Deliv. Rev. 63, 886-889.
Tran, E., Chinnasamy, D., Yu, Z., Morgan, R.A., Lee, C.C., Restifo, N.P., and Rosenberg, S.A.
(2013). Immune targeting of fibroblast activation protein triggers recognition of multipotent
bone marrow stromal cells and cachexia. J. Exp. Med. 210, 1125-1135.
Truman, L.A., Bentley, K.L., Smith, E.C., Massaro, S.A., Gonzalez, D.G., Haberman, A.M., Hill, M.,
Jones, D., Min, W., Krause, D.S., and Ruddle, N.H. (2012). ProxTom lymphatic vessel reporter
mice reveal Prox1 expression in the adrenal medulla, megakaryocytes, and platelets. Am. J.
Pathol. 180, 1715-1725.
Uchida, D., Onoue, T., Kuribayashi, N., Tomizuka, Y., Tamatani, T., Nagai, H., and Miyamoto, Y.
(2011). Blockade of CXCR4 in oral squamous cell carcinoma inhibits lymph node metastases. Eur.
J. Cancer 47, 452-459.
Vakoc, B.J., Lanning, R.M., Tyrrell, J.A., Padera, T.P., Bartlett, L.A., Stylianopoulos, T., Munn, L.L.,
Tearney, G.J., Fukumura, D., Jain, R.K., and Bouma, B.E. (2009). Three-dimensional microscopy of
the tumor microenvironment in vivo using optical frequency domain imaging. Nat. Med. 15,
1219-1223.
Van Cutsem, E., Vervenne, W.L., Bennouna, J., Humblet, Y., Gill, S., Van Laethem, J.L., Verslype,
C., Scheithauer, W., Shang, A., Cosaert, J., and Moore, M.J. (2009). Phase III trial of bevacizumab
in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J.
Clin. Oncol. 27, 2231-2237.
Veikkola, T., Jussila, L., Makinen, T., Karpanen, T., Jeltsch, M., Petrova, T.V., Kubo, H., Thurston,
G., McDonald, D.M., Achen, M.G., Stacker, S.A., and Alitalo, K. (2001). Signalling via vascular

261
endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice.
EMBO J. 20, 1223-1231.
Verweij, J., and Sleijfer, S. (2013). Pazopanib, a new therapy for metastatic soft tissue sarcoma.
Expert Opin. Pharmacother. 14, 929-935.
Vigl, B., Aebischer, D., Nitschke, M., Iolyeva, M., Rothlin, T., Antsiferova, O., and Halin, C. (2011).
Tissue inflammation modulates gene expression of lymphatic endothelial cells and dendritic cell
migration in a stimulus-dependent manner. Blood 118, 205-215.
Viola, K., Kopf, S., Huttary, N., Vonach, C., Kretschy, N., Teichmann, M., Giessrigl, B., Raab, I.,
Stary, S., Krieger, S., et al. (2013). Bay11-7082 inhibits the disintegration of the lymphendothelial
barrier triggered by MCF-7 breast cancer spheroids; the role of ICAM-1 and adhesion. Br. J.
Cancer 108, 564-569.
Vlahakis, N.E., Young, B.A., Atakilit, A., and Sheppard, D. (2005). The lymphangiogenic vascular
endothelial growth factors VEGF-C and -D are ligands for the integrin alpha9beta1. J. Biol. Chem.
280, 4544-4552.
von der Weid, P.Y., and Zawieja, D.C. (2004). Lymphatic smooth muscle: the motor unit of lymph
drainage. Int. J. Biochem. Cell Biol. 36, 1147-1153.
von Haehling, S., and Anker, S.D. (2014). Prevalence, incidence and clinical impact of cachexia:
facts and numbers-update 2014. J. Cachexia Sarcopenia Muscle 5, 261-263.
Von Marschall, Z., Scholz, A., Stacker, S.A., Achen, M.G., Jackson, D.G., Alves, F., Schirner, M.,
Haberey, M., Thierauch, K.H., Wiedenmann, B., and Rosewicz, S. (2005). Vascular endothelial
growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal
pancreatic cancer. Int. J. Oncol. 27, 669-679.
Wang, X., Pang, Y., Ku, G., Xie, X., Stoica, G., and Wang, L.V. (2003). Noninvasive laser-induced
photoacoustic tomography for structural and functional in vivo imaging of the brain. Nat.
Biotechnol. 21, 803-806.
Wang, Z., Wu, J., Li, G., Zhang, X., Tong, M., Wu, Z., and Liu, Z. (2012). Lymphangiogenesis and
biological behavior in pancreatic carcinoma and other pancreatic tumors. Mol. Med. Rep. 5, 959963.
Wehler, T., Wolfert, F., Schimanski, C.C., Gockel, I., Herr, W., Biesterfeld, S., Seifert, J.K., Adwan,
H., Berger, M.R., Junginger, T., Galle, P.R., and Moehler, M. (2006). Strong expression of
chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease. Oncol. Rep.
16, 1159-1164.
Wetterwald, A., Hoffstetter, W., Cecchini, M.G., Lanske, B., Wagner, C., Fleisch, H., and Atkinson,
M. (1996). Characterization and cloning of the E11 antigen, a marker expressed by rat
osteoblasts and osteocytes. Bone 18, 125-132.

262
Whipple, A.O. (1941). The Rationale of Radical Surgery for Cancer of the Pancreas and Ampullary
Region. Ann. Surg. 114, 612-615.
Wigle, J.T., and Oliver, G. (1999). Prox1 function is required for the development of the murine
lymphatic system. Cell 98, 769-778.
Wilentz, R.E., Iacobuzio-Donahue, C.A., Argani, P., McCarthy, D.M., Parsons, J.L., Yeo, C.J., Kern,
S.E., and Hruban, R.H. (2000). Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia:
evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res. 60, 20022006.
Wiley, H.E., Gonzalez, E.B., Maki, W., Wu, M.T., and Hwang, S.T. (2001). Expression of CC
chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J. Natl.
Cancer Inst. 93, 1638-1643.
Wilhelm, S.M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X.,
Vincent, P., McHugh, M., et al. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor
activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor
progression and angiogenesis. Cancer Res. 64, 7099-7109.
Winter, J.M., Cameron, J.L., Campbell, K.A., Arnold, M.A., Chang, D.C., Coleman, J., Hodgin, M.B.,
Sauter, P.K., Hruban, R.H., Riall, T.S., et al. (2006). 1423 pancreaticoduodenectomies for
pancreatic cancer: A single-institution experience. J. Gastrointest. Surg. 10, 1199-210; discussion
1210-1.
Witte, M.H., Dellinger, M.T., McDonald, D.M., Nathanson, S.D., Boccardo, F.M., Campisi, C.C.,
Sleeman, J.P., and Gershenwald, J.E. (2011). Lymphangiogenesis and hemangiogenesis: potential
targets for therapy. J. Surg. Oncol. 103, 489-500.
Woo, H.M., Bentley, E., Campbell, S.F., Marfurt, C.F., and Murphy, C.J. (2005). Nerve growth
factor and corneal wound healing in dogs. Exp. Eye Res. 80, 633-642.
Wu, H., Xu, J.B., He, Y.L., Peng, J.J., Zhang, X.H., Chen, C.Q., Li, W., and Cai, S.R. (2012). Tumorassociated macrophages promote angiogenesis and lymphangiogenesis of gastric cancer. J. Surg.
Oncol. 106, 462-468.
Wu, P.C., Hsieh, T.Y., Tsai, Z.U., and Liu, T.M. (2015). In vivo quantification of the structural
changes of collagens in a melanoma microenvironment with second and third harmonic
generation microscopy. Sci. Rep. 5, 8879.
Xiong, L., Shuhendler, A.J., and Rao, J. (2012). Self-luminescing BRET-FRET near-infrared dots for
in vivo lymph-node mapping and tumour imaging. Nat. Commun. 3, 1193.
Xu, Y., Yuan, L., Mak, J., Pardanaud, L., Caunt, M., Kasman, I., Larrivee, B., Del Toro, R., Suchting,
S., Medvinsky, A., et al. (2010). Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting
together with VEGFR3. J. Cell Biol. 188, 115-130.

263
Yagi, H., Tan, W., Dillenburg-Pilla, P., Armando, S., Amornphimoltham, P., Simaan, M., Weigert,
R., Molinolo, A.A., Bouvier, M., and Gutkind, J.S. (2011). A synthetic biology approach reveals a
CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer
cells. Sci. Signal. 4, ra60.
Yamamoto, S., Tomita, Y., Hoshida, Y., Nagano, H., Dono, K., Umeshita, K., Sakon, M., Ishikawa,
O., Ohigashi, H., Nakamori, S., Monden, M., and Aozasa, K. (2004). Increased expression of
valosin-containing protein (p97) is associated with lymph node metastasis and prognosis of
pancreatic ductal adenocarcinoma. Ann. Surg. Oncol. 11, 165-172.
Yamamoto, Y., Ikoma, H., Morimura, R., Konishi, H., Murayama, Y., Komatsu, S., Shiozaki, A.,
Kuriu, Y., Kubota, T., Nakanishi, M., et al. (2014). The clinical impact of the lymph node ratio as a
prognostic factor after resection of pancreatic cancer. Anticancer Res. 34, 2389-2394.
Yan, J., Jiang, Y., Ye, M., Liu, W., and Feng, L. (2014). The clinical value of lymphatic vessel
density, intercellular adhesion molecule 1 and vascular cell adhesion molecule 1 expression in
patients with oral tongue squamous cell carcinoma. J. Cancer. Res. Ther. 10 Suppl, C125-30.
Yan, Z.X., Jiang, Z.H., and Liu, N.F. (2012). Angiopoietin-2 promotes inflammatory
lymphangiogenesis and its effect can be blocked by the specific inhibitor L1-10. Am. J. Physiol.
Heart Circ. Physiol. 302, H215-23.
Yang, F., Jin, C., Yang, D., Jiang, Y., Li, J., Di, Y., Hu, J., Wang, C., Ni, Q., and Fu, D. (2011a).
Magnetic functionalised carbon nanotubes as drug vehicles for cancer lymph node metastasis
treatment. Eur. J. Cancer 47, 1873-1882.
Yang, H., Kim, C., Kim, M.J., Schwendener, R.A., Alitalo, K., Heston, W., Kim, I., Kim, W.J., and
Koh, G.Y. (2011b). Soluble vascular endothelial growth factor receptor-3 suppresses
lymphangiogenesis and lymphatic metastasis in bladder cancer. Mol. Cancer. 10, 36-4598-10-36.
Yang, X.M., Han, H.X., Sui, F., Dai, Y.M., Chen, M., and Geng, J.G. (2010). Slit-Robo signaling
mediates lymphangiogenesis and promotes tumor lymphatic metastasis. Biochem. Biophys. Res.
Commun. 396, 571-577.
Ye, Y., Dang, D., Zhang, J., Viet, C.T., Lam, D.K., Dolan, J.C., Gibbs, J.L., and Schmidt, B.L. (2011).
Nerve growth factor links oral cancer progression, pain, and cachexia. Mol. Cancer. Ther. 10,
1667-1676.
Yeo, C.J., and Cameron, J.L. (1998). Prognostic factors in ductal pancreatic cancer. Langenbecks
Arch. Surg. 383, 129-133.
Yeo, C.J., Cameron, J.L., Lillemoe, K.D., Sohn, T.A., Campbell, K.A., Sauter, P.K., Coleman, J.,
Abrams, R.A., and Hruban, R.H. (2002). Pancreaticoduodenectomy with or without distal
gastrectomy and extended retroperitoneal lymphadenectomy for periampullary
adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and
mortality. Ann. Surg. 236, 355-66; discussion 366-8.

264
Yeo, C.J., Cameron, J.L., Sohn, T.A., Coleman, J., Sauter, P.K., Hruban, R.H., Pitt, H.A., and
Lillemoe, K.D. (1999). Pancreaticoduodenectomy with or without extended retroperitoneal
lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality
and short-term outcome. Ann. Surg. 229, 613-22; discussion 622-4.
Yi, S.Q., Miwa, K., Ohta, T., Kayahara, M., Kitagawa, H., Tanaka, A., Shimokawa, T., Akita, K., and
Tanaka, S. (2003). Innervation of the pancreas from the perspective of perineural invasion of
pancreatic cancer. Pancreas 27, 225-229.
Yoshitomi, H., Kobayashi, S., Ohtsuka, M., Kimura, F., Shimizu, H., Yoshidome, H., and Miyazaki,
M. (2008). Specific expression of endoglin (CD105) in endothelial cells of intratumoral blood and
lymphatic vessels in pancreatic cancer. Pancreas 37, 275-281.
You, L., Kruse, F.E., and Volcker, H.E. (2000). Neurotrophic factors in the human cornea. Invest.
Ophthalmol. Vis. Sci. 41, 692-702.
Yu, C.Q., Zhang, M., Matis, K.I., Kim, C., and Rosenblatt, M.I. (2008a). Vascular endothelial
growth factor mediates corneal nerve repair. Invest. Ophthalmol. Vis. Sci. 49, 3870-3878.
Yu, J., Zhang, X., Kuzontkoski, P.M., Jiang, S., Zhu, W., Li, D.Y., and Groopman, J.E. (2014). Slit2N
and Robo4 regulate lymphangiogenesis through the VEGF-C/VEGFR-3 pathway. Cell. Commun.
Signal. 12, 25-811X-12-25.
Yu, S., Duan, J., Zhou, Z., Pang, Q., Wuyang, J., Liu, T., He, X., Xinfa, L., and Chen, Y. (2008b). A
critical role of CCR7 in invasiveness and metastasis of SW620 colon cancer cell in vitro and in
vivo. Cancer. Biol. Ther. 7, 1037-1043.
Yuan, Z.Y., Luo, R.Z., Peng, R.J., Wang, S.S., and Xue, C. (2014). High infiltration of tumorassociated macrophages in triple-negative breast cancer is associated with a higher risk of
distant metastasis. Onco Targets Ther. 7, 1475-1480.
Zacharias, T., Jaeck, D., Oussoultzoglou, E., Neuville, A., and Bachellier, P. (2007). Impact of
lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal
adenocarcinoma of the pancreas. J. Gastrointest. Surg. 11, 350-356.
Zamder, E., and Weddell, G. (1951). Observations on the innervation of the cornea. J. Anat. 85,
68-99.
Zeng, Q., Cheng, Y., Zhu, Q., Yu, Z., Wu, X., Huang, K., Zhou, M., Han, S., and Zhang, Q. (2008).
The relationship between overexpression of glial cell-derived neurotrophic factor and its RET
receptor with progression and prognosis of human pancreatic cancer. J. Int. Med. Res. 36, 656664.
Zhang, B., Zhao, W.H., Zhou, W.Y., Yu, W.S., Yu, J.M., and Li, S. (2007). Expression of vascular
endothelial growth factors-C and -D correlate with evidence of lymphangiogenesis and
angiogenesis in pancreatic adenocarcinoma. Cancer Detect. Prev. 31, 436-442.

265
Zhang, B.C., Gao, J., Wang, J., Rao, Z.G., Wang, B.C., and Gao, J.F. (2011). Tumor-associated
macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis
in lung adenocarcinoma. Med. Oncol. 28, 1447-1452.
Zhang, G., Brady, J., Liang, W.C., Wu, Y., Henkemeyer, M., and Yan, M. (2015). EphB4 forward
signalling regulates lymphatic valve development. Nat. Commun. 6, 6625.
Zhang, Z., Procissi, D., Li, W., Kim, D.H., Li, K., Han, G., Huan, Y., and Larson, A.C. (2013). High
resolution MRI for non-invasive mouse lymph node mapping. J. Immunol. Methods 400-401, 2329.
Zhao, B., Cui, K., Wang, C.L., Wang, A.L., Zhang, B., Zhou, W.Y., Zhao, W.H., and Li, S. (2011). The
chemotactic interaction between CCL21 and its receptor, CCR7, facilitates the progression of
pancreatic cancer via induction of angiogenesis and lymphangiogenesis. J. Hepatobiliary.
Pancreat. Sci. 18, 821-828.
Zheng, W., Nurmi, H., Appak, S., Sabine, A., Bovay, E., Korhonen, E.A., Orsenigo, F., Lohela, M.,
D'Amico, G., Holopainen, T., et al. (2014). Angiopoietin 2 regulates the transformation and
integrity of lymphatic endothelial cell junctions. Genes Dev. 28, 1592-1603.
Zhou, H.J., Chen, X., Huang, Q., Liu, R., Zhang, H., Wang, Y., Jin, Y., Liang, X., Lu, L., Xu, Z., and
Min, W. (2014). AIP1 mediates vascular endothelial cell growth factor receptor-3-dependent
angiogenic and lymphangiogenic responses. Arterioscler. Thromb. Vasc. Biol. 34, 603-615.
Zhu, Z., Friess, H., diMola, F.F., Zimmermann, A., Graber, H.U., Korc, M., and Buchler, M.W.
(1999). Nerve growth factor expression correlates with perineural invasion and pain in human
pancreatic cancer. J. Clin. Oncol. 17, 2419-2428.
Zorgetto, V.A., Silveira, G.G., Oliveira-Costa, J.P., Soave, D.F., Soares, F.A., and Ribeiro-Silva, A.
(2013). The relationship between lymphatic vascular density and vascular endothelial growth
factor A (VEGF-A) expression with clinical-pathological features and survival in pancreatic
adenocarcinomas. Diagn. Pathol. 8, 170-1596-8-170.
Zuckerman, D.S., and Ryan, D.P. (2008). Adjuvant therapy for pancreatic cancer: a review.
Cancer 112, 243-249.
Zumsteg, A., Baeriswyl, V., Imaizumi, N., Schwendener, R., Ruegg, C., and Christofori, G. (2009).
Myeloid cells contribute to tumor lymphangiogenesis. PLoS One 4, e7067.
Zuo, H.D., Tang, W., Zhang, X.M., Zhao, Q.H., and Xiao, B. (2012a). CT and MR imaging patterns
for pancreatic carcinoma invading the extrapancreatic neural plexus (Part II): Imaging of
pancreatic carcinoma nerve invasion. World J. Radiol. 4, 13-20.
Zuo, H.D., Zhang, X.M., Li, C.J., Cai, C.P., Zhao, Q.H., Xie, X.G., Xiao, B., and Tang, W. (2012b). CT
and MR imaging patterns for pancreatic carcinoma invading the extrapancreatic neural plexus
(Part I): Anatomy, imaging of the extrapancreatic nerve. World J. Radiol. 4, 36-43.

266

Appendix A: Skeletal Muscle Total RNA Extraction Protocol
DAY 1:
Homogenization
1. Spray with RNaseZap, rinse, and wipe dry work surface, pipettor, spatulas, tweezers and
gloves. Get liquid nitrogen, dry ice, and wet ice. May also need mortar and pestle to
break up tissue pieces.
2. Place spatulas, tweezers, and polycons containing tissue on dry ice.
3. Work in fume hood with double gloves and lab coat. Lay down paper towels to work
over.
4. Add 3 mL TRIzol to one 15 mL conical per sample.
5. Clean VirTishear homogenizer with 1 N NaOH and rinse with several L of purified water.
6. Use tweezers to place piece of tissue in conical.
7. Homogenize tissue using VirTishear homogenizer until in suspension. Three to four
cycles at speed 5 for about 10 - 15 seconds each works well.
8. Add another 7 mL TRIzol to each sample.
9. Vortex vigorously; incubate 5 minutes at room temperature.
10. Add 0.2 mL chloroform per 1 mL of TRIzol (2 mL) and shake vigorously by hand for 30
seconds. Incubate 5 minutes at room temperature.
11. Centrifuge 45 minutes at 3200 rpm at 4°C.

267
RNA Isolation
1. Remove the top aqueous phase and transfer to a new tube without disturbing the
interphase or lower organic phase. Organic phase can be stored overnight at 4°C.
2. Add 0.5 mL isopropanol per 1 mL TRIzol (5 mL) and incubate overnight at -20°C.
DAY 2:
3. Centrifuge 45 minutes at 3200 rpm at 4°C; decant supernatant.
4. Wash in 1 mL 75% EtOH per 1 mL TRIzol (10 mL). Vortex and centrifuge 45 minutes at
3200 rpm at 4°C; decant supernatant.
5. Resuspend pellet in small volume (<500 μL) 75% EtOH. Transfer to microfuge tube.
Rinse conical with 500 μL 75% EtOH and add to microfuge tube. Mix well. RNA can be
stored in 75% EtOH at -20°C if necessary.
6. Centrifuge 5 minutes at 16,100 rcf at 4°C. Remove supernatant. Repeat.
7. Allow pellet to air dry in hood for 10 minutes.
8. Resuspend pellet in 50 μL RNase-free water.
9. Analyze

RNA

concentration

and

quality

by

NanoDrop

spectroscopy

BioAnalyzer/Fragment Analyzer RNA Integrity Number/RNA Quality Number.
10. Store RNA at -80°C.

and

